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The Relationship Between Knowledge and Beliefs About HPV, Acceptance of the HPV 
Vaccine and Intentions to Practice Safer Sex Behaviors Among Female College Students 
Theresa Scorcia-Wilson 
ABSTRACT 
 
Introduction. Sexually transmitted infections (STIs) continue to be highly 
prevalent among young women, and STIs continue to be a challenging health issue on 
college campuses.  Studies have shown that the highest prevalence of human 
papillomavirus (HPV) is among young adult women, ages 20 to 24, including female 
college students.  While the HPV vaccine has proven to be highly effective in preventing 
certain high-risk types of HPV, it is not effective in preventing all types of HPV or other 
STIs.  Practicing other safer sex behaviors, in addition to condom use, also can help 
individuals protect themselves and their partners from acquiring HPV and other STIs.  
Purpose. Relationships between knowledge about HPV and the HPV vaccine, beliefs 
about HPV, acceptance of the HPV vaccine, and intentions to practice safer sex behaviors 
were assessed to determine if female college students who had a high acceptance of the 
HPV vaccine were also more likely to practice safer sex behaviors.  Methods. A 
convenience sample of 2,706 undergraduate female college students, ages 18 to 24, from 
three U.S. public universities, completed an online survey that measured the following 
study variables: knowledge about HPV; knowledge about the HPV vaccine; acceptance 
 ix
of the HPV vaccine, specifically influential factors and barriers to vaccination; as well as 
attitudes, normative beliefs, control beliefs and intentions for practicing safer sex 
behaviors.  Results. The majority of participants had a high level of knowledge of HPV 
(70.4%) and the HPV vaccine (73.7%).  Over one-third of the participants (37.3%) 
received at least one dose of the HPV vaccine.  Most participants thought they had a low 
susceptibility to HPV, as 54% thought they were unlikely to contract HPV; however, 
most (53.6%) thought that HPV would be a serious problem for them.  The safer sex 
behavior that participants thought was the easiest was refusing to have sex with a partner 
that would not use a condom (51.8% “Strongly agree”) and the safer sex behavior that 
participants thought to be the most difficult was asking a partner to get tested for STIs 
(54.5% “Disagree”).  Attitudes, normative beliefs, and control beliefs combined to 
strongly predict intentions (R = .730, p < .001), and attitudes was the strongest predictor 
for intentions to practice safer sex behaviors (β = .666), 95% CI [.649, .711].  There was 
a significant positive correlation between vaccine acceptance and intentions to practice 
safer sex behaviors (r = .087, p < .001), including likelihood of getting vaccinated against 
HPV (r = .098, p < .001).  Conclusions.  Findings from this study demonstrate the need 
for university student health centers to provide information about the HPV vaccine as 
part of broader STI prevention and social marketing campaigns, targeting female college 
students who are single, as well as those in monogamous relationships.  Furthermore, 
because young men can be carriers of HPV and the HPV vaccine is now available to 
them, follow-up studies are needed to determine acceptance of the HPV vaccine among 
male college students as it relates to HPV knowledge, knowledge of the vaccine, and 
intentions to practice safer sex behaviors. 
 1
 
 
 
Chapter One 
Introduction 
Sexually Transmitted Infections  
The transition from adolescence to young adulthood presents special challenges 
and opportunities for the individual.  Young adults experience significant biological, 
cognitive, emotional, and social changes.  In addition, young adults establish patterns of 
behaviors and make lifestyle choices that affect both their current and future health 
(Centers for Disease Control and Prevention [CDC], 2004). 
 Compared to older adults, sexually active adolescents, ages 10 to 19, and young 
adults, ages 20 to 24, are at high risk of acquiring sexually transmitted infections (STIs) 
as they are more likely to have multiple sex partners, and they may select partners who, 
themselves, are at higher risk of acquiring an STI (CDC, 2001).  Significant progress has 
been made in the treatment and prevention of reportable STIs, such as chlamydia and 
gonorrhea, over the past few decades.  However, STIs continue to be highly prevalent 
among young people, and incidence of certain reportable STIs, such as syphilis, increases 
each year (CDC, 2004).  In a nationally representative sample, Forhan, Gottlieb, 
Sternberg, Xu, Datta, McQuillan, et al. (2009) demonstrated that 1 in every 4 girls, ages 
14 to 19, have had an STI.  Furthermore, 19.2% of these teens developed an STI in one 
year after having their first sexual experience, with only one sex partner.  Approximately 
19 million new STIs occur each year in the U.S., with almost half of them being among 
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persons ages 15 to 24 (Weinstock, Berman, & Cates, 2004).  STIs pose serious public 
health, social and economic problems for young adults (Brown, 1998).  In addition to the 
negative physical and psychological consequences associated with STIs, the direct 
medical costs associated with diseases caused by STIs are estimated at $14.7 billion each 
year (CDC, 2006). 
STIs and College Students  
STIs continue to be a challenging public health issue on college campuses. The 
majority of college students are sexually active (Eisenberg, 2001), and engage in 
activities that put themselves at high risk of acquiring STIs (Gately, 2003).   In addition 
to having multiple sex partners or selecting high-risk partners, many college students that 
are sexually active do not take some of the necessary precautions, such as wearing a 
condom, to decrease their risk of acquiring STIs (Eisenberg, 2001).  Abstaining from 
sexual intercourse and other high-risk sexual behaviors is the most effective way to 
prevent transmission of most STIs.  For persons having sexual intercourse, correct and 
consistent use of latex condoms reduces risk of spreading and contracting STIs (Conant, 
Hardy, Sernatinger, Spicer, & Levy, 1986; Van de Perre, Jacobs, & Sprecher-Goldberger, 
1987). 
However, according to a national survey by the Society for Adolescent Medicine 
in 2003, more than 50% of college students living away from home reported that they 
were sexually active, and 73% of those sexually active students reported having 
unprotected sex, thereby increasing the risk of contracting STIs.  In addition, 68% of 
those students who reported having unprotected sex did not believe they were at risk of 
contracting STIs (Gately, 2003). 
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Furthermore, the majority of adolescents and college students underestimate their 
vulnerability to injuries and diseases including, but not limited to, STIs  (Brown, 2000; 
Cohn, Macfarlane, Yanez, & Imai, 1995; Finch, Donohue, & Garnham, 2002; Green, 
Grant, Hill, Brizzolara, & Belmont, 2003; Johnson, McCaul, & Klein, 2002; Kershaw, 
Ethier, Niccolai, Lewis, & Ickovics, 2003; Kontos, 2004; Omori & Ingersoll, 2005; 
Ramirez, Ramos, Clayton, Kanowitz, & Moscicki, 1997). 
Human papillomavirus 
Human papillomavirus (HPV) is thought to be the most common STI in the 
United States, and is most often contracted by adolescents and young adults (Winer, Lee, 
Hughes, Adam, & Koutsky, 2004).  Forhan, et al. (2009) also found HPV to be the most 
common STI among adolescents, ages 14 to 19.  The prevalence of HPV among young 
people of all racial and ethnic backgrounds is of rising concern (Koutsky, 1997).  
Incidence and prevalence data for HPV infection are limited as there is no mandate on 
HPV reporting by health agencies or health care providers (CDC, 2003).  However, it is 
estimated, that at any one time, 20 million people in the U.S. have genital HPV infection 
that can be sexually transmitted, approximately 6.2 million people acquire an HPV 
infection each year, and an estimated 75% of persons of reproductive age have been 
infected with sexually transmitted HPV (CDC, 2001).  There are over 100 types of HPV, 
and more than 30 of these HPV viruses are sexually transmitted by skin-to-skin contact 
(National Cancer Institute [NCI], 2003).  There are at least two low-risk types of sexually 
transmitted HPV that have been identified to cause genital warts – HPV types 6 and 11 – 
and at least 18 high-risk types that are considered to cause cervical cancer – HPV types 
16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82 (Partridge & Koutsky, 
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2006).  Approximately half of all cervical cancers are caused by HPV-16 (Stone, Karem, 
Sternberg, McQuillan, Poon, Unger, & et al., 2003) and approximately 70% of cervical 
cancers are caused by HPV types 16 or 18 (Hager, Bush, & Mcilhaney, 2004; Munoz et  
al., 2003).  These high-risk HPV types can lead to cancer of the cervix, vulva, vagina, 
anus, or penis (Kiviat & Koutsky, 1999).   Studies also suggest that a high-risk type of 
HPV may be associated with a cancer in the middle part of the throat, called the 
oropharynx, that includes the soft palate, the base of the throat, and the tonsils (Gillison, 
et al., 2000; NCI, 2003). 
Studies consistently demonstrate high levels of HPV infection among women, but 
exact numbers are not known.  Studies have shown that 10% to 46% of all sexually active 
women are infected with HPV at any given point in time, depending on the population 
evaluated (Burk et al., 1996; Koutsky, 1997; Lorincz, 1996).  Dunne et al. (2007) found 
that the prevalence of HPV was 26.8% among females, ages 14 to 59, and the highest 
prevalence of HPV, at 44.8%, was among young women, ages 20 to 24.  Several studies 
preceding Dunne et al. (2007) have shown that men and women also between the ages of 
20 and 24 have the highest risk of HPV infection (Becker, Stone, & Alexander, 1987; 
Burk et al., 1996; Ho, Bierman, Beardsley, Chang, & Burk, 1998; Koutsky, 1997; Stone, 
1989).  The peak prevalence of genital warts appears to be in men and women, between 
the ages of 20 and 29 years (CDC, 2006).  Therefore, the college-aged population is at 
high risk for exposure and acquisition of HPV, and the virus has been shown to infect 
more than 40% of sexually active college students (Eisenberg, 2001).  The highest levels 
of HPV are among young women, including female college students.  A review of studies 
conducted on the prevalence and incidence of HPV among U.S. women revealed that 
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HPV prevalence ranged from 14% to more than 90%.  The highest HPV prevalence was 
among women attending STI clinics and college students, identifying them as priority 
populations for prevention intervention (Revzina & Diclemente, 2005). 
The Impact of HPV Among College Students 
Research has demonstrated a low level of awareness among college students 
about the risk factors and symptoms of STIs that most threaten them, including HPV 
(Eisenberg, 2001; Gately, 2003; Yacobi, Tennant, Ferrante, & Roetzheim, 1999).  Female 
college students, across different ethnic groups, are more knowledgeable about HPV 
compared to male college students (D’Urso, Thompson-Robinson, & Chandler, 2007; 
Gerend & Magloire, 2008; Kenney, 1996).  However, studies of U.S. female college 
students show that despite the high prevalence of HPV in this population, there is low 
awareness and knowledge of this viral infection (D’Urso et al., 2007; Lambert, 2001; 
Ramsum, Marion, & Mathias, 1993; Vail-Smith & White, 1992; Yacobi et. al., 1999).  
Gerend and Magloire (2008) revealed that since U.S. approval of the HPV vaccine 
GARDASIL®, the level of knowledge and awareness about HPV, and its link to cervical 
cancer, may be increasing among college students.  However, misconceptions about HPV 
remain, as studies have also revealed that the majority of female college students do not 
understand how HPV is transmitted and are not aware of its link to genital warts (Allen, 
et al., 2009; Geren & Magloire, 2008; Sanfordt & Pleasant, 2009). 
Daley et al. (2008) found that women expressed confusion about HPV and could 
not accurately communicate true meaning of an HPV diagnosis.  Human papillomavirus 
infection poses a serious public health concern for women, as specific types of HPV have 
been well established as the main cause of cervical cancer (Kiviat, Koutsky, & Paavonen, 
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1999; Montero, Larkin, Houston, & Toney, 1999; Munoz & Bosch, 1996; National 
Institutes of Health, 1996).  Over 99% of cervical cancers contain at least one high-risk 
type of HPV, and approximately 70% of cervical cancers contain HPV types 16 or 18 
(Munoz et al., 2003).  Studies have also demonstrated that HPV types 16 and 18 are 
associated with anogenital diseases, such as vulvar, vaginal, and anal cancers.  However, 
not all vulvar and vaginal cancers are caused by HPV, and the exact number of these 
cancer cases caused by HPV types 16 and 18 is unknown (Watson, Saraiya, Ahmed, 
Cardinez, Reichman, Weir et al., 2008).  Hampl, Sarajuuri, Wentzensen, Bender, and 
Kueppers (2006) detected HPV types 16 or 18 in surgical samples from women.  Human 
papillomavirus types 16 or 18 were detected in 76% of surgical samples with vulvar 
intraepithelial neoplasia or precancer, 64% of samples with vaginal intraepithelial 
neoplasia, 81% of samples with anal vaginal intraepithelial neoplasia, and 42% of 
samples with vulvar carcinoma. 
In most cases, HPV is asymptomatic – the virus does not have any associated 
symptoms – so many women may harbor it for a long time without knowing it, and if 
undetected and untreated, the HPV types noted above, principally types 16 and 18, can 
lead to cervical cancer.  In addition, those persons who have HPV, but are unaware of it, 
may continue to be sexually active and practice unsafe sexual behaviors believing they 
are not infected.  Therefore, they can transmit the virus to their sex partners (Schiffner & 
Buki, 2006).  Studies also have found that the majority of young women are not aware of 
the link between HPV and cervical cancer (Lambert, 2001; Lazcano-Ponce et al., 2001; 
Waller, McCaffrey, Forrest, Szarewski, Cadman, & Wardle, 2003; Waller, McCaffrey, & 
Wardle, 2004).  Human papillomavirus is less common among men, but prevalence rates 
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for both low-risk and high-risk types of HPV have increased over the past several 
decades (Sawyer & Moss, 1993).  A review of studies conducted of men revealed that the 
prevalence of low-risk and high-risk types of HPV ranged from approximately 2% to 
35% (Partridge & Koutsky, 2006).  The highest rates of infection were found to occur 
among men aged 20 to 24 (Becker et al., 1987; Burk et al., 1996; Koutsky, 1997; 
Koutsky, Galloway & Holmes, 1988) and some studies have found similar HPV 
prevalence rates, at approximately 28%, among men and women between 18 and 20 
years of age attending the same universities (Van Doornum et al., 1994; Weaver et al., 
2004). 
Studies involving different racial and ethnic groups have consistently 
demonstrated that men are not as knowledgeable about HPV compared to women 
(D’Urso et al., 2007; Kenney, 1996).  Furthermore, the influence of cultural factors can 
increase the risk of HPV for college students in certain ethnic groups.  Two cultural 
factors, cited in the literature, that can have an influence on sexual health are culturally 
set gender roles (Suarez & Siefert, 1998) and the inability to negotiate condom usage 
(Buzi, Wiemnan, & Smith, 1998; Suarez & Siefert, 1998).  For example, studies have 
demonstrated that cultural factors in the Latino population can increase the risk of HPV 
among females.  Gender roles related to social norms suggest that Latino men are 
encouraged to be sexually knowledgeable and as a result, they tend to have multiple 
partners while Latina women are encouraged to remain faithful and refrain from 
discussions about sexual issues.  Therefore, Latina women often find it difficult to 
discuss and insist on the use of condoms with their partners (Buzi et al., 1998).  Schiffner 
and Buki (2006) conducted a study on health beliefs among Latina female college 
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students and concluded that women who do not discuss sexual health with their partners 
may be less likely to utilize condoms consistently, placing them at high risk for acquiring 
HPV. 
Men often do not have any visible symptoms of HPV, a point of concern in terms 
of transmission to sex partners.  Men who are less aware of HPV and have no symptoms 
will be more likely to transmit the virus to a sexual partner without knowing it.  
Moreover, most of the time, men will not have any health risks associated with the high-
risk types of HPV, such as cancer, so it is the women who need to be monitored for 
abnormal cell changes in the cervix.  In men, sexual activity is positively correlated with 
HPV infection (Giuliano, 2007).  Dunne, Nielson, Stome, Markowitz, & Giuliano (2006) 
reported that HPV prevalence among men was typically 20% and infection rates of up to 
72.9% have been documented.   Furthermore, studies of HPV prevalence often among 
men have reported that HPV-16 is the most prevalent high-risk type (Baldwin et al., 
2003; Bosch et al., 1996; Franceschi et al., 2002; Kataoka, Claesson, Hansson, Eriksson, 
& Lindh, 1991; Lazcano-Ponce et al., 2001; Nielson et al., 2007, Weaver et al, 2004; 
Wikstrom, Popescu, & Forslund, 2000).  Evidence from a recent study in patients with 
penile carcinoma demonstrated that HPV was present in 77.5% of cases, and HPV types 
16 and 18 were present in 84.2% and 10.5% of cases, respectively (Pascual et al., 2007). 
Studies of heterosexual couples have reported that concordant type-specific HPV 
infections occur more often than would be expected by chance (Baken et al., 1995; 
Bleeker et al., 2005).  Therefore, both men and women need to be targeted for HPV 
prevention because men can play a role as carriers and, unknowingly, spread the virus to 
female partners. 
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Prevention of HPV 
The most effective method of HPV prevention is avoidance of direct contact with 
the virus, such as sexual skin-to-skin contact with a partner that has HPV, until it is 
treated.  However, many individuals with HPV are asymptomatic and do not have genital 
warts.  Consequently, they may not know that they have the virus or can transmit it to a 
partner.  Numerous studies have demonstrated that the use of condoms is not completely 
effective in preventing HPV, as HPV infection can occur on sites that are not covered or 
protected by a condom.  However, the use of condoms does provide partial protection and 
may reduce the risk of transmitting or acquiring HPV (National Institute of Allergy and 
Infectious Diseases [NIAID], 2001).  Winer et al. (2006) demonstrated that consistent use 
of condoms by male partners reduced the risk of specific low-risk and high-risk types of 
cervical and vulvovaginal HPV infection in women.  Research has demonstrated that men 
primarily use condoms as a contraceptive method (Santelli et al., 1997). 
Practicing other safer sex behaviors, in addition to condom use, also can help 
individuals protect themselves and their partners from contracting HPV and other STIs.   
Safe sex, also referred to as “safer sex,” is defined as taking precautions prior to or during 
sex that decrease the potential for transmitting or acquiring STIs (National Institutes of 
Health, 2004).  According to The Planned Parenthood Federation of America (2004), 
safer sex behaviors are what individuals can do to lower their risk of getting STIs.  Safer 
sex behaviors that can significantly reduce the risk of contracting STIs include:  
abstinence or not participating in any kind of sexual activity; practicing alternative types 
of sexual activity other than intercourse that reduce a person’s risk of getting an STI, such 
as kissing, embracing, and massage; asking a partner to get tested for STIs before 
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participating in sexual activity with them; staying in a monogamous, sexual relationship 
with someone who has no history of STIs; using a condom; avoiding using drugs or 
alcohol while having sex – because of their role in judgment impairment; communicating 
concerns about contracting STIs with partners and how to protect each other; finding 
information about HPV and other STIs and asking for information and assistance from 
health care providers, including receiving regular physical examinations and testing for 
the detection of HPV and other STIs. 
Health care providers can perform visual physical examinations and other tests of 
reproductive tissue to identify the presence of HPV among men and women.  Urine 
sampling and penile swabs have been used to detect HPV among men, but more research 
is needed to determine the accuracy of these methods (Baldwin et al., 2003). 
Transmission of HPV from a female partner can be prevented through early 
detection via a gynecological exam that includes a Pap test. The Pap test is the standard 
method of detecting cell and tissue abnormalities that alert practitioners to the possibility 
of early to advanced stages of cervical cancer.  The Pap test can reveal abnormal cell 
changes known as cervical dysplasia, a precancerous condition (American Social Health 
Association, 2001).  Abnormal cervical cell changes can be detected more accurately 
through the administration of a Pap test in combination with an HPV DNA test, versus 
administering a Pap test alone.  The HPV DNA tests, Cervista HPV 16/18 and Cervista 
HPV HR, are now available and can detect DNA sequences of all high risk types of HPV.  
The Cervista HPV 16/18 differs from Cervista HPV HR in that it can detect the specific 
DNA sequences for HPV 16 and 18.  Differentiating these HPV types provides health 
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care providers with more information on a client’s risk of subsequently developing 
cervical cancer (Food and Drug Administration [FDA], 2009). 
Although there is no cure for HPV, there are various treatments for HPV, 
depending on the type and severity.  In addition, most forms of HPV, including the high-
risk types, often disappear on their own.  However, there is no guarantee that an infection 
will not reappear or develop into a pre-cancerous or cancerous condition (CDC, 2002; 
NCI, 2003; NIAID, 2004). 
Vaccination as a Prevention Strategy 
Vaccines are an effective way to prevent some STIs.  A vaccine to prevent 
Hepatitis B, also a sexually transmitted disease, has been available for over a decade.  A 
vaccine to prevent HPV and the development of genital warts and cervical cancer was 
was approved by the FDA in 2006 for use in girls, adolescents and young women in the 
United States.  Two different variations of an HPV vaccine have been tested through 
numerous clinical trials. 
Both vaccines consist of L1 virus-like particles, which have the same form and 
antigen properties as the L1 protein of HPV.  The L1 virus-like particles self-assemble 
into an empty capsid, and once they enter the body’s blood circulation, the particles 
trigger an antibody response that is significantly higher than the antibody response from 
natural HPV infection (Harper, et al., 2006; Villa, et al., 2005). 
Clinical trials involving adolescent and young women, between the ages of 9 and 
26, demonstrated GARDASIL®, developed by the pharmaceutical company, Merck & 
Co., Inc., was effective in preventing incidence and persistent infection with two high-
risk types of HPV – HPV-16 and HPV-18.  The vaccine has been found to have the 
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highest efficacy for adolescents and young women ages 16 through 26 (Gilsdorf & 
Markowitz, 2006).  This vaccine has been proven effective in preventing HPV types 16 
and 18 from progressing into pre-cancerous cells (Reinis, 2004).  The HPV-16 and HPV-
18 types are responsible for nearly 70% of all cervical cancers (Munoz, et al., 2003).  The 
vaccine also has been proven effective against HPV-6 and HPV-11, the two types that 
cause the majority of cases of genital warts.  Therefore, GARDASIL® protects against 
four types of HPV – 6, 11, 16, and 18 (Gravitt & Shah, 2005; Koutsky et al., 2002).  
Because high vaccine efficacy against infection and cell abnormalities has been 
replicated in numerous studies for different female age groups, the FDA approved 
GARDASIL® in 2006 for use in girls, adolescents, and young women, ages 9 to 26.  
Vaccine availability in the U.S. began at the end of June 2006.  The vaccine includes a 
series of three shots administered over six months (Merck & Co. Inc., 2006).  Since 
vaccine approval in 2006, 25% of girls in the United States, aged 13 to 17 years, have 
received at least 1 to 3 recommended doses of GARDASIL® (CDC, 2008). 
Clinical trials have demonstrated that GARDASIL® was also highly effective in 
preventing anogenital diseases, such as vulvar and vaginal precancers in women three to 
five years after receiving the vaccine (Garland et al., 2007; Merck & Co., Inc., 2008; 
Schiller, Castellsague, Villa, & Hildesheim, 2008).  Therefore, in September 2008, the 
FDA also approved the use of GARDASIL® to protect against vulvar and vaginal 
cancers caused by HPV types 16 and 18 in girls and young women, ages 9 to 26 (Merck 
& Co., Inc., 2008).  GARDASIL® has been approved for use in 106 countries including 
the United States, European Union, Australia, New Zealand, Mexico, Brazil, and Canada.  
Additional applications are also under review with regulatory agencies in several 
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countries throughout the world, and Merck & Co., Inc. is awaiting approval from the 
FDA to expand the use of GARDASIL® in women, ages 27 to 45 (Merck & Co. Inc., 
2008a, 2008b). 
Cervarix® is another HPV vaccine that has been developed by the pharmaceutical 
company, GlaxoSmithKline.  The main clinical study included more than 18,000 women, 
ages 15 to 25, in the United States and 11 other countries.  Clinical trials in this study 
demonstrated that Cervarix® was approximately 93% effective in preventing HPV-16 and 
HPV-18 and related pre-cancerous cell changes in women not previously infected with 
either of these HPV types.  In addition, the vaccine was about 53% effective in 
preventing precancerous cervical lesions associated with HPV-16 and HPV-18 in women 
who tested positive at the start of the study.  Additional studies demonstrated that the 
immune response to the vaccine was similar to that of women ages 15 to 25.  Therefore, 
the vaccine has been approved for use in girls and young women, ages 10 to 25 
(GlaxoSmithKline, 2009; U.S. Department of Health and Human Services [USDHHS], 
2009; Harper et al., 2004).  This vaccine also includes a series of three shots administered 
over six months.  Cervarix® has been approved for use among girls and women, ages 10 
to 25, in 100 countries, including the United States, European Union, Brazil, Mexico, 
Australia, Singapore, South Korea, Philippines, and Taiwan.  The vaccine was made 
available in the United States in late 2009 (GlaxoSmithKline, 2009). 
The most important factor regarding the impact of the HPV vaccine in reducing 
cervical cancer is duration of protection (Jeurissen & Makar, 2009).  At this point, it is 
not known how long the HPV vaccines will be effective.   Clinical trials of GARDASIL® 
have demonstrated that the vaccine may be effective against HPV infection for up to five 
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years (CDC, 2006; Garland et al., 2007; FUTURE II Study Group, 2007; FUTURE II 
Study Group, 2007; Villa et al., 2006), and clinical trials of Cervarix® have demonstrated 
that the vaccine may be effective for up to 6.4 years (Schwarz & Leo, 2008). 
Men also have the potential to increase the incidence of genital warts and cervical 
cancer among women because they can have asymptomatic HPV and transmit the virus 
unknowingly.  Bosch et al. (1996) measured the association between detection of high-
risk type HPV-16 DNA found in men and cervical cancer diagnosis in their female 
partners, and found an increased risk of cervical cancer in female partners of men who 
were positive for HPV.  Several studies in Colombia and Spain demonstrated that penile 
HPV DNA prevalence was higher in spouses of women with cervical cancer compared to 
women without cervical cancer (Castellsague et al., 1997).  The findings from these 
aforementioned studies may provide evidence that vaccinating boys and men against 
HPV can help to prevent the occurrence of the virus in unvaccinated women, and could 
potentially reduce the incidence of cervical cancer.  Universal vaccination, rather than 
only targeting the vaccine to girls and women, may be more effective in preventing HPV 
and cervical cancer because of men’s role in HPV transmission (Koutsky, 2005). 
Studies have been conducted to determine the vaccine’s effectiveness in 
preventing HPV among these additional populations.  A Phase III clinical trial 
demonstrated the effectiveness of GARDASIL® in boys 10-to-15 years of age (Block et 
al., 2006).  Additional clinical trials, sponsored by Merck & Co., demonstrated the 
effectiveness of GARDASIL® among men and boys, ages 10 to 26 (Merck & Co., 2009).  
Based on the results of these clinical trials, in October 2009, after data was collected for 
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this study, the FDA approved the vaccine for use in boys and men, ages 9 to 26, to 
prevent genital warts caused by HPV-types 6 and 11 (FDA, 2009). 
In addition, a study by Petaja et al. (2009) found Cervarix® to be effective and 
well-tolerated in Finnish males, ages 10 to 18.  An ongoing Finnish study, to be 
completed in 2014, will determine if vaccinating males with Cervarix®will prevent the 
transmission of HPV-types 16 and 18 in females (Petaja et al., 2009). 
Target Populations for the HPV Vaccine 
   The HPV vaccines are considered prophylactic vaccines because they prevent 
the infections that lead to genital warts and cervical cancer (Kahn, 2005).  Therefore, the 
optimal time to vaccinate girls at risk is in pre-adolescence and early adolescence, before 
most become sexually active (Rosenthal, 2005).  In addition to preventing HPV infection, 
HPV vaccines also have demonstrated that they may be effective in preventing persistent 
infection with HPV, thereby preventing the virus from progressing into precancerous 
cervical cells.  Therefore, the vaccine will benefit older adolescents and young adults 
because there is no guarantee that a previous HPV infection will not reappear or develop 
into a precancerous or cancerous condition (CDC, 2002; NCI, 2003; NIAID, 2004). 
Cost-effectiveness studies of the HPV vaccine, in terms of increases in life 
expectancy, decreased cancer incidence and mortality, and cost savings relevant to 
current screening, have revealed discrepant results.  There are many factors that can 
influence the cost-effectiveness of the vaccine, including cost of the vaccine, duration of 
protection, health insurance coverage, screening, number of sexual partners, and 
background incidence of HPV-related conditions (Jeurissen & Makar, 2009).  Most 
studies have shown that either the Cervarix® or GARDASIL® would be cost-effective if 
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high immunity from the vaccines lasts long enough.  Based on these studies, researchers 
recommended vaccinating adolescents by the age of 12, before most girls are sexually 
active (Koutsky, 2005; Sanders & Taira, 2003), or at age 18, in conjunction with annual 
or biennial Pap screening.  In addition, vaccination and screening among females until 
the age of 24 also has shown to be cost-effective (Kulasingam & Myers, 2003).  Studies 
have demonstrated that vaccinating males may not be cost-effective due to the cost of 
vaccine coverage (Elbasha, Dasbach, & Insinga, 2007; Sanders & Taira, 2003; Taira, 
Neukermans, & Sanders, 2004). 
Although the vaccine is most efficacious when administered to youth before they 
become sexually active, there are some challenges in vaccinating young girls.  
Vaccination of pre-adolescents and adolescents against an STI has become a 
controversial issue among certain groups, as there are concerns about whether the HPV 
vaccine will increase high-risk sexual behaviors among children and youth and whether 
vaccination will condone sexual activity before marriage (Stein, 2005).  Furthermore, 
there are concerns among health care providers about screening behaviors among 
adolescents (Kahn, 2005), and whether the vaccine will be accepted among parents and 
health care providers (Zimet, 2005).  Parental consent is required for vaccination of 
females under 18 years of age; therefore, parent acceptability is a critical issue (Zimet, 
2005). 
Parental and pediatrician acceptance of the HPV vaccine for young girls are 
crucial for successful vaccine delivery (Zimet, Mays, & Fortenberry, 2000). Few studies 
have been conducted on parental acceptance of vaccinating their children against STIs, 
including HPV.  Most of these studies have found high parental acceptance of 
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vaccinating girls, and the most important influences for acceptability are severity of 
infection, vaccine efficacy, physician recommendation, and school requirement (Davis, 
Dickman, Ferris, & Dias, 2004; Lazcano-Poncen et al., 2001; Mays, Sturm & Zimet, 
2004).  However, a study by Zimet et al. (2005) of STI vaccine acceptance among parents 
also found that parents were more likely to accept a vaccine if there were no other 
behavioral interventions for prevention of the infection.  A study by Noakes, Yarwood, 
and Salisbury (2006) examining parental acceptance of the HPV vaccine for girls and 
boys in the United Kingdom, found that most parents had concerns about offering a 
vaccine to children that protected against an STI and thought that the vaccine should be 
offered to children older than 10 years of age, in conjunction with a sex education 
program.  A study by Kahn et al. (2009) found that mothers’ intentions to vaccinate their 
daughters against HPV increased with the daughters’ age.  The greatest intentions among 
mothers were to vaccinate their daughters if they were 16 to 18, and the lowest intentions 
were for daughters ages 9 to 12. 
Raley, Followwill, Zimet, and Ault (2004) found that professional society 
recommendation is important for physician acceptance of an HPV vaccine.  They found 
the majority of members of the American College of Obstetricians and Gynecologists 
(ACOG) were willing to include the vaccine in their office practice, but not willing to 
vaccinate persons under the age of 17.  However, most pediatricians support vaccination 
for older age groups, such as over 15 years of age, compared to younger age groups, 12 
years and under (Daley et al., 2006).  A study by Ishibashi, Koopmans, Curlin, Alexander 
and Ross (2008) found that pediatricians were much more supportive of HPV vaccination 
than the general public, and that pediatricians should be aware of these differences when 
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counseling and educating patients and parents about the HPV vaccine.  There is a wide 
range of pediatricians’ attitudes about the HPV vaccine.  Factors influencing 
pediatricians’ intentions to recommend HPV vaccines to patients and parents include 
knowledge, personal and professional characteristics, office procedures, vaccine cost and 
reimbursement, parental factors, and specific attitudes about HPV vaccination.  Perceived 
benefits among pediatricians about the vaccine include prevention of HPV-related disease 
and the opportunity to educate adolescents, while perceived barriers include anticipated 
parental beliefs, such as denial that their child would be at risk for an STI, and provider 
beliefs, such as reluctance to discuss sexuality with pre-adolescents (Kahn et al., 2007). 
 Additionally, screening is a concern among pre-adolescents and adolescents as 
they often do not routinely visit their health care provider (Kahn, 2005), and HPV 
vaccination requires three visits over a six-month period (Harper et al., 2004; Koutsky et 
al., 2002; Mao et al., 2006; Reinis, 2004; Villa et al., 2005).  Furthermore, there is the 
issue of vaccinating adolescents who may be particularly vulnerable to acquiring STIs, 
such as homeless youth, street youth or incarcerated youth.  These high-risk youth 
populations are less likely to receive preventive health screenings, and they may be more 
difficult to reach for vaccination education and programs (Kahn, 2005). 
 Another barrier to vaccine delivery is cost.  The cost of the three-shot series is 
$120 per dose for a total of $360, and Merck is providing GARDASIL® to the poor and 
uninsured populations through their vaccine assistance program  (Merck & Co., Inc., 
2006).  Insurance plans covering approximately 60% of Americans’ health care costs are 
covering part of the cost for the vaccine.  However, half of 9- to 18-year-old girls are 
covered under the federal government’s Vaccines for Children (VFC) program. The VFC 
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program provides free vaccines to children who are uninsured, underinsured who visit 
Federally Qualified and Rural Health Centers, on Medicaid, or an American Indian 
(CDC, 2004).  The CDC issued a recommendation to use GARDASIL® under the VFC 
contract (Merck & Co., Inc., 2006), and the vaccine is now available in states through the 
VFC program. 
Although the vaccine is most efficacious in young girls and adolescents, there are 
other female age groups that can benefit from the vaccine.  In addition to vaccinating 
children and adolescents, studies have also demonstrated that it also may be beneficial to 
vaccinate 18-year-old women, in conjunction with a Pap test, at the first annual 
gynecological exam (Kulasingham & Myers, 2003).  Therefore, college-aged women 
with no history of HPV infection could receive the HPV vaccine in conjunction with 
regular Pap screening before or after they become sexually active.  Furthermore, young 
women, including college students, could receive GARDASIL® if they receive a positive 
HPV DNA test for HPV types 16 or 18 to prevent other types of HPV infections. 
A presentation by GlaxoSmithKline, the developer of the HPV vaccine Cervarix®, 
proposed there is a medical need for this vaccine for females in three different age 
groups.  The first group would be targeted before most sexual activity starts, before 15 
years of age.  The second group involves girls, ages 15 to 25, as the first sexual encounter 
and most sexual activity occurs among this age group.  The second group, would, 
therefore, include most college students.  The third target group is women older than 25 
years of age that may have already been diagnosed with HPV, may have persistent 
infection with HPV, and who may have HPV, but may not know it.  Research has 
demonstrated that Cervarix® is well-tolerated in women over 25 years of age (Harper et 
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al., 2006; GlaxoSmithKline, 2007; Monteyne, 2006). The purpose of vaccinating women 
over the age of 25 would primarily be to prevent HPV infection from progressing into a 
precancerous state and cervical cancer.  However, early findings have demonstrated that 
Cervarix® does not increase HPV viral clearance rates after six to 12 months, in women, 
ages 18 to 25, who are already infected with HPV 16 and 18 (Hildesheim et al., 2007). 
Based on the high prevalence of HPV among young adult women and the high 
efficacy of the vaccine among this population, young adult women, in addition to girls 
and adolescents, have been identified as one of the populations to benefit from the HPV 
vaccine.  As a result, Merck’s HPV vaccine GARDASIL® has been approved by FDA to 
be used in young adult women from 18 through 26 years of age. 
A study by Jain et al. (2009) revealed that, since approval of the HPV vaccine in 
2006, awareness of HPV and the HPV vaccine was significantly higher (p < .05) among 
young adult women, ages 18 to 26 (88.6%) compared to women, ages 27 to 49 (82.9%).  
Approximately one-fourth of young adults ages 18 to 24, are college students (CDC, 
1997).  A study by Gerend and Magloire (2008) found that since the approval of the HPV 
vaccine, awareness about HPV has increased among college students.  However, the 
majority of students had misconceptions about how HPV was transmitted and some were 
not aware of the link between HPV and genital warts.  Most college students have a low 
level of knowledge about HPV because this population has been poorly educated about 
HPV and there is a great desire for information about HPV infection, transmission and 
prevention from this population (Lambert, 2001; Ramsum et. al, 1993; Vail-Smith & 
White, 1992; Yacobi et al., 1999).  The college setting presents an important opportunity 
for addressing health issues, such as STIs, that have a significant impact on young adults.  
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Students’ health behaviors are practiced and experienced in community, and students 
influence each other’s choice and experience shared health challenges (Keeling, 2001).  
Most college students are over the age of 18 and can make informed choices about their 
health.  Therefore, the type of controversy over vaccinating this population, as there is 
currently is for youth under the age of 18, is not posing a challenge in vaccine delivery.  
The majority of student health centers at U.S. public colleges and universities have 
supplies of the vaccine, and vaccinations are highest among college females that have 
been educated about HPV risks (Vollmer, 2006).  Therefore, the collegiate venue is a 
promising environment for delivering the HPV vaccine, and vaccination may offer the 
opportunity to further educate students about how to protect themselves against STIs by 
practicing safer sex behaviors. Staff from some of these student health centers reported 
interest in developing on-campus vaccine education campaigns (S. Campbell, personal 
communication, December 8, 2006; H. Rayko, personal communication, December 15, 
2006; C. Robertson, personal communication, December 15, 2006). 
The college student population could benefit from the HPV vaccine for the 
following reasons: 
• HPV has been shown to infect more than 40% of sexually active college students 
due to their high-risk sexual behaviors (Eisenberg, 2001). 
• Approximately half of all college students are sexually active while they are at 
college and living away from home (Gately, 2003). 
• The HPV vaccine has been approved for use in females ages 9 through 26, an age 
group that includes traditional-aged college students. 
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• The college population often does not obtain high quality STI prevention services, 
due to lack of health insurance, or inability to pay for health insurance or services 
(CDC, 2003).  The cost of the vaccine is covered by Merck for female college 
students, ages 19 to 26, who are uninsured and meet income requirements. 
• Most college students may have HPV and may not know it; therefore, an HPV 
vaccine potentially could prevent a high-risk type of HPV from progressing into a 
precancerous or cancerous condition. 
In addition, college students often are victims of sexual assault (i.e., forced sex or 
rape) that increases their risk of acquiring STIs.  According to the Violent Victimization 
of College Students Report, between 1995 and 2002, approximately 15% to 20% of 
college women and 5% to 15% of college men, ages 18 to 24, reported that they 
experienced forced intercourse (Baum & Klaus, 2005).  Also, a study by Abma, Driscoll, 
and Moore (1998) found that 10% of young women, between the ages of 19 to 24, have 
reported that their first pre-marital sexual intercourse experience was involuntary.  The 
HPV vaccine could potentially reduce the risk of college students acquiring genital warts 
and cervical cancer, depending on the specific type of HPV infection, from being raped 
or having forced intercourse. 
A major barrier in vaccinating college students may be the high cost of the 
vaccine.  Merck has created a patient assistance program for vaccines that provide free 
vaccines, including GARDASIL®, to adults who are uninsured and who are unable to 
afford vaccines (Merck & Co., Inc., 2006).  The young adult population, including 
college students, is the most likely age group to be uninsured in the United States 
(Agency for Healthcare Research and Quality, 2005).  Eligibility requirements for the 
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uninsured population to receive the free vaccine include that the person must be age 19 
and older with the following income limits. 
• $43,320 for individuals 
• $58,280 for couples 
• $88,200 for a family of four (Merck & Co., Inc., 2009) 
Based upon these requirements, uninsured college students have been factored 
into the population to receive a free vaccine.  Uninsured and low-income clients and their 
licensed health care providers must obtain approval from Merck prior to administration of 
the vaccine (Merck & Co., Inc., 2009). 
HPV Vaccine Acceptance 
Because GARDASIL®  has received FDA approval, it is important to know 
whether the populations prioritized to receive the vaccine are being vaccinated (World 
Health Organization [WHO]-UNAIDS-CDC, 2003).  There is limited research on the 
number of college students that have received the vaccine since its approval, and the 
numbers that have been reported vary by college campus.  A study by Gerend & 
Magloire (2008) revealed that 4 out of 64 female college students from two college 
campuses received the vaccine, and pilot test data from an unpublished study by Scorcia-
Wilson (2008) revealed that 43 out of 125 female college students, from three college 
campuses, received the vaccine.  Some studies on vaccine acceptance among college 
students, indicate that persons in this population are highly receptive to the HPV vaccine 
with acceptance rates as high as 88.6% among women and 77.5% among men (Gerend & 
Magloire, 2008; Jones & Cook, 2008).  Common factors associated with increased 
vaccine acceptability among adolescents and young adults are low cost, vaccine efficacy, 
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physician endorsement, and increased number of sex partners (Boehner, Howe, 
Bernstein, & Rosenthal, 2003; Gerend et al., 2008; Kahn, Rosenthal, Hamann, & 
Bernstein, 2003; Zimet et al., 2000).  Boehner et al. (2003) found that an additional factor 
associated with positive attitudes about the vaccine among college students was partner 
and parental acceptance of the vaccine.  This study also reported no gender differences 
with respect to vaccine acceptance.  Crosby, Schoenberg, Hopenhayn, Moore, and 
Melhan (2007) found that additional factors significantly associated with HPV vaccine 
acceptance among college-aged females were having vaginal sex in the past 12 months, 
ever having an STI and ever having an abnormal pap smear.  Gerend et al. (2008) found 
that among a racially diverse sample of female college students, additional factors 
associated with a greater acceptance of the HPV vaccine were being in a committed 
relationship or dating, being sexually active, and feeling susceptible to HPV infection. 
Whereas the aforementioned studies on vaccine acceptance among adolescents 
and young adults have some common findings, there are conflicting results about whether 
individuals are significantly more likely to get the HPV vaccine if it is targeted toward 
preventing an STI versus if it is targeted toward preventing cervical cancer.   Hoover, 
Carfioli, and Moench (2000) found that adolescent girls and young women had higher 
acceptance of a vaccine that targeted an STI rather than cervical cancer.  However, 
Boehner et al. (2003) and Zimet et al. (2000) did not find any significant differences in 
preferences in vaccinations against HPV versus cervical cancer.  Researchers believed 
that the way the vaccine would be promoted (i.e., cervical cancer vaccine vs. an HPV or 
STI vaccine) would be crucial for its acceptance (Horton, 2005).  Merck is marketing 
GARDASIL® as a cervical cancer vaccine (Merck & Co., Inc., 2006).  Because the 
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vaccine is being promoted as one that prevents cervical cancer, then adolescents, young 
adults, and parents need to be educated about the fact that the primary cause of cervical 
cancer is a STI, and the vaccine’s therapeutic effect is to prevent HPV and its progression 
into cervical cancer. 
Based on findings from HPV vaccine acceptance studies, most parents, 
adolescents, and college students are comfortable with a vaccine that prevents the STI.   
A review by of studies on acceptance of the HPV vaccine by Zimet (2005) revealed that 
the majority of parents want more detailed information from pediatricians and health care 
providers about HPV so they can better understand prevalence of HPV infection, how 
HPV is transmitted, the consequences of HPV, and why there is a lack of clear prevention 
strategies.  Also, young adults, including college students, are concerned about HPV, and 
want to be better informed about HPV infection, transmission, screening, and prevention. 
Merck is promoting GARDASIL® as a cervical cancer vaccine through the 
national advertising campaign “One Less”.   Merck has not yet promoted the vaccine’s 
role in preventing vulvar, vaginal or anal cancer through this campaign.  The “One Less” 
campaign is focused on educating the public about the HPV vaccine and the continued 
importance for cervical cancer screening.  However, this is a separate campaign from 
Merck’s national HPV educational campaign “Tell Someone”.  The “Tell Someone” 
campaign was launched before GARDASIL® was available, and the purpose of the 
campaign was to ensure the public’s understanding of the link between HPV and cervical 
cancer (Merck & Co., Inc., 2006).  Merck recently launched the campaign “3 IS KEY”, 
and developed a brochure for health care providers to distribute to those patients who 
receive their first shot out of the three-shot series.  The purpose of the campaign and the 
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brochure is to remind teens and young women, either via mail, e-mail or phone text 
message, when to get their next two doses (Merck & Co., Inc., 2008).  However, as with 
“Tell Someone” and “One Less”, there is no information included in the “3 IS 
KEY”campaign, nor materials, that reminds the target audience of how HPV is 
transmitted and other methods of STI prevention. 
Merck has also funded professional medical associations to assist in marketing the 
vaccine, such as ACOG, the American Society for Colposcopy and Cervical Pathology, 
the Society of Gynecologic Oncologists, and the American College Health Association 
(ACHA).  These associations developed educational programs and materials about the 
HPV vaccine for health care providers to educate themselves as well as their clients.  
However, Rothman & Rothman (2009) revealed that most of the material did not address 
the full complexity of the issues related to the vaccine, including costs and benefits, and 
recommendations for HPV and cervical cancer screening.  In addition, materials 
contained information that downplayed the sexually transmitted infection issues related to 
HPV, primarily because of the perception that most parents might be uncomfortable 
discussing a vaccine for an STI.  Furthermore, the materials promoted the vaccine as an 
anti-cancer vaccine rather than one that prevents an STI. 
The ACHA developed an “HPV Vaccine Toolkit”, funded by Merck, for 
clinicians, including talking points, sample e-mail messages to students and parents, 
sample press releases, and public service announcements (AHCA, 2006).   The letters to 
students and parents focused on getting vaccinated to reduce worrying about getting 
cervical cancer and to save one’s life, without addressing the prevention of STIs.  
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Furthermore, Merck funding was not mentioned in any of the toolkit materials (Rothman 
& Rothman, 2009). 
Due to how the vaccine has been and is currently being promoted, it is not known 
whether members of the target population and parents have a better understanding of the 
cause of HPV as a result of these campaigns.  In addition, it is not known whether 
adolescent girls, young women and parents are being educated about the importance of 
practicing safer sex behaviors to prevent additional types of HPV and other STIs at the 
time of vaccination. 
Statement of the Problem 
Sexually active adolescents and young adults, ages 15 to 24, are at high risk of 
acquiring STIs due to practicing high-risk sexual behaviors.  Young adults, ages 20 to 24, 
including the college-aged population, have the highest rates of HPV infection, and STIs 
continue to be a challenging public health issue on college campuses.  Numerous studies 
have documented a low level of awareness about HPV among college students.  
Consequently, they do not perceive themselves to be at high risk for HPV or other STIs, 
and most college students do not practice safer sex behaviors to protect themselves 
against STIs (Eisenberg, 2001; Gately, 2003; Yacobi et al., 1999).  Despite the continued 
practice of high-risk sexual behaviors among college students, there is a high level of 
acceptance of an HPV vaccine for this population.  Furthermore, research has indicated 
that those who consider themselves at higher risk, such as those who have many sex 
partners, have a higher acceptance of the HPV vaccine (Boehner et al., 2003).  However, 
the majority of college students who are at high risk are also those who report that they 
do not practice safer sex behaviors to protect themselves against STIs  (Eisenberg, 2001; 
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Gately, 2003).  These findings may be a cause for concern if college students become 
vaccinated against HPV but continue to participate in risky sexual behaviors.  Because 
more than 50% of college students are sexually active, practice high-risk sexual 
behaviors, and are, therefore, at high risk of acquiring HPV, there is a great medical need 
to vaccinate this population against HPV.  Because there is a high incidence of HPV 
among college students, the HPV vaccine may benefit those who are already infected 
with HPV by preventing infection with other types of HPV that the vaccine guards 
against.  Young women, including college students, have been identified as a priority 
population for the HPV vaccine (Monteyne, 2005), and GARDASIL® has been approved 
for use in young girls and women, ages 9 to 26 (Merck & Co., Inc., 2006).  Research is 
limited on the percentage of female college students, ages 18 to 26, that have received the 
vaccine since its approval.  However, college-aged women are obtaining the HPV 
vaccine.  A study by Jain et al., (2009) that incorporated data from the 2007 National 
Immunization Survey among 1,102 participants, revealed that two to five months 
following the release of national HPV vaccine recommendations, one in ten women 18 to 
26 years old had initiated the HPV vaccine series. 
Some studies have been published on the female college student population with 
respect to their beliefs about the HPV vaccine and factors that influence its acceptance or 
non-acceptance (Boehner et al., 2003; Crosby et al., 2007; Gerend & Magloire, 2008; 
Jones & Cook, 2008).  However, these studies have not examined whether a relationship 
exists between knowledge about HPV, health beliefs about HPV, attitudes about or 
acceptability of the HPV vaccine, likelihood of being vaccinated, and intentions to 
engage in other protective sex behaviors.  Because GARDASIL® does not protect against 
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all types of HPV, college students’ willingness to practice safer sex behaviors, in addition 
to being vaccinated against HPV, will be necessary to protect themselves from all types 
of HPV, as well as other STIs.  This study assesses different factors that may play a role 
in college women’s acceptance of the HPV vaccine and intentions to practicing safer sex 
behaviors. Understanding these factors may be helpful in determining what approach 
health care providers need to take in educating this population about the vaccine.  Also, 
the information from this study may be helpful for university and college campuses in the 
development of HPV vaccine education and promotion campaigns.  Determining whether 
there is a relationship between knowledge about HPV and intentions to practice safer sex 
behaviors may help to reinforce the need for increased education about HPV and other 
STIs by health care providers for college-aged women, and encourage providers to also 
utilize the time for vaccination as a teachable moment to educate students about HPV and 
safer sex behaviors. 
The purpose of this study was to determine if women attending college who have 
high acceptance of the HPV vaccine and are likely to become vaccinated against HPV, 
also intend to practice other safer sex behaviors.  Also, this study contributes to the 
literature by further assessing female college students’ knowledge and beliefs about HPV 
and the HPV vaccine.  It examined female college students’ beliefs about their risk, and 
whether their perceived susceptibility to, and perceived severity of HPV, is associated 
with acceptance of the vaccine, likelihood of getting vaccinated against HPV, and 
practicing other safer sex behaviors.  Understanding the relationship between vaccine 
acceptance and intentions to practice safer sex behaviors can assist university health 
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centers in developing vaccine educational campaigns for women that also includes 
promotion of other safer sex practices. 
Theoretical Application 
The health belief model (HBM) (Rosenstock, 1974) has been applied in several 
studies to examine knowledge and beliefs about STIs, to predict behaviors against STIs, 
such as condom use, and STI vaccine acceptance, including the genital herpes and HPV 
vaccine (Auslander et al., 2005; Hiltabiddle, 1996; Kahn et al., 2003; Lollis, Johnson & 
Antoni, 1997; McKinley & Billingham, 1998; Orr & Langefeld, 2003; Zak-Place & 
Stern, 2004).  The HBM will be applied in this study to measure college students’ health 
beliefs related to HPV and the HPV vaccine.  Health beliefs assessed among college 
students include perceived susceptibility to getting HPV, perceived severity of HPV, 
perceived benefits and barriers to getting vaccinated against HPV, and beliefs that certain 
actions can protect themselves and others from HPV, such as practicing safer sex 
behaviors and being vaccinated against HPV.  Perceived susceptibility to HPV in this 
study is defined as whether or not individuals believe, they and others, such as peers, are 
at risk of getting HPV and their perceived level of risk, in addition to whether they 
believe they are personally responsible for taking precautions against getting HPV.  
Perceived severity of HPV is defined in this study as how serious individuals perceive 
HPV to be in terms of emotional, social, and medical consequences.  According to the 
HBM, both perceived susceptibility and severity of an illness or disease are partly 
dependent on knowledge about the illness or disease (Rosenstock, 1974).  Therefore, 
before perceived susceptibility and severity about HPV was assessed among college 
students, knowledge about HPV was determined.  Individuals with little or no knowledge 
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about HPV most likely will neither believe they are at risk of acquiring an STI, nor 
believe the STI to be an emotional, social or medical threat to themselves or others.  Self-
efficacy is another component of the HBM that was used to measure college students’ 
perceived capability to practice certain safer behaviors. 
 Whereas the HBM has been used to predict health-related behavior in terms of 
certain belief patterns, it does not incorporate an individual’s perceptions of beliefs held 
by prominent persons or figures in their life.  These beliefs are also referred to as 
normative beliefs.  Furthermore, because the HBM is focused solely on health beliefs that 
represent perceived benefits and barriers in explaining and predicting health behaviors, it 
does not include the construct of an individual’s perceived behavioral control.  According 
to Ajzen (1988), an individual’s attitudes about performing a certain behavior, normative 
beliefs of others for an individual to perform the behavior, and perceived behavioral 
control effect an individual’s intention to perform that behavior.  Because the HBM does 
not incorporate these constructs, it cannot be used to predict intentions to perform 
behaviors.  The theory of planned behavior (TPB) was applied in this study as a 
theoretical framework to complement the HBM.  The TPB has been applied in several 
studies to predict intentions of practicing safer sex behaviors among adolescents and 
college students (Bensley et al., 2004; Boily, Godin, Hogben, Sherr, & Bastos, 2005; 
Bryan, Fisher, & Brian, 2002; Koniak-Griffin, Lesser, Uman, & Nyamathi, 2003).  The 
TPB was used to measure college students’ normative beliefs regarding being vaccinated 
against HPV and practicing safer sex behaviors, self-efficacy or capability in performing 
safer sex behaviors, and perceived behavioral control of performing safer sexual 
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behaviors.  These constructs were used to measure college students’ intentions to practice 
safer sex behaviors and to become vaccinated against HPV. 
The constructs of the HBM and TPB were measured through an online survey 
developed primarily by this researcher.  Because Cervarix® was made available in the 
United States in late 2009, the assessment of HPV vaccination among college students in 
this study was for GARDASIL®. 
Items assessing knowledge and health beliefs about HPV and the HPV vaccine, 
and HPV vaccine acceptance, including influential factors and barriers to becoming 
vaccinated against HPV, were adapted from an instrument developed by researchers at 
the University of South Florida to assess the impact of receiving an HPV diagnosis 
among women.  Items assessing attitudes about practicing safer sex behaviors, and 
perceptions of partners’ and friends’ attitudes about practicing safer sex behaviors were 
constructed from a questionnaire development guide by Ajzen (2006).  Items assessing 
perceived self-efficacy and control in practicing safer sex behaviors will be adapted by a 
scale developed by Morrison, Ho, Beardsley, Bierman, and Burke (1998) to assess low- 
risk and high-risk sexual behaviors among female college students. The most promising 
application of the health belief model is for helping to develop messages that are likely to 
persuade individuals to make healthy decisions, such as through education, media, and 
counseling (Glanz, Lewis, & Rimer, 1990).  This study may provide valuable information 
for health care providers in educating students about HPV and designing HPV vaccine 
educational and promotion programs.  Determining if there is a relationship between 
HPV vaccine acceptance, likelihood of being vaccinated against HPV, and intention to 
practice other safer sex behaviors among college students should help inform the design 
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of educational campaigns or materials that are specific to the college student population.  
If college students are more likely to get a vaccine than engage in other protective sex 
behaviors, then vaccine educational campaigns also will need to focus on STI prevention, 
in general, and include messages that promote other safe sex practices, such as 
communicating with partners about STIs and asking partners to get tested before having 
sex, avoiding alcohol and other drug use before and during sexual activity, and using 
condoms.  This more comprehensive approach may be especially necessary because the 
vaccine is being promoted as a cervical cancer vaccine and not an STI vaccine.  
Administering the vaccine to college students may provide a teachable moment for health 
care providers, such as physicians, nurses, nurse practitioners, and physician assistants, to 
relay information about additional safer sex practices. 
Research Questions 
• What is the relationship between knowledge about HPV and intentions to practice 
safer sex behaviors among women attending college? 
 
o What is the relationship between knowledge about HPV and attitudes 
towards practicing safer sex behaviors? 
 
o What is the relationship between knowledge about HPV and normative  
beliefs about practicing safer sex behaviors? 
 
o What is the relationship between knowledge about HPV and perceived 
control towards practicing safer sex behaviors? 
 
• What is the relationship between knowledge of the HPV vaccine and acceptance 
of the HPV vaccine among women attending college? 
 
• What is the relationship between health beliefs about HPV and acceptance of the 
HPV vaccine among women attending college? 
 
o What is the relationship between perceived susceptibility to HPV and 
vaccine acceptance? 
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o What is the relationship between perceived severity of the HPV vaccine 
and vaccine acceptance? 
 
• What is the relationship between acceptance of the HPV vaccine and intentions to 
practice other safer sex behaviors among women attending college? 
 
o What is the relationship between acceptance of the HPV vaccine and 
attitudes towards practicing safer sex behaviors? 
 
o What is the relationship between acceptance of the HPV vaccine and 
normative beliefs about practicing safer sex behaviors? 
 
o What is the relationship between acceptance of the HPV vaccine and 
perceived control towards practicing safer sex behaviors? 
 
Definition of Terms 
 
Cervical cancer 
A malignant neoplasm of the cervix, or the neck, of the uterus. The primary cause of 
cervical cancer is infection with certain types of HPV (American Cancer Society, 2006; 
Thomas, 1993). 
College student 
“Traditional age undergraduates, 18 to 24 years of age, who are enrolled full-time or part-
time in public or private, two- or four-year institutions of higher education.  Many 
undergraduates are no longer of traditional age, and some students, ages 20 to 24, have 
already started graduate or first professional study” (Keeling, 2001, p.2). 
Genital warts 
Also called “condylomata acuminate” or venereal warts.  They are soft, moist, or flesh-
colored bumps, caused by HPV infections, that may appear in the genital area within 
weeks or months after infection (www.niaid.nih.gov/factsheets/stdhpv.htm). 
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Health Belief Model 
A model focused on an individual’s health beliefs and is used to explain and predict 
preventive health and illness behavior in terms of certain belief patterns such as general 
health values that include interest and concern about health, specific health beliefs about 
vulnerability to a particular health threat and beliefs about consequences of the health 
problem.  
Human papillomavirus 
The name of a group of viruses that includes more than 100 different types.  More than 
30 of these viruses are sexually transmitted and they can infect the genital area of men 
and women including the skin of the penis, vulva (area outside of the vagina), or anus, 
and the linings of the vagina, cervix or rectum (CDC, 2004). 
Model 
A diagrammatic representation of the relationship between a number of variables  
(Boss, Doherty, LaRossa, Schumm, & Steinmetz, 1993). 
Sexually transmitted infection  
A group of infections spread through any kind of sexual contact, not just by intercourse.  
These infections are caused by tiny organisms passed between individuals through 
contact with the genitals, skin, mouth, rectum, or bodily fluids.  Types of sexually 
transmitted infections include bacterial, viral, and parasites (American College of 
Obstetricians and Gynecologists, 2003). 
Theoretical framework 
A set of theoretical assumptions that explain the relationships among a set of phenomena 
(Camp, 2001). 
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Theory 
A set of interrelated concepts, definitions, and propositions that present a systematic view 
of events or situations by specifying relations among variables in order to explain and 
predict the events or situations (Kerlinger, 1986). 
Theory of planned behavior 
A theory that proposes that attitudes about performing a behavior, perceived benefits of 
others regarding its performance, and perceived behavioral control over one’s ability to 
perform the behavior all affect the intention to perform that behavior. 
Vaccine 
A suspension of infectious agents, or some part of them, given for the purpose of 
establishing resistance to an infectious disease (Thomas, 1993). 
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Chapter Two 
Review of the Literature 
 
 
 To understand the purpose of studying college students’ knowledge and attitudes 
about HPV and the HPV vaccine, their willingness to get vaccinated against HPV, and 
their intentions to practice safer sex, relevant background literature is presented.  This 
literature review is presented in the areas of the history of infectious disease with a focus 
on STIs in the United States; epidemiology, detection, and natural history of HPV; 
cervical cancer; transmission and prevention of HPV; vaccine therapy and vaccine 
acceptance; and the application of the health belief model and the theory of planned 
behavior. 
Infectious Disease 
Infectious diseases have always been a threat to humankind, from the biblical 
plagues and the Plague of Athens in ancient times, to the Black Death of the Middle 
Ages, the 1918 “Spanish Flu” pandemic, and more recently, the HIV/AIDS pandemic.  In 
addition, historically established infectious diseases, such as West Nile Virus, human 
monkey pox, dengue fever, tuberculosis, and malaria have reemerged, and some in 
populations that had not previously been susceptible to getting these diseases.  In 
addition, common strains of bacterial infection such as Staphylococcus aureus and 
Mycobacterium tuberculosis have continued to develop resistance to the antibiotics that 
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were once effective against them (Fauci, 2001; Institute of Medicine, 2003; Morens, 
Folkers, & Fauci, 2004).  Infectious diseases remain a dominant feature of the domestic 
and international public health considerations for the 21st century, as infectious diseases 
continue to emerge and re-emerge in a manner that does not fit with accurate and 
scientific predictions.  During the past ten years, many new and reemerging microbial 
threats have continued to challenge the public health and infectious disease research 
communities worldwide.  The infectious disease community has confronted several other 
newly emerging pathogens that are threatening to humans, such as severe acute 
respiratory syndrome-associated coronavirus (SARS-CoV), henipaviruses – viruses that 
infect bats and can be spread to humans and livestock, the avian influenza viruses, – and, 
more recently, the influenza viruses that have caused illness and death and the potential 
to evolve into a pandemic (Fauci, 2001; Institute of Medicine, 2003; Morens, et al., 
2004).   Each year, influenza or “flu” develops in up to 20% of all Americans, and over 
200,000 Americans are hospitalized with the disease.  Although influenza is a common 
infectious disease, an estimated 36,000 Americans die each year from flu-related 
complications (CDC, 2006).  The first case of avian influenza, also referred to as 
influenza A virus H5N1, was recognized in 1997 infecting 18 people in Hong Kong, 
where it caused six deaths.  Since 2003, over 500 humans have been infected with H5N1, 
and nearly 300 of those infected have died from the virus (World Health Organization 
[WHO], 2010).  The current strain of H5N1 virus is highly pathogenic, as it causes 
diseases in humans and animals, and the virus has killed millions of chickens and other 
birds.  Although the virus can cross species to infect humans, few suspected cases of 
human-to-human transmission have been reported (WHO, 2006).  However, the H5N1 
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virus could acquire characteristics that allow it to be readily transmitted among humans, 
and that could cause a worldwide pandemic, with the potential of killing millions of 
people.  There is a new global pandemic of influenza A, H1N1 virus also referred to as 
the “swine flu,” that is spreading from person-to-person.  The first case of the H1N1 virus 
originated in Mexico in March 2009, and the first case in the United States was reported 
on April 15, 2009.  Since the first outbreak of H1N1 was reported, an increasing number 
of states and over 70 countries have reported human cases.  To-date, there have been 
approximately 60 million cases and over 12,000 deaths associated with H1N1 in the 
United States (CDC, 2010).  In 1918, a pandemic of the “Spanish Flu” killed more than 
500,000 people in the U.S. and 20 million to 50 million people worldwide (NIAID, 
2005).  A vaccine to protect humans from H1N1 has been developed (CDC, 2009) and 
vaccine development and acceptance of vaccines in preventing infectious diseases will be 
discussed later. 
Overall, infectious disease is the third leading cause of death each year in the U.S. 
and the second leading cause of death in the world (World Health Organization [WHO], 
2004).  The infectious diseases that cause death worldwide are acute lower respiratory 
tract infections, malaria, diarrheal disease, tuberculosis, and HIV/AIDS (Fauci, 2001). 
The AIDS pandemic is an example of a truly new and emerging infectious disease 
whose public health impact had not been previously experienced.  Although significant 
efforts have been accomplished in trying to reduce the incidence of Human 
Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS), such as 
through antiviral therapy, the incidence of this sexually transmitted infection continues to 
increase in the U.S. and developing countries. 
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Sexually transmitted infections.  Sexually transmitted infections have been in 
existence for thousands of years, with the earliest records dating back 5,000 years 
(Handsfield, 1997) and were commonly known as venereal diseases (VD).  In Latin 
terms, “veneris” translates into “Venus” – the Roman goddess of love.  The term sexually 
transmitted disease was created approximately 90 years ago by physician Sir William 
Osler who recognized the need to have a specialist who understood everything about 
STIs (Royal Commission on Venereal Diseases, 1916).  However, the term venereal 
disease was the commonly used term until the 1990s when public health officials 
introduced the new term of sexually transmitted disease to increase the public’s 
understanding of how these diseases were spread and contracted (McCormack, 2000). 
Venereal diseases were defined as those transmitted by sexual intercourse 
(ASHA, 2005).  Prior to the 1960s, syphilis and gonorrhea were the only major known 
venereal diseases (Waugh, 1990).  Although historical information on the exact origins of 
gonorrhea and syphilis is limited, the literature contains some estimates on when and how 
these diseases were recognized. 
Gonorrhea is one of the oldest known venereal diseases and is referred to in the 
literature as one of the first recorded diseases in history.  In the Dark Ages, the term 
“Clap” for gonorrhea first materialized in 1378 in La Clapier district in France, where all 
the prostitutes gathered.  The main medical symptoms of gonorrhea were illustrated in the 
Old Testament and also by the ancient people of China, Egypt, Rome and Greece 
(Edwards & Apicella, 2004).   The Book of Leviticus, included in the Old Testament 
contained a description of gonorrhea in a man with urethral discharge.  In the fourth and 
fifth centuries, the physician, Hippocrates, referred to acute gonorrhea as “strangury.”  
 41
Hippocrates also believed that this infection stemmed from the pleasures of Venus, 
demonstrating that the Greeks knew the cause of the disease (Sparling, 1999).  It was not 
until 130 A.D. that a famous Greek physician, Galen, introduced the term gonorrhea 
when he mistakenly confused the discharge associated gonococcal urethritis with semen, 
and referred to it as the “flow of seed.”  In 1879, Dr. Albert Neisser, a German physician 
who specialized in dermatology and venereal diseases, discovered the small bacterium 
gonococcus as the second identified bacterial pathogen, and named it Neisseria 
gonorrheae.  He accomplished this discovery with stained smears of urethral, vaginal, 
and conjunctival fluids (Haines et al., 1988; Sparling, 1999).  The most notable account 
of gonorrhea is in the personal diary of James Boswell, the famous biographer of Samuel 
Johnson.  Boswell describes his bouts with 19 different gonorrheal infections that 
ultimately led to his death.  He also describes his concerns over the asymptomatic 
characteristic of the disease for women and how that might have resulted in several of his 
wife’s miscarriages (Ober, 1970).  The discovery and applications of sulfonamide 
therapy, discovered by German scientist Gerhard Domagk in 1936 and penicillin 
antibiotic therapy, discovered by Scottish scientist Sir Alexander Fleming in 1943, led to 
a rapid decrease in gonorrhea prevalence (Hook & Handsfield, 1999; Sparling, 1999).  
This trend reversed, in the early 1960s, with the onset of oral contraceptive methods, and 
N. gonorrhoeae infections reached a peak incidence of over one million reported cases in 
1978 in the United States.  The incidence of gonococcal infection again declined in the 
late 1980s, with the onset of the HIV epidemic and a coincident widespread use of barrier 
contraceptives, (Handsfield, 1990; Knapp & Rice, 1995). 
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Syphilis is also one of the first recorded diseases in history, but debates about its 
origins have continued for nearly 500 years.  There are two conflicting theories about the 
origins of syphilis, also referred to as the “pox.”  The Americanist theory is that the 
sailors of the Christopher Columbus expedition were infected with syphilis by the natives 
in the U.S. and in 1493, brought the disease with them when they returned from the New 
World to Spain.  The Europeanist theory is that syphilis was endemic in Europe 
throughout the middle ages and became a pandemic at the end of the fifteenth century.  
Another possible explanation is that syphilis was always present in Europe but was not 
identified as a separate disease from leprosy before A.D. 1500.  Ancient and medieval 
sources have long been cited as evidence for syphilis in Europe before Columbus, but 
none of the descriptions by the Greek and Roman authors are specific enough to be 
certain (Rose, 1997).  The earliest signs of syphilis date back to nearly 2,000 years ago 
from skeletal remains found in the western region of the United States, providing more 
supportive evidence for the Americanist versus the Europeanist theory (Rothschild, 
2005). 
The term syphilis was rarely used in its current meaning (Porter, 1999) and was 
often referred to as an indeterminate range of conditions until the late nineteenth century, 
and until that time was often confused with gonorrhea.  Between 1500 and 1800, the 
medical world was divided on the pathology of these two venereal diseases (Waugh, 
1990).  The first unambiguous descriptions of syphilis started at the beginning of the 
fifteenth century, and these descriptions included the specific bacterium associated with 
the disease, called Treponema pallidum, and that the disease was transmitted by direct 
skin-to-skin contact or by sharing drinking cups (Rose, 1997).  Despite conflicting ideas 
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about its origin, its passage was well described as a new epidemic pox arriving in Italy in 
1495, following Charles VIII’s campaign against the Spaniards for the control of Naples. 
The Italians called it ‘the French sickness’; and the French called it ‘the Neapolitan 
sickness’.  Although each nation identified it as a disease of their enemy, syphilis was 
most commonly referred to as morbus gallicus (Quetel, 1990), and believed to be due to a 
new contagion that spread venereally, and called the French disease (Arrizabalaga, 1993). 
The morbus gallicus spread throughout Europe as the mercenary army composed of men 
from Belgium, Germany, France, Italy and Spain disbanded and returned to their 
homelands. Within a decade of the first outbreak, epidemic syphilis had spread 
throughout Europe. Girolamo Fracastoro, an Italian physician and poet who was also 
infected with the disease, first called the disease syphilis in 1530.  Syphilis was 
distributed among the upper and lower rungs of society, and had reached its peak in the 
sixteenth century (Rose, 1997). 
Prior to the invention of modern medicines, venereal diseases were generally 
incurable, and treatment was limited to treating the symptoms of the disease (Porter, 
1999).  In Europe, the first venereal disease clinic opened on January 31, 1747 at London 
Dock Hospital.  The history of sexually transmitted infections recorded in the U.S. is 
fairly recent, and in 1778, a Congressional order imposed fines on any officer or enlisted 
man who was admitted to a hospital with a venereal disease (Moore, 1941).  This order 
increased stigmatization and adversely affected the regulation of these diseases over the 
next 150 years (Waugh, 1990).  Data on venereal disease in the army go back to 1820, 
but no special measures for venereal disease control were undertaken. In the nineteenth 
century, the combination of prostitution and venereal disease was an enormous problem, 
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especially in New York, and it was estimated that 1 in 20 of the U.S. population was 
infected with syphilis (Waugh, 1990).  In 1873, the first permanent venereal disease 
clinic was opened at the Boston Dispensary.  As early as 1876, the American Medical 
Association considered extending public health techniques to the treatment of venereal 
disease and J. Marion Sims, as president of AMA stated that, “Each new case of syphilis 
or gonorrhea represents a failure of both public health and society” (Amstey, 1994, p. 17; 
Vonderlehr & Hiller, 1946).  In the early 1900s, Prince A. Morrow, a prominent New 
York physician and also known as the “Father of Social Hygiene” brought the problem of 
venereal disease into full public view, and as a result, several local groups and societies 
formed in major U.S. cities to address sex hygiene.  Two of these groups merged into the 
American Social Hygiene Association, now known as the American Social Health 
Association (ASHA).  These groups shared an optimistic outlook and were committed to 
fighting an undesirable social condition that they believed could be improved through 
medical and educational means (ASHA, 1999).  Major breakthroughs and treatments 
appeared to contribute to this optimism, particularly the discovery of Arsphenamine, 
referred to by the trade name Salvarsan.  Salvarsan was discovered by German scientist 
Paul Erhlich and Japanese scientist Sahachiro Hata in 1910 and was an effective 
treatment for syphilis (Izumi & Isozumi, 2001). 
Recorded data show that syphilis peaked in the U.S. in the decade following 1910, 
and then again in 1947 at 76 cases per 100,000, and then fell to a low of about 4 per 
100,000 in 1955-58 (Aral & Holmes, 1990). Analysis of surveillance data on cases of 
syphilis and congenital syphilis reported by state and city health departments to the 
Centers for Disease Control and Prevention has shown that historically, syphilis was 
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distributed widely throughout the country and declined rapidly after the introduction of 
penicillin therapy and broad-based public health programs, attaining its lowest levels in 
the 1950s (Nakashima, Rolfs, Flock, Kilmarx, & Greenspan, 1996).  The trend reversed 
in 1959, and syphilis levels rose to 12 per 100,000 in 1965, and the incidence of primary 
and secondary (P&S) syphilis remained static until 1980. 
As stated previously, syphilis and gonorrhea were the first major STIs known 
before the 1960s, and although some early trend data are included, it should be noted that 
gaps exist in this data due to lack of funding for surveillance.  Following the AMA’s 
extension of public health control techniques, including reporting and tracking of 
venereal diseases, certain states extended its contagious disease reporting to include 
venereal disease.  After World War I, Congress cut funding for venereal disease services 
in 1920, and by 1922, Congress discontinued appropriations for state diagnosis and 
treatment clinics, assuming that venereal disease was no longer a problem.  With the 
onset of the Great Depression, funding dropped further, resulting in venereal disease 
cases being underreported and inaccurate estimates for disease incidence and prevalence 
(Parran, 1937).  To reduce ignorance, and thereby, decrease the risk of venereal infection, 
the U.S. government just before and after World War II encouraged publicity on the 
matter, for the taboo long associated with public discussion of these contagious diseases 
had given rise to serious public-health problems. A nationwide campaign was initiated in 
1937 by Thomas Parran, then serving as U.S. Surgeon General, to educate the public 
about the incidence, cause, and cure of venereal diseases. As a result, the number of new 
cases in the United States steadily declined each year until the 1950s, when a rise was 
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noted, especially among teenagers and young adults (Jones, Shainberg, & Byer, 1974; 
Rosebury, 1971). 
Additional venereal diseases were discovered after the 1960s and due to the 
coordinated effort by the Communicable Disease Center, now known as the Centers for 
Disease Control and Prevention, and their expertise in disease surveillance, with the 
assistance of local and state health departments (CDC, 1996), more reliable trend data are 
available for reportable STIs.  The 1980s brought additional challenges, as incurable, 
viral STIs became prevalent, such as genital herpes and HIV.  In addition, more 
information about the complications on women’s reproductive health was being 
discovered.  In 1992, pelvic inflammatory disease (PID) was recognized, along with it 
being a cause of infertility among women in the United States, and, in 1996, HPV was 
recognized as the primary cause of cervical cancer (McCormack, 2000).  In 1998, 
concerned by high U.S. rates of such common STIs as HPV, genital herpes, and 
chlamydia, as well as local outbreaks of syphilis and gonorrhea, the Centers for Disease 
Control and Prevention began a new far-reaching campaign to combat STIs (Stolberg, 
1998). 
More than 25 pathogens are spread primarily through sexual activity, and 
although there is a smaller group that is more prevalent than others (Table 1), they pose a 
significant public health challenge.  More is known about the frequency and trends of 
some of these STIs than others, because many of the diseases are difficult to track (CDC, 
2001). 
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Table 1 
Major STI Pathogens 
Pathogen Disease Name or  
Associated Condition  
Type of Infection 
Neisseria gonorrhoeae Gonorrhea Bacterial 
Treponema pallidum Syphilis Bacterial 
Chlamydia trachomatis Chlamydia Bacterial 
Haemophilus ducreyi Chancroid Bacterial 
Klebsiella granulomatis Granuloma inguinale or 
donovanosis 
Bacterial 
 
Herpes simplex virus Genital herpes Viral 
Human papilloma virus Genital warts Viral 
Hepatitis B virus  Viral 
Cytomegalovirus  Viral 
Trichonomas vaginalis Vaginitis Parasitic 
Candida albicans Yeast infection in women 
and inflammation of the 
glans penis and foreskin in 
men 
Parasitic 
 
Adapted from the Joint United Nations Programme on HIV/AIDS (UNAIDS). (May 
1998).  The public health approach to STD control:  UNAIDS Technical Update. 
  
The Centers for Disease Control and Prevention (2004) estimate that 19 million 
new infections occur each year, with almost half of them being among young people, 
ages 15 to 24 (Weinstock, Berman, & Cates, 2004).  Only three out of numerous STIs 
that affect adolescents and young people are reportable – chlamydia, gonorrhea, and 
syphilis – and they have been useful for examining overall trends among these high-risk 
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populations.  However, the data on these populations represents only a small proportion 
of the true burden of STIs in the U.S.  Many cases of the notifiable STIs are not 
diagnosed because of being asymptomatic or not treated, and some highly prevalent viral 
infections that are not curable, such as genital herpes and HPV, are not reported at all 
(CDC, 2004).  Neither HPV infection nor genital warts are routinely reported to the state 
health departments for the following reasons: 1) No justification exists for recommending 
STI case reporting – even though numerous epidemiological studies have demonstrated 
that HPV is the most prevalent of all the sexually transmitted infections; 2) most HPV 
and genital herpes infections clear spontaneously, and 3) case reporting would create a 
large burden for providers, health departments and laboratories due to the high 
prevalence of HPV infection (CDC, 1999). 
Epidemiology, Detection, and Natural History of HPV 
Epidemiology of HPV.  Data on HPV prevalence and incidence is limited 
because it is not a reportable STI.  Because of HPV being non-reportable, the scope and 
magnitude of genital HPV infection is derived from extrapolations of epidemiological 
studies.  Those studies that detect HPV DNA measure current infection, and studies that 
detect HPV antibodies using blood tests provide approximation of lifetime infection 
(CDC, 2004).  The HPV trend data that are available demonstrate that HPV prevalence 
has increased at an alarming rate, as millions of people have been diagnosed with the 
virus over the past two decades (Hager et. al, 2004).  Based on the available data and 
comparison with other STI infections, HPV is reported as the most prevalent of all viral 
sexually transmitted infections, more common than herpes and HIV combined, and HPV 
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has been referred to as the most common STI among young, sexually active people 
(CDC, 2001). 
Overall, in the U.S., an estimated 20 million people, or 15% of the population, are 
currently infected with HPV, and 50% to 75% have the high-risk type of HPV, or the 
type of HPV that can potentially cause cancer.  The most recent incidence rate reported is 
that approximately 6.2 million people are infected with HPV each year (Weinstock & 
Cates, 2004).  It is important to note, however, that the annual HPV infection rates are 
likely to be higher than 6.2 million people, because this figure is from 2000.  The data 
from the CDC STD –Surveillance 2008 report indicates that the overall STI infection has 
risen to 19 million in 2008 from 15 million in 2000.  Because almost half of the 19 
million new infections occur among sexually active youth, ages 15 to 24, and HPV is 
reported as the most prevalent STI among this age group, the annual HPV infection rate 
may currently be higher than 6.2 million people. 
The DNA HPV virus causes infection among both sexually active men and 
women, although it is most common among adolescent and young adult women (Hager et 
al., 2004).  It has been estimated that at least 50% of sexually active men and women 
acquire genital HPV infection at some point in their lives, and 80% of women will have 
acquired genital HPV by age 50 (Koutsky et al., 1988; Myers, McCrory, Nanda, Bastian, 
& Matchar, 2000). 
Prevalence studies in the U.S. have included primarily convenience samples of 
women attending managed care, STI, or university clinics.  These studies have found that 
the prevalence of HPV infection is lowest in women who have never had sexual 
intercourse (Fairly et al., 1992; Koutsky & Kiviat, 1999; Rylander, Ruusuvaara, 
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Almstromer, Evander, & Wadell, 1994; Winer et al., 2003), and is especially common 
among sexually active women, less than 25 years of age, with prevalence decreasing with 
increased age (Baken et al., 1995; Bauer et al., 1993; Bauer et al., 1991; Burk et al., 1996; 
Giuliano et al., 2002; Ho, Bierman, Beardsley, Chang, & Burk, 1998; Ley et al., 1991; 
Peyton et al., 2001; Wheeler et al., 1993). 
Detection of HPV.  Human papillomaviruses are members of the 
Papillomaviridae family of DNA viruses.  Because HPV cannot be cultured easily in the 
laboratory, HPV infection is most commonly diagnosed by detecting abnormal cells in 
the cervix by a Pap test and detecting HPV DNA via a sampling of the cervical cells 
(CDC, 2004).  Blood tests that detect the antibodies to the outer protein of the DNA have 
been useful in detecting previous HPV infection (Stone et al., 2002).  However, an HPV 
DNA test is now available that can analyze biopsies and cells from a liquid- based Pap by 
nucleic acid hybridization to detect the presence of high-risk types of DNA (Digene 
Corporation, 2004).  There can be false negatives with the Pap test, as it has been shown 
to be 50% to 80% accurate in identifying women with cancer and cervical disease.  A 
study by Leyden, et al. (2005) revealed that one-third of all cervical cancers occurred due 
to Pap test failure.  Therefore, the ability to detect women at high risk of cervical cancer 
is greater when the HPV test is used in conjunction with the Pap test, than using the Pap 
test alone. 
Some researchers and clinicians have expressed concern that increased public 
awareness of the link between HPV and cervical for screening cancer could lead to 
stigmatization of cervical cancer, resulting in women’s reluctance to be screened because 
the virus is sexually transmitted (Waller, Marlow, & Wardle, 2007).  This idea is 
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consistent with findings from studies on other STI screening, such as chlamydia, 
gonorrhea and HIV (Duncan, Hart, Scoular, & Bigrigg, 2001; Fortenberry et al., 2002).  
Some qualitative studies assessing reaction to HPV testing have had similar results, as 
women testing positive for HPV in the context of cervical screening report feelings of 
stigma and shame, but only when they are aware that the virus is sexually transmitted. 
Studies have also demonstrated that higher anxiety is associated with a HPV diagnosis 
compared to an abnormal Pap test result.  However, a recent study demonstrated that 
increasing awareness about the sexually transmitted nature of HPV among young women 
may reduce stigma, shame and anxiety associated with HPV diagnosis, perhaps by 
increasing the normalization and social acceptability about the infection (Waller et al., 
2007). 
The prevalence of genital HPV infection in men is more difficult to assess 
because it is not clear which are the optimal anatomic sites or specimens to test.  Most 
published studies have been conducted outside the U.S., in men attending STI or 
university clinics, or among male partners of women with HPV infection, and have 
demonstrated that HPV DNA in men can be detected in the penis, urethra, scrotum or 
anus as well as in urine and semen (Baldwin et al., 2003; Aynaud, Poveda, Huynh, 
Guillemotonia, & Barrasso, 2002; Svare et al., 2002). 
Differences in DNA sequences are used to determine different types, and more 
than 100 types of HPV DNA sequences have been identified.  Over 30 HPV sequences 
identified can infect the genital area.  Although the majority of genital HPV infections 
cause no symptoms and may go away on their own, some HPV types can cause cervical 
cancer in women (CDC, 2004). 
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Natural history and progression of HPV.  Adolescent and young adult women 
are biologically more susceptible to HPV disease because the cervix has not yet reached 
its maturity, and the cells of the cervix are more susceptible to bacterial and viral 
infection with STI pathogens, such as chlamydia, gonorrhea, and HPV.  Sometimes the 
cells on the immature cervix can form into pre-cancerous cells, also called cervical 
dysplasia, and cervical dysplasia can evolve to cervical cancer (Joffe et al., 1992). 
Most HPV infections are transient and asymptomatic, causing no clinical 
problems.  For most adolescents, HPV infection is cleared by the immune system (Hillard 
& Kahn, 2005).  Studies have shown that 70% of new HPV infections clear within one 
year and as many as 91% clear within two years (Molano et al., 2003; Franco et al., 1999; 
Ho et al., 1998).  Some types of HPV may cause warts to appear on or around the genitals 
and anus.  Genital warts, technically known as condylomata acuminata, are most 
commonly associated with two HPV types, HPV-6 and HPV-11 (NCI, 2004).  Only about 
10% of patients infected with HPV have genital warts, and the incubation period between 
HPV infection and genital warts ranges from 30 days to 9 months and once a person is 
infected, the virus persists for an average of 8 months, with a range of 3 to 15 months (Ho 
et al., 1998). 
Some types of HPVs are referred to as “low-risk” viruses because they rarely 
develop into cancer, and those HPVs that are referred to as “high-risk” are more likely to 
develop into cancer.  Both high-risk and low-risk types of HPVs can cause abnormal cell 
growth, but generally only the high-risk HPV types will lead to cervical cancer.  
Approximately 18 high-risk types have been identified that potentially can cause cancer 
but most of these disappear and do not evolve into cancer.  However, there are two high-
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risk types that are most likely to persist than others, HPV-16 and HPV-18.  These high-
risk types are responsible for more than 70% of all cervical dysplasia and cancer 
(Clifford, Smith, Plummer, Munoz, & Franceschi, 2003; Handsfield, 1990; NCI, 2004). 
HPV and Cervical Cancer 
Since the late 1800s, researchers have suspected that cervical cancer was sexually 
transmitted as medical records from this time noted that nuns and virgins were not likely 
to have cervical cancer.  Also, wives of men who traveled often, or who were previously 
married to women who died of cervical cancer, were more likely to develop cervical 
cancer (Cockerell, 1995).  At the present time, certain types of HPV have been 
established as causal agents in the development of cellular changes that can evolve into 
cervical cancer (Janicek & Averette, 2001).  Persistent infection with HPV is the leading 
cause of cervical cancer, and progression from HPV into cervical cancer is estimated to 
take 10 to 15 years (NCI, 2005). The mechanism through which HPV causes cancer is 
related to specific parts of the virus’s genetic structure called oncogenes.  The genetic 
mechanisms of cervical cancer are still unknown as there are opposing scientific views as 
to whether there is a gene associated with susceptibility to HPV-associated cervical 
cancer (de Araujo Souza & Villa, 2003).  Studies have demonstrated that HPV itself 
causes a change in the cell’s genetic structure that can cause abnormal cell growth and 
cancer (O’Brien et al., 2001; Goodwin & DiMaio, 2001).  HPV has two oncogenes – E6 
and E7 - that can interfere with normal cell function, cause abnormal cell growth, and can 
prevent the repair of damaged cells. The action of these oncogenes can cause 
precancerous changes in cervical cells, called dysplasia, or even more serious, squamous 
cancer cells of the cervix, also referred to as cervical cancer.  This same process also can 
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damage and transform cells of the vulva and anus of females, and cells of the penis and 
anus in males (Hager et al., 2004). 
 Based on numerous studies, the International Agency for Research on Cancer and 
the U.S. National Institutes of Health (NIH) have concluded that high-risk genital HPV 
infections act as carcinogens in the development of cervical cancer (NIH, 1996; WHO, 
1995).  Therefore, while infection with the high-risk types of HPV appears to be 
necessary for the development of cervical cancer, it is not sufficient because the majority 
of women infected with HPV do not develop cervical cancer (NIH, 1996; WHO, 1995).  
Other co-factors appear to be necessary for HPV to evolve into cervical cancer, such as 
smoking, long-term use of hormonal contraceptives, immune suppression, low vitamin 
intake or absorption, and co-infection with other STIs such as chlamydia, HIV, syphilis, 
cytomegalovirus, herpes simplex virus type-2, and, possibly, regular exposure to 
secondhand smoke (Castellsague, Bosch, & Munoz, 2002; Castellsague & Munoz, 2003; 
Castle et al., 2003; Gunnell et al., 2006; Harris et al., 2004; Hildesheim et al., 2001; 
Munoz, 2000; Munoz & Bosch, 1989; Sedjo et al., 2003; Smith et al., 2002; Trimble et 
al., 2005). 
Several decades ago, cervical cancer was one of the most common and deadly 
cancers in women in the U.S. (Eddy, 1990).  Since the middle of the 20th century, cervical 
cancer mortality has decreased by over 70% in the U.S. because of cervical cancer 
screening through the use of the Pap test (Kahn & Hillard, 2005).  However, cervical 
cancer is the third most common cancer worldwide, as nearly 500,000 new cases are 
identified each year, with 80% of cases being identified in developing countries (Ferlay, 
Bray, Pisani, & Parkin, 2004).  Cervical cancer remains a leading cause of death among 
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women in some developing countries where there is a high incidence of cervical cancer, 
such as Latin America, the Caribbean, Sub-Saharan Africa, South Asia, and where access 
to cervical cancer screening is limited (Danaei et al., 2005; Katz & Wright, 2006; Pisani, 
Parkin, Bray, & Ferlay, 1999).  In the United States, high cervical cancer mortality has 
been found among African-Americans in the South, Latinos along the Texas-Mexico 
border and Caucasians in Appalachia, most likely due to poor access to health care and 
Pap screening (Freeman & Wingrove, 2005). 
The purpose of the Pap test is to detect abnormal changes in cervical cells, so that 
the cells can be treated, preventing the progression of abnormal cells into cervical cancer.  
In addition, the Pap test can be used to detect cervical cancer at a very early stage (Myers, 
McCrory, Nanda, Bastian, & Matchar, 2000).  Survival rates for cervical cancer are high 
if the disease is detected early and managed promptly (American Cancer Society, 2003).  
The Pap test is often included in the standard gynecological exam but the optimal age to 
begin Pap screening is unknown.  Data on the natural history of HPV infection and the 
incidence of high grade lesions and cervical cancer suggest that screening can be safely 
delayed until three years after a woman has become sexually active or by age 21, 
whichever comes first (Smith et al., 2002).  How often a woman should receive a Pap test 
depends upon multiple factors, such as age, results of past Pap tests, medical history, 
history of STIs, and whether or not she is a smoker (U.S. Food and Drug Administration, 
2005).  The American College of Obstetricians and Gynecologists recommend that 
women under the age of 30 receive annual Pap tests (USDHHS, 2005).  The U.S. 
Preventive Services Task Force guidelines recommend that women have a Pap test at 
least once every three years, beginning about three years after they begin to have sexual 
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intercourse, but no later than age 21 (NCI, 2005).  Experts recommend waiting 
approximately three years following the first sexual encounter because most HPV 
infections and cervical cell changes are transient and it takes a few years for any 
significant cell abnormalities to develop.  In addition, cervical cancer is rare in women 
under the age of 25.  Therefore, having a first Pap by the age of 21 should help detect 
cervical cell changes at early stages (NCI, 2003). 
Because of the Pap test, cervical cancer has become relatively uncommon among 
women in the U.S. because the Pap test can detect precancerous cells in the cervix before 
they develop into cancer.  However, cervical cancer has a major global impact on 
women’s health.  Nearly 500,000 new cases of cervical cancer occur each year among 
women, and 274,000 of women die of this disease annually.  Over 80% of cervical cancer 
cases occur in developing countries (Parkin, Bray, Ferlay, & Pisani, 2005).  Cervical 
cancer is the most common cause of cancer in developing countries and the leading cause 
of cancer death among women in developing countries, especially in the poorest regions, 
where cervical cancer screening is not available or limited (Danaei et al., 2005; WHO, 
2004).   Regions with the highest incidence of cervical cancer include Central and South 
America, the Caribbean, sub-Saharan Africa, and Asia (Parkin, et al., 2005). 
 Although cervical cancer is not as common in the U.S. as it was 40 or more years 
ago, the disease remains a serious health threat among women.  All women are at risk for 
cervical cancer, and it is most often diagnosed in women aged 30 and older (CDC, 2008). 
Approximately 12,200 women develop cervical cancer each year in the U.S., and 
approximately 4,100 women die from cervical cancer each year (American Cancer 
Society, 2003).  Approximately half of these cases will occur among women who have 
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never been screened, and an additional 10% will occur in women who have not been 
screened in the past five years (National Institutes of Heatlh, 1996).  It is estimated that 
approximately 1.7 billion dollars each year is spent annually on cervical cancer treatment 
in the U.S. (Brown, Riley, Schussler, & Etzioni, 2002). 
Recent trends show that the cervical cancer incidence rates for Hispanic women 
are higher than for non-Hispanic women. Furthermore, the cervical cancer death rate 
among African-Americans continues to be twice as high as that among Caucasian women 
(NCI, 2005).  In addition, both screening and treatment procedures are costly.  A recent 
National Health Interview Survey (2000) indicated that cervical cancer screening is not 
adequate among some women in the U.S., as approximately 18% of women of 
reproductive age have not had a Pap test in the last three years (Swan, Breen, Coates, 
Rimer, & Lee, 2003).  The higher cervical cancer rates among these ethnic populations 
demonstrate that racial and ethnic health disparities remain a challenge in cervical cancer 
screening.  In addition to racial and ethnic issues, additional challenges exist in cervical 
cancer prevention, such as the high cost of screening and treatment procedures, abnormal 
results of a Pap test may lead to psychological distress, and treatment procedures may be 
painful and associated with long-term health consequences.  The availability of a vaccine 
for primary prevention of the high-risk types of HPV associated with cervical cancer may 
help to remove some of the limitations that are currently involved with cervical cancer 
screening and treatment (Hillard & Kahn, 2005). 
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Transmission and Prevention of HPV 
Transmission of HPV.  HPV is transmitted by skin-to-skin contact, as the virus 
requires access to superficial skin cell layers or basal cells.  HPV can infect basal cells 
through micro-abrasions or small tears in the superficial or mucosal layers of the skin that 
are often produced by sexual activity (Schiffman & Kjaer, 2003).  In rare cases, HPV also 
can be transmitted from a mother to her newborn baby during vaginal delivery, and this 
process can result in recurrent respiratory papillomatosis (RRP) that can be fatal if the 
papillomas or small growths block the airway  (Moscicki, 2005; Recurrent Respiratory 
Papillomatosis Foundation, 2005).  In addition, unexplained and rare cases of HPV have 
been reported in newborns delivered by cesarean section (Smith et al., 2004).  Finally, 
casual contact or sexual abuse may produce genital warts in children (Kahn, 2005). 
Genital HPV infection occurs primarily as a consequence of genital contact, 
mostly through sexual intercourse (Koutsky & Kiviat, 1999; Schiffman & Kjaer, 2003).  
HPV infection has been reported among women who have had sex with women and who 
have never had sexual intercourse with men, and among women who had genital contact 
but not sexual intercourse with men (Marrazzo, Koutsky, Kiviat, Kuypers, & Stine, 2001; 
Winer et al., 2003).  Therefore, HPV can be transmitted through other types of genital 
contact, such as skin-to-skin contact during finger and genital foreplay that does not 
include intercourse, oral-genital contact and through the use of sex toys (Moscicki, 2005; 
Winer et al., 2003).  In rare cases, individuals who have oral-genital sex with other 
persons infected with HPV may also be at risk of developing RRP (Kashima, Mounts, & 
Shah, 1996; Clarke, Terry, & Lacey, 1991). 
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Alternative routes of HPV transmission are less common than the route of sexual 
intercourse (Coutlee et al., 1997; Marrazzo, Stine, & Koutsky, 2000).  Adolescents or 
young adults who abstain from sexual intercourse, but not other forms of sexual activity, 
remain at risk, and those persons who use condoms to protect themselves from STIs and 
pregnancy during sexual intercourse are still at risk of acquiring HPV at infected skin 
sites not covered by a condom (Winer et al., 2003). 
The most consistent predictor of HPV infection has been the total number of sex 
partners (Ho, Bierman, Beardsley, Chang, & Burk, 1998; Karlsson et al., 1995; Koutsky, 
1997; Moscicki et al., 2001).  Among women, the risk of contracting HPV infections 
increases with an increased number of lifetime sex partners.  In addition, having sex with 
a new partner may place a person at higher risk than having sex with a steady partner 
(Castle et al., 2002; Karlsson et al., 1995; Ley et al., 1991; Peyton et al., 2001).   
Furthermore, a woman’s risk of HPV infection is impacted by the sexual activity of her 
partner.  Studies have shown that female adolescents and young women with partners 
who had previous multiple sex partners and with an unknown number of prior sex 
partners had a significantly greater risk of contracting HPV compared to those females 
who had male partners with no prior sex partners (Winer et al, 2003; Moscicki et al., 
2001).  Infection with HPV among women may be controlled by factors other than 
having sex with an infected partner.  The likelihood that an uninfected person woman 
will become infected with HPV may be influenced by age and immunity.  The risk of 
HPV infection decreases with increased age, and this may be due to older women 
developing an acquired immunity to HPV from previous exposure (Burk et al., 1996; 
Centers for Disease Control and Prevention, 2004; Moscicki, 2005).  However, it is 
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difficult to determine when a woman is more susceptible to being infected with HPV 
based upon whether her immune system will be able to combat the virus or if she has had 
past exposure to the virus.  The detectability of HPV DNA in a given individual varies 
over time.  Therefore, determining if a person is infected or if an infection is new or pre-
existing is an arduous task (Moscicki et al., 1998; Schneider, Kirchhoff, Meinhardt, & 
Gissmann, 1992).  Due to the asymptomatic and transient nature of the virus and the fact 
that it is difficult to confirm current or past infection with the virus at any given time, 
sexually active adolescents and young adults must take preventive measures to ensure as 
much protection as possible from becoming infected with HPV. 
Prevention of HPV.  The most effective method to prevent HPV transmission is 
to abstain from sexual activity that can result in direct contact with the virus.  However, 
this practice is not a realistic one for many adolescents and young adults, as most are, and 
continue to be, sexually active.  Therefore, adolescents and young adults need to be 
educated about HPV, the risks associated with HPV, and methods of protection. 
The most common approach to preventing HPV and other STIs is the use of 
physical barriers such as condoms.  Although condom use is often perceived by health 
care professionals as important in the control of HPV infections (Moscicki, 2005), recent 
reviews of studies involving the male latex condom in the prevention of STIs concluded 
there is no substantial evidence from epidemiological studies that demonstrates its 
effectiveness in preventing HPV infection.  However, some authorities view these studies 
as inadequate for drawing conclusions due to their methodological shortcomings 
(Manhart & Koutsky, 2002; NIAID, 2001). 
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Use of latex condoms during sexual intercourse may provide some protection in 
reducing HPV infection on some parts of the penis as studies have demonstrated that 
latex condoms provide an adequate barrier to molecules that are the size of HPV (Lytle, 
Duff, et al., 1997; Lytle, Routson, et al., 1997).  Some studies also suggest that condoms 
reduce the risk of outcomes of genital warts and cervical cancer.  Possible explanations 
for reducing these outcomes is that condoms reduce the quantity of HPV transmitted or 
decrease the likelihood of re-exposure , thereby decreasing persistent infection and the 
chance of the progression of the virus into genital warts or cervical cancer (CDC, 1999; 
Hogewoning et al., 2003; Manhart & Koutsky, 2002).  Another alternative explanation is 
that condom use may reduce the risk of an individual developing a co-factor, such as 
chlamydia or genital herpes, thereby reducing the risk of a high-risk type of HPV 
progressing into cervical cancer (Manhart & Koutsky, 2002).  However, correct and 
consistent use of condoms would not be expected to offer complete protection against 
HPV because infections also may occur at sites not covered by a condom, such as the 
scrotum, groin area, base of the penis, and anus (Change, Perry, Kurland, & Ilstrup, 1984; 
Hippelainen et al., 1993; Kennedy, Buntine, O’Connor, & Frazer, 1988; Krebs & 
Schneider, 1987; Schultz et al., 1990; van den Hoek, Coutinho, & Quin, 1994; Van 
Doornum et al., 1994; Weaver et al., 2004).  For women, HPV infection can occur on the 
outside of the vulva, an area that comes into contact with the genital skin of a man using 
a condom during intercourse.  In addition, HPV infection can be transmitted through 
finger-to-genital contact during foreplay and oral-genital contact during oral sex, further 
supporting the belief that condom use is not a completely effective method in preventing 
HPV.  Based on these studies, latex condoms would not be a good primary strategy for 
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preventing HPV, but, perhaps, could be used in combination with other methods of 
prevention. 
Practicing other safer sex behaviors, in addition to condom use, also may be 
effective in preventing HPV.  Engaging in safer sex behaviors is what individuals can do 
to lower their risk of developing HPV (Planned Parenthood Federation of America, 
2004).  Examples of safer sex behaviors include abstinence from sexual intercourse or 
any type of sexual activity that increases the risk of getting an STI.  Safer sex behaviors 
also can include communication, such as asking a partner to get tested for HPV before 
participating in sexual activity and communicating with partners about concerns about 
STIs.  Practicing intimate behaviors that are alternatives to sexual intercourse, such as 
kissing and massaging, are considered safer sex practices.  For individuals who are 
sexually active, staying in a monogamous relationship with a partner who has been tested 
and has not had any history of STIs can be considered practicing safer sex.  If a vaccine 
were available for a particular STI, being vaccinated against that STI also could be 
considered a protective behavior. 
 Topical microbicides have been proposed as agents to prevent transmission of 
certain STIs, including HPV.  These agents are thought to prevent HPV by inactivating 
the virus at the mucosal surface where infection can occur (Coutlee & Voyer, 1998; 
Howett & Kuhl, 2005).  Evaluation of the ability of microbicides to prevent genital HPV 
infection has been limited by the difficulties in cultivating HPV in vitro (CDC, 1999).  
Recent laboratory studies suggest that some compounds may inhibit HPV infection 
(Coutlee & Voyer, 1998; Christensen et al., 2001; Howett et al., 1999; Sokal & 
Hermonat, 1995).  Currently, over 60 microbicides are in clinical trials and over 40 are in 
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pre-clinical development, and some of these future microbicides may be effective in 
preventing HPV as well as other STIs (CDC, 2004; Howett & Kuhl, 2005). 
 In addition to certain preventive measures, treatment for genital warts and 
precursors to cervical cancer may reduce disease infectiousness.  Current treatment 
options for both genital warts and pre-cancerous cells include a variety of local 
procedures that remove high-grade and low-grade cervical lesions, such as cryotherapy, 
electrocautery, laser therapy, and surgical incision.  Genital warts also are treated with 
topical agents and immune stimulating drugs, such as Imiquimod (Beutner, Reitano, 
Richwald, & Wiley, 1998).  Although topical agents for genital warts and removal of 
cervical lesions do not cure the virus, they may lower its infectivity by reducing the 
amount of HPV DNA in the skin, although the impact that these agents have in reducing 
the virus remains unclear (Beutner et al., 1998; Bodner et al., 2002; Bollen et al., 1999; 
Costa et al., 2003; Elfgren, Jacobs, Walboomers, Meijer, & Dillner, 2002; Centers for 
Disease Control and Prevention, 2004; Jain, Tseng, Horng, Soong, & Pao, 2001; 
Kjellberg et al., 2000).  There is often a 10% to 20% recurrence rate of HPV-associated 
lesions following standard therapy (Mitchell et al., 1998; Wright, Cox, Massad, Twiggs, 
& Wilkinson, 2002) and 20% to 50% recurrence rate after treatment of genital warts 
(Beutner et al., 1998).  The area between normal skin and the cervical mucosal layer near 
HPV-associated lesion may create a reservoir that harbors HPV.  Such a reservoir may be 
the explanation for the recurrence of cervical lesions and genital warts (Colgan et al., 
1989; Ferenczy, Mitao, Nagai, Silverstein, & Crum, 1985).  In addition, treatment of 
partners of persons infected with HPV does not influence recurrence rates of genital 
warts or cervical lesions.  This lack of influence may be due to the persistence of HPV 
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infection in the skin and mucosal layer (Krebs & Helmkamp, 1991).  Therefore, current 
available therapies may reduce, but not eliminate, HPV infection, in the cases where HPV 
does not subside on its own. 
 Vaccination as an effective prevention strategy.  Vaccination is an essential 
component of modern public health programs and is among some of the most cost-
effective medical interventions.  Vaccines have been the most effective public health 
tools for preventing disease, disability and death and controlling health care costs (CDC, 
1999; Hilleman, 2000; WHO, 1999).  Prevention can save the health care industry 
billions of dollars in health care costs by eliminating physician visits, hospitalizations and 
treatments for diseases that are otherwise preventable, such as through vaccination.  
Vaccination can be an effective preventive strategy for reducing the incidence and 
prevalence of STIs.  Vaccines that protect against the most common and progressive 
HPV types are predicted to prevent thousands of cases of cervical cancer worldwide 
(Harper, 2004).  In addition, significant savings in health costs associated with treating 
HPV can result (Goldie et al., 2004; Kulasingam & Myers, 2003; Taira, Neukermans, & 
Sanders, 2004). 
Vaccines in development fall into two categories – prophylactic and therapeutic.  
Prophylactic vaccines are designed to prevent primary HPV infection by inducing a 
virus-neutralizing antibody that provides protection against infection with the virus.  The 
HPV vaccines developed by Merck & Co., Inc. and GlaxoSmithKline are referred to as 
prophylactic vaccines, as they are effective in preventing HPV infection and the 
progression of HPV into pre-cancerous cells.  Therapeutic vaccines are designed to 
prevent progression of HPV infection to low-grade or high-grade squamous 
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intraepithelial lesions that can lead to cervical cancer, to reduce cervical intraepithelial 
neoplasia or the amount of abnormal cells in the cervical lining, and to prevent the 
development of genital warts.  In addition to preventive characteristics, the design of 
therapeutic HPV vaccines enables them to treat cervical cancer, by eliminating residual 
malignant cells (Kahn, 2005, Marshall, 2003). 
The purpose of the HPV vaccine is to prevent infection with HPV-16 and HPV-
18, two high-risk types that cause over 70% of all cervical cancer cases, and to prevent 
infection with HPV-6 and HPV-11, two low-risk types that are primarily responsible for 
the development of genital warts.  Currently, there are two competing vaccines: 
GARDASIL® developed by Merck & Co., Inc., and Cervarix® developed by 
GlaxoSmithkline.  GARDASIL® is a quadrivalent vaccine that protects against HPV-16, 
18, 6 and 11; therefore, it protects against HPV types implicated in genital warts and 
cervical cancer.  Cervarix® is a bivalent vaccine that protects against HPV-16 and HPV-
18, and therefore, protects only against cervical cancer. 
Numerous clinical studies have demonstrated that the vaccines are effective in 
three different doses, with a low dose administered over a six-month time period, 
specifically at baseline, two months, and six months (Harper et al., 2004; Koutsky et al., 
2002; Mao et al., 2006; Villa et al., 2005; Reinis, 2004; Wheeler et al., 2005).  These 
clinical trials have demonstrated that the vaccine is nearly 100 percent effective in 
preventing HPV in girls and women between the ages of 9 and 26.  Due to high vaccine 
efficacy, the FDA approved the use of the GARDASIL® vaccine in pre-adolescents, 
adolescents and young women.  GARDASIL® or Cervarix® may also benefit women over 
the age of 26; however, it will depend on the duration of vaccine efficacy.  According to 
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Harper (2009), if the duration of vaccine efficacy is greater than 15 years, there may be 
health benefits and cost savings associated with the prevention of new HPV infections 
and cervical cancers in young women and women over 25 years of age.    A clinical trial 
by Shwarz (2006) has demonstrated that GlaxoSmithKline’s vaccine is effective in 
preventing HPV types 16 and 18 in adolescents and women ages 15 to 55, and Merck & 
Co., Inc. is awaiting approval from the FDA to expand the use of GARDASIL® in 
women, ages 27 to 45 (Merck & Co., Inc., 2008a)  
Overall, there are many positive outcomes associated with the HPV vaccines. 
Clinical trials suggest that the vaccines are capable of producing an immune response 
against specific types of HPV, are safe, well tolerated with minimal side effects, and 
prevent both HPV infection and cervical cancer.  One clinical trial demonstrated that 
GARDASIL® is also safe and effective when administered with the Hepatitis B vaccine – 
the only other STI vaccine in the U.S. (Merck & Co., Inc., 2006).  However, certain 
clinical outcomes remain in question, such as how long the vaccine is effective, 
expressed in duration of antibody response after vaccination, and impact of vaccination 
on cervical cancer screening and other health-related behaviors, including safer sex 
behaviors (Christensen, 2005; Schiller & Davies, 2004). 
Potential priority populations identified by pharmaceutical companies and 
immunization experts to receive the HPV vaccine have included children and 
adolescents, ages 11 to 15, young adult women, ages 18 to 25, and women over the age 
of 25 who have been diagnosed with an infection from HPV-16 or HPV-18 and need to 
protect themselves against cervical cancer (Kahn, 2005; Koutsky, 2005; Monteyne, 
2005).  In June 2006, FDA approved the use of GARDASIL® in girls and young women, 
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ages 9 to 26.  Before vaccine approval, it was unclear as to whether the vaccine would be 
promoted as an STI vaccine or a cervical cancer vaccine, and which approach would be 
more acceptable, not only to those included as priority populations, but to society in 
general.  Acceptance of the HPV vaccine among those prioritized for receiving the 
vaccine and those administering the vaccine, in addition to societal acceptance, are 
critical components for development and success of future HPV vaccination programs.  
Merck & Co., Inc. is marketing the vaccine as a cervical cancer rather than an STD/STI 
vaccine, and is providing GARDASIL® to the poor and uninsured (Associated Press, 
2006). 
Vaccine Therapy and Acceptance 
 At the beginning of the 20th century, the most serious threat to human life and 
well-being was infectious disease.  Outbreaks of diseases such as diphtheria and pertussis 
were common, and mortality was significant.  For example, 160 of every 1,000 children 
born at the beginning of the 20th century died of an infectious disease before the age of 
five years (Waldman & Kluge, 1984).  Today, parents in developed countries no longer 
fear these diseases due to vaccine availability. 
However, the development of vaccines has a history of provoking controversy.  In 
the late 1800s, Louis Pasteur’s administration of the first rabies vaccines to humans was 
strongly protested by physicians and the public, and efforts to immunize British troops 
against typhoid at the turn of the 20th century were bitterly opposed despite the 
encouraging results of earlier immunization efforts and the serious risk of typhoid faced 
by troops serving in the Boer War (Plotkin & Mortimer, 1994).  In the mid-1950s, 
vaccines were developed that were effective against diphtheria, pertussis, tetanus, 
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typhoid, rabies, and polio, and as vaccines came into more widespread use, the incidence 
of these diseases rapidly declined.  In addition, advances in vaccine technology brought 
substantial reductions in the incidence and severity of side effects associated with rabies 
and typhoid vaccines.  Especially after the availability of the Salk polio vaccine, the 
benefit to any vaccinated child was clear, and eliminating the possibility of contracting 
disease far outweighed the small risk of a serious adverse side effect.  As a result, public 
concerns about vaccines lessened and there was an increased acceptance of vaccination as 
a valuable safeguard of individual and public health (Ellenberg & Chen, 1997).  In the 
late 1970s and early 1980s, there was concern over the safety of the whole-cell pertussis, 
also referred to as “whooping cough”, vaccine (CDC, 1997).  A few parents who believed 
their children had been seriously injured as a result of vaccination brought their concerns 
to the public about adverse events in Japan and the United Kingdom. Such notoriety led 
to a decline in immunization rate, and pertussis, once again, became the cause of an 
epidemic (Kimura & Kuno-Sakai, 1990; Miller, Madge, Diamond, Wadsworth, & Ross, 
1993).  A similar increase in pertussis occurred in Sweden after the country discontinued 
the pertussis vaccination due to concerns over its efficacy and safety (Krantz, Taranger, 
& Trollfors, 1989).  Whereas public acceptance of the pertussis vaccine remained high in 
the United States, numerous lawsuits were filed against vaccine manufacturers (Hinman, 
1986).  This flurry of litigation resulted in major increases in prices and decisions by 
pharmaceutical companies to discontinue pertussis vaccines, thereby creating a temporary 
vaccine shortage (CDC, 1984; Mariner & Clark, 1986). 
In response to these events, significant steps were taken in the United States to 
assess and increase the safety of vaccinations, such as the passage of the National 
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Childhood Vaccine Injury Act (NCVIA) in 1986 that led to the development of the 
Vaccine Adverse Event Reporting System (VAERS) (Chen et al., 1994).  The VAERS, 
Vaccine Safety Datalink and Clinical Immunization Safety Assessment are three systems 
currently used to monitor the safety of vaccines after they are licensed and administered 
in the United States.  The safety of the HPV vaccine, GARDASIL®, has been closely 
monitored by these systems since its licensure in 2006 (CDC, 2008). 
In addition to the existence of vaccine safety surveillance programs, vaccines 
must go through extensive clinical testing before they are marketed.  However, unlike 
many other initiatives of the medical and pharmaceutical communities, vaccination 
programs primarily focus on children, and society is less willing to accept and impose 
unnecessary risks on healthy infants and children.  Therefore, vaccine developers must be 
particularly sensitive to the risks of adverse effects (Ellenberg & Chen, 1997). 
Although vaccines have proven to be effective in reducing the risk of diseases that 
have caused millions of deaths among certain populations and disabled many people, 
there is still controversy over their benefits (Ellenberg & Chen, 1997).  There has been an 
increasing concern, especially among parents, that the negative side effects of vaccines 
and vaccines that have prevented so much morbidity and mortality now cause more harm 
than is justified by the benefits they offer (Ellenberg & Chen, 1997).  As a result, 
increasing numbers of parents are refusing immunizations for their children.  A variety of 
factors are responsible for this concern:  religious and philosophical beliefs; freedom and 
individualism; mistrust of the government; misinformation and overperception about 
health risks associated with vaccines.  A major concern regarding negative vaccine side 
effects has been related to the preservatives in certain childhood vaccines and autism.  
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The internet exacerbates this fear regarding vaccine safety as numerous web sites publish 
unfounded, alarming information about the risks of vaccines (Calandrillo, 2004).  
However, studies haved found no definitive link between any of the childhood 
vaccinations and autism or autistic spectrum disorders (Fombonne & Chakrabarti, 2001; 
Halsey, Hyman, & Conference Writing Panel, 2000). 
There have been over 10,000 VAERS report of adverse events following 
GARDASIL®, and 94% of these reports are considered to be non-serious, and 6% of 
these reports are considered to be serious.  The most common non-serious side effects 
associated with GARDASIL® vaccination have included fainting, pain and swelling at the 
injection site, headache, nausea, and fever.  Based on all the information about the 
vaccine to-date, the CDC and FDA have determined that GARDASIL® is safe to use and 
effective in preventing four types of HPV.  However, as with all vaccines, the CDC and 
FDA will continue to  monitor the safety of the HPV vaccine (CDC, 2008). 
Although the HPV vaccine has proven to be safe with limited side effects (CDC, 
2008; Zahn, 2005), the vaccine poses another challenge for acceptance as it is a vaccine 
that has been designed to prevent STI infection, and therefore, vaccinating children 
before they become sexually active is a priority.  This vaccine, therefore, requires 
parental consent for children under the age of 18, and before the vaccine was approved, 
there was concern as to whether parents would accept a vaccine to prevent an STI that is 
administered to children.  There were questions as to whether health care providers, 
parents, and adolescents would be comfortable with administering an STI vaccine for an 
STI that is poorly understood by many adolescents and young women (Rosenthal, 2005; 
Zimet et al., 2000).  There have been questions as to whether most parents would be 
 71
willing to have their children vaccinated.  The research to-date on parental attitudes about 
HPV/STI vaccination has revealed that the majority of parents, across a variety of 
countries, are interested in protecting their children against HPV and other STIs, and 
would view an HPV vaccine beneficial for their adolescents.  Parent acceptability has 
been the best predictor of their adolescents’ attitudes about STI vaccines, a point 
suggesting that parents’ beliefs influence adolescent beliefs about STI prevention and 
vaccines.  Vaccine efficacy was the most important issue regarding vaccination against 
STIs, followed by severity of infection, availability of behavioral prevention, and sexual 
transmissibility (Zimet et al., 2005).  Concern about STI vaccination leading to unsafe 
sex was associated with lower acceptability, but the majority of parents recognized that 
the benefits of an HPV vaccine significantly outweigh the risks of becoming infected 
with HPV (Davis, Dickman, Ferris, & Dias, 2004; Dempsey, Zimet, Davis, & Koutsky, 
2006; Lazcano-Ponce et al., 2001; Olshen, Woods, Austin, Luskin, & Bauchner, 2005; 
Zimet, Mays, et al., 2005; Zimet et al., 2005).  Whereas studies have demonstrated that 
most parents accept STI vaccines, some do not perceive their children at risk for STIs, or 
express concerns that adolescents who are vaccinated may practice risky sexual behaviors 
(Zimet et al., 2005; Olshen et al., 2005; Mays et al., 2004).  Therefore, the high 
acceptance among parents may not necessarily mean that they would have their children 
vaccinated if it were offered by a pediatrician. 
Health care providers should anticipate that parents will have different degrees of 
comfort with vaccination, including those in complete opposition.  Complete opposition 
may come from those who are broadly anti-vaccine, as well as those who have specific 
concerns about STI vaccines and the belief that permitting their child to get an STI 
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vaccination also gives their child permission to be sexually active.  Themes emerging 
from some of these studies on parental acceptance of an HPV vaccine are consistent with 
past research reports that included the importance of pediatrician recommendations about 
vaccination, and that physicians had the strongest influence on parents’ decisions about 
vaccinating their children (Davis et al., 2004; Olshen et al., 2005).  Parents and caregivers 
will look to health care providers as an important source of information and for guidance 
in making decisions on whether or not to vaccinate their child and adolescent against 
HPV.  Therefore, the success of the HPV vaccination programs will depend on physician 
willingness and ability to recommend HPV vaccines to their patients (Zimet, 2005). 
There are few studies that have evaluated health care provider attitudes about STI 
vaccinations.  In one study, nurse acceptance of a vaccine to prevent mononucleosis, 
genital herpes, and HIV were highest for older adolescent patients and if the American 
Academy of Pediatrics endorsed the vaccine (Mays & Zimet, 2004).  The first national 
study of mothers’ attitudes and intentions to vaccine their daughters and themselves 
against HPV was conducted among mothers who were all nurses.  Mothers’ intention to 
vaccinate against HPV decreased with a daughter’s age, with the lowest intentions to 
vaccinate for a daughter less than 13 years old.  Forty-eight percent of these mothers also 
intended to vaccinate themselves, if it was clinically recommended (Kahn, et al., 2009). 
There have been two studies specifically assessing physician acceptance of an 
HPV vaccine.  Raley et al. (2004) found that obstetricians and gynecologists rated 
vaccine efficacy and ACOG approval as the most important factors influencing their 
decision to recommend vaccination, and physicians were reluctant to recommend 
vaccination for younger patients, such as 13-year-old girls or to recommend a vaccine 
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that only prevented warts.  Another study found that family physicians were significantly 
more willing to consider vaccination of older adolescent girls, such as ones ages 14 
through 17, versus girls, ages 11 and younger.  As in similar studies, endorsement by 
professional organizations, such as the American Academy of Family Physicians was 
viewed as important.  A majority of these family physicians also viewed vaccine safety 
and efficacy as important factors in their decision to recommend the vaccine.  These 
studies revealed that endorsement from professional associations and reluctance to 
vaccinate younger children, 13 years of age or younger, are common influential factors 
among pediatricians, OB/GYNs, and family physicians decision to recommend the 
administration of an HPV vaccine.  Although these studies demonstrate overall positive 
attitudes among physicians regarding the HPV vaccine, research has shown inconsistent 
utilization of another type of STI vaccine, the hepatitis B vaccine, by pediatricians (Rupp, 
Stanberry, & Rosenthal, 2004) and studies also have demonstrated the reluctance of 
health care providers to discuss sexuality with adolescent patients (Maheux, Haley, 
Rivard, & Gervais, 1995; Millstein, Igra, & Gans, 1996; Schuster, Bell, Petersen, & 
Kanouse, 1996; Siegel, Baker, Kotagal, & Balistreri, 1994; Torkko, Gershman, Crane, 
Hamman, & Baron, 2000).  These issues will need to be addressed in planning HPV 
vaccine educational and promotional campaigns. 
Primary care physicians also report challenges and barriers in educating their 
patients, including young adults about STI prevention (Ashton et al., 2002), and sub-
optimal communication between the high-risk young adult population, such as 
homosexual men and women, and their providers concerning protection from STIs, such 
as HIV (Elford, Bolding, Maquire, & Sherr, 2000).  Discussion of sexuality and 
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prevention of STIs, especially HPV, among young adults is also an important issue that 
needs to be addressed because HPV is highly prevalent among young adults, especially 
college students since they do not consider themselves at high risk of STIs yet often do 
not protect themselves from STIs during sexual activity.  Furthermore, many college 
students may have HPV and do not know it. 
A review of HPV studies by Revzina and DiClemente (2005) demonstrated that 
the highest prevalence of HPV was identified among women attending STD clinics and 
college students, identifying them as priority populations for HPV prevention 
interventions.  The college population would benefit from the HPV vaccine because it 
prevents both HPV and cervical cancer (Harper et al., 2004; Reinis, 2004).  Therefore, 
the vaccine may benefit older adolescents and young adults who are infected with HPV-
type 16 or 18 that has not yet evolved into pre-cancer.  Acceptance of the HPV vaccine is 
important among college students and other young adults because they have been 
identified as priority populations for the vaccine (Monteyne, 2005), and they do not need 
parental consent to acquire the vaccine. 
Although the majority of women have been poorly educated about HPV, research 
indicates that there is a desire for information about HPV infection, such as how the virus 
is transmitted and how they can prevent becoming infected (Anhang, Wright, Smock, & 
Goldie, 2004; Holcomb, Bailey, Crawford, & Ruffin, 2004).  Furthermore, despite the 
fact that women and adolescents have a limited understanding of HPV, there is interest in 
HPV vaccination among young women as well as adolescents (Boehner et al., 2003; 
Hoover et al., 2000; Kahn et al., 2003; Zimet et al., 2000), and both of these groups view 
vaccine efficacy and physician recommendation as important factors in their decision to 
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get vaccinated against HPV (Zimet et al., 2000).  Studies have found that most college 
students have a positive attitude about HPV vaccination, and that parental and partner 
acceptance are associated with positive attitudes (Boehner et al., 2003).  In the majority 
of vaccine acceptability studies among college students, individuals who consider 
themselves at higher risk, such as by having a higher number of sex partners, have a 
higher acceptance of the vaccine (Boehner et al., 2003; Kahn et al., 2003; Hoover et al., 
2000; Zimet et al., 2000).  In addition, Boehner et al. found that acceptance rates do not 
differ by sex or on the basis of whether the vaccine was described as a cervical cancer 
vaccine or as an STI vaccine.  One study also found that a vaccine that protected against 
genital warts was more acceptable among female college students compared to a cervical 
cancer vaccine (Hoover et al., 2000).  The authors of this study did not explain the 
rationale for why a genital warts vaccine would be more acceptable but one thought is 
that women would prefer it to reduce the embarrassment of the visibility of genital warts 
or any associated discomfort.  Further research is needed on sex differences in acceptance 
among young adults and college students and differences in acceptance for an STI versus 
a cervical cancer vaccine.  Furthermore, no studies have been conducted on college 
students’ willingness to practice other safer sex behaviors in addition to being vaccinated 
against HPV.  Given that HPV is an STI, potential barriers to acceptance may include the 
stigma associated with STIs and the possibility that acceptance of the vaccine may be 
viewed as an invitation to participate in risky sexual behavior (Zimet et al., 2000).  
Therefore, research is needed to determine if college students perceive being vaccinated 
against HPV as protection against other STIs. 
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Politics, Science, and HPV 
 The administration of a vaccine that protects against a sexually transmitted virus 
among children and adolescents has resulted in opposition from certain groups expressing 
concern over the possibility of making the vaccine mandatory, as the groups think it 
could send the message to the public, especially parents, condoning sexual activity before 
marriage (Stein, 2005). 
The CDC added GARDASIL® to the Vaccines for Children Program (VFC) 
contract (Merck & Co., Inc., 2006).  The VFC program supplies vaccines to all U.S. 
states, territories and the District of Columbia for use by participating providers.  All 
childhood vaccines recommended by the Advisory Committee on Immunization Practices 
(ACIP) are available through VFC program.  The ACIP is a panel of experts brought 
together by the CDC.  The ACIP sets the nation’s list of recommended immunizations, 
setting vaccine standards for physicians and insurers and for public funding of 
vaccinations.  The ACIP’s rulings are not mandates, but most states look to its 
recommendations to mandate which vaccines children must get before they enter the 
public school system.  The panel issues widely followed guidelines, including 
recommendations for childhood vaccines that become the basis for vaccination 
requirements set by public schools.  The ACIP recommends routine vaccination of three 
doses of the HPV vaccine for girls, ages 11 to 12, with vaccination starting as early as 
nine years of age.  The ACIP also recommends vaccination for girls and young women, 
ages 13 to 26 who have not previously been vaccinated or who have not completed the 
vaccination series (Markowitz et al., 2007).  Following the approval of GARDASIL®, 
there have been debates in numerous states about whether to mandate the vaccine for 
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school entry.  Nineteen states have enacted legislation to require, fund, or educate the 
public about the HPV vaccine.  In 24 states and Washington, D.C., legislation has been 
introduced to mandate the vaccine for school entry.  The Michigan Senate was the first to 
introduce legislation in September 1996 to mandate the HPV vaccine for all girls entering 
sixth grade, but the bill was not enacted.  Whereas Texas was the first state to mandate 
the vaccine in 1997 for girls entering the sixth grade, through the Governor’s executive 
order, the Texas legislature subsequently voted to override the executive order.  The 
District of Columbia has enacted the legislation that mandates all girls receive the 
vaccination before the age of 13, but parents can opt out of this requirement.  Virginia 
also has a state law that mandates HPV vaccination for girls entering the sixth grade 
(National Conference of State Legislatures, 2010). 
Professional provider organizations, such as the American College of 
Pediatricians, and leading researchers that conducted clinical trials on the HPV vaccine 
strongly oppose requiring students to obtain the HPV vaccine for public school 
attendance.  The reasons for opposing mandatory vaccination for public school entry is 
because HPV is spread only by sexual activity, not in a classroom, and the duration of the 
vaccine’s effectiveness, as well as the long-term side effects of the vaccine are unknown.  
Dr. Diane Harper, a lead researcher and developer of the HPV vaccine, states that 
administering GARDASIL® to 11-year-old girls is a “great big public health experiment” 
as the clinical trial data are not representative of 11 and 12-year-old girls (Alliance for 
Human Research Protection, March 14, 2007).  Harper’s clinical trials were on girls and 
women between the ages of 15 to 25.  Because of the unknown side effects and duration 
of effectiveness in young girls, Harper believes the ideal way of administering the 
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vaccine is to offer it to women ages 18 and older (Alliance for Human Research 
Protection, 2007; American College of Pediatricians, 2007). 
The HPV vaccine, GARDASIL®, is being promoted as a cervical cancer vaccine.   
However, marketing the vaccine as a cervical cancer vaccine leads to the concern of how 
parents, caregivers and young adults will be educated about the vaccine, and whether 
parents will be given all of the necessary and accurate information about the vaccine 
needed to make an informed decision about whether to get their child or themselves 
vaccinated.  Regardless of whether or not the vaccine to prevent HPV is promoted on 
terms related to cervical cancer, parents need to be informed that the vaccines’ 
therapeutic effects are targeted to an STI to which their child could be exposed.  Studies 
have shown that parents who initially have reservations about the HPV vaccine favored 
vaccination when they learned that HPV was an STI and is the main cause of cervical 
cancer (Mays, Sturm, et al., 2004; Olshen, et al., 2005).  This finding demonstrates the 
importance of educating parents about the link between HPV and cervical cancer. 
Although HPV vaccines may be presented to adolescents and their parents as a 
vaccine that prevents cervical cancer, thereby avoiding or minimizing the STI issue, any 
vaccine that protects against the HPV types responsible for both genital warts and 
cervical cancer must be categorized as an STI vaccine.  In addition, all consumers of 
health care have a right to receive complete, accurate information about HPV infection 
and vaccination (Zimet, 2005).  Merck & Co., Inc. has developed a free information kit 
that includes a patient information sheet on GARDASIL®, in addition to other 
educational brochures for consumers that are available at www.GARDASIL.com.  This 
information sheet does include a statement about the link between HPV and cervical 
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cancer.  However, there is not a clear explanation about how HPV is an STI and 
transmitted solely through sexual activity.  HPV is referred to as a “common virus,” on 
the information sheet, and under the section of key information about the vaccine, there is 
a statement that reads “This vaccine will not protect against other diseases not caused by 
HPV” (Merck & Co., Inc., 2006).  These types of statements do not clearly describe HPV 
as an STI.  Health care providers, such as physicians and nurses who administer the 
vaccine, will need to provide additional information about HPV and STI prevention. 
 Vaccinating adolescents against HPV has become a controversial issue and has 
received more focus in the media compared to other priority populations.  Because the 
vaccine is licensed for use in girls and women ages 9 to 26, young adults are a priority 
population (Merck & Co., Inc., 2006).  One of the benefits in vaccinating young adults, in 
addition to the protecting them against specific types of HPV and cervical cancer, is that 
persons in this population can make their own decision to become vaccinated.  Thus far, 
there has been no controversy in vaccinating this population, perhaps due to the fact that 
sexual activity among young adults is deemed more socially acceptable in society 
(Ambert, 2005). 
Education about the HPV vaccine should be included as part of comprehensive 
health education, including education about other STIs, Pap smears, DNA testing for 
HPV, and other behavioral risk factors that can exacerbate cervical cancer risk.  
Information about the HPV vaccine also can be provided to young adults and college 
students at non-traditional settings, such as bars and concert venues, and through social 
norms marketing and promotional media campaigns.  
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Application of the Health Belief Model and Theory of Planned Behavior 
The most common models, theories, and frameworks that have been used to 
explain the likelihood of behavior change are the health belief model (Rosenstock, 1974), 
the theory of reasoned action (Ajzen & Fishbein, 1980), the theory of planned behavior 
(Ajzen, 1988), social cognitive theory (Bandura, 1986), and the stages of change theory, a 
portion of the transtheoretical model (Prochaska & DiClemente, 1982). Contemporary 
models of health behavior at the individual and interpersonal levels usually fall within the 
broad category of cognitive-behavioral theories.  There are two core concepts associated 
with these theories: 1) Behavior is considered to be mediated through cognitions, for 
instance, what we think and know affects how we act, and 2) Knowledge is necessary but 
not sufficient to produce behavior change.  Perceptions, motivations, skills, and factors in 
the social environment also play important roles in behavior change (Glanz, Lewis, & 
Rimer, 1990).  A combination of the health belief model and the theory of planned 
behavior will be applied in this study. 
The health belief model (HBM), originally introduced by psychologists working 
in the U.S. Public Health Service in the 1950s, was one of the first models that adapted 
theory from the behavioral sciences to health problems (Rosenstock, 1974).  The HBM is 
one of the most researched models of the relationship between cognitive-attitudinal 
factors and health behavior change (Patterson, 2001), and it is one of the most widely 
recognized conceptual frameworks of health behavior (Hochbaum & Lorig, 1992).  The 
HBM is used in explaining and predicting preventive health behavior, as well as sick-role 
and illness behavior.  Although the HBM was originally developed to explain health 
behavior, the HBM has also been successfully used to search for why high-risk health 
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behaviors occur and to identify possible points for behavior change.  The HBM has been 
used to help in developing health education messages to persuade people to make healthy 
decisions in areas such as hypertension, eating disorders, breast-self examination, and 
contraceptive use (Garcia & Mann, 2003; Middleton, 2009; Roye & Hudson, 2003; 
Tavafian, Hasani, Aghamolaei, Zare, & Gregory, 2009). 
The HBM attempts to predict health-related behavior in terms of certain belief 
patterns. The HBM includes four constructs representing perceived health threats and 
perceived benefits:  perceived susceptibility, perceived severity, perceived benefits and 
perceived barriers. These concepts are proposed as accounting for people’s “readiness to 
act” (Figure 1). 
An added concept, cues to action, activates readiness and stimulates overt 
behavior or action (Rosenstock, 1974).  A recent addition to the HBM is the concept of 
“self-efficacy,” or one’s confidence in the ability to perform an action successfully.  This 
concept was added by Rosenstock et al. (1988) so the HBM could fit better with the 
interpersonal challenges of changing unhealthy behaviors. 
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Figure 1.  The Health Belief Model (Adapted from Rosenstock, 1974, p. 334). 
The HBM states that the perception of a personal health behavior threat is itself 
influenced by at least three factors: general health values, including interest and concern 
about health; specific health beliefs about vulnerability to a particular health threat; and 
beliefs about consequences of the health problem.  Once an individual perceives a threat 
to his/her health and is simultaneously cued to action, and his/her perceived benefits 
outweighs his/her perceived barriers, then that individual is most likely to undertake the 
recommended preventive health action.  There may be some variables that can influence 
an individual’s decision, such as demographics (e.g., age, sex, race or ethnicity), socio-
psychological factors (e.g., personality, social class, peer pressure) and structural (e.g., 
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knowledge about the disease and prior experience with the disease).  Rosenstock (1974) 
explained that the role of demographic, socio-psychological and structural variables was 
that they served to condition both individual perceptions and the perceived benefits of 
preventive actions.  The HBM has been successful in identifying differences in individual 
perceptions and predicting preventive health behavior for a variety of diseases, including 
STIs. 
For example, the HBM has predicted adolescent behavior in the prevention of 
STIs, specifically for condom use (Hiltabiddle, 1996; Orr & Langefeld, 2003).  The HBM 
also has been used to examine college students’ knowledge and beliefs about STIs and to 
predict their behaviors associated with STIs, such as condom use (Lollis, Johnson, & 
Antoni, 1997; Mahoney, Thombs, & Ford, 1995; Zak-Place & Stern, 2004).  Gielen, 
Faden, O’Campo, Kass, and Anderson (1994) applied the constructs of the HBM to 
distinguish women who would practice protective measures to protect themselves from 
HIV versus those who would fail to take protective measures.  The importance of the 
participants’ health beliefs to the adoption of protective sexual behaviors was also 
measured.  Gielen et al. (1994) found that beliefs about personal susceptibility and 
barriers were highly associated with adopting multiple sexual protective behaviors, such 
as having sex less often, deciding not to have sex, and carrying condoms. 
The HBM has also been applied to examine health beliefs about cervical cancer 
screening in college women (Burak & Meyer, 1997), and to assess attitudes about the 
HPV vaccine among college women (Kahn et al., 2003).  Kahn et al. (2003) also studied 
the relationship between attitudes about HPV vaccination and intention to receive the 
vaccine, applying a theory-based model with constructs from the HBM to study attitudes 
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and constructs from other theories and to study how attitudes can predict behavioral 
intention, such as the theory of reasoned action (TRA) (Ajzen & Fishbein, 1980).  The 
TRA will be discussed later in this chapter.  Kahn et al. (2003) found that young women 
who reported a positive attitude about receiving the HPV vaccine also had high intention 
to receive the vaccine for themselves and their daughters.  A more recent study by Kahn 
et al. (2009) applied the TPB, HBM and social cognitive theory to determine variables 
associated with mothers’ intention to vaccinate daughters’ against HPV.  The researchers 
found that positive beliefs about the HPV vaccine were significantly associated with 
intention to vaccinate. 
The HBM is used in the current study to measure college students’ perceptions 
about HPV, including perceived susceptibility of getting HPV, perceived severity of 
HPV, perceived benefits of protecting themselves against HPV, including getting 
vaccinated against HPV, what motivates college students to take action in protecting 
themselves against HPV, and their level of self-efficacy in practicing safer sex behaviors.  
The constructs of the HBM are applied in the following way: 
A) Perceived Susceptibility – College students’ beliefs of their risks of contracting 
HPV, in addition to the risks of others.  This perception is measured by a series of 
Likert-type scales, from the low end, where individuals deny any possibility of 
contracting HPV, to the high end where individuals feel they are at a real danger 
of contracting HPV. 
B) Perceived Severity – College students’ beliefs concerning the health effects of 
contracting HPV.  For instance, symptoms and long-term consequences, such as 
susceptibility to developing cervical cancer. 
 85
C) Perceived Benefits and Barriers of Taking Action – College students’ perceptions 
about the importance of certain influential factors and barriers to becoming 
vaccinated against HPV. 
D) Cues to Action – College students’ beliefs about what would influence them to 
become vaccinated against HPV.  Differences in perceptions about what factors 
are more influential over others also are determined among college students. 
E) Self-Efficacy – College students’ perceived abilities in carrying out certain safer 
sex behaviors.  Safer sex behaviors include those defined by The Planned 
Parenthood Federation of American (2004), and questions on perceived 
behavioral control in carrying out certain safer sex behaviors are included.  
However, self-efficacy is addressed through measuring perceived behavioral 
control, by applying the theory of planned behavior.  Differences in perceived 
behavioral control over carrying out certain safer sexual behaviors also are 
determined and may reveal which behaviors college students are more confident 
in practicing to protect themselves against STIs. 
There are some weaknesses associated with the HBM that are relevant to 
examining if there are any relationships between individual’s beliefs about HPV, vaccine 
acceptance and intentions to practice safer sex behaviors.  One of the limitations of the 
HBM is that it does not incorporate social norms as a modifying factor in an individual’s 
health beliefs (Brown, 1999).  Also, the health belief model focuses on the health 
behavior beliefs of an individual, and individual behavioral beliefs can compete with 
other beliefs and attitudes that can influence behaviors, such as social normative beliefs.   
Furthermore, the HBM does not measure behavioral intentions (Weinstein, 1993).  In 
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addition to examining college students’ beliefs about HPV, perceived barriers and 
benefits of becoming vaccinated against HPV, this study also assesses college students’ 
intentions to practice safer sex behaviors.  Additional beliefs that can affect an 
individual’s intentions are normative beliefs – or beliefs about the normative expectations 
of others and motivation of the individual to comply with others’ expectations and 
control beliefs – beliefs about the presence of factors that may facilitate or impede 
performance of the behavior and perceived power of these factors.  Therefore, a theory 
that incorporates normative beliefs and control beliefs to predict behavioral intention is 
used to supplement the HBM in this study. 
The theory of reasoned action (TRA) and the theory of planned behavior (TPB) 
also provide frameworks to study attitudes towards behaviors.  These models have been 
used extensively to explain knowledge, attitudes, and predict behaviors in different 
populations for reducing risk of contracting STIs, in addition to designing STI prevention 
and STI intervention programs (Baker, Morrison, Carter, & Verdon, 1996; Blecher, 
Steinberg, Pick, Hennink, Durcan, 1995; Boehner, Howe, Bernstein, & Rosenthal, 2003; 
Jemmott, 2000; Manhart, Dialmy, Ryan, Mahjour, 2000; O'Donnell, San Doval, Vornfett, 
& DeJong, 1994; Strader, Beaman, & McSweeney, 1992; Strader & Beaman, 1991, 
1992). 
According to the TRA, the most important determinant of an individual’s 
behavior is behavioral intention, and an individual’s intention to perform a behavior is a 
combination of attitude and subjective norms related to that behavior.  Ajzen and 
Fishbein (1980) theorized that intentions are a function of two major determinants: 1) 
attitudes toward the behavior and 2) the subjective norms related to the behavior.  
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Attitude is the first antecedent of behavioral intention and it is an individual’s positive or 
negative belief about performing a specific behavior.  Attitudes are determined by the 
individual’s beliefs about the consequences of performing a behavior (behavioral beliefs), 
weighted by his or her evaluation of those consequences (outcome evaluations).  These 
attitudes are believed to have a direct effect on behavioral intention and are linked with 
subjective norms.  Subjective norms also are assumed to be a function of beliefs that 
specific individuals approve or disapprove of performing the behavior, and these beliefs 
are termed normative beliefs.  According to the TRA, an individual will intend to perform 
a certain behavior when he/she perceives that prominent persons or figures in their life 
think they should.  Prominent persons may be partners, spouses, parents, close friends, 
physicians, or other key individuals.  The TRA was developed to predict behaviors that 
are under a person’s volitional or actual control, and the TRA works most successfully 
with behaviors that are perceived to be under a person’s control (Ajzen & Fishbein, 
1980).  Boehner et al. (2003) applied the TRA in a study assessing the genital herpes and 
HPV vaccine among college students, and found that persons who believed their parents, 
partners, or physicians would encourage vaccination were more likely to accept the HPV 
vaccine.  Whereas this study found that beliefs about the HPV vaccine were influential in 
an individual’s acceptance about the vaccine, it was not clear whether the beliefs of 
others had any effect on an individual’s intentions to become vaccinated.  Furthermore, 
the researchers did not measure individual’s attitudes, beliefs or abilities related to 
practicing other safer sex behaviors, including their perceptions of control over practicing 
safer sex behaviors in current or future relationships, and how these perceptions were 
associated with their acceptance of the HPV vaccine.  Assessing attitudes, beliefs – 
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individual and normative, and abilities in practicing safer sexual behaviors can predict 
college students’ intentions in practicing these behaviors.  Assessing the relationship 
between college students intentions to practice safer sex behaviors and likelihood of 
becoming vaccinated against HPV, may help to reveal whether college students that 
intend to become vaccinated, would also continue to protect themselves, by practicing 
other safer sex behaviors against other types of HPV and STIs. 
This study applies the TPB as a theoretical framework to complement the HBM to 
determine college students’ perceived behavioral control and intentions to practice other 
safer sexual behaviors.  The TPB differs from the TRA through the addition of the 
construct of “perceived behavioral control.”  Researchers have realized that one of the 
greatest limitations of the TRA occurs when people feel they have little power over their 
behaviors and attitudes (Godin & Kok, 1996; Madden, Ellen, & Ajzen, 1992).  Ajzen 
(1988) described the aspects of behavior and attitudes as being on a continuum, from one 
of little control to one of great control, and to predict behaviors that are or that are not 
perceived to be under a person’s control.  Ajzen (1988) added the third determinant of 
“perceived behavioral control” to the TRA to address behaviors that are or may not be 
perceived as being under a person’s control, and this addition resulted in the newer, TPB. 
The TPB proposes that attitudes about performing a behavior, perceived benefits 
of others regarding its performance, and perceived behavioral control over one’s ability 
to perform the behavior all affect the intention to perform that behavior and, in turn, 
predicts actual behavior (Figure 2).  Perceived behavioral control is determined by two 
factors - control beliefs and perceived power.  Perceived behavioral control indicates that 
a person's motivation is influenced by how difficult the behaviors are perceived to be, as 
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well as the perception of how successfully the individual can, or cannot, perform the 
activity.  If a person holds strong control beliefs about the existence of factors that 
facilitate a behavior, then the individual will have highly perceived behavioral control 
over that behavior.  Conversely, the person has a low perception of control if she or he 
holds strong control beliefs that impede the behavior.  This perception can reflect past 
experiences, anticipation of upcoming circumstances, and the attitudes of the influential 
norms that surround the individual.  As a general rule, the more favorable the attitude and 
subjective norm, and greater the perceived behavioral control, the stronger is the person’s 
intention to perform the behavior in question.  Given a sufficient degree of actual control 
over the behavior, people are expected to carry out their intentions once they have the 
opportunity to do so.  However, some behaviors are too difficult to carry out, and 
therefore, may not be perceived as being under an individual’s control.  Therefore, 
perceived behavioral control, in addition to intention, needs to be considered to help 
predict the behavior in question (Ajzen, 2002). 
Whereas there have been no studies that have applied the TPB to the study of 
sexual behavior, specifically in regards to the prevention of HPV, there have been 
numerous studies that have applied the TPB to predict sexual behaviors and condom use 
in the prevention of STIs, with the majority of studies focusing on HIV/AIDS prevention 
and risk reduction (Bensley et al., 2004; Boily, Godin, Hogben, Sherr, & Bastos, 2005; 
Bowen, 1996; Koniak-Griffin, Lesser, Uman, & Nyamathi, 2003). 
 
 
 
 90
 
 
 
 
 
 
 
 
 
______________________________________________________________________ 
Figure 2.  Theory of Planned Behavior (Ajzen, 2002).   
Bryan, Fisher, and Fisher (2002) applied the TPB to determine whether 
preparatory safer sex behaviors, such as discussing safer sex with partners and obtaining 
condoms, can have a mediational role between attitudes and perceived social norms about 
safer sex and condom use among high school and college students.  The authors found 
that safer sex behaviors can have a highly significant mediation role and bridge the gap 
between attitudes about safer sex and carrying out the intended action of using condoms. 
The normative beliefs, control beliefs, and behavioral intent aspects of the TPB 
will be applied in this study, as a complimentary theoretical framework to the HBM, to 
measure college students’ perceived behavioral control over practicing certain safer sex 
behaviors, by measuring difficulty in carrying out those behaviors (See Figure 3). 
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Figure 3.  A theoretical framework of the HBM with the addition of the TPB constructs 
of “normative beliefs,” “control beliefs,” and “behavioral intention.” 
 
The TPB has been chosen over the TRA for a theoretical framework in this study 
because this study includes measuring perceived difficulty of behaviors that may or may 
not be perceived as being under a person’s control.  For example, staying in a 
monogamous relationship with a person that does not have an STI, or only having sex 
with partners that have been tested and have no history of STIs, may not be perceived as 
behaviors that are under an individual’s control, but rather, more under a partner’s 
control.  Measuring the difficulty in carrying out different sexual behaviors also may help 
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to determine which behaviors are most often or less often perceived to be under an 
individual’s control. 
The TPB is used in this study to examine college students’ perceived beliefs of 
others regarding the HPV vaccine and beliefs in practicing other safer sex behaviors, and 
college students’ perceived behavioral control beliefs over practicing in safer sex 
behaviors.  Measuring social normative beliefs and perceived behavioral control in 
getting vaccinated against HPV and practicing in safer sex behaviors, may help to 
determine the level of college students’ intentions for getting vaccinated against HPV and 
practicing in safer sex behaviors.  
Online Surveys and College Students 
The variables in this study will be measured through an online survey.  Increasing 
number of studies are utilizing online surveys to collect data among college students on 
high risk behaviors and health beliefs, including assessing STI behaviors and acceptance 
of preventive measures to reduce risk of STIs (Collins, Logan, & Neighbors, 2010; 
Gullette & Lyons, 2006; Lindley, Nicholson, & Kerby, 2003; Opt, Loffredo, Knowles, & 
Fletcher, 2007).  The majority of college students use the Internet for social and 
educational purposes, and, therefore, are experienced in navigating through web sites and 
online programs.  Furthermore, an equal percent of female and male students use 
computers regularly (Hargittai, 2002).  Online surveys are also beneficial as data can be 
downloaded directly into analysis software programs compared to manual data entry or 
scanning paper-and-pencil surveys.  Further detail on the rationale for choosing an online 
survey as the data collection instrument in this study is provided in Chapter 3. 
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Chapter Three 
Methods 
 
Introduction 
 
 Sexually transmitted infections continue to be a challenging public health issue on 
college campuses, as the majority of college students are sexually active and engage in 
unsafe sex behaviors that put them at risk of contracting STIs (Eisenberg, 2001; Gately, 
2003).  Human papillomavirus (HPV) is estimated to be the most common STI in the 
United States and has been shown to infect more than 40% of sexually active college 
students (Eisenberg, 2001; Winer, Lee, Hughes, Adam, & Koutsky, 2004).  HPV among 
college women poses a serious public health concern as high-risk types of HPV are 
associated with nearly 100% of cervical cancer cases (Munoz et al., 2003).  Despite the 
high prevalence of HPV among college students, there continues to be a low level of 
awareness about the risk factors, symptoms and methods of prevention of STIs, including 
HPV (Eisenberg, 2001; Gately, 2003; Yacobi, Tennant, Ferrante, & Roetzheim, 1999).  
There are numerous methods of HPV prevention that involves behavioral intervention, 
and the HPV vaccine is the most recent innovation in HPV prevention.  The vaccine is 
available for women at most university and college campuses, and there is a high 
acceptance of the vaccine among female college students.  Although the HPV vaccine 
protects against multiple types of HPV, including those that are primarily responsible for 
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cervical cancer and genital warts, it does not protect against all types of HPV or other 
STIs.  Therefore, it will be imperative for female college students who receive the HPV 
vaccine to receive accurate information about transmission and prevention of HPV, in 
addition to all other types of STIs and diseases associated with STIs. This education also 
should include information and reinforcing messages concerning how college students 
can practice safer sex behaviors to prevent contracting other types of HPV and other 
STIs. 
Purpose of the Study 
 
The purpose of this study is to expand previous research on female college 
student perceptions and acceptance of the HPV vaccine through assessing knowledge 
about HPV and the HPV vaccine, assessing the relationship between health beliefs about 
HPV and vaccine acceptance, and the relationship between vaccine acceptance and 
intentions to practice in safer sexual behaviors, including their willingness to become 
vaccinated against HPV.  This information is expected to be helpful in understanding 
whether female college students intend to practice safer sex behaviors if they are 
vaccinated against HPV, or if they expect to feel less susceptible to acquiring STI 
infections, and consequently, engage in risky sexual behaviors.  Determining whether 
there is a relationship between knowledge about HPV and intentions to practice safer sex 
behaviors may help to reinforce the need for increased education about HPV and other 
STIs by health care providers for college-aged women, and also encourage providers to  
use the time for vaccination as a teachable moment to educate students about HPV and 
safer sex behaviors.  University student health centers that are administering the vaccine 
are interested in targeting female college students with vaccine education and promotion 
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campaigns. Understanding the factors that play a role in vaccine acceptance, and the 
relationship between vaccine acceptance and intentions to practice safer sex behaviors 
may help university student health centers in developing these campaigns. 
Research Questions 
 
The questions to be investigated are: 
 
• What is the relationship between knowledge about HPV and intentions to practice 
safer sex behaviors among women attending college? 
 
o What is the relationship between knowledge about HPV and attitudes 
towards practicing safer sex behaviors? 
 
o What is the relationship between knowledge about HPV and normative 
beliefs about practicing safer sex behaviors? 
 
o What is the relationship between knowledge about HPV and perceived 
control about practicing safer sex behaviors? 
 
• What is the relationship between knowledge of the HPV vaccine and acceptance 
of the HPV vaccine among women attending college? 
 
• What is the relationship between health beliefs about HPV and acceptance of the 
HPV vaccine among women attending college? 
 
o What is the relationship between perceived susceptibility to HPV and 
acceptance of the HPV vaccine? 
 
o What is the relationship between perceived severity of HPV and 
acceptance of the HPV vaccine? 
 
• What is the relationship between acceptance of the HPV vaccine and intentions to 
practice safer sex behaviors among women attending college? 
 
o What is the relationship between acceptance of the HPV vaccine and 
attitudes towards practicing safer sex behaviors? 
 
o What is the relationship between acceptance of the HPV vaccine and 
normative beliefs about practicing safer sex behaviors? 
 
o What is the relationship between acceptance of the HPV vaccine and 
perceived control towards practicing safer sex behaviors? 
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Study Design 
 
This study was a descriptive, cross-sectional study that used primarily quantitative 
methods to explore undergraduate female college students’ knowledge and awareness of 
HPV, examine the relationships between college students’ perceived susceptibility in 
contracting HPV, their perceived ability to engage in safer sexual behaviors, cues to 
action, and their willingness to become vaccinated against HPV.  The study included the 
implementation of an online questionnaire adapted from an instrument developed by 
researchers at the University of South Florida (USF) in 2001 to assess the impact of 
receiving an HPV diagnosis among women (CDC, 2005).  This questionnaire included 
several items assessing knowledge and awareness of HPV, the HPV vaccine, and vaccine 
acceptance, including perceived barriers and benefits of getting vaccinated against HPV.  
It also included items that assessed attitudes about practicing safer sex behaviors and 
perceptions of partners’ and friends’ attitudes about practicing safer sex behaviors.  Items 
that assessed perceived ability and control over practicing safer sexual behaviors were 
adapted from a sexual behavior scale developed by Morrison, Ho, Beardsley, Bierman, 
and Burke (1998).  The survey also assessed demographic information about the 
participants, such as age, ethnicity, income, sexual preference, relationship status, 
whether they have children, educational status, and whether they have health insurance. 
Sample, Recruitment, and Size 
A convenience sample of female undergraduate students, 18 to 24 years of age, 
were recruited to complete the online survey on the University of South Florida (USF), 
Office of Academic Computing online survey tool site, Survey.acomp, at 
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http://survey.acomp.usf.edu.  Students enrolled at three public universities, USF, Central 
Michigan University (CMU), and Western Michigan University (WMU) were recruited 
to complete the survey in the spring and summer 2009 semesters.  Students were 
recruited to participate in the study via student health services at each university and via 
e-mail.  Letters of commitment for participation in the study were submitted by student 
health center staff for each participating university. 
Student health centers were an appropriate venue for recruiting students to 
complete an online survey about the HPV vaccine, as there is a large number of women 
who seek care for medical and preventive health services (Boehm, Selves, Raleigh, 
Ronis, Butler, & Jacobs, 1993; Sawyer & Moss, 1993; Foote, Harris, Gilles, Ahner, 
Roice, Becksted, Messinger, Bunch, & Bilant, 1996). Students also were recruited 
through snowball sampling where, at the end of the survey, a statement encouraged 
survey takers to ask other eligible female students or friends attending the university 
about the survey and to provide them with the survey web site address.  Students who 
completed the online survey were entered into a one-time cash drawing for $500, and one 
student was randomly selected to receive the incentive. 
The three participating universities employed different methods to recruit female 
undergraduate students to maximize outreach to students and sample size.  Fliers that 
included the direct URL address to the survey were posted on bulletin boards throughout 
the student health centers and were distributed to female students when they checked in 
for clinic visits, or attended student health services seminars and on-campus events at all 
three universities.  Though it was proposed that all three universities include a direct link 
to the survey on the student health center web site, only Western Michigan University did 
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so (http://www.wmich.edu/shc/), as the student health center web sites at the other two 
participating universities were being updated and the information technology staff could 
not add the survey link. 
An additional recruitment strategy was employed as response rates were low from 
recruiting participants through student health services. The other option for recruitment 
was to e-mail the students directly.  The USF Registrar’s Office dispatched the survey to 
13,120 undergraduate female students, ages 18 to 24 (E. Rosenthal, personal 
communication, May, 12, 2009).  Western Michigan University Sindecuse Health Center 
dispatched the survey to 2,493 female undergraduate students, ages 18 to 24 (C. 
Cumming, personal communication, June 4, 2009).  However, access to student e-mail 
was not granted by CMU as the university’s policy does not permit surveys to be sent to 
students via e-mail. 
The principal investigator’s contact information was provided at the end of the 
online informed consent, as well as at the end of the survey, if participants had any 
questions regarding their participation in the survey.  Contact information for each 
participating university student health center also was included at the end of the online 
informed consent if students had any questions about HPV and the HPV vaccine.  A 
statement was also included, at the end of the informed consent, reminding students that 
they would be contacted via e-mail by the principal investigator for the purpose of 
receiving an incentive for participation. 
All students had the chance to receive free educational materials about HPV and 
the HPV vaccine from the university student health centers.  A monetary incentive was 
offered to students by entering them into a one-time cash drawing of $500.  Students also 
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were given contact information for questions regarding their participation in the study as 
well as for HPV-related resources after they complete the survey.  Students were eligible 
to participate in the study regardless of whether they have ever been diagnosed with 
HPV. 
Only women attending college were recruited to participate because the vaccine 
was available to them at the time the data was collected for this study, and vaccine 
acceptance was assessed.  Assessing acceptance among men may have threatened the 
validity of the study because they would have answered questions related to a 
hypothetical situation of becoming vaccinated against HPV.  Male responses may have 
been biased by the fact that the vaccine was not yet available to them, and therefore, 
males were excluded from participating in this study. 
Undergraduate female students, between the ages of 18 and 24, from the main 
campuses of three public universities, were eligible to participate in this study.  A total of 
15,356 female undergraduate students, ages 18 to 24, were enrolled at the USF main 
campus in Tampa, Florida (D. Hayward, personal communication, September 10, 2008) 
compared to 9,486 female undergraduate students at the Central Michigan University 
(CMU) main campus in Mt. Pleasant, Michigan (M. Meier, personal communication, 
September 11, 2008), and 8,528 female undergraduate students at the Western Michigan 
University (WMU) main campus in Kalamazoo, Michigan (J. Jach, personal 
communication, September 12, 2008).  Although there are limitations in non-probability 
sampling, such as increased risk of participant bias and the sample being non-
representative of the priority population, there are methods that can be employed to 
increase the study’s statistical power.  A strategy to increase the study’s power is to set a 
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clear sampling frame with specific exclusion and inclusion criteria and to increase the 
sample size. 
An adequate sample size is jointly determined by the power, the alpha or 
significance level, such as .05, effect size, and variability expected to be present in the 
data collected.  Power is the ability of a statistical test to detect a statistically significant 
difference when one exists between two study variables or study groups.  A power level 
of .80 is an acceptable standard among researchers in the social and behavioral sciences 
(Cohen, 1988).  Effect size is the minimum size of the expected difference or, in the case 
of this study, the relationship you would expect to see between two variables. The 
significance test of multiple linear regression was applied in this study to determine 
sample size because degree of relationships and predictor variables for intentions to 
practice safer sex behaviors were addressed through the research questions.  According to 
Cohen (1988), .02 is indicative of a small effect, 0.15 a medium effect, and 0.35 a large 
effect size for multiple correlation and regression tests.  As the effect size is made 
smaller, a larger sample size is needed to detect statistically significant differences (Eng, 
2003).  There is limited research on factors predicting female college student intentions to 
practice safer sex behaviors, including becoming vaccinated against HPV.  Crosby et al. 
(2007) found three correlates from multiple linear regression were significantly linked to 
HPV vaccine acceptance among college-aged women.  These correlates were having sex, 
having an STI, and having an abnormal Pap smear but they were not linked to intentions. 
The following three predictor variables for intentions to practice safer sex 
behaviors were measured in this study: attitudes, normative beliefs and control beliefs.  
The level of relationships between these predictor variables and intentions were 
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calculated via multiple linear regression, from participant data (N = 125) from the second 
pilot test of the survey instrument in SPSS 13.  The results of this analysis were used to 
determine the sample size of female undergraduate students needed to participate in the 
study based upon a power of .80, a medium effect size of .15 and an alpha of .05.  
Multiple linear regression assessing the strength of the relationship between attitudes, 
normative beliefs and perceived control beliefs and intentions was calculated via SPSS 
13.  The R-squared value was calculated for the three predictor model (attitudes vs. 
normative beliefs vs. control beliefs) on intentions, and for each of three 2-predictor 
models (attitudes vs. normative beliefs, normative beliefs vs. control beliefs, attitudes vs. 
control beliefs) on intentions.  The differences between each of the 2-predictor models 
and the three-predictor model were then calculated to determine the strength of each 
factor in predicting intentions, and these differences were entered as estimated values into 
a sample size estimation calculation in a SAS software program.  Results of the analyses 
demonstrated that attitudes had the strongest relationship with intentions (effect size or f2 
= .90) followed by normative beliefs (f2 = .049), and control beliefs (f2 = .0046).  Based 
upon the results of the analysis, a total of 1700 female college students were needed to 
participate in this study to have a power of .80 for all three predictor variables (Appendix 
A). 
Instrument 
There are conflicting results from studies assessing college student response to 
online surveys.  Some studies have found that paper-and-pencil survey have higher 
response rates among college students (Hanwerk, Carson & Blackwell, 2000; Matz, 
1999; Tomsic, Hendel, & Matross, 2000), some have found that online surveys elicit 
 102
higher response rates among college students (Antons, Dilla, & Fultz, 1997), whereas 
other studies have found no difference between the two types of surveys with respect to 
response rates (Carini, Hayek, Kuh, Kennedy, & Ouimet, 2003; Underwood, Kim, and 
Matier, 2000).  Some studies of online survey methods have found that response rates in 
e-mail surveys are equal to or greater than those for traditional mailed surveys (Mehta & 
Suvadas, 1995; Stanton, 1998; Thompson, Surface, Martin, & Sanders, 2003) and others 
have found that online surveys have a lower response than mail surveys.  One of the 
issues for lower response rates is invalid e-mail addresses or the participant not 
completing the survey in a timely manner (Solomon, 2001; Couper, 2000).  Invalid e-
mail addresses and participants not completing online surveys in a timely manner were 
not issues for lower response rates in the two pilot tests conducted for this study.  
Participant e-mail addresses were legitimate, as the principal investigator did not receive 
any of the e-mail addresses back in error.  Furthermore, participants were reminded by  
e-mail to complete the survey re-test, and 45% of the participants who took the initial 
survey, responded and completed the survey re-test. 
An online survey was chosen as the instrument for this study based upon the 
positive outcomes from the three pilot tests, as there were no major barriers or challenges 
in participants completing the online survey.  The majority of college students use the 
Internet and online surveys can be more convenient for more “computer savvy” 
participants (Carini et al., 2003).  Research on gender gaps in new educational 
technologies has demonstrated that nearly an equal percent of female and male students 
use computers regularly.  Research has demonstrated no significant gender difference in 
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ability to navigate the Web or in the time it takes to learn how to browse the Web 
(Hargittai, 2002). 
A Pew Internet and American Life Project found that 86% of college students 
have gone online, and the majority of college students own their own computers, have 
access to computers at school, or use the Internet as part of their daily routine (Jones, 
2002).  The majority of college students use the Internet for social networking, as a way 
to communicate with friends about social issues, such as via Friendster, Facebook, 
Twitter and MySpace, for entertainment, and for online courses (Jones, Johnson-Yale, 
Millermaier, & Perez, 2009).  College students often participate in online polls and 
surveys including ones related to health, job preferences, entertainment and politics.  
Therefore, college students comprise a population that is accustomed to participating in 
online surveys.  In addition, there are additional benefits to completing online surveys 
compared to paper-and-pencil surveys that are relevant to this study, such as elimination 
of paper, copying, and postage costs.  Also, processing data is easier with the ability to 
download survey data directly into spreadsheets, databases, and data analysis programs. 
An online informed consent was provided to students upon going to the survey 
link (Appendix B).  Upon going to the survey site, students were provided with a 
summary of the purpose of the survey, their participation, why they were being asked to 
participate and how they can participate, information about anonymity and 
confidentiality, and a statement about how they are giving their consent to participate by 
logging onto the site and completing the survey.  Students were informed that they would 
be required to include their e-mail address at the end of the survey for the purposes of 
receiving an incentive and the last four digits of their student identification number to 
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prevent any participant from taking the survey more than once.  Because the survey  
assesses their personal attitudes, beliefs, and behaviors, students were asked to answer the 
questions as honestly as possible. Students were informed that the survey contains 
questions about sexual activity and that they do not have to answer any questions that 
make them uncomfortable and they can stop taking the survey at any time.  A statement 
was included that choosing not to participate would not affect their status or the services 
they receive from the university.  In addition, in the informed consent, participants were 
reminded that because they were completing a survey over the Internet that there was a 
slight chance, albeit a small one, that an unauthorized person, such as a hacker, could 
gain access to their survey, and pose a risk to confidentiality of their responses.  To 
minimize this risk, the principal investigator downloaded all survey responses into 
another secure electronic database for data analysis once the surveys were completed.    
Students were informed that once they completed their survey, their responses would be 
downloaded into an off-line, secured electronic database, and their responses would be 
coded and not contain any of their identification information.  The principal 
investigator’s contact information was provided at the end of the informed consent 
section, as well as at the end of the survey, if participants had any questions regarding the 
survey.  Contact information for each participating university student health center was 
also included if students had any questions or needed information about HPV and the 
HPV vaccine. A statement was included, at the end of the informed consent section, 
reminding students that they would be contacted via e-mail by the principal investigator 
for the purpose of receiving an incentive for participation. 
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An online survey was developed and pilot tested with three samples of 
participants representative of the target population for this study (Appendix C).  
Undergraduate, female college students, between the ages of 18 to 24, completed the 
survey at http://survey.acomp.usf.edu - the USF, Office of Academic Computing online 
survey tool site.  This survey tool is free, offers a more secured data collection site for 
students compared to online commercial survey tools, does not feature pop-up 
advertisements that can distract respondents, and includes university staff support that is 
easily accessible for questions and technical difficulties.  The URL for the survey was 
http://survey.acomp.usf.edu/survey/entry.jsp?id=1172716175300. 
The survey contained 57 items and took approximately 10 minutes to complete.  
The survey was designed to answer the research questions and assess the relationships 
among study variables.  Items were developed to measure the following study variables: 
knowledge about HPV; knowledge about the HPV vaccine; health beliefs through 
perceived severity of and susceptibility to HPV; vaccine acceptance through perceptions 
about the influential factors and barriers to becoming vaccinated against HPV; and 
attitudes, normative beliefs, and perceived control in practicing safer sex behaviors. 
Demographic and other personal information about participants, such as age, 
gender, ethnicity, educational status, sexual orientation, number of sexual partners during 
the past 12 months, current sexual activity, marital status, and whether they have children 
was also collected.  An item assessing whether the participant had health insurance was 
included on the survey as insurance status may influence vaccine acceptance (Appendix 
C, Section Nine, question eleven). 
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The survey consists of a variety of closed-ended questions, such as true/false, 
yes/no/not sure, and Likert-type scales.  Survey items assessing HPV knowledge were 
adapted from a questionnaire developed by researchers at the USF College of Public 
Health in a study conducted from 2001 to 2004 to assess the impact of an HPV-related 
diagnosis among women (CDC, 2005).  Items in this subscale addressed the research 
question concerning the relationship between knowledge about HPV and intentions to 
practice safer sex behaviors (Appendix C, Section One, question one).  The subscale 
assessing knowledge about the HPV vaccine also has been adapted from the 
questionnaire described above.  This item addressed the research question concerning the 
relationship between knowledge about the HPV vaccine and HPV vaccine acceptance 
(Appendix C, Section Three, question one). 
Vaccine acceptance was assessed through the constructs of general vaccine 
acceptance, influential factors to becoming vaccinated against HPV and barriers to 
becoming vaccinated against HPV.  These subscales are comprised of items also adapted 
from the questionnaire developed by USF researchers described above (CDC, 2005).  
Items in this section were also developed based upon responses from individual 
interviews with undergraduate female college students, ages 18 to 24.  Items in this 
subscale assessed participant perception of the importance of vaccination, whether 
participants received at least one dose of the HPV vaccine, whether they are likely to 
become vaccinated if they have not yet received the vaccine, what would influence them 
to become vaccinated against HPV, and what are the barriers to becoming vaccinated 
against HPV (Appendix C, Section Five, questions one through five).  These items are 
related to the research questions on the following relationships: knowledge about the 
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HPV vaccine and HPV vaccine acceptance, health beliefs about HPV and HPV vaccine 
acceptance, and HPV vaccine acceptance and intentions to practice safer sex behaviors. 
Health beliefs about HPV were assessed through the constructs of perceived 
susceptibility and severity questions about HPV and were adapted from items developed 
by Kahn, Goodman, Slap, Huang, and Emans (2001) to assess health beliefs about the 
perceived susceptibility and severity of having an abnormal Pap smear among adolescent 
girls and young women.  The construct of perceived susceptibility was measured by a 
subscale that included items related to the research question about relationships among 
health beliefs, specifically, perceived susceptibility, and HPV vaccine acceptance.  This 
subscale included items that assessed perceived risk of contracting HPV (Appendix C, 
Section Seven, questions one through five).  The construct of perceived severity was 
measured by a subscale that included items related to the research question concerning 
the relationship among health beliefs, specifically, perceived severity, and HPV vaccine 
acceptance.  This subscale included items that assessed perceptions about how serious a 
health problem HPV is and the consequences of HPV (Appendix C, Section Eight, 
questions one through four). 
Although the most reliable way to prevent transmission of STIs is to abstain from 
sexual intercourse, defined as vaginal, oral, or anal sex (CDC, 2002), there are some 
STIs, such as HPV that can be transmitted through any sexual activity that involves 
“skin-to-skin” contact (Moscicki, 2005; Winer et al., 2003).  Because the survey assessed 
attitudes and behaviors related to preventing and transmitting HPV, the terms sexually 
active and sexual activity were used to describe sexual behavior instead of sexual 
intercourse. 
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The safer sex behaviors measured in this study were several of those described 
previously in Chapter One.  The behaviors were defined by Planned Parenthood (2004) 
and were selected because they can be effective methods of reducing the risk of acquiring 
HPV infection and other STIs.  Furthermore, some of these same behaviors, specifically 
those related to condom use, talking with partners about STIs, and refusing to have sex 
with someone that has not been tested for an STI, were included as protective sexual 
behaviors in the Gielen et al. (1994) study that applied the HBM to assess the extent to 
which women in an urban area protected themselves against HIV.  The safer sex 
behaviors measured in this study were also based upon the results of an expert panel 
review and pilot testing the survey instrument to be a valid and reliable measure. 
The following safer sex behaviors were measured in this study: 
1)  Abstinence 
2)  Communicating with a new partner about STIs 
a. Telling a new partner that you will not be sexually active with them 
until they have been tested for an STI 
3) Refusing to have sex with a new partner if they will not use a condom 
4) Avoiding using drugs or alcohol before engaging in sexual activity 
5) Asking a health care provider about how to reduce the risk of getting STIs 
An attitude toward a behavior is defined as a person’s overall evaluation of 
performing the behavior in question (Ajzen, 1991).  Therefore, attitudes towards a 
behavior play a significant role in an individual’s perceived ability, and according to the 
TPB, attitude, along with normative beliefs and behavioral control beliefs can directly 
affect intention to carry out a certain behavior.  Likert-type scales assessing attitudes 
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practicing in safer sex behaviors, and perceptions of others’ beliefs towards practicing in 
safer sex behaviors was adapted from the guide “Constructing a TPB Questionnaire:  
Conceptual and Methodological Considerations” developed by TPB author, Icek Ajzen 
(2006).  To be sure the subscales of the instrument were compatible with each other, the 
constructs of attitudes, subjective norms, and perceived control were defined in terms of 
the same elements (Ajzen, 2002).  Although the Likert-type scales used to measure some 
of the constructs differed, the behavior of interest was defined in the same manner.  
According to Ajzen (2006), in the final questionnaire the different items assessing each 
construct are separated and listed in a non-systematic order, interspersed with items 
measuring other constructs.  Therefore, the subscales of the instrument measuring 
attitudes, perceived normative beliefs, perceived control, and intentions to practicing 
safer sex behaviors were interspersed with each other.  Furthermore, items measuring the 
subscales of attitudes, normative beliefs, perceived control and intentions regarding 
practicing safer sex behaviors were divided throughout the survey to minimize reader 
fatigue (Appendix C, Sections Two, Four and Six).  Items assessing attitudes, normative 
beliefs, perceived control, and intentions addressed the research questions concerning the 
relationship between knowledge and intentions to practice safer sex behaviors and the 
relationship between HPV vaccine acceptance and intentions to practice safer sex 
behaviors. 
Some of the items assessing the construct of attitudes have been adapted from 
Morrison et al. (1998) to measure low-risk and high-risk sexual behaviors among college-
aged women.  The subscale assessing attitudes includes items assessing the extent to 
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which a participant agrees that practicing certain safer sex behaviors are easy with Likert-
type scale “Strongly agree” and “Strongly disagree” endpoints. 
The construct of normative beliefs, or perceived beliefs of others, about practicing 
safer sex behaviors was assessed by asking participants if they agreed that college 
students could practice certain safer sex behaviors.  In addition to measuring subjective 
norms through beliefs of others, it is important to include questions that measure 
descriptive norms, such as whether persons considered important to the participant also 
would practice safer sex behaviors themselves (Ajzen, 2006).  Items assessing normative 
beliefs were adapted from Ajzen’s (2006) questionnaire development guide.  This 
subscale included items assessing normative beliefs about practicing certain safer sex 
behaviors with a Likert-type scale with “Strongly agree” and “Strongly disagree” 
endpoints. 
Perceived control to carry out safer sex behaviors were determined by assessing 
the individual’s confidence in performing the behavior and perceived control in 
performing it.  Perceived self-efficacy, a behavioral belief that is influential on outcomes 
in the HBM and TPB, also determines people’s confidence with respect to what they are 
capable of achieving.  Self-efficacy is defined as “beliefs in one's capability to organize 
and execute the courses of action required to manage prospective situations" (Bandura, 
1997, p. 2).  According to Bandura (1997), self-efficacy beliefs are key elements in a 
person’s perceived behavioral control and the exercise of control over a certain action. 
To the extent that individuals are realistic in their judgment and confident in 
carrying out a behavior, perceived behavioral control can substitute for actual control and 
contribute to the prediction of the individual’s intention to take action.  According to the 
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TPB, the combination of attitudes, beliefs, subjective norms, and perceived behavioral 
control lead to the formation of a behavioral intention (Ajzen, 1988).  A perceived 
behavioral control scale should contain items assessing a person’s perceived capability or 
self-efficacy and control over performing a certain behavior (Ajzen, 2002).  An 
individual’s perceived capability and self-efficacy is strengthened by experience 
(Bandura, 1997).  The construct of perceived behavioral control includes items assessing 
how much control participants have in performing certain safer sex behaviors with a 
Likert-type containing “Complete control” and “No control” endpoints. 
 Items assessing behavioral intention are included in the survey to compare with 
participant responses to the constructs that, according to the TPB can predict intentions, 
such as attitudes, normative beliefs and perceived behavioral control.  According to 
Ajzen (2006), including only direct measures of the TPB constructs, such as intentions, 
can yield low reliabilities and lead to an underestimate of the relations among the theories 
constructs and its predicative validities.  The construct of intentions included items that 
assessed intentions to practice safer sex behaviors.  These items were related to the 
research questions concerning the relationship between knowledge of HPV and intentions 
to practice safer sex behaviors and the relationship between HPV vaccine acceptance and 
intentions to practice safer sex behaviors. 
For data analysis, each Likert-type scale with a neutral response and forced choice 
format, included in the online survey instrument, were scored in a unipolar fashion from 
5, 4, 3, 2, 1 without any negative numbers.  The responses were coded consistently with 
the meaning of the response.  Thus, scores were higher for favorable beliefs, with the 
strongest favorable attitude or belief having the highest value (e.g., 5).  The score was 
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lower for the strongest unfavorable attitudes or beliefs.  Dichotomous scales were scored 
as “2” for “Yes” and “1” for “No, and certain scales included a score of “1.5” for “Not 
sure” and “True/False” items were scored “1” for the correct answer and “0” for the 
incorrect answer.  Data were analyzed using multiple methods described in the analysis 
section of this chapter. 
Protection of Human Subjects 
 
 The survey instrument was revised based upon a review by a panel of experts and 
pilot testing.  The study, including each of the pilot tests, and a copy of the instrument 
was approved by the USF Institutional Review Board (IRB), CMU, and the WMU IRB.   
Pilot Testing 
Individual telephone interviews were conducted in a sample of 15 undergraduate 
female college students, between the ages of 18 to 24, from the three participating 
universities.  Five undergraduate female students from each university participated in the 
interview and the average duration of the interview was 15 minutes. The interview 
questions assessed participant beliefs about becoming vaccinated against HPV  
(Appendix D).  The purpose of these interviews was to refine the survey instrument, 
specifically for items assessing barriers to, benefits, and influential factors to becoming 
vaccinated.  Student health services staff recruited participants by posting fliers in health 
clinics and other campus locations, and distributing fliers to students at clinic visits and at 
health education workshops.  Participants were undergraduate female students, between 
the ages of 18 to 24, including those who were and who were not vaccinated against 
HPV.  Students provided verbal informed consent over the phone before participating in 
the interview (Appendix D), and each respondent received $25 for their participation.  
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Interview responses were categorized into themes (Appendix E).  The instrument was 
revised based upon the themes, as additional barriers, benefits, influential factors to 
becoming vaccinated against HPV were identified and added to the survey.  A question 
concerning whether the participants had health insurance was added to the demographic 
section of the survey, as health insurance status was reported to be a factor in influencing 
and being a barrier participants from becoming vaccinated against HPV. 
The instrument was revised based upon the interview data, content analyses by a 
panel of experts and pilot test results.  The instrument was pilot tested for construct 
validity, internal consistency reliability, and test-retest reliability.    
Reliability and Validity of Instruments 
It is important to assess the reliability and validity of data collection instruments 
so that the instruments measure what they are supposed to measure and that the data are 
free from measurement error (Sarvela & McDermott, 1993).  Validity is the most 
important consideration in designing and developing an instrument, as it refers to the 
quality of the data derived from the instrument and whether the instrument measures 
what it is supposed to measure. 
After development, the instrument underwent a preliminary review by a panel of 
experts (Appendix F).  There were specific criteria for membership on the expert panel.  
Membership required that individuals have longevity in the fields of HPV-related 
research and content areas, STI prevention and education, application of health education 
and behavioral change theories in STI prevention and treatment , and research methods 
and design.  Longevity was defined by having published scholarly papers, being 
instructors and serving as consultants in the above fields.  The HPV-related content areas 
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relative to this study include: HPV knowledge and awareness among young adults and 
college students, vaccine acceptance, and HPV vaccine development.  Panel members 
with experience in research design, methods, measurement, and behavioral change 
theories are the following advisors and members of the dissertation committee: Dr. 
Robert McDermott, Dr. Karen Perrin, and Dr. Ellen Daley from the USF College of 
Public Health.  In addition to providing direction and guidance in the logistics of the 
dissertation process, these panel members were asked to provide assistance with the 
research methodology of the study.  These members were asked to provide feedback on 
sample recruitment and selection, and instrument validation to ensure that the survey 
items are representative of the study constructs the instrument is intended to measure.   
These individuals also provided feedback on the instrument’s readability, format and 
directions.  Dr. Jeffrey Kromrey from the USF College of Education, Department of 
Educational Measurement and Research, is also a member of the dissertation committee 
and provided assistance in statistical methods and data analysis.  Dr. Kromrey assisted 
with sample size determination for the study and the factor and reliability analyses of the 
pilot test data.  Dr. Kromrey also provided assistance with analysis of the survey data. 
Additional individuals were asked to assist in the process of instrument 
development and validation, specifically for instrument content and construct validity. 
For content validity, this expert panel of reviewers helped to reduce the number of items 
by assigning scale items to factor labels and selecting the most salient items for factor 
analysis for construct validity.  The methods for content and construct validity is further 
described in a later section of this chapter. 
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Dr. Richard Roetzheim from the USF Department of Family Medicine 
participated in the panel review for content validation of the instrument.  Dr. Roetzheim 
has conducted research and published in the areas of HPV knowledge and awareness 
among college students. 
Dr. Gregory Zimet from the Department of Pediatrics at the Indiana University 
School of Medicine also participated in the panel review of the survey instrument for 
content validation.  In addition to publishing in the areas of HPV vaccine acceptance and 
prevention, Dr. Zimet applied the HBM in studying STI vaccine acceptance. 
Additional expertise for validation of the survey was sought from Dr. Anna 
Guiliano from H. Lee Moffitt Comprehensive Cancer Center, Dr. Jessica Kahn from the 
Cincinnati Children’s Hospital Medical Center, and Dr. Laura Koutsky from the 
University of Washington School of Public Health.  However, these individuals were not 
able to review the survey due to time constraints. 
Content and Construct Validity 
Content validity demonstrates the degree to which a sample of items or questions 
on a test or survey are representative of a defined content domain.  This type of validity 
should be used when developing all data collection instruments (Sarvela & McDermott, 
1993).  Content validity is especially important in developing achievement and aptitude 
tests, and for instruments measuring social behavior (Isaac & Michael, 1995).  The 
content domains developed and tested in this study were as follows:  knowledge about 
HPV, knowledge about the HPV vaccine, perceived susceptibility to HPV, perceived 
severity of HPV, HPV vaccine acceptance, attitudes about practicing other safer sex 
behaviors, normative beliefs about practicing safer sex behaviors, perceived control in 
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practicing safer sex behaviors, and intentions to practice safer sex behaviors.  The initial 
instrument included a total of 96 survey items assessing nine constructs from the HBM 
and TPB for the panel review.  To ensure content validity, the panel of experts  
(Appendix F) was asked to assess the degree to which the instrument items matched the 
objectives of the instrument through Instructional Quality Inventory (IQI) methods 
(Wulfeck, Ellis, Richards, Wood, & Merrill, 1978).  Experts were e-mailed a synopsis of 
the study, including the study research questions and the IQI method that included each 
item and an assessment matrix for each question.  Reviewers were asked to assess the 
following elements for each item: appropriateness of the question based upon the 
construct being measured; if the question was clearly stated, and if the response options 
were adequate or inadequate.  A comments box was also included for each item for 
reviewers to include suggestions for revisions, additions or deletions. Three members of 
the expert panel completed the instrument review.  The number of survey items, from this 
review, was reduced from 96 to 76 for pilot testing among female, undergraduate 
students, ages 18 to 24  
Construct validity demonstrates whether the instrument adequately measures the 
construct under study.  Factor analysis can be used to determine how well items in a 
specific subscale measure a particular construct, and which items in each subscale can be 
retained or discarded.  One of the purposes of factor analysis is to validate a scale or 
index by demonstrating that scale items or variables load on the same factor, and to 
eliminate scale items that load on more than one factor.  Factor analysis produces factor 
scores that can be used as weights in creating an index of constructs with their related 
items.  Factor analysis results can reveal whether more than one survey item is associated 
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with one or more construct being studied.  A factor loading of .30 was used as the cut-off 
or criterion score in this study, as this score is one of the most popular criteria for the 
interpretation of factor analysis results (Nunnally, 1978; Tabachnick & Fidell, 1983). 
Exploratory factor analysis, specifically principal axis factoring, was used for 
factor analysis and data reduction in this study.  Principal axis factoring is recommended 
when the primary concern is determining the minimum number of factors that account for 
maximum variance in the data for use in subsequent data analysis (Bryant & Yarnold, 
1995).  Principal axis factoring was used to detect whether the subscale items in the 
survey instrument adequately measure the constructs in the combined model of the HBM 
and the TPB.  The constructs measured were those included in the HBM and TPB, as 
follows: knowledge of HPV and the HPV vaccine, perceived susceptibility of HPV, 
perceived severity of HPV, HPV vaccine acceptance, attitudes, normative beliefs, 
perceived behavioral control, and intentions in practicing safer sex behaviors, including 
being vaccinated against HPV.  The Kaiser rule is to drop all components with 
eigenvalues under 1.0, as it may overestimate or underestimate the true number of 
factors. 
Interval or ratio level measurement is preferred for factor analysis, and extra 
caution is needed for interpretation of ordinal scales (Neuman, 1997).  Factor 
interpretations and labels must be rooted in theory, with scale items that are focused on 
theorized dimensions or constructs (Froman, 2001).  The subscale items in the survey for 
this study were developed to measure the constructs in the HBM and TPB. 
Certain precautions can be taken to ensure meaningful results and address 
challenges related to factor analysis, such as the non-normal distribution of data, 
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multivariate outliers, linear bivariate relationships between variables, and sufficient 
multicollinearity of the variables.  If distributions are non-normal, data may require 
transformations or other special procedures to adjust data from dichotomous response 
scales before conducting a factor analysis.  Factor analysis was conducted in the first and 
second pilot tests.  Each data set was analyzed for kurtosis and skewness in SPSS 13, and 
the distribution of data was normal in each pilot test.  Therefore, additional procedures to 
normalize the pilot test data were not necessary. 
Outliers can impact correlations between scale items, and therefore, distort factor 
analysis (Bryant & Yarnold, 1995).  Mahalanobi’s distance was applied in the pilot test to 
identify the cases that were multivariate outliers, using the same number of predictors for 
intentions that were used to calculate the study sample size.  A rule of thumb is l chi-
square value with degrees of freedom distance should not exceed the critical chi-square 
value at α = .001 or outliers could be equal to the number of predictors and that the 
maximum value for Mahalanobi’s a problem in the data (Tabachnick & Fidell, 2001).  A 
chi-square distribution table was referred to (Kuzma, 1992), and the maximum value for 
Mahalanobi’s distance for the predictors of attitudes, normative beliefs and control 
beliefs did not exceed the critical chi-square value at df = 3 and α = .001.  Therefore, the 
results demonstrated there were no multivariate outliers in the pilot test data.  These same 
procedures were used to test the study data for normal distributions, skewness, and 
multivariate outliers. 
At the stage of factor analysis, it is easier to remove items in a survey rather than 
add them, as adding items would require selection of another sample size for a second 
round of pilot testing.  An excess of items may demand a large sample to allow a 
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reasonable subject to item ratio, and may be difficult to assess for exploratory factor 
analysis.  For exploratory factor analysis, Thurstone recommends at least three items per 
factor (Kim & Mueller, 1978), whereas other researchers have recommended at least five 
items but fewer than ten items for each dimension defining the construct (Tabachnick & 
Fidell, 2001).  There were at least three items for each factor in the survey instrument. 
Reliability  
In addition to testing for practicality and construct validity, the pilot test data were  
used to measure the internal consistency and test-retest reliability of the survey 
instrument. A reliable instrument is one that is reliable, consistent, and stable (Kerlinger, 
1973), and reliability is measured by the degree to which measurement instruments are 
free from measurement error (Sarvela & McDermott, 1993).  The survey questionnaire 
was tested for internal-consistency reliability to determine how well the survey items 
used to measure particular study variables relate to each other or “hang together” 
(Nunally, 1978).  Because internal consistency is important in determining how items on 
test or scale relate to each other, researchers recommend calculating internal-consistency 
reliability for knowledge and attitude scales (Sarvela & McDermott, 1993).  Cronbach’s 
alpha is a measure of the degree to which scale items co-vary and indicates the proportion 
of variance of the scale that is due to the variance in underlying variables or to 
measurement error or random variation.  The sexual behavior scale developed by 
Morrison et al. (1998) was tested for its reliability.  A Cronbach’s alpha score of .79 
demonstrated adequate reliability (DeVellis, 1991).  Because the survey includes a 
section of the sexual behavior scale with items that specifically measure college students’ 
perceived ability to engage in safer sex behaviors, along with items from other attitude 
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and knowledge scales, the survey developed in this study was tested for internal 
consistency reliability using Cronbach’s alpha.  The Kudar-Richardson-20 is a test that is 
analogous to Cronbach’s alpha, and was used to assess internal consistency reliability for 
dichotomous scale items, such as yes/no and true/false.  There is no set interpretation as 
to what is an acceptable alpha value; however, a rule of thumb applied in most research 
situations is that an alpha score of .70 is considered acceptable (George & Mallery, 2006; 
Nunnally, 1978). 
The instrument was also tested for stability or test-retest reliability.  Test-retest 
reliability is estimated by correlating the results of a test that have been administered to 
the same group of participants two or more times (Ferguson, 1981).  The mean factor 
scores of participant responses from the pre-test and retest were calculated for items 
measuring each construct. The pre-test and retest data for each construct were correlated 
to determine the scale’s test-retest reliability. 
Pilot test #1.  The online survey was pilot tested in Fall 2007, with a convenience 
sample of undergraduate students (N = 140) ages 18 to 24 enrolled in undergraduate 
courses at USF College of Public Health, Central Michigan University, and Western 
Michigan University.  The participants completed the survey on the University of South 
Florida’s online survey tool, Survey.acomp.  Five instructors from the three participating 
universities assisted with the recruitment of female, undergraduate students from the 
following health-related courses:  “Assessment, Planning and Evaluation,” “Community 
Health,” “Critical Issues in Public Health,” “Health and Wellness,” “Healthy Lifestyles,” 
“Survey of Human Disease,” and “School Health Methods”.  Two of these courses, 
specifically, “Critical Issues in Public Health” and “Survey of Human Disease” were 
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online courses.  Female, undergraduate students enrolled in an athletic training program 
at Central Michigan University also were recruited to participate in the pilot test.  
Participants who completed the survey and provided their e-mail address and last four 
digits of their student ID were entered into a one-time $500 cash drawing.  Students were 
recruited by instructors posting the online survey link to their course web sites via the 
university Blackboard system and e-mailing the link directly to students via Blackboard 
sites.  Some instructors also made announcements about the pilot test to students in class. 
Although the survey was pilot tested with a total of 140 undergraduate students, 
ten participants were omitted for the data analysis.  These participants were omitted for 
one or more of the following reasons: 1) Five percent or more of survey items had 
missing responses, 2) Age or gender was not reported, or 3) Age reported did not match 
the criteria for participation in the study.  Therefore, pilot test data were analyzed for 130 
undergraduate female students, between the ages of 18 to 24.  A random selection of 
survey code numbers was generated via SPSS 13, and one participant was randomly 
selected and received a cashier’s check for $500. The instrument was initially pilot-tested 
with students for practicality, and to obtain reactions to the survey, specifically to 
determine readability, clarity, scope, and sequence of the survey items, completion time, 
and ease of use in completing the survey online.  The purpose of the pilot test also was to 
reduce the number of survey items. 
The average time it took participants to complete the survey was 14.8 minutes.  
Forty-seven percent (N = 61) of participants reported that the survey was too long, and 
20% (N = 26) of the participants reported that the questions were repetitive.  The data 
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were normally distributed as skewness and kurtosis values for the majority of survey 
items were between ±2. 
The survey was revised based upon participant feedback, specifically re-wording 
questions and response options and revising skip patterns in the survey.  In addition, the 
number of survey items, was reduced from 76 to 59 items through factor analysis.  A 
second pilot test was necessary to determine the duration of the revised survey, to  
reconduct a factor analysis of revised survey items to ensure construct validity of the 
revised instrument, to further reduce the number of survey items, if warranted, and to 
conduct a test-re-test to determine the reliability of the revised survey. 
 Pilot test #2.  The second pilot test of the revised instrument was conducted in 
Spring 2008 with a convenience sample of female, undergraduate students (N = 127), 
ages 18 to 24, at the three participating universities.  The same instructors from the three 
participating universities who assisted with recruitment for the first pilot test also assisted 
with recruitment for the second pilot test.  Participants were recruited in the same manner 
as the first pilot test and were recruited from the following courses:  “Community 
Health,” “Critical Issues in Public Health,” “Diversity,”  “Foundations of Maternal and 
Child Health,” “Health and Wellness,” “Healthy Lifestyles,” and “Teaching Methods”.  
Participants were asked to complete the online survey and then re-take the same 
instrument two-weeks later for test-re-test reliability.  Participants who completed the 
initial survey were sent e-mail reminders by the principal investigator one week and one 
day before their scheduled date to re-take the survey. 
Although 127 participants completed the initial survey, two participants were 
omitted from the data analysis.  These participants were omitted for one or more of the 
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following reasons: 1) Five percent or more of survey items had missing responses and 2) 
Age or gender was not reported.  Therefore, pilot test data were analyzed for 125 
undergraduate female students, between the ages of 18 to 24. 
Because the number of items in the survey was reduced from 76 to 59 items from 
the first pilot test, the duration required by participants to complete the revised survey 
was reduced by approximately five minutes.  The average time it took participants to 
complete the revised survey was 9.6 minutes, compared to 14.8 minutes in the first pilot 
test.  Furthermore, approximately 5% of participants (N = 7) reported that the length of 
the revised survey was too long, compared to 47% of participants (N = 61) in the first 
pilot test, and 2% of participants (N = 2) reported that the questions were repetitive 
compared to 20% of participants (N = 26) in the first pilot test.  The data were normally 
distributed as skewness and kurtosis values for the majority of survey items were 
between ±2. 
 Approximately 45% of the participants (N = 57) who completed the initial survey 
also completed the survey re-test, and the majority (76%) of these participants completed 
the re-test in exactly two weeks from the initial survey.  Twenty-four percent of the 
participants (N = 13) completed the retest before or after the two week interval, ranging 
from 10 to 23 days.  Three participants were omitted from the reliability analysis as one 
participant had missing data for over 5% of the items on the re-test and two participants 
did not include an e-mail address, and therefore, their re-test data could not be matched to 
data from the initial survey. 
A factor analysis was conducted on the pilot test data to ensure construct validity 
and the data was analyzed for internal consistency reliability, described in a later section.   
 124
The results from the factor analysis demonstrated that each study construct was 
represented by one factor, except HPV vaccine acceptance (Appendix G).  The additional 
section on benefits was removed, as the results of factor analysis revealed none of the 
items intended to measure benefits had a factor loading of .30 or higher on any of the 
factors representing vaccine acceptance (i.e., influential factors, benefits, barriers).  The 
construct of vaccine acceptance was represented by the follow three factors: general 
vaccine acceptance, issues that would influence one to become vaccinated against HPV 
and barriers to becoming vaccinated against HPV.  The number of questions was reduced 
from 59 to 56 items.  One item was removed from the scale on knowledge about HPV 
and two items were removed from two of the following scales measuring HPV vaccine 
acceptance – issues that would influence one to become vaccinated and barriers to 
becoming vaccinated.  In addition, five response options were removed from the item 
measuring knowledge about the HPV vaccine. 
The analysis of data from the second pilot test also helped to determine a sample 
size needed for the study.  Multiple regression analysis of mean factor scores from the 
pre-test data revealed that 1700 participants were needed to participate in the study, based 
upon a medium effect size (f2 = .15) and a power of .80.  Participants who completed the 
survey re-test were entered into a one-time $500 cash drawing, and one participant was 
randomly selected to receive the incentive. 
 The survey was tested for internal consistency reliability.  Cronbach’s alpha was 
calculated for each scale measuring the different study constructs.  Although some of the 
scale values were below .70, the values were considered to be in an acceptable range by 
the statistics advisor on the committee (Appendix H).  However, the test-retest reliability 
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analysis demonstrated that there was not a significant correlation between mean factor 
scores for the scale measuring the severity of HPV.  There were significant correlations 
between the mean factor scores for each of the scales measuring the other study 
constructs (Appendix I).  A fourth item was added to increase the reliability of the scale 
on the severity of HPV, and a third pilot test was conducted only for this scale.  This item 
was included in the scale on the severity of HPV in the initial survey instrument, but was 
removed because it did not meet a criterion score of .45 for factor loading that was 
initially selected.  This factor loading was determined by a calculation that incorporated 
the sample size of the pilot test.  However, because the sample size for the study was 
unknown, and anticipated to be larger, it was determined that .45 was too stringent and a  
criterion score of .30 was used in the factor analysis of survey data from the second pilot 
test.  The fourth item loaded well on the one factor for severity of HPV from the factor 
analysis of the first pilot test with a cut-off score of .352 for factor loading.  Therefore, 
this item was added back to the existing scale to pilot test for test-retest reliability, instead 
of developing a new survey item. 
Pilot test #3.  A sample size of 15 to 20 participants was necessary for this pilot 
test as only one section of the survey (entitled “How HPV can affect you”) was tested.  
The online pilot test survey included four items intended to measure the severity of HPV, 
in addition to items assessing age, gender, year in college, and university, to ensure that 
only eligible participants completed the test-retest.  An online informed consent was 
included before the survey, and participants were asked to review the informed consent 
before proceeding with the pilot test.  Participants were also asked to include the last four 
digits of their student ID and e-mail address to be eligible to receive an incentive.  
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Participants were recruited in the same manner as the first and second pilot tests and were 
recruited from the following courses:  “Contemporary Health Sciences,” Health and 
Wellness,” “Healthy Lifestyles,” and “School Health Methods”.  Instructors from the 
three participating universities assisted with the recruitment for the pre-test.  However, 
the sample size that was necessary consisted of students only from Central Michigan 
University and the University of South Florida.  A convenience sample of undergraduate 
female college students (N = 27), between the ages of 18 to 24, completed the test-retest.  
There was no missing data among the participants, and the data was normally distributed 
as skewness and kurtosis values for each of the survey items were between ±2.  
Participants who completed the test-retest were entered into a one-time $25 cash drawing, 
and one participant was selected to receive the incentive.  The test-re-test reliability 
analysis demonstrated that there was a significant correlation between mean factor scores 
for the revised scale measuring HPV severity (Appendix J).  Because the item increased 
the reliability of this scale, the item was added back to the survey, and there were a total 
of 57 items on the final survey instrument. 
Analysis of Data 
 The data was analyzed using multiple methods in SPSS 13.  Frequency 
percentages and measures of central tendency, such as the mean and standard deviation, 
were calculated for univariate data.  The univariate data include demographics and sexual 
history, knowledge about HPV and the HPV vaccine, in addition to attitudes and beliefs 
about practicing safer sex behaviors.  Linear correlation can be calculated to confirm 
relationships and strength of relationships between quantitative variables, for example, 
age and number of sexual partners, and number of sexual partners and level of HPV 
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vaccine acceptance.  The Pearson product-moment correlation coefficient (r) was 
calculated to measure relationships between variables in this study.  The Pearson r 
coefficient may take on values from –1 to +1.  Coefficient values that are close to +1 
indicate a high positive correlation, values close to -1 indicate a high inverse correlation, 
and values close to zero indicate no correlation.  To determine if the correlations are 
significant and to test the null hypothesis that there are no linear correlations between the 
variables – a test of significance will be performed and confidence intervals will be 
estimated. 
 Multiple linear regression was used to measure the degree of relationships 
between the same variables by calculating the regression coefficient or the amount of 
change in the dependent variable for a given change in the independent variable (Kuzma, 
1992).  Multiple regression shares the same assumptions as correlation and the 
assumptions are as follows: the relationships are linear so there is a constant rate of 
change between 2 variables, there is the same level of relationship throughout the ranges 
of the independent variable or “homoscedasticity,” absence of outliers, normal 
distribution of data and independence of data or observations (Kleinbaum, Kupper, & 
Muller, 1988). 
Specifically, the degree of relationships was assessed among variables such as the 
relationship between HPV vaccine acceptance and attitudes, normative beliefs, control 
beliefs, and intentions to practice safer sex behaviors.  Multiple linear regression was 
used determine the strongest predictors of the relationships between study variables, for 
instance, the variables that are the strongest predictors for intentions. To determine how 
reliable the regression equation is in predicting the degree of relationships between 
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variables, a test of significance using the standard error of estimate was calculated, and 
confidence intervals were estimated. 
Below are lists of the research questions, followed by an explanation of the data 
analysis procedures that addressed each question. 
• What is the relationship between knowledge about HPV and intentions to practice 
safer sex behaviors among women attending college? 
 
o What is the relationship between knowledge about HPV and attitudes 
towards practicing safer sex behaviors? 
 
o What is the relationship between knowledge about HPV and normative  
beliefs about practicing safer sex behaviors? 
 
o What is the relationship between knowledge about HPV and perceived 
control towards practicing safer sex behaviors? 
 
The Pearson product-moment correlation coefficient (r) was calculated between 
the mean values of knowledge about HPV to determine if there were significant 
relationships between knowledge about HPV and the predictors of intentions, including  
attitudes, normative beliefs, and control beliefs, as well as a signficant relationship 
between knowledge and the variable of intentions as measured via survey items. 
• What is the relationship between knowledge of the HPV vaccine and acceptance 
of the HPV vaccine among women attending college? 
The Pearson product-moment correlation coefficient (r) was calculated between 
the variables of general vaccine acceptance and knowledge of the HPV vaccine.  For 
those variables of acceptance that had a significant correlation with knowledge of HPV, 
multiple linear regression was calculated to determine the strength of the relationship 
between each influential factor to acquiring the HPV vaccine and knowledge of the 
vaccine and each barrier to acquiring the HPV vaccine and knowledge of the vaccine. 
 129
• What is the relationship between health beliefs about HPV and acceptance of the 
HPV vaccine among women attending college? 
 
o What is the relationship between perceived susceptibility to HPV and 
vaccine acceptance? 
 
o What is the relationship between perceived severity of the HPV vaccine 
and vaccine acceptance? 
 
The Pearson product-moment correlation coefficient (r) was calculated between 
the perceived susceptibility of HPV and each variable of vaccine acceptance (i.e., general 
vaccine acceptance, influential factors, and barriers) and perceived severity of HPV and 
each variable of vaccine acceptance.  For those correlations that were significant, 
multiple linear regression was calculated to determine the strength of the relationship 
between each influential factor to acquiring the HPV vaccine and perceived susceptibility 
and perceived severity and the strength of the relationship between each barrier to 
acquiring the HPV vaccine and perceived susceptibility and perceived severity. 
• What is the relationship between acceptance of the HPV vaccine and intentions to 
practice other safer sex behaviors among women attending college? 
 
o What is the relationship between acceptance of the HPV vaccine and 
attitudes towards practicing safer sex behaviors? 
 
o What is the relationship between acceptance of the HPV vaccine and 
normative beliefs about practicing safer sex behaviors? 
 
o What is the relationship between acceptance of the HPV vaccine and 
perceived control towards practicing safer sex behaviors? 
 
 
The Pearson product-moment correlation coefficient (r) was calculated between 
each variable of vaccine acceptance (i.e., general vaccine acceptance, influential factors, 
and barriers) and attitudes, normative beliefs, perceived control, and intentions towards 
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practicing safer sex behaviors.  For those correlations were significant, multiple linear 
regression was calculated to determine the strength of the relationship between each 
influential factor to acquiring the HPV vaccine and attitudes, normative beliefs, perceived 
control, and intentions and each barrier to acquiring the HPV vaccine and attitudes, 
normative beliefs, perceived control, and intentions. 
Missing Data 
 Because the survey content was about STIs and protective sexual behaviors, some 
students may have chosen not to answer certain questions.  Students were provided an 
informed consent option before they were asked to participate in the pilot tests and study 
survey, and this informed consent included the nature of the survey and informed them 
that the survey contained items about their sexuality and sexual behaviors that may make 
them feel uncomfortable.  Consequently, they did not have to complete the survey if they 
thought it would make them feel uncomfortable; also, they did not have to answer any 
questions that made them feel uncomfortable.  In addition, students were informed of 
their right to stop taking the survey at any time through the informed consent (Appendix 
B). 
One of the purposes of pilot testing is to rephrase and omit questions that make 
the majority of participants feel uncomfortable.  By rephrasing questions so they are less 
intimidating or intrusive, removing controversial questions after the pilot test, and 
informing students about the nature of the survey, missing data were anticipated to be 
minimal.  However, missing data continue to be problematic in behavioral research 
(Azar, 2002), so it was expected that there would be some missing data in this study. 
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According to Little and Rubin (1997), the rule of thumb for analyzing missing 
data and not deleting missing cases, is when a particular subject or variable has more than 
5% missing values, but many researchers are more stringent. Participants with less than 
5% of missing data were not omitted from the pilot tests or study, i.e., they were included 
in the data analysis.  Omitting participants could have potentially skewed data and 
resulted in biased study conclusions.  Although the pilot test and study samples were not 
randomly selected, omitting data from participants could have resulted in the loss of 
valuable data, as individuals who refused to respond to certain questions may be 
systematically different than those who agree to take part, and those differences could be 
related to variables of interest in the study.  Also, if most participants have missing data 
for the same questions, it may indicate that the questions were not well understood by 
participants. 
Missing data, for the pilot tests and study, were assigned a missing value code of 
“99” so they could be analyzed separately from other survey responses.  Analyzing 
missing data separately reduced the chanced of skewed results, minimizing the risk that 
study conclusions could become biased.  Missing values for the pilot test and survey data 
were analyzed to determine if they were missing completely at random (MCAR) when 
the missing values are randomly distributed across all observations, or are missing at 
random (MAR), when missing values are not randomly distributed across all observations 
but are randomly distributed within one or more stratified samples, such as certain ethnic 
groups. 
Little’s MCAR test, a chi-square test, was calculated for each pilot test to 
determine if missing data values were completely at random.  Mean differences were 
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calculated on demographic variables using t-tests and other key variables to establish that 
the two groups did not differ significantly from each other.  Because the data were 
MCAR, missing values did not need to be imputed. 
Missing data for “Pilot Test #1” and “Pilot Test #2” were MCAR; therefore, 
pairwise deletion was conducted to remove cases with missing data for specific 
calculations.  Participants or cases that had more than 5% missing data were removed 
from the data analysis, and t-tests for mean differences and analysis of variance 
(ANOVA) were calculated to determine if there were significant differences for 
demographic variables between the group of participants with missing data and the group 
of participants without missing data.  There were no significant differences between 
groups in the first pilot test.  However, there were significant differences between groups 
in the second pilot test.  Participants who were in their senior year of college and who 
were 21 years of age had significantly more missing data compared to participants of 
other class rankings and ages.  Cross-tabulation results revealed that the majority of 
students who were seniors were also age 21.  There were no missing data among 
participants in the third pilot test. 
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Chapter Four 
Results 
This chapter describes the study participants, their responses to the survey, 
including lack of survey responses or missing data, and results related to the research 
questions. 
Description of Respondents 
 A convenience sample of 2,872 undergraduate students enrolled at CMU, USF 
and WMU completed the online “HPV Vaccine Survey” between January 12 to July 3, 
2009.  A formula was developed in Microsoft Excel to identify survey takers who 
participated in one of the three pilot tests, and to identify ones who completed the survey 
twice.  For persons who completed the survey twice, the second survey was deleted (N = 
73).  In addition, 12 participants were omitted due to their dual participation in the survey 
and one of the three survey pilot tests. 
For the main survey, three participants who completed it were male, and 19 
participants did not respond to the gender question.  An additional 12 participants did not 
respond to the question on age.  Because of these participants being male, or of unknown 
gender or age, these 34 participants also were omitted from the study. 
Missing data analysis was conducted for 2,753 participants.  An additional 47 
participants were omitted from the study due to having five percent or more of survey 
items with missing responses. 
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 A sample size of 2,706 female undergraduate students, between the ages of 18 
and 24 were included in the data analysis.  There were of 8.3% of participants that had 
missing responses for < 5 percent of the survey items.  Little MCAR’s test was conducted 
with missing data for these participants.  Because the chi square test statistic was not 
significant (χ 2 = 3324.496, df = 3424, p = .886), missing data were assumed to be 
MCAR.  Independent-sample t-tests, for two groups, and one-way analysis of variance 
(ANOVA), for three or more groups, were conducted to determine if there were any 
significant differences for demographic variables between groups with and without 
missing data.  Tukey’s honestly significant difference (HSD) post hoc test was conducted 
to determine which specific groups significantly differed from each other for missing data 
(Appendix K).  The difference in means for missing data between certain ethnic groups 
was statistically significant F(8, 2690) = 2.951, p = .003.  Specifically, African-American 
participants were significantly more likely to have missing data than White participants, 
MD = .079, p = .001.  In addition, the difference in means for missing data between 
participant groups with different sexual orientations was statistically significant F(3, 
2695)  = 2.930, p = .032.  Participants who had sex with women were more likely to have 
missing data compared to participants who had sex with men; however, the difference in 
means was not significant at the .05 level (MD  = .094, p = .061).  There were no 
significant differences between participants with and without missing data for any of the 
other demographic variables: age, marital status, number of sexual partners, whether they 
were currently sexually active, whether they had children, year in college, university 
enrollment, and whether they had health insurance that covered the HPV vaccine.  
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Pairwise deletion was conducted to remove cases with missing data for specific 
calculations. 
There was a normal distribution of participants, based on measures of skewness 
and kurtosis, for nearly all of the demographic variables, except for number of sexual 
partners.  See description of frequencies below under “Sexual orientation, number of 
sexual partners, and current sexual activity” for further detail.  Appendix L contains 
statistics tables that include measures of central tendency (i.e., mean, median, mode), 
standard error of the mean, standard deviation, variance, and skewness and kurtosis 
values. 
Age and ethnicity.  The mean age of the participants was 20.7 years (SD = 1.580) 
with a range of 18 to 24 years.  The majority of participants (70.1%) were White, 
followed by Multi-racial (8.6%), African-American (8.3%), Hispanic or Latino (8.1%), 
Asian (3.0%), Other (1.0%), Arab-American (0.4%), Native Hawaiian or other Pacific 
Islander (0.3%), American-Indian or Alaska Native (0.1%). Age distribution by ethnicity 
is reported in Table 2.  Age and ethnic distributions are illustrated in Figure 4 and Figure 
5. 
University and year in college.  The majority of participants (73.8%) were 
enrolled at USF, 24.7% were enrolled at WMU and 1.5% were enrolled at CMU.  The 
highest percentage (46.4%) of students were seniors, and the majority of seniors (87%) 
were 21 years of age and older.  University enrollment by year in college is reported in 
Table 3 and illustrated in Figure 6. 
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Table 2 
Age of Respondents by Ethnicity 
________________________________________________________________________ 
Age 
________________________________________________________________________ 
 18            19            20            21             22            23            24 
________________________________________________________________________ 
Ethnicity                                           Percent 
________________________________________________________________________ 
White            6.2%       17.3%       22.4%      24.9%       15.2%       9.0%        5.0% 
 
 
African-          9.3%   20.4%       18.7% 12.9%      17.8%     12.4%         8.4% 
American 
 
Multi-racial     9.0%    23.2%      20.6% 17.6%     15.9%        8.6%         5.2%          
   
Hispanic or 7.3%    21.5%      22.8% 19.6%      16.4%        5.9%         6.4% 
Latino 
 
Asian             11.1%       11.1%      21.0%  23.5%      17.3%      13.6%        2.5% 
 
 
Arab-       8.3%       8.3%      33.3%  16.7%      16.7%      16.7%     0.0% 
American 
 
Native   
Hawaiian       14.3%     14.3%      28.6%  14.3%      14.3%      14.3%        0.0%        
or Pacific 
Islander 
 
American- 
Indian or     .0%       25.0%      50.0%   25.0%       0.0%        0.0%     0.0%           
Alaska         
Native 
 
Other                 -     15.4%      19.2%   15.4%     23.1%       11.5%      15.4%_____ 
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Figure 4.  Age distribution 
Sexual orientation, marital status, number of sexual partners, and current 
sexual activity.  Only women between the ages of 18 and 24 participated in this study.  
Most participants (80.1%) reported that they were heterosexual, by responding that they 
had sex with men, whereas the remainder of participants reported that they did not have 
sex (15.2%), had sex with men and women (2.7%), or had sex exclusively with women 
(2%).  The highest percentage of participants (49%) reported that they were single and in 
a monogamous relationship.  Over half of participants (51%) reported having one sexual 
partner in the past 12 months, 14.4% reported having two partners, 17.8% had three or 
more partners, and 16.6% reported having no sexual partners.  Because the majority of 
participants reported having only one sexual partner, and the range for this response was 
between one and 20, the skewness (3.057) and kurtosis (15.608) values were larger than 
what is considered acceptable for a normal distribution. 
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Figure 5.  Ethnic distribution 
Most participants (70.4%) reported that they were currently sexually active.  
Based on a chi-square test of independence, it appears that participants who reported 
having a greater number of sex partners in the past year were also significantly more 
likely to be currently sexually active, χ2(4, N = 2663) = 1289.54, p < .001.  There was a 
significant difference in current sexual activity among groups of participants in different 
types of relationships, χ2(4, N = 2685) = 1461.55, p < .001.  Participants who reported 
that they were married were more likely to be currently sexually active compared to 
participants who were in any other type of relationship.  There was also a significant 
 139
difference in current sexual activity among groups of participants based on age, χ2(6, N = 
2692) = 64.205, p < .001.  Current sexual activity increased with age, except for 
participants older than 23 years of age (Figure 7). 
 
Table 3 
University Enrollment by Year in College 
________________________________________________________________________ 
                                                             University 
_______________________________________________________________________ 
                                  CMU        USF             WMU                  Totals 
                                _______________________________________________________  
Year in College       N       Percent     N       Percent        N       Percent       N       Percent       
                  
_______________________________________________________________________ 
Freshman          5          3.2%  125  80.1%        26         16.7%   156 100% 
 
Sophomore          7          1.6%  375  84.4%        62         14.0%   444 100%    
 
Junior           8          .9%  664      78.5%      174         20.6%   846    100% 
 
Senior         20          1.6%  827      66.1%      405         32.3%      1252 100%  
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Figure 6.  University enrollment by year in college 
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Figure 7.  Current sexual activity by age 
 
Children, marital status, and age.  The majority of participants (97.5%) 
reported that they did not have children.  The skewness (6.062) and kurtosis values 
(34.769) were out of the normal range for this item.  There were 68 (2.5%) participants 
who reported they had children.  A chi-square test of independence revealed that there 
was a significant difference in marital status with children, χ2(4, N = 2692) = 118.97, p < 
.001.  The majority of participants with children were separated or divorced (50.0%), 
compared to participants who were married (16.0%) and participants who were single 
and sexually active (2.7%).  
A chi-square test of independence revealed that there was a significant difference 
in age of participants with children, χ2(6, N = 2698) = 56.05, p < .001, and the highest 
percentage of participants with children were 24 years of age (10.3%).  Number of 
children by age is reported in Table 4.  
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Table 4 
Children by Age of Participants 
________________________________________________________________________ 
               Children 
________________________________________________________________________
                       Yes                            No                                           Totals      
                              _________________________________________________________ 
Age          N      Percent            N      Percent                             N      Percent 
________________________________________________________________________ 
18         3              1.6%           183      98.4%                          186     100%  
 
19               5            1.0%           481      99.0%                          486     100%    
           
20                     9              1.5%           585      98.5%                          594     100%  
 
21                    8              1.3%               604      98.7%                          612     100% 
 
22                         20              4.7%               404      95.3%                          424     100% 
            
23                    8              3.2%           243      96.8%                           251    100% 
 
24                         15            10.3%               130      89.7%                           145    100%__ 
 
Health insurance status.  Forty-one percent (N = 1119) of participants reported 
that they had health insurance that covered the HPV vaccine, whereas 24.2% (N = 654) of 
participants reported that they did not have health insurance that covered the HPV 
vaccine and 34.3% (N = 925) reported that they were “not sure.”   The relationships 
between each of the demographic variables and health insurance status were assessed.  A 
chi-square test of independence revealed that participants who were freshman, χ2(6, N = 
2693) = 30.983, p < .001 were more likely to report that they had health insurance that 
covered the HPV vaccine, compared to those who were in any other year in college.  In 
addition, those who reported that they did have health insurance that covered the HPV 
vaccine were more likely to be sexually active compared to those who had health 
insurance that covered the vaccine or who were not sure about their health insurance 
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status, χ2(2, N = 2684) = 8.785, p =.012.  The relationship between having health 
insurance that covered the vaccine and cost of the vaccine being a barrier was assessed.  
Participants who did not have health insurance that covered the HPV vaccine were 
significantly more likely to perceive cost as an important barrier to becoming vaccinated 
compared to those who were not sure if they had insurance or who had insurance, χ2(4, N 
= 1693) = 293.168, p < .001.   Most participants who had health insurance that covered 
the vaccine reported that they were “Very Likely” to become vaccinated, 36% (N = 72).  
However, it is interesting to note that those who were unsure about their health insurance 
covering the vaccine were more likely to become vaccinated compared to those who were 
or who were not covered, χ2(8, N = 1692) = 62.337, p < .001.  Health insurance status by 
year in college is reported in Table 5 and illustrated in Figure 8.  Health insurance status 
by sexual activity is reported in Table 6 and illustrated in Figure 9.   Cost of the vaccine 
being a barrier by health insurance status is reported in Table 7 and reported in Figure 10.  
Likelihood of getting the vaccine by health insurance status is reported in Table 8 and 
Figure 11.   
Knowledge about HPV and the HPV Vaccine 
   Most participants 70.4% (N = 1904) responded accurately to all three 
True/False statements about HPV.  In addition, most (44.8% , N = 1211) checked all of 
the four correct statements about the HPV vaccine and 28.9% (N = 781) checked three 
out of the four correct statements about the vaccine.  The statement that was checked the 
most frequently by participants (81%) was, “The vaccine prevents women from getting 
high-risk HPV,” followed by “The vaccine will protect against cervical cancer” (78.4%).   
Cross-tabulation, as shown in Table 10, demonstrated that most participants (67%) 
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checked off both of these statements.  Three percent of participants (N = 81) had not 
heard about the HPV vaccine. 
 
Table 5 
Health Insurance by Year in College 
________________________________________________________________________ 
                                                                   Health Insurance 
                          ___________________________________________________________
                      Yes                  No                        Not sure                Totals      
                          ___________________________________________________________ 
Year in College     N      Percent         N      Percent          N      Percent         N      Percent 
________________________________________________________________________ 
Freshman              77       49.0%        26      16.6%           54     34.4%         157      100% 
 
Sophomore    214       48.3%       105      23.7%         124     28.0%         443      100% 
 
Junior                 369     43.8%       189      22.4%         285     33.8%         843      100% 
 
Senior                457       36.6%        333     26.6%         460     36.8%       1250      100%_ 
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Figure 8.  Health insurance by year in college 
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Table 6 
Health Insurance by Current Sexual Activity 
_______________________________________________________________________ 
                                                   Sexually activity in the past 60 days 
                          __________________________________________________________                      
      No                         Yes                             Totals      
                          __________________________________________________________ 
Health insurance              N          Percent             N         Percent             N        Percent  
that covers the  
HPV vaccine 
_______________________________________________________________________ 
No                                  166          25.5%            485         74.5%            651       100% 
 
Not sure                298          32.4%            621         67.6%            919       100% 
 
Yes                                 332        29.8%      782         70.2%          1114       100%___ 
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Figure 9.  Health insurance by current sexual activity 
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Table 7 
Cost of the Vaccine as a Barrier by Health Insurance Status 
________________________________________________________________________ 
                              Cost of the Vaccine Would Prevent Me From Becoming Vaccinated 
                          ___________________________________________________________
                    Not important         Somewhat              Very                    Totals 
                                      at all                 important           important                                           
                          ___________________________________________________________ 
Health                    N      Percent          N      Percent      N      Percent         N    Percent    
insurance that  
covers the  
HPV vaccine     
________________________________________________________________________ 
Yes                       160      42.2%        129      34.0%         90     23.7%       379      100% 
 
Not sure      115      14.0%        326      39.8%       379     46.2%       820      100% 
 
No                    26        1.7%        123      24.9%       345     69.8%       494      100% 
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Figure 10.  Importance of cost of the vaccine as a barrier by health insurance status 
 
 
 
 146
Table 8 
 
Health Insurance Status and Likelihood of Becoming Vaccinated 
____________________________________________________________________________ 
                                                            Health Insurance Status 
             _______________________________________________________________                                                            
                                         No                  Not sure                 Yes                      Totals                     
                          _______________________________________________________________ 
                                    N      Percent          N      Percent         N      Percent         N    Percent    
Likelihood of   
becoming vaccinated                                       _____________________________________ 
   Very unlikely          101     25.8%         171      43.6%       120      30.6%       392      100% 
                      
   A little likely           123     31.8%         206      53.2%         58      15.0%       387      100% 
 
   Somewhat likely     134     32.0%         221      52.7%         64      15.3%       419      100% 
 
   Likely                        92     31.3%        139       47.3%         63   21.4%       294      100% 
  
   Very likely                44     22.0%          84       42.0%         72      36.0%       200      100%___ 
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Figure 11.  Likelihood of becoming vaccinated against HPV based upon insurance status 
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Table 10 
Knowledge about the HPV Vaccine 
________________________________________________________________________ 
                                               The vaccine will protect against cervical cancer 
                          ___________________________________________________________
                              Not Checked            Checked                            Totals 
                          ___________________________________________________________ 
The vaccine                     N        Percent                N        Percent                N        Percent             
protects women  
from getting  
high risk HPV     
________________________________________________________________________ 
Not checked                  207         40.2%               308       59.8%                515       100.0% 
 
 
Checked               377         17.2%             1814       82.8%              2191      100.0% 
________________________________________________________________________ 
 
 There were 16.1% (N = 436) of participants who were told they had HPV by a 
health care provider, compared to 82% (N = 2215) who had not been told and 1.9% (N = 
51) who were “Not sure.”  Appendix M contains tables of participant responses to items 
assessing knowledge of HPV and the HPV vaccine.    
HPV Vaccine Acceptance 
 The majority (68.9%) of participants thought that vaccinations, in general, were 
“Very important”, and 37.3% (N = 1006) received at least one dose of the HPV vaccine. 
There were 1,693 participants who reported that they had not received at least one dose of 
the vaccine, and there were seven participants who had missing data on whether they 
received the vaccine.  It is important to note that some of the seven participants who did 
not respond to whether they were vaccinated against HPV did respond to subsequent 
questions assessing HPV vaccine acceptance, including likelihood on becoming 
vaccinated.  Because these participants had missing data, and therefore, may not have 
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been vaccinated, or mistakenly skipped the question, their responses were included in the 
assessment of the specific factors measuring HPV vaccine acceptance, in addition to the 
assessment of overall acceptance to address the study research questions.   Over one-
fourth of the participants (N = 494) who reported that they had not yet received the HPV 
vaccine responded that they were either “Very likely” or “Likely” to get vaccinated.   
A skip pattern was included in the survey and participants who reported they 
received the vaccine were directed to skip the questions on HPV vaccine acceptance.  
The majority of participants who received the vaccine followed the skip pattern.  
Responses to items on vaccine acceptance from participants who had received the 
vaccine were coded as “skipped” items.   
The influential factor in becoming vaccinated against HPV, that most participants 
rated as “Very Important” was “If I had an abnormal pap smear” (77.2%, N = 1307) and 
the influential factor that most participants rated as “Not important at all” was “If my 
friends think I should get it,” (50.4%, N = 856).  The importance of influential factors to 
becoming vaccinated against HPV, rated from highest to lowest for “Very important” is 
reported in Table 11.  The factor that most participants reported as “Very important”  to 
being a barrier in becoming vaccinated against HPV was the “The cost of the vaccine” 
(48.0%, N = 814),  and the factor that was rated by most participants as “Not important at 
all” to being a barrier in becoming vaccinated against HPV was “Fear of vaccines” 
(72.6%, N = 1232).   The importance of barriers in becoming vaccinated against HPV, 
rated from highest to lowest for “Very important” is reported in Table 12.  Appendix M 
contains tables, including frequency percentages, item means and standard deviations, of 
participant responses to factors associated with HPV vaccine acceptance.   
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Table 11  
HPV Vaccine Acceptance – Influential Factors for Vaccination 
________________________________________________________________________ 
                  Issues that would influence you to become vaccinated against HPV 
                          ___________________________________________________________
                    Very            Somewhat              Not at all  Totalsa    
      important             important        important 
                       ___________________________________________________________ 
Issues     N       Percent         N       Percent         N       Percent        N       Percent      
_______________________________________________________________________ 
If I had an       1307       77.2           322       19.0            63          3.7        1692      100.0 
abnormal Pap 
smear 
 
If my health    1140     67.2           381       22.4     176       10.4        1697      100.0 
insurance covers 
it 
 
If someone      1093       64.4           474       27.9          130          7.7        1697      100.0 
in my family 
has cancer 
 
If my health    1078       63.6           506       29.8          112          6.6        1696      100.0 
care provider 
thinks I should 
get it  
 
Whether          1077       63.6           447       26.4           170       10.0        1694      100.0 
I practice 
safe sex 
 
If my family   791       46.7           716       42.3           186       11.0        1693      100.0 
thinks I 
should get 
it 
 
If my sex   721        42.6          751       44.4           220       13.0        1692       100.0 
partner thinks  
I should get it 
 
If my friends    172    10.1          670       39.5    856       50.4        1698       100.0 
think I should  
get it___________________________________________________________________ 
Note. a The total N includes only those participants that did not receive at least one dose of the 
HPV vaccine. 
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Table 12  
 
HPV Vaccine Acceptance – Barriers to Vaccination  
________________________________________________________________________ 
                                     Issues that would be barriers to becoming vaccinated HPV 
                          ___________________________________________________________
                    Very            Somewhat              Not important Totalsa    
      important             important              at  all 
                       ___________________________________________________________ 
Issues     N       Percent         N       Percent         N       Percent        N       Percent      
_______________________________________________________________________ 
The cost of   814        48.0          580       34.2    302        17.8        1696      100.0 
the vaccine 
 
Possible             512        30.2          793       46.7      391      23.1        1696      100.0 
side effects 
of the vaccine 
 
Not knowing    293        17.3          537       31.7     864       51.0        1694       100.0 
where to get   
the vaccine  
 
Having to          258        15.3          691       40.9           741       43.8        1690      100.0 
get additional 
boosters after 
getting three 
shots 
 
Fear of          166         9.8           299       17.6          1232      72.6        1697      100.0 
vaccines  
 
Getting three     146       8.6          410       24.2  1141        67.2        1697      100.0 
shots over a 
six-month 
period 
 
Having to   135        8.0           502       29.7           1053      62.3        1690      100.0 
wait at my 
doctor’s office 
for approval  
to get the vaccine_________________________________________________________ 
Note. a The total N includes only those participants that did not receive at least one dose of the 
HPV vaccine. 
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Attitudes, Beliefs, and Intentions Regarding Practicing Safer Sex Behaviors 
 Attitudes.  The majority of participants had a favorable attitude towards 
practicing safer sex behaviors.  The mean response (M = 3.95) for items measuring 
attitudes was approximately “Agree” on the Likert-type scale.  The safer sex behavior 
that most participants reported would be very easy for them was refusing to have sex with 
a partner that will not use a condom by reporting “Strongly agree” (N = 1399, 51.8%)  
and“Agree” (n = 702, 26.0%), followed by avoiding the use of drugs or alcohol before 
engaging in sexual activity [“Strongly Agree” (N = 1380, 51.1%) and “Agree” (N = 602; 
22.3%].  Over 50% (N = 1403) of participants responded that they “Agree” and “Strongly 
agree” that telling a partner that they would not be sexually active with them until they 
have been tested for STIs would be very easy for them.  However, telling a partner that 
they will not be sexually active with them until they have been tested for STIs was also 
the safer sex behavior that had the highest percentage of participants “Disagree” (N = 
512, 19.0%) and “Strongly disagree” (N = 67, 2.5%) that it would be easy for them.  
Appendix M contains tables, including frequency percentages, item means and standard 
deviations, of participant responses to attitudes regarding practicing safer sex behaviors. 
The number and type of responses to survey items measuring attitudes about practicing 
safer sex behaviors are also illustrated in Figures 12 through 14. 
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Figure 12.  Refusing to have sex with a partner if they will not use a condom would be 
                     very easy for me. 
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Figure 13. Telling a partner that I will not be sexually active with them until they have 
                     been tested for sexually transmitted infections would be very easy for me. 
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Figure 14.  Avoiding the use of drugs or alcohol before engaging in sexual activity 
                        would be very easy for me. 
 
Normative beliefs.  The majority of participants had negative normative beliefs 
in terms of their peers practicing safer sex behaviors compared to their own attitudes 
about practicing safer sex behaviors.  The mean (M = 2.30) response for items measuring 
normative beliefs was between “Somewhat agree” and “Disagree” on the Likert-type 
scale.  The safer sex behavior that most participants did not think would be easy for their 
peers was telling a partner to get tested for sexually transmitted infections before 
becoming sexually active with them by responding “Disagree (N = 1473, 54.5%) and 
“Strongly disagree” (N = 503; 18.6%).  In addition, the majority of participants did not 
think that most of their peers would avoid the use of drugs or alcohol before engaging in 
sexual activity, by responding “Disagree” (N = 1398, 51.7%) or “Strongly disagree” (N = 
531; 19.6%).  The safer sex behavior that the highest percentage of participants thought 
their peers would do, by responding “Agree” (N = 369, 13.7%) and “Strongly agree” (N = 
76, 2.8%), was ask their health care provider about how to reduce their risk for sexually 
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transmitted infections.  Compared to the results for attitudes, a larger percentage of 
participants thought that practicing certain safer sex behaviors, such as avoiding the use 
of drugs or alcohol before engaging in sexual activity and telling a partner to get tested 
before becoming sexually active with them would be very easy to do themselves, but 
would not be done by their peers.   Appendix M contains tables, including frequency 
percentages, item means and standard deviations, of participant responses to normative 
beliefs regarding practicing safer sex behaviors. The number and type of responses to 
survey items measuring normative beliefs regarding practicing safer sex behaviors are 
also illustrated in Figures 15 through 17. 
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Figure 15.  Most college students would avoid using drugs or alcohol before engaging 
in sexual activity. 
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Figure 16.  Most college students would ask their health care provider about how to 
reduce their risk for STIs. 
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Figure 17.  Most college students would tell a partner to get tested for STIs before 
becoming sexually active with them. 
 
Control beliefs.  Overall, participants reported they had a high level of perceived 
control over practicing safer sex behaviors.  The mean response (M = 4.26) for items 
measuring control beliefs was between “A lot of control” and “Complete control” on the 
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Likert-type scale.  The safer sex behavior that had the highest percentage of participants 
report they had complete control was asking a health care provider about how to reduce 
their risk of sexually transmitted infections, as 67.8% (N = 1827) of participants reported 
they had “Complete control” and 21.6% (N = 582) of participants reported they had “A 
lot of control.”  The safer sex behavior that had the highest percentage of participants 
report lack of control was being abstinent from sexual activity until they were married, as 
11.7% (N = 315) reported “No Control”  and 8.4% (N = 227) of participants reported 
“Little control.”  According to results of crosstabulations, the highest percentage of 
participants who reported little control or no control for this item were women who were 
either “single and in monogamous relationship” or “single and sexually active.”  The 
majority of participants (N = 2057) in this study were from both of these groups; 
therefore, it may be that these participants reported that they did not have control in being 
abstinent from sexual activity until they were married because they already had sex.  The 
majority of participants (N = 343, 64.4%) that were “single and abstinent” reported the 
highest level of control in being abstinent from sexual activity.  Appendix N contains the 
cross-tabulation between marital status and level of control in being abstinent from sexual 
activity until marriage.  Appendix M contains tables, including frequency percentages, 
item means and standard deviations, of participant responses to control beliefs regarding 
practicing safer sex behaviors.  The number and type of responses to survey items 
measuring control beliefs regarding practicing safer sex behaviors are also illustrated in 
Figures 18 through 22. 
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Figure 18.  Control in being abstinent from sexual activity until marriage   
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Figure 19.  Control in refusing to have sex with a partner who will not use a condom   
Intentions.  Overall, participants had a high level of intention to practicing safer 
sex behaviors, as the mean response (M = 3.86) for items measuring intentions was 
between “Somewhat agree” to “Agree” on the Likert-type scale. 
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Figure 20.  Control in avoiding the use of drugs or alcohol before engaging in sexual 
                       activity   
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Figure 21.  Control in telling a partner to get tested for STIs before becoming sexually 
                      active with them 
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Figure 22.  Control in asking a health care provider about how to reduce my risk of STIs 
 
Forty-eight percent (N = 1295) of participants reported that they “Strongly agree” 
and 23.4% (N = 632) “Agree” to intending to refuse to have sex with a partner that will 
not use a condom, and this was the safer sex behavior with the greatest reported 
intentions.  Telling a partner to get tested for STIs before becoming sexually active with 
them was the safer sex behavior with the lowest reported intentions, as the highest 
percentage of participants disagreed with this item, by choosing either “Disagree” 
(14.6%, N = 393) or “Strongly disagree” (1.3%, N = 36).  The fact that participants had 
the lowest intentions for telling a partner to get tested for an STI before becoming 
sexually active is in parallel with participants also reporting the most negative attitudes 
and normative beliefs regarding this particular safer sex behavior.  Multiple linear 
regression was used to determine the strongest predictors for intentions in carrying out 
safer sex behaviors and is further described in a subsequent section of this chapter.  
Appendix M contains tables, including frequency percentages, item means and standard 
deviations, of participant responses to intentions regarding practicing safer sex behaviors.  
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The number and type of responses to survey items measuring intentions to practice safer 
sex behaviors are also illustrated in Figures 23 through 25. 
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Figure 23.  Intentions to tell a partner to get tested for STIs before becoming sexually 
                      active with them 
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Figure 24.  Intentions to refuse to have sex with a partner if they will not use a condom 
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Figure 25.  Intentions to avoid drugs or alcohol before engaging in sexual activity 
 
Perceived Susceptibility and Severity 
 Overall, participants perceived themselves as having a low susceptibility to 
contracting HPV.  Approximately 68% (N = 1845) of participants thought they were 
“Very Unlikely” to currently have HPV, and approximately 54% (N = 1480) of 
participants did not think they were likely to contract HPV.  Although only 8.2% (N = 
221) of participants reported that they were either “Very likely” or “Likely” to contract 
HPV within the next year, a higher percentage (22.5%, N = 609) of participants reported 
that they were more likely to get HPV sometime in their life.  Participants reported that 
they thought their peers were likely to contract HPV (50.2%, N = 1352) compared to 
themselves (18.6%, N = 502).   
 Most participants thought HPV would be a serious problem for them by reporting 
“Serious” (N = 1450, 53.6%) or “The most serious” (N = 286, 10.6%).  However, based 
on cross-tabulations, many of these participants also thought that HPV was not a big 
problem because it is very easy to treat by reporting “Somewhat agree” (N = 797, 29.5%) 
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and “Strongly agree” (N = 638, 23.6%) and 33.9% (N = 915) of participants were “Not 
sure.”   The majority of participants were “Not sure” (N = 1416, 52.5%) if it was likely 
that they would get genital warts from HPV, but most reported “Somewhat likely” (N = 
1319, 48.9%) and “Not sure” (N = 907, 33.6%) that they would get cancer.   
Appendix M contains tables, including frequency percentages, item means and 
standard deviations, of participant responses to perceived susceptibility and severity to 
HPV.   The number and types of responses to survey items measuring perceived 
susceptibility and severity are also illustrated in Figures 26 through 34. 
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Figure 26.  Whether participants think they are likely to contract HPV 
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Figure 27.  Likelihood of currently having HPV 
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Figure 28.  Whether participants think their friends or peers are likely to contract HPV 
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Figure 29.  Likelihood of getting HPV within the next year 
 
0
100
200
300
400
500
600
700
800
900
Very unlikely A little likely Somewhat likely Likely Very likely
N
u
m
be
r 
o
f p
a
rt
ic
ip
a
n
ts
 
Figure 30.  Likelihood of getting HPV some time in life 
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Figure 31. How serious a health problem HPV would be 
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Figure 32.  If you get HPV, it is not a big problem because it is very easy to treat 
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Figure 33.  Likelihood of getting genital warts if you get HPV 
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Figure 34.  Likelihood of getting cancer if you get HPV 
 
Predictors of Intentions 
 Multiple linear regression was calculated to determine the strongest predictors of 
intentions, such as attitudes, normative beliefs or control beliefs.  Mean values for each 
predictor and intentions were used in the regression calculation.   
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The variables of attitudes, normative beliefs, and control beliefs combined to 
strongly predict intentions, R = .730, p < .001.  The predictor that had the greatest 
influence on intentions was attitudes (β = .666), 95% CI [.649, .711], followed by control 
beliefs (β = .082), 95% CI [.062, .132], and then normative beliefs (β = .076), 95% CI 
[.062, .129].   Linear regression analysis for outliers using Mahalanobi’s distance 
revealed 141 outliers among participants for residuals or discrepancies for “Mean 
Intentions” (χ2 > 25.113, p = .001) at two standard deviations from the mean.  Linear 
regression analysis was performed both with and without the outliers but the influence of 
predictors did not change.  Attitudes remained the most influential predictor of intentions 
(β = .768), followed by control beliefs (β = .074) and then normative beliefs (β = .063).  
Because the results for the predictors for intentions did not change, the results are 
reported with the outliers in the sample.  Appendix O contains tables displaying the 
multiple linear regression results for the predictors of intentions.   
Research Questions 
Research question #1. What is the relationship between knowledge about HPV 
and intentions to practice safer sex behaviors among women attending college? 
Subquestions. 
o What is the relationship between knowledge about HPV and attitudes 
towards practicing safer sex behaviors? 
 
o What is the relationship between knowledge about HPV and normative  
beliefs about practicing safer sex behaviors? 
 
o What is the relationship between knowledge about HPV and perceived 
control towards practicing safer sex behaviors? 
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The Pearson product-moment correlation coefficient (r) was calculated between 
the mean values of knowledge about HPV to determine if there were significant 
relationships between knowledge about HPV and the predictors of intentions, including  
attitudes, normative beliefs, and control beliefs, as well as a significant relationship 
between knowledge and the variable of intentions as measured by survey items.   
Significant negative correlations were found between knowledge of HPV and 
attitudes (r = -.097, p < .01) and knowledge of HPV and intentions (r = -.099, p < .01) 
towards practicing safer sex behaviors.  There was also a negative correlation between 
knowledge and normative beliefs, and a negative correlation between knowledge and 
control beliefs; however, these correlations were not significant.  Appendix O contains 
tables displaying the correlation results. 
 Research question #2. What is the relationship between knowledge of the HPV 
vaccine and acceptance of the HPV vaccine among women attending college?   
 Vaccine acceptance was measured in this study by general vaccine acceptance,  
factors that would influence vaccination against HPV, and barriers to HPV vaccination.  
The Pearson product-moment correlation coefficient (r) was calculated between the 
variables of general vaccine acceptance and knowledge of the HPV vaccine, and there 
was a significant positive correlation between these two variables, r =.215, p < .001.  
There was not a significant correlation between knowledge about the HPV vaccine and 
importance of factors that would influence HPV vaccination, r = .034, p = .166, or the 
importance of barriers to vaccination, r = -.010, p = .680.  Multiple linear regression was 
employed to determine if any of the eight influential factors were significantly correlated 
with knowledge about the HPV vaccine.  Multiple linear regression demonstrated that 
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there was a significant linear relationship between knowledge of the vaccine and certain 
influential factors to becoming vaccinated, R = .130, p < .001, RMSE = .21593.  Of the 
eight influential factors, there was a significant positive relationship between “If someone 
in my family has cancer” (β = .130, B = .045), 95% CI [.028, .062] and knowledge of the 
HPV vaccine, and there was a significant negative relationship between “If my friends 
think I should get it” (β = -.065, B = -.021), 95% CI [-.037, -.005] and knowledge of the 
HPV vaccine.  Multiple linear regression demonstrated that there was a significant linear 
relationship between knowledge of the vaccine and certain barriers to vaccination, R = 
.132, p < .001, RMSE = .21588.  Of the seven barriers, there was a significant negative 
relationship between “Possible side effects of the vaccine” (β = -.113, B = -.034), 95% CI 
[-.048, -.020] and “Not knowing where to get the vaccine” (β = -.059, B = -.017), 95% CI 
[-.031, -.003] and knowledge of the HPV vaccine.  Appendix O contains tables 
displaying the correlation and multiple linear regression results. 
Research question #3. 
 
• What is the relationship between health beliefs about HPV and acceptance of the 
HPV vaccine among women attending college? 
 
Subquestions. 
 
o What is the relationship between perceived susceptibility to HPV and 
vaccine acceptance? 
 
o What is the relationship between perceived severity of the HPV vaccine 
and vaccine acceptance? 
 
 Vaccine acceptance was measured by general vaccine acceptance, factors that 
would influence vaccination, and barriers to vaccination: health beliefs were measured by 
perceived susceptibility to and severity of HPV based on the HBM.  The Pearson 
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product-moment correlation coefficient (r) was calculated for the variables of general 
vaccine acceptance and perceived susceptibility.  There was a significant positive 
correlation between general vaccine acceptance and perceived susceptibility to HPV, r = 
.067, p = .001.  Multiple linear regression could not be calculated for the three specific 
items measuring general vaccine acceptance because one of the items had a dichotomous 
response scale compared to the other two items that had a ranked scale.  Further 
correlation analysis, via the Pearson r, revealed a low correlation between whether 
participants thought if universal vaccination was important and perceived HPV 
susceptibility, r = .008, p = .696.  A chi-square statistic was calculated to assess the 
differences in perceived susceptibility in participants who had received the HPV vaccine 
and those who had not, because one of the items had a dichotomous response scale and 
the other item had an ordinal response scale.  The results were significant revealing that 
participants who received the HPV vaccine had a lower perceived susceptibility to HPV,   
compared to those who had not received the vaccine, χ2(31, N = 2699) = 63.945, p < .01.  
There was a significant positive correlation between perceived susceptibility and 
likelihood of becoming vaccinated against HPV, r = .145, p < .01.   
 There was not a significant correlation between perceived susceptibility and 
influential factors or barriers to becoming vaccinated against HPV per the Pearson r 
calculation.  However, multiple linear regression demonstrated that there was a 
significant linear relationship between perceived susceptibility to HPV and certain 
influential factors to becoming vaccinated, R = .172, p < .001, RMSE = .72662.  Of the 
eight influential factors, there was a significant positive relationship between perceived 
susceptibility and “if my health insurance covers it” (β = .143, B = .157), 95% CI [.098, 
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.216] and “if my health care provider thinks I should get it”, (β = .086, B = .103), 95% CI 
[.038, .168], whereas there was a significant negative relationship between perceived 
susceptibility and “if I had an abnormal pap smear” (β = -.068, B = -.096), 95% CI [-.173, 
-.019].  Multiple linear regression demonstrated that there was a significant linear 
relationship between perceived susceptibility to HPV and certain barriers to becoming 
vaccinated against HPV, R = .107, p < .001, RMSE = .73315.  Of the seven barriers, there 
was a significant positive relationship between perceived susceptibility and the cost of the 
vaccine (β = .063, B = .061), 95% CI [.015, .108] and a significant negative relationship 
between perceived susceptibility and possible side effects of the vaccine (β = -.087, B = -
.088), 95% CI [-.137, -.040].   
 There was a significant positive correlation between general vaccine acceptance 
and perceived severity of HPV, r = .088, p < .001.  Further correlation analysis, via the 
Pearson r, revealed a significant positive correlation between whether participants 
thought if universal vaccination was important and perceived HPV severity, r = .077, p < 
.001.  As with perceived susceptibility described above, a chi-square statistic was 
calculated to determine the differences in perceived severity among participants who had 
received the HPV vaccine versus those who had not, because one of the items had a 
dichotomous response scale and the other item had an ordinal response scale.  There was 
not a significant relationship between perceived severity and vaccine status.  Based on 
previous results of perceived severity, most participants agreed that HPV was not a 
serious problem because it was very easy to treat.  The Pearson product-moment 
correlation coefficient (r) was calculated to determine if there was a relationship between 
likelihood of becoming vaccinated and the perception that HPV was not a serious 
 172
problem because it is very easy to treat.  The Pearson r revealed that there was a small, 
non-signficant negative relationship between these this type of perceived severity and 
likelihood of becoming vaccinated,   r = -.009, p = .717.  There was a significant, positive 
correlation between perceived severity and likelihood of becoming vaccinated against 
HPV, r = .110, p < .01. 
 The Pearson product-moment correlation revealed that there was a significant 
positive correlation between perceived severity and influential factors to becoming 
vaccinated against HPV, r = .072, p = .003.  Multiple linear regression was then used to 
determine the influential factors that had the strongest relationship with perceived 
severity.  There was a significant linear relationship between influential factors to getting 
vaccinated and perceived severity, R = .152, p < .001, RMSE = .43833.  Of the eight 
influential factors, “if someone in my family has cancer” (β = .118, B = .083), 95% CI 
[.048, .118], followed by “if my family thinks I should get it” (β = .062, B = .041), 95% 
CI [.008, .074] had significant positive relationships with perceived severity.  The 
Pearson product-moment correlation revealed that there was not a significant correlation 
between perceived severity and barriers to becoming vaccinated against HPV, r = .072, p 
= .003.  However, multiple linear regression demonstrated was calculated to determine if 
there was a significant linear relationship between perceived severity to HPV and certain 
barriers to becoming vaccinated.  Of the seven barriers, “cost of the vaccine” (β = .059, B 
= .035), 95% CI [.007, .063] was the only factor that had a significant, positive 
relationship with perceived severity, R = .059, p = .016, RMSE = .44256.  Appendix O 
contains tables displaying the correlation and multiple linear regression results. 
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Research question #4. 
• What is the relationship between acceptance of the HPV vaccine and intentions to 
practice other safer sex behaviors among women attending college? 
 
Subquestions. 
 
o What is the relationship between acceptance of the HPV vaccine and 
attitudes towards practicing safer sex behaviors? 
 
o What is the relationship between acceptance of the HPV vaccine and 
normative beliefs about practicing safer sex behaviors? 
 
o What is the relationship between acceptance of the HPV vaccine and 
perceived control towards practicing safer sex behaviors? 
 The Pearson product-moment correlation coefficient (r) was calculated and there 
was not a significant correlation between the variables of general vaccine acceptance and 
mean attitudes towards practicing safer sex behaviors and, r = .029, p = .128.  Further 
correlational analysis revealed a significant, positive relationship between the importance 
of vaccinations in general among participants and attitudes towards practicing safer sex 
behaviors, r = .059, p = .002; however, there was a low, non-significant, positive 
correlation between attitudes towards practicing safer sex behaviors and likelihood of 
becoming vaccinated against HPV, r = .024, p = .326.  A chi-square statistic was 
calculated to determine the differences in attitudes among participants who had received 
the HPV vaccine and those who had not, and there were no significant differences, χ2(12, 
N = 2699) = 15.543, p = .213.  Multiple linear regression was used to determine 
differences in strengths in relationships among influential factors for becoming 
vaccinated against HPV and attitudes towards practicing safer sex behaviors.  There was 
a significant linear relationship between influential factors for becoming vaccinated 
against HPV and attitudes toward practicing safer sex behaviors, R = .195, p < .001, 
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RMSE = .77713.  Of the eight influential factors, “if my health insurance covers it” (β = -
.165, B = -.194), 95% CI [-.251, -.137] had a significant negative relationship with 
attitudes towards practicing safer sex behaviors, and there was a significant positive 
relationship between “whether I practice safe sex” and attitudes towards practicing safer 
sex behaviors (β = .152, B = .180), 95% CI [.122, .237].  There was also a significant 
linear relationship between barriers to vaccination against HPV and attitudes towards 
practicing safer sex behaviors, R = .167, p < .001, RMSE = .78119.  Of the seven 
barriers, there was a significant negative relationship between the cost of the vaccine (β = 
-.122, B = -.128), 95% CI [-.180, -.077] and not knowing where to get the vaccine (β = -
.086, B = -.090), 95% CI [-.142, -.039] and attitudes towards practicing safer sex 
behaviors. 
 There was a significant positive correlation between general vaccine acceptance 
and normative beliefs regarding practicing safer sex behaviors, r = .113, p < .001.  
Further correlational analysis revealed a significant, positive relationship between the 
likelihood of getting the HPV vaccine and normative beliefs, r = .111, p < .001.   
A chi-square statistic was calculated to determine the differences in normative beliefs 
among participants who had received the HPV vaccine and those who had not, and there 
were no significant differences, χ2(13, N = 2699) = 20.169, p = .091.  Multiple linear 
regression was employed to determine differences in the strength of the relationships 
among influential factors for becoming vaccinated against HPV and normative beliefs 
towards practicing safer sex behaviors.  There was a significant linear relationship 
between influential factors for becoming vaccinated against HPV and normative beliefs 
regarding practicing safer sex behaviors, R = .159, p < .001, RMSE = .63422.  Of the 
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eight influential factors, there was a significant, positive relationship between “whether I 
practice safe sex” (β = .098, B = .094), 95% CI [.046, .141], “if my friends think I should 
get it” (β = .062, B = .059), 95% CI [.009, .110] and “if my family thinks I should get it” 
(β = .058, B = .056), 95% CI [.005, .106] and normative beliefs regarding safer sex 
behaviors.  There were no significant relationships between any of the barriers to 
vaccination against HPV and normative beliefs regarding practicing safer sex behaviors. 
 There was not a significant relationship between general vaccine acceptance and 
perceived control beliefs in practicing safer sex behaviors, r = .005, p = .778.  Further 
correlational analysis revealed a significant, positive relationship between the importance 
of vaccinations in general among participants and perceived control towards practicing 
safer sex behaviors and, r = .054, p = .005.  However, there was a low, non-significant, 
negative correlation between likelihood of becoming vaccinated against HPV and 
perceived control beliefs in practicing safer sex behaviors and, r = -.029, p = .226. 
A chi-square statistic was calculated to determine the differences in control beliefs among 
participants who had received the HPV vaccine and those who had not, and there were no 
significant differences, χ2(19, N = 2699) = 21.011, p = .336.  Multiple linear regression 
was used to determine the difference in the strength of the relationships of influential 
factors for becoming vaccinated against HPV and perceived control beliefs in practicing 
safer sex behaviors.  There was a statistically significant linear relationship between 
influential factors to becoming vaccinated against HPV and perceived control beliefs in 
practicing safer sex behaviors, R = .163, p < .001, RMSE = .67421.  Of the eight 
influential factors, there was a statistically significant, negative relationship between “if 
my health insurance covers it” (β = -.151, B = -.154), 95% CI [-.203, -.104] and perceived 
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control beliefs and there was a significant positive relationship between “whether I 
practice safe sex” (β = .108, B = .110), 95% CI [.060, .160] and perceived control beliefs.  
There was also a statistically significant linear relationship between barriers to becoming 
vaccinated against HPV and perceived control beliefs in practicing safer sex behaviors, R 
= .166, p < .001, RMSE = .67402.  Of the seven barriers, there was a statistically 
significant negative relationship between “the cost of the vaccine” (β = -.123, B = -.111), 
95% CI [-.155, -.067] and “having to wait at my doctor’s office for approval to get the 
vaccine” (β = -.083, B = -.089), 95% CI [-.141, -.036] and perceived control beliefs.  In 
addition, there was a statistically significant positive relationship between “possible side 
effects of the vaccine would prevent me from becoming vaccinated” and perceived 
control beliefs (β = .053, B = .050), 95% CI [.004, .095]. 
 The Pearson product-moment correlation coefficient (r) was calculated and there 
was a statistically significant positive correlation between the variables of general 
vaccine acceptance and mean intentions towards practicing safer sex behaviors,  r = .087, 
p < .001.  Further correlational analysis revealed that there was also a statistically 
significant positive correlation between the importance of vaccinations in general, and 
intentions to practice safer sex behaviors, r = .081, p < .001.  Additional correlational 
analysis revealed that there was also a statistically significant positive correlation 
between the likelihood of becoming vaccinated against HPV and intentions to practice 
safer sex behaviors, r = .098, p < .001.  The application of multiple linear regression 
revealed a statistically significant linear relationship between influential factors to 
becoming vaccinated against HPV and intentions to practice safer sex behaviors, R = 
.244, p < .001, RMSE = .78479.   Of the eight influential factors, there was a statistically 
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significant positive relationship between “whether I practice safe sex” (β = .191, B = 
.230), 95% CI [.169, .290], “if someone in my family has cancer” (β = .062, B = .079), 
95% CI [.013, .145], and “if my friends think I should get it” (β = .056,  
B = .068), 95% CI [.008, .129] and intentions.  There was a statistically significant 
negative relationship between “if my health insurance covers it” (β = -.183, B = -.219), 
95% CI [-.281, -.158] and intentions.  Based upon the results of multiple linear 
regression, there was also a statistically significant linear relationship between certain 
barriers to vaccination and intentions to practicing safer sex behaviors, R = .128,  
p < .001, RMSE = .80225.  There was a statistically significant, negative relationship 
between “the cost of the vaccine” (β = -.101, B = -.109), 95% CI [-.162, -.056] and “not 
knowing where to get the vaccine” (β = -.055, B = -.059), 95% CI [-.112, -.006] and 
intentions to practicing safer sex behaviors.  Appendix O contains tables displaying the 
correlation and multiple linear regression results. 
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Chapter Five 
Discussion 
 
This study produced a large sample size (N = 2,872) of undergraduate students, 
across three universities, participating in the online survey in less than six months.  At 
one university, 1,195 students completed the survey within 48 hours of it becoming 
available.  This level of participation suggests the topics of HPV and the corresponding 
vaccine were of great salience to this audience.  It is further indicative of the importance 
and timeliness of educating female undergraduates about their risks of getting HPV, the 
availability of the HPV vaccine, and the need for practicing safer sex behaviors. 
Studies have examined whether the vaccine will lead to riskier sexual behaviors 
among adolescents (Forster, Wardle, Stephenson, & Waller, 2010; Marlow, Forster, 
Wardle, & Waller, 2009; Waller, Marlow, & Wardle, 2006).  However, no published 
studies to-date have yet examined whether the vaccine will lead to riskier sexual 
behaviors among college-aged females who are also a target population for the vaccine 
and are of legal age to make the decision to become vaccinated.  This is the first study to 
assess the relationship between HPV vaccine acceptance and intentions to practice safer 
sex behaviors among female college students.  Studying attitudes, beliefs, and intentions 
to practicing safer sex behaviors in relation to HPV vaccine acceptance may provide a 
better understanding of whether the vaccine will lead to riskier sexual behaviors among 
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the female college student population.  This information is vital to the reproductive health 
of female college students because the HPV vaccine does not protect against all high-risk 
types of HPV and other STIs.  The relationship between knowledge about HPV and 
intentions to practice safer sex behaviors was also assessed to determine if those students 
who knew more about HPV were also more likely to protect themselves against not only 
getting HPV, but other STIs.  Globally, there have been many studies on the relationship 
between knowledge about HPV, perceived risk and severity of HPV, and intentions for 
vaccination among female college students (Kang and Moneyham, 2010; Licht, et al., 
2010; Mehu-Parant, Rouzier, & Soulat, 2010; Wong and Sam, 2010).  However, this was 
the first comprehensive study to assess the relationship between knowledge about HPV, 
health beliefs regarding HPV, HPV vaccine acceptance, and intentions to practice safer 
sex behaviors through the application of a combined framework of the HBM and TPB. 
Relationship Between Knowledge about HPV and Intentions to Practice Safer Sex 
Behaviors 
Though past studies have assessed knowledge about HPV among college 
students, this study was the first to assess the relationship between knowledge about HPV 
and intentions to practice safer sex behaviors.  The majority of participants in this study 
had a high level of knowledge about HPV, also found in similar studies among college-
aged women, since FDA approval of the GARDASIL® in 2006 (Licht et al., 2010; 
Sandfort and Pleasant, 2009).  The high level of knowledge about HPV among this 
population may be due to consumer media campaigns, university-based education 
programming or education by health care providers.  There were significant negative 
relationships between HPV knowledge and attitudes and HPV knowledge and intentions 
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towards practicing safer sex behaviors among participants in this study, and a non-
significant negative relationship between HPV knowledge and normative beliefs and 
HPV knowledge and control beliefs to practice safer sex behaviors.  These findings may 
indicate that although female college students have a high level of knowledge about 
HPV, they may not think that practicing safer sex behaviors would be easy, they have 
control over practicing these behaviors, or have intentions to practice these behaviors.  
Furthermore, the majority of participants in this study reported that they were currently 
sexually active in monogamous relationships, and these findings may also indicate that 
they do not practice safer sex behaviors in those relationships.  These findings 
demonstrate the need for university student health centers to develop marketing 
campaigns that include the combination of promoting the HPV vaccine, in addition to the 
promotion of safer sex behaviors that are targeted not only to females, but also to couples 
who are in monogamous relationships.  Targeting heterosexual couples for the vaccine 
would be relevant since the vaccine is now available to college-aged men (Merck & Co., 
Inc., 2009), and studies have demonstrated a high level of vaccine acceptance among 
male college students (Daley et al., 2010; Liddon, et al., 2010).  University student health 
centers can also incorporate education on STIs into their peer education classes for first 
year students, with an emphasis on how sexually active students who are single or in 
monogamous relationships can protect themselves from STIs by continuing to practice 
safer sex behaviors, including acquiring the HPV vaccine.  This education can be offered 
through seminars, such as those offered at residence halls.  College campuses can also 
utilize different types of social media (i.e., Facebook, Twitter, YouTube, and Myspace) to 
reach female college students through these media campaigns. 
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Regarding perceived control beliefs, it is important to note that the survey item 
that assessed the level of control in being abstinent from sexual activity until marriage 
was answered by participants who had already engaged in sexual activity, such as 
participants who were “single and sexually active”, “single and in a monogamous 
relationship”, “married”, and “separated/divorced.” Although this item was intended to 
measure perceived control in a hypothetical situation, having all participants answer this 
item may have reduced the validity of assessing perceived control beliefs about 
abstinence since most participants were sexually active.  Future studies assessing 
attitudes or beliefs regarding safers sex behaviors, including abstinence, may want to 
incorporate additional skip patterns into surveys so that participants who had not 
previously engaged in sexual activity respond to questions about abstinence. 
Relationship Between Knowledge of the HPV Vaccine and Acceptance of the HPV 
Vaccine Among Women Attending College 
Most participants in this study knew about the HPV vaccine and had a high level 
of acceptance of the HPV vaccine and vaccinations in general, and over a third of the 
participants received at least one dose of the vaccine.  Studies have not shown whether 
there are more benefits to receiving three doses of the HPV vaccine compared to one or 
two doses (CDC, 2009).  A subset of participants, females ages 16 to 23 years, from the 
phase II clinical trial of the quadrivalent GARDASIL® vaccine, are being followed for 
vaccine efficacy after 60 months after receiving one dose, but the results are not yet 
known (Villa, et al., 2006).  The average duration of protection against the HPV vaccine 
types ranges, on average, from five to six years, depending upon the type of vaccine – 
GARDASIL® or Cervarix®.  Additional studies are needed to determine if one dose is just 
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as effective or if additional boosters beyond the three doses of the vaccine are necessary.  
Regardless of knowledge level of HPV, the major influences to becoming vaccinated 
against HPV were having an abnormal Pap smear, whether they had health insurance that 
covered the HPV vaccine, and whether someone in their family had cancer.  Though it 
was not the most influential factor, Crosby et al. (2007) also found that having an 
abnormal Pap smear was significantly linked to HPV vaccine acceptance among college-
aged women, in addition to having vaginal sex in the past 12 months and having an STI. 
An abnormal Pap smear being the most significant influential factor to becoming 
vaccinated for college women who have a high level of knowledge of HPV is interesting 
because the HPV vaccines, Cervarix® and GARDASIL®, do not protect against HPV 
types 16 and 18 after a person has contracted these viruses, and there is no guarantee the 
vaccine will prevent cervical cancer in a person who already has either of these virus 
types.  Furthermore, getting the vaccine after being diagnosed with an abnormal Pap 
smear will not prevent further abnormal Pap tests results, as the vaccines do not protect 
against existing HPV infections and the vaccines do not protect against all types of HPV.  
However, both HPV vaccines, Cervarix® and GARDASIL®, can protect against persistent 
infection against the high-risk vaccine HPV types that cause cervical cancer (Gilsdorf & 
Markowitz, 2006; GlaxoSmithKline, 2009).  Because items assessing HPV vaccine 
knowledge in this study did not measure students’ understanding of how the vaccine 
worked, it cannot be determined whether students that were most influenced to become 
vaccinated based upon an abnormal Pap smear, knew about the role of HPV vaccine in 
preventing persistent infection or thought the vaccine can cure an existing HPV infection.  
Items that assess students’ knowledge of the mechanics of the HPV vaccine in preventing 
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infection and cervical cancer should be included on surveys in future studies that assess 
the relationship between knowledge and acceptance of the vaccine. 
 The influence of whether their health care provider or their family members 
thought they should get the vaccine were nearly equal in importance, possibly indicating 
that family members and health care providers may have a similar level of influence for 
female college students in their decision to get vaccinated against HPV.  Interestingly, the 
factor that had the most influence in becoming vaccinated for participants with a high 
level knowledge about the HPV vaccine, was whether someone in the family had cancer, 
and the factor that had the least importance was whether their friends thought they should 
get the vaccine.  These results may indicate that students who know more about the 
vaccine, are more likely to be influenced by family history of cancer and less likely 
influenced by peer pressure.  This is an interesting finding, as research has demonstrated 
that hereditary factors are not linked to cervical cancer, but rather that it is a virally 
induced cancer caused only by behavioral factors (Vink, et al., 2010).  However, a 
hereditary component, such as a mutation in the p53 gene and certain gene complexes, 
has been found that may increase an individual’s susceptibility of HPV developing into 
cancer.  Additional research is needed to determine if there is a familial genetic link 
between HPV and its progression into cervical cancer (de Araujo Souza & Villa, 2003; 
Maciag & Villa, 1999; Magnusson & Gyllensten, 2000).  Furthermore, future studies 
need to determine if certain high risk health behaviors, such as smoking or unsafe sexual 
behaviors that can cause persistent infection with HPV, can impact those who have a 
genetic susceptibility of HPV developing into cervical cancer. 
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 Social marketing campaigns that promote the fact that a high percentage of 
students have already received the vaccine may not have an impact on students who have 
a high level of knowledge about the vaccine, but rather campaigns focused on the health 
consequences of not becoming vaccinated, such as risk of cervical cancer, may be more 
influential on targeting a more educated college female population.  However, these 
findings also reinforce the need for university student health centers to convey messages 
about the importance of practicing safer sex behaviors targeted to all students through on-
campus educational campaigns and to combine these messages with information about 
the etiology of cervical cancer, specifically how it is caused only by environmental 
factors, specifically sexual behaviors. 
Major barriers to becoming vaccinated were cost of the vaccine, possible side 
effects of the vaccine, and not knowing where to get the vaccine.  However, for 
participants with a high level of knowledge about the vaccine, possible side effects and 
not knowing where to get the vaccine were barriers of least importance.  These results 
indicate that barriers associated with knowledge of the vaccine, such as possible side 
effects and places where the vaccine is available, are not issues for those female college 
students who are more educated about the vaccine. 
Overall, the study findings on HPV vaccine acceptance associated with 
knowledge about the vaccine among female college students demonstrate the need for 
university student health center staff to educate students about their options in paying for 
the vaccine, and to help students determine if the cost of the vaccine is covered under 
their health insurance or if uninsured, whether they are eligible and how to apply for 
coverage through Merck & Co., Inc. or GlaxoSmithKline.  Having university student 
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health center staff conduct a community assessment of the local availability of the 
vaccine may be useful for students in knowing where they can obtain the vaccine. 
A university or college media campaign that includes multiple components, such as 
promoting the availability of the vaccine on campus and throughout the community, how 
both insured and uninsured students can determine if they are eligible to receive the 
vaccine at no cost; and, educating students on the limited, though possible side effects of 
the vaccine may help students make an informed decision on whether to become 
vaccinated. 
Relationship Between Health Beliefs About HPV and Acceptance of the HPV 
Vaccine Among Women Attending College 
The majority of participants in this study believed that HPV would be a serious 
problem for them; however, many participants also agreed that HPV would not be a big 
problem because it was very easy to treat.  In addition, there was a high percentage of 
participants who were unsure, and it may be because of how the survey question was 
worded.  Participants might have had conflicting responses to each part of the question, 
for instance, they may have thought that HPV was not a big problem but they may not 
have known how to respond whether it was very easy to treat, because it depended upon 
what stage HPV was diagnosed.  Therefore, future studies assessing health beliefs about 
HPV among young women, may want to include more specific survey items that measure 
perceived severity, for instance, when HPV is diagnosed early compared to a later 
diagnosis. 
There was a small, non-significant negative relationship between likelihood of 
getting the vaccine and agreeing that HPV was not a serious problem because it is very 
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easy to treat.  These findings indicate that female college students who think that HPV is 
easy to treat may not be likely to get the vaccine to protect themselves from the types of 
HPV viruses that pose the highest risk of getting cervical cancer and genital warts.   In 
addition, these results may indicate that those students who think HPV is easy to treat are 
more likely to get recommended Pap and HPV DNA tests for early detection, rather than 
become vaccinated.  Future studies may help to determine if female college students who 
have been vaccinated against HPV, and have a low perceived susceptibility of HPV, are 
more likely to get tested for early diagnosis and treatment rather than acquire the HPV 
vaccine. 
Participants in this study were also more likely to think that they would get cancer 
as most were not sure if they would be likely to get genital warts.  This perception may 
be due to the education they are receiving from the consumer marketing campaigns for 
the HPV vaccine that are focused more on HPV being linked to cervical cancer, with less 
emphasis on genital warts.  This finding may indicate a need for university health centers 
to include a greater, but equal focus on the association between HPV and genital warts, in 
addition to cervical cancer, in on-campus HPV education and vaccine marketing 
campaigns targeting female college students. 
 There was a significant positive relationship between general vaccine acceptance 
and perceived susceptibility to and perceived susceptibility of HPV.  This finding may 
indicate that those students who think vaccines are important in general, perceive 
themselves to be more susceptible to getting those vaccine-preventable diseases, 
including HPV, and perceive vaccine-preventable diseases to be more serious.  In 
addition, those students who were more likely to report that they would get the HPV 
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vaccine also perceived themselves to be more susceptible to contracting HPV and 
perceived HPV to be more serious compared to those who were less likely to get the 
vaccine.  This finding is consistent with the framework of the HBM, where those 
individuals who perceive themselves at high risk of getting a disease and associate a 
disease with greater severity, are more likely to take action to prevent the disease 
compared to those individuals who perceive themselves at lesser risk or think there is less 
severity associated with a disease (Rosenstock, 1988). 
 Participants who perceived themselves to be more susceptible to HPV were more 
likely to be influenced by certain factors in becoming vaccinated against HPV.  Those 
participants who perceived themselves to be more susceptible to HPV were more likely 
to be influenced by whether their health insurance covered the vaccine and whether their 
health care provider recommended that they become vaccinated against HPV. 
Interestingly, participants who perceived themselves to be more susceptible were 
significantly less likely to be influenced to becoming vaccinated based upon whether they 
had an abnormal pap smear.  Therefore, these findings may indicate that there may be 
other non-health related factors that play a role in female college students’ decision to 
become vaccinated against HPV, even those who perceive themselves to be susceptible to 
getting the STI or that female college students who think they are more susceptible do not 
know the purpose of a Pap test.   This finding may indicate that university student health 
centers may need to increase their education on the role that Pap tests have in diagnosing 
HPV and its importance as a primary prevention measure for cervical cancer, regardless 
of their health beliefs.  As with the majority of participants, regardless of their health 
beliefs participants that perceived HPV to be more severe were most influenced by 
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whether or not someone in the participant’s family had cancer, followed by if their family 
thought they should get the vaccine.  This finding may be different than the previous one, 
described earlier in the discussion, on the relationship between influential factors to 
vaccination and knowledge, where students who were more educated about the vaccine 
were more influenced by whether someone in their family had cancer on their decision to 
become vaccinated against HPV.  The issue here may not just be that college students are 
not knowledgeable about the etiology of cervical cancer, but that those students who have 
a family history of any type of cancer, may be more likely to perceive HPV to be severe 
because is associated with cervical cancer, regardless of whether the cancer is caused by 
environmental or hereditary factors.  Future studies are needed to confirm the relationship 
between students’ knowledge of the etiology of cervical cancer, perceived severity of 
HPV and influential factors to becoming vaccinated. 
 This study found that the greatest barrier to vaccination, for female college 
students who perceived themselves as the most susceptible and perceived HPV to be the 
most severe, was the cost of the vaccine, and this was a similar finding for the majority of 
participants, regardless of health beliefs.  These results further reinforce the need for 
university student health center staff to provide education on all of the different options 
available to pay for the HPV vaccine, as well as consultation on what options may work 
best for students, depending upon their income and insurance status.  Primary care 
providers in the general community could also play a role in providing education and 
consultation on the cost of the HPV vaccine to all young adult female clients who are 
eligible to receive the vaccine, and this is relevant to college students as not all of 
members of this population obtain health care on campus. 
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Relationship Between Acceptance of the HPV Vaccine and Intentions to Practice 
Other Safer Sex Behaviors Among Women Attending College 
The safer sex behavior that seemed to be the easiest for female college students in 
this study, based upon attitudes, was refusing to have sex with a partner that would not 
wear a condom, followed by avoiding drugs or alcohol before engaging in sexual activity. 
The purpose of measuring students’ attitudes, normative beliefs and perceived control in 
avoidance of drugs or alcohol before engaging in sexual activity was primarily to assess 
practicing this specific safer sex behavior compared to others, not to assess the frequency 
of this behavior among students to control for having safe sex.  However, this study 
finding is interesting since research has demonstrated that most college students use 
alcohol and that its use is often involved in sexual activity.  The Youth Risk Behavior 
Survey (1995) conducted among college students at four-year institutions, showed that 
nearly 20% of students had drunk alcohol or used drugs at last sexual intercourse (CDC, 
1997).  Furthermore, results from the Core Institute Survey (2006), completed mostly by 
female undergraduate students from 134 universities in the U.S., revealed that over 70% 
of students used alcohol over the past 30 days, and over 80% used alcohol at least once 
during the past year, with freshman to seniors, averaging approximately from 5 to 6 
drinks per week.  Although this survey did not measure the relationship between alcohol 
use and sexual activity, results revealed that over 10% of college students were taken 
advantage of sexually and over 3% took advantage of others sexually as a consequence of 
alcohol use a year before taking the survey.  Studies have demonstrated that female 
college students with higher self-regulation and use drinking protective behavioral 
strategies, such as not drinking or limited alcohol consumption before or during sexual 
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activity, have lower risk sexual behavior and fewer sex-related alcohol negative 
consequences (Lewis, Rees, Logan, Kaysen, & Kilmer, 2010; Quinn & Fromme, 2010). 
The prevalence of alcohol and drug use was not measured in this study; therefore, it 
cannot be determined whether students who had a positive attitude about avoiding using 
drugs or alcohol before engaging in sexual activity did not use alcohol or drugs or 
whether these students have high self-regulation or use drinking protective behavioral 
strategies before engaging in sexual activity.  Future studies assessing safer sex behaviors 
related to the use of alcohol or drugs among college students should also assess the 
prevalence of drugs or alcohol to determine if there is a relationship between the use of 
drugs or alcohol and avoiding this behavior before engaging in sexual activity and 
whether alcohol and drug use is avoided by students to reduce high risk sexual behaviors 
and sex-related alcohol negative consequences. 
Overall, participants reported having a high level of control over practicing all of 
the safer sex behaviors, especially refusing to have sex with a partner that would not wear 
a condom and asking a health care provider about how to reduce their risk of STIs.  
Sandfort and Pleasant (2009) found that male and female undergraduate students 
preferred to receive information about sexual health from their primary health care 
providers.  Therefore, female college students may prefer to receive health care 
information from health care providers because they may feel like they have more control 
in doing so.  Although students in this study had a positive attitude and seemed in control 
over having partners use condoms, it is still concerning because condom usage does not 
fully protect an individual from getting certain STIs, including HPV.  This finding 
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reinforces the need for university-based STI prevention campaigns to include an 
emphasis on practicing other safer sex behaviors in conjunction with correct condom use. 
The safer sex behavior that seemed to be the most difficult and that participants 
perceived they had less control over and less intention to carry out, was telling a partner 
they would not be sexually active with them until they were tested for STIs.  Therefore, 
university student health centers may want to run ad campaigns that focus on men and 
women talking with partners about getting tested for STIs before becoming sexually 
active with them, as well as provide tips, in new or existing educational pamphlets on STI 
prevention, on how couples can talk to each other about getting tested.  In addition, 
information on types of STIs, tests for STIs, and where individuals can get tested can be 
included in these pamphlets. 
Most participants did not believe that their peers would carry out certain safer sex 
behaviors, compared to their own positive attitudes and perceived control about carrying 
out those same behaviors.  Participants also perceived their peers being more susceptible 
to contracting HPV compared to themselves.  These findings are similar to results of 
other studies on students’ perceived norms about high risk behaviors, including alcohol 
use and sexual behaviors.  College students often overestimate peers engaging in certain 
high risk behaviors more than they actually do and more than themselves (Martens, Page, 
Mowry, Damann, Taylor, & Cimini, 2006; Pedersen & LaBrie, 2008; Scholly, Katz, 
Gascoigne, & Holck, 2005).  However, findings from this study are critical because 
normative beliefs can be influential in peer behavior, and university student health 
centers can address these beliefs by implementing social norm campaigns for the 
prevention of STIs by promoting the message that most female college students have 
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positive attitudes about practicing safer sex behaviors, despite commonly held beliefs that 
peers practice risky sexual behaviors. 
 A combination of the HBM and the TPB was applied in this study to determine 
the greatest predictor of intentions regarding practicing safer sex behaviors.  The 
strongest predictor of intentions to practice safer sex behaviors in this study was attitudes, 
followed by control beliefs and then normative beliefs.   The positive relationship 
between attitudes and intentions to practicing preventive health risk behaviors among 
young adult women has been well documented in the literature (Auslander et al., 2005; 
Hiltabiddle, 1996; Kahn et al., 2003; Lollis, Johnson & Antoni, 1997; McKinley & 
Billingham, 1998; Orr & Langefeld, 2003; Zak-Place & Stern, 2004).  In addition, the 
TPB has been applied in studies assessing college students’ intentions to practice safer 
sex behaviors (Bensley et al., 2004; Boily, Godin, Hogben, Sherr, & Bastos, 2005; Bryan, 
Fisher, & Brian, 2002; Koniak-Griffin, Lesser, Uman, & Nyamathi, 2003).  However, 
this was the first study to apply both the HBM and TPB to assess attitudes, normative 
beliefs, and control beliefs to predict intentions to practice safer sex behaviors and to 
assess the relationship between those intentions with HPV vaccine acceptance. 
Findings from this study revealed that there was a significant positive relationship 
between vaccine acceptance, specifically likelihood of becoming vaccinated, and 
normative beliefs to practicing safer sex behaviors; however, there was a non-significant 
relationship between likelihood of getting vaccinated and attitudes and a non-signficant 
negative relationship between likelihood of getting vaccinated and perceived control in 
practicing safer sex behaviors.  These findings may indicate that those female college 
students who are more likely to become vaccinated have a greater perception of their 
 193
peers practicing safer sex behaviors, compared to those who do not perceive their peers to 
be practicing safer sex behaviors.  Although the finding was not significant, there was a 
weak, positive relationship between likelihood of becoming vaccinated and attitudes 
regarding practicing safer sex behaviors, and a weak, non-signficant negative relationship 
between likelihood of becoming vaccinated and perceived control beliefs in practicing 
safer sex behaviors.  This finding is concerning because attitudes was the strongest 
predictor of intentions to practicing safer sex behaviors in this study, based upon the 
combined application of the HBM and the TPB.  These findings may indicate that female 
college students who become vaccinated may not have strong positive attitudes or 
perceived control in practicing safer sex behaviors.  In measuring intentions directly, via 
survey items on intentions, participants who were more likely to become vaccinated 
against HPV had higher intentions to practicing safer sex behaviors.  The factor most 
likely to influence vaccination for those who had greater intentions to practice safer sex 
was whether or not they practiced safe sex.  Those with greater intentions on practicing 
safer sex behaviors were least likely influenced by health insurance coverage for 
vaccination.  For participants with greater intentions, cost was the least likely barrier for 
vaccination against HPV, followed by not knowing where to get the vaccine.  This was 
the only group of students that reported they would not be affected by the cost of the 
vaccine, indicating that certain factors that may prevent others from getting the vaccine, 
such as those who perceive themselves to be highly susceptible to HPV and those who 
perceive HPV to be more severe, would not prevent those who have greater intentions to 
practicing safer sex behaviors.  This is an interesting finding because getting vaccinated 
against HPV can also be considered a safer sex behavior, and it may be that those 
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students who have greater intentions to practice safer sex behaviors, as defined in this 
study, are also more likely to carry out other actions to protect themselves against STIs.  
To confirm these findings, longitudinal studies are needed to determine whether female 
college students and young women who become vaccinated against HPV are also more 
likely to practice safer sex behaviors.  Additional studies are needed to determine whether 
female college students who have been vaccinated against HPV have lower rates of STIs 
overall, compared to those female college students who have not been vaccinated. 
Conclusions and Recommendations 
Findings from this study confirm the need for university health centers to include 
HPV vaccination as part of a broader STI educational campaign targeting female college 
students who are single, as well as those in monogamous relationships, on how to 
practice other safer sex behaviors, emphasizing how to ask partners to get tested for STIs 
before becoming sexually active with them.  Campaigns can also include localized 
information on where to get the vaccine in the community and how to determine 
eligibility for low-cost or free vaccination. 
To further prevent and reduce the rate of HPV among female college students, 
follow-up studies are needed to determine acceptance of the HPV vaccine among male 
college students as it relates to HPV knowledge, knowledge of the vaccine, and intentions 
to practice safer sex behaviors.  Findings from these studies would also be valuable in 
preventing HPV among young women because males are often carriers of HPV and they 
can actively assist their female partners in carrying out safer sex behaviors that includes 
becoming vaccinated against HPV.  Furthermore, a national survey conducted among a 
randomly selected sample of undergraduate male and female students from a randomly 
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selected group of universities across the U.S. may be valuable to researchers as well as 
health educators and health care providers in understanding the level of awareness and 
acceptance of the HPV vaccine among college students, including the percentage who 
have been vaccinated and intentions to practice other safer sex behaviors. 
Study Delimitations 
 
The study was delimited to college students enrolled at three public universities – 
two in Michigan and one in Florida.  Thus, results may not be generalizable to the 
national population of college students.  Participants were delimited to those who 
volunteered to respond to the survey items constructed for this study and who were 
accessible at the time of administration.  The study was also delimited to the specific 
universe of questions and items contained in the survey instrument to measure health 
beliefs and behavioral intentions. 
Study Limitations 
 
• Not all invited subjects participated in this study, limiting the generalizability of 
the results primarily to the respondent groups at the University of South Florida, 
Central Michigan University, and Western Michigan University.  Students who 
chose to participate in this study may have differed in health beliefs about HPV 
and the HPV vaccine, HPV vaccine acceptance and intentions to be vaccinated 
against HPV and practice safer sex behaviors from those who chose not to 
participate. 
• A small number of participants did not respond to the question concerning their 
HPV vaccine status, but did provide responses to the questions measuring HPV 
 196
vaccine acceptance, certain measures of HPV vaccine acceptance may have 
included responses from participants that had already been vaccinated. 
• Participants in the study were from a convenience sample rather than a random 
sample, so there may have been self-selection bias - a threat to internal validity 
through inherent differences in students who complete the survey compared to 
those who choose not to complete the survey.  Offering the online survey to all 
female students who visit university student health services, attend wellness 
seminars in residence halls, as well as offering the survey to all female, 
undergraduate students, ages 18 to 24, via campus e-mail listservs may have 
helped to reduce self-selection bias. 
• There may have been a social desirability response bias whereby respondents 
provided answers to survey items that illustrated their carrying out a socially 
desirable practice, or assuming positions on issues that do not represent their true 
feelings or likely behaviors.  Through the informed consent, informing students 
that the survey contains personal questions about their past and current sexual 
behaviors and asking students to respond as honestly as possible to survey items 
may have helped to reduce social desirability response bias.  Re-wording 
questions to increase the likelihood of participants responding more honestly to 
questions may have also helped to reduce this type of bias. 
• Participation was not controlled for those few students who participated in Pilot 
Test #1 and Pilot Test #2 and did not provide their e-mail address and last four 
digits of their student ID number, but who also may have participated in the final 
survey.  Recruiting students via the same ten courses that participated in the pilot 
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tests would have possibly prevented pilot test participants from participating in 
the survey; however, this recruitment method would not have offered the 
opportunity to gather a sample size of at least 1,700 female undergraduate 
students from the three participating universities.  Furthermore, the total number 
of students registered in all ten courses, for each pilot test, did not exceed 600 
students and not at all of the students were females.  Furthermore, any participants 
that had matching student IDs and e-mail addresses for any of the pilot tests and 
the final survey were omitted from the study. 
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Appendix A: Sample Size Estimates for Regression 
 
 
 
Power Estimate for Test of Partial Regression Weight for Control Beliefs       
              Obs       rsq_big  rsq_sml    n     k_big    k_sml        alpha          f2                nc            power 
                1           0.572     0.57     1700      3           2              0.05    .004672897    7.93458    0.80380 
 
 
Power Estimate for Test of Partial Regression Weight for Normative Beliefs          
              Obs       rsq_big  rsq_sml      n     k_big    k_sml        alpha          f2                nc            power 
                1           0.572     0.551      165      3           2              0.05    0.049065        7.99766    0.80266 
 
 
Power Estimate for Test of Partial Regression Weight for Attitudes   
              Obs       rsq_big  rsq_sml      n     k_big    k_sml        alpha          f2                nc            power 
                1           0.572     0.184       13        3          2              0.05       0.90654     9.97196      0.80201 
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Appendix B: Online Informed Consent 
 
The purpose of this survey is to find out about your knowledge and beliefs about 
human papillomavirus (HPV), the HPV vaccine, and practicing other safer sex behaviors. 
Your responses will be very helpful in understanding what college students know about 
human papillomavirus (HPV), thoughts about being vaccinated against HPV, and 
intentions in carrying out safer sex behaviors.  Ultimately, your responses will be helpful 
in developing programs and materials for the prevention and treatment of sexually 
transmitted infections among college students and young adults.   
Because the purpose of this survey is to assess your attitudes, thoughts, and 
beliefs, please answer the questions as honestly as possible.  There are some personal 
questions on the survey that will ask you about your past and current sexual practices and 
your attitudes and beliefs about practicing safer sexual behaviors.   Because you are 
completing the survey on the Internet, there is a slight chance that an authorized person, 
such as a hacker, can gain access to your survey responses.  Although access by an 
authorized person is highly unlikely, this poses a potential risk to the confidentiality of 
your survey responses.  Therefore, you do not have to answer any questions that make 
you feel uncomfortable, and you can stop completing the survey at any time.  You will 
not be penalized in any way for choosing not to complete the survey, and your decision to  
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participate or not participate in this survey will not affect your student status in any way 
nor the student services available to you. 
 You have the option to not include identification information on the survey if you 
want to participate but do not want to receive an incentive.  You can participate in the  
survey without including identifiers.  At the end of the survey, there is an option to 
include your e-mail address and the last four digits of your student identification (ID) 
number.  You have the option of not including this information if you do not want your 
survey responses linked to your identification information.  The principal investigator 
will not follow up with you regarding an incentive because they will not have your 
contact information. 
If you want to participate and be eligible to receive an incentive, you will be 
asked to provide your university e-mail address so the principal investigator of the study 
can contact you regarding your incentive for participation.  You will be entered into a 
random, one-time $500 cash drawing.  A code number will be assigned to your survey.  If 
your survey code number is selected, the principal investigator will e-mail you and ask 
for a name and address where the incentive will be mailed.  The name and address will be 
printed directly on to the envelope where the check will be mailed and will not be written 
down on any other place, nor shared with anyone.  The name and address you provide 
will not be linked to your survey responses.  The principal investigator will ask for you to 
confirm, by e-mail, that you have received the incentive because the name and address  
where the check is to be mailed will not be kept.  You will also be asked to provide the 
last four digits of your student ID number as an identifier, and this is to ensure that  
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participants take the survey only once since an incentive is being offered.  Therefore, 
your e-mail address and the last four digits of your student ID will be linked to your 
survey responses. However, your identification information will not be shared with 
anyone nor used for any other purpose and will be kept in a secured file.    
Participant e-mail addresses and student ID numbers will be tracked so that each 
participant receives only one incentive.  Once you have received your incentive, your e-
mail address and the last four digits of your student ID will be discarded in a secure 
manner and no one will have access to it.  A code consisting of numbers will be assigned 
to your survey, instead of the last four digits of your student ID or e-mail  
address, and the survey responses will be analyzed directly from the secured electronic 
database, to further protect your identity and confidentiality of your responses.   
If you continue to take this survey after reading this web greeting, you are giving 
your consent to participate, and you can start taking the survey at any time.  If you 
include your e-mail address and last four digits of you student ID number, and your 
survey code number is selected, you will be notified about the cash incentive within one 
week after student participation in this survey has ended.  As a reminder, you are not 
required to include your e-mail address and your student ID number if you do not want to 
be eligible to receive an incentive. 
If you have any questions about this study or your participation in this survey, 
please contact Teri Wilson at (248) 231-2007.  If you have any questions or need  
information about HPV and other STI prevention and treatment, the HPV vaccine, or 
would like a copy of the study results, please contact your student health center.  
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Contact information for all participating student health centers is included below.  Thank 
you for your participation in this online survey. 
Participating university health centers: 
University of South Florida, Student Health Services – 813-974-2331 
Central Michigan University Health Services – 989-774-6599 
Western Michigan University, Sindecuse Health Center – 269-387-3284 
Please start the survey below. 
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Appendix C: HPV Vaccine Survey Online Questionnaire 
Section One. What you know about HPV 
1. Please mark the following items as "True" or "False". 
 
HPV is more common than HIV. 
□ True 
□ False 
 
Only women get HPV. 
□ True 
□ False 
 
You can always tell when someone else has HPV. 
□ True 
□ False 
 
2. Has a health care provider ever told you that you have HPV? (A health care 
provider would be a doctor, nurse practitioner or physician assistant.) 
□ Yes 
□ No 
□ Not sure 
 
Section Two. Your attitudes and intentions regarding practicing safer sex 
behaviors*  
*Please note: This section includes questions on your thoughts about sex and sexual 
activity. Sex is defined in this survey as sexual intercourse. Sexual activity is defined in 
this survey as having oral, anal or vaginal sex. 
 
1. Refusing to have sex with a partner if they will not use a condom would be very 
easy for me. 
□ Strongly agree 
□ Agree 
□ Somewhat agree 
□ Disagree 
□ Strongly disagree 
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2. I intend to tell a partner to get tested for sexually transmitted infections before I 
become sexually active with them. 
□ Strongly agree 
□ Agree 
□ Somewhat agree 
□ Disagree 
□ Strongly disagree 
 
3. Telling a partner that I will not be sexually active with them until they have been 
tested for sexually transmitted infections would be very easy for me. 
□ Strongly agree 
□ Agree 
□ Somewhat agree 
□ Disagree 
□ Strongly disagree 
 
4. I intend to refuse to have sex with a partner if they will not use a condom. 
□ Strongly agree 
□ Agree 
□ Somewhat agree 
□ Disagree 
□ Strongly disagree 
 
5. Avoiding the use of drugs or alcohol before engaging in sexual activity would be 
very easy for me. 
□ Strongly agree 
□ Agree 
□ Somewhat agree 
□ Disagree 
□ Strongly disagree 
 
6. I intend to avoid drugs or alcohol before engaging in sexual activity. 
□ Strongly agree 
□ Agree 
□ Somewhat agree 
□ Disagree 
□ Strongly disagree 
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Section Three. What you know about the HPV vaccine 
 
1. What have you heard about the HPV vaccine from the media, friends, family or 
your health care provider? (Check all the following you have heard.) 
□ The vaccine is safe. 
□ The vaccine prevents women from getting high risk HPV. 
□ The vaccine will protect against cervical cancer. 
□ The vaccine consists of three shots over a six-month period. 
□ I have not heard about the HPV vaccine. 
 
Section Four. Your beliefs regarding practicing safer sex behaviors*  
*Please note: This section includes questions on your thoughts about the beliefs of others 
regarding sexual activity. Sexual activity is defined in this survey as having oral, anal or 
vaginal sex. 
 
1. Most college students would avoid using drugs or alcohol before engaging in 
sexual activity. 
□ Strongly agree 
□ Agree 
□ Somewhat agree 
□ Disagree 
□ Strongly disagree 
 
2. Most college students would ask their health care provider about how to reduce 
their risk for sexually transmitted infections. 
□ Strongly agree 
□ Agree 
□ Somewhat agree 
□ Disagree 
□ Strongly disagree 
 
3. Most college students would tell a partner to get tested for sexually transmitted 
infections before becoming sexually active with them. 
□ Strongly agree 
□ Agree 
□ Somewhat agree 
□ Disagree 
□ Strongly disagree 
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Section Five. Your acceptance of the HPV vaccine 
 
1. How important do you think vaccinations are, in general? 
□ Very important 
□ Somewhat important 
□ Not important at all 
 
2. Have you received at least one dose of the HPV vaccine? (IF "Yes", PLEASE 
SKIP TO SECTION SIX OF THE SURVEY, IF "NO", PLEASE GO TO 
QUESTION #3.) 
□ Yes 
□ No 
 
3. The vaccine is currently available for young girls and women between the ages of 
9 through 26. How likely is it that you will get vaccinated against HPV? 
□ Very likely 
□ Likely 
□ Somewhat likely 
□ A little likely 
□ Very unlikely 
 
4. How important are the following issues in influencing your decision to become 
vaccinated against HPV? Please check the following statements below as "Very 
important", "Somewhat important", or "Not important at all". 
 
If my friends think I should get it 
□ Very important 
□ Somewhat important 
□ Not important at all 
 
If my health insurance covers it 
□ Very important 
□ Somewhat important 
□ Not important at all 
 
If I had an abnormal Pap smear 
□ Very important 
□ Somewhat important 
□ Not important at all 
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If my family thinks I should get it 
□ Very important 
□ Somewhat important 
□ Not important at all 
 
If my sex partner thinks I should get it 
□ Very important 
□ Somewhat important 
□ Not important at all 
 
If my health care provider thinks I should get it 
□ Very important 
□ Somewhat important 
□ Not important at all 
 
If someone in my family has cancer 
□ Very important 
□ Somewhat important 
□ Not important at all 
 
Whether I practice safe sex 
□ Very important 
□ Somewhat important 
□ Not important at all 
 
5. How important are the following issues in preventing you from becoming 
vaccinated against HPV? Please check the following statements below as "Very 
important", "Somewhat important", or "Not important at all". 
 
The cost of the vaccine would prevent me from becoming vaccinated. 
□ Very important 
□ Somewhat important 
□ Not important at all 
 
Getting three shots over a six-month period would prevent me from becoming 
vaccinated. 
□ Very important 
□ Somewhat important 
□ Not important at all 
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Fear of vaccines would prevent me from becoming vaccinated. 
□ Very important 
□ Somewhat important 
□ Not important at all 
 
Possible side effects of the vaccine would prevent me from becoming vaccinated. 
□ Very important 
□ Somewhat important 
□ Not important at all 
 
Having to get additional boosters after getting three shots would prevent me from 
becoming vaccinated. 
□ Very important 
□ Somewhat important 
□ Not important at all 
 
Having to wait at my doctor's office for approval to get the vaccine would prevent 
me from becoming vaccinated. 
□ Very important 
□ Somewhat important 
□ Not important at all 
 
Not knowing where to get the vaccine would prevent me from becoming vaccinated. 
□ Very important 
□ Somewhat important 
□ Not important at all 
 
 
Section Six. Your beliefs about practicing safer sex behaviors*  
*Please note: This section includes questions on your thoughts about abstinence, sex and 
sexual activity. Abstinence is defined in this survey as not participating in sexual activity, 
such as oral, anal or vaginal sex, with anyone until you are married. Sex is defined in this 
survey as sexual intercourse. Sexual activity is defined in this survey as having oral, anal 
or vaginal sex. 
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1. How much control do you have in being abstinent from sexual activity until you 
are married? 
□ Complete control 
□ A lot of control 
□ Some control 
□ Little control 
□ No control 
 
2. How much control do you have in refusing to have sex with a partner that will not 
use a condom? 
□ Complete control 
□ A lot of control 
□ Some control 
□ Little control 
□ No control 
 
3. How much control do you have in avoiding the use of drugs or alcohol before 
engaging in sexual activity? 
□ Complete control 
□ A lot of control 
□ Some control 
□ Little control 
□ No control 
 
4. How much control do you have in telling a partner to get tested for sexually 
transmitted infections before becoming sexually active with them? 
□ Complete control 
□ A lot of control 
□ Some control 
□ Little control 
□ No control 
 
5. How much control do you have in asking a health care provider about how to 
reduce your risk for sexually transmitted infections? 
□ Complete control 
□ A lot of control 
□ Some control 
□ Little control 
□ No control 
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Section Seven. Your thoughts about HPV risk 
1. Do you think you are likely to contract HPV? 
□ Yes 
□ No 
□ Not sure 
 
2. How likely is it that you currently have HPV? 
□ Very likely 
□ Likely 
□ Somewhat likely 
□ A little likely 
□ Very unlikely 
 
3. Do you think your friends or peers are likely to contract HPV? 
□ Yes 
□ No 
□ Not sure 
 
4. What is the likelihood that you could get HPV within the next year? 
□ Very likely 
□ Likely 
□ Somewhat likely 
□ A little likely 
□ Very unlikely 
 
5. What is the likelihood that you could get HPV some time in your life? 
□ Very likely 
□ Likely 
□ Somewhat likely 
□ A little likely 
□ Very unlikely 
 
Section Eight. How HPV can affect you 
 
1. How serious a health problem would HPV be for you? 
□ The most serious 
□ Serious 
□ Not sure 
□ A little serious 
□ Not at all serious 
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2. If you get HPV, it is not a big problem because it is very easy to treat. 
□ Strongly agree 
□ Somewhat agree 
□ Not sure 
□ Somewhat disagree 
□ Strongly disagree 
 
3. If you get HPV, how likely is it that you will get genital warts? 
□ Very likely 
□ Somewhat likely 
□ Not sure 
□ Somewhat unlikely 
□ Very unlikely 
 
4. If you get HPV, how likely is it that you will get cancer? 
□ Very likely 
□ Somewhat likely 
□ Not sure 
□ Somewhat unlikely 
□ Very unlikely 
 
 
Section Nine. Information about you 
 
1. How old are you? _________ 
 
2. What is your gender? 
□ Male 
□ Female 
 
3. How do you describe yourself? (Check all that apply.) 
□ African-American 
□ Hispanic or Latino 
□ Asian 
□ American Indian or Alaska Native 
□ Native Hawaiian or other Pacific Islander 
□ Arab-American 
□ White 
□ Multi-racial 
□ Other, please specify here: __________________________ 
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4. What is your sexual orientation? 
□ I have sex with men. 
□ I have sex with women. 
□ I have sex with men and women. 
□ I don't have sex. 
 
5. Within the past 12 months, with how many partners, if any, have you had oral, 
anal or vaginal sex? ______________ 
 
6. Have you had oral, anal or vaginal sex with a partner in the past 60 days? 
□ Yes 
□ No 
 
7. What is your marital status? 
□ Single and abstinent 
□ Single and sexually active 
□ Single and in a monogamous relationship 
□ Married 
□ Separated/Divorced 
□ Widowed 
 
8. Do you have children? 
□ Yes 
□ No 
 
9. What is your current year in college? 
□ Freshman 
□ Sophomore 
□ Junior 
□ Senior 
 
10. What university are you attending? 
□ Central Michigan University 
□ University of South Florida 
□ Western Michigan University 
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11. Do you currently have health insurance that covers the cost of the HPV vaccine? 
□ Yes 
□ No 
□ Not sure 
 
If you want to be eligible to receive an incentive for your participation, please 
include the last four digits of your student ID and your e-mail address before you 
click "Submit" to complete your survey.What is the last four digits of your student 
ID?_______________ 
 
What is your e-mail address? ________________________________________ 
 
Please click on the "Submit" button below to submit your survey. 
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Hi, my name is Teri Wilson, and I will be conducting this interview with you.  
The purpose of this interview is to ask you some questions regarding what you think are 
some benefits and barriers to becoming vaccinated against HPV.  The information you 
provide will help with the development of questions for an online survey that will be 
conducted among undergraduate female college students for a study on vaccine 
acceptance and intentions to practice safer sex behaviors.  I am the principal investigator 
for this study. Your participation in this interview is completely voluntary, you can stop 
taking the survey at any time, and you do not have to answer any questions that make you 
feel uncomfortable.  Your responses will remain anonymous and your name nor your 
telephone number will not be linked to your responses.  There will be no identification 
information linking you with your responses.  The information you provide will be kept 
confidential and will only be shared with me during our phone conversation. I will be 
writing your responses down and after the interview, I will enter and save them in an 
electronic document.  I will keep your unidentifiable responses in a secure electronic file 
and I will not share them with anyone, but will only use them to help me develop 
questions for the online survey.  You will receive a cash stipend of $25 for participating 
in this interview and once we complete the survey, I will ask need to ask you for a name 
and address where you would like the stipend sent.  I will only write the name and  
 275
Appendix D (Continued)Verbal Informed Consent and Interview Questionnaire 
address you provide me on the envelope where the check is being sent and will not write 
that information anywhere else.  I will provide you with my phone number and e-mail 
after the interview and will ask you to contact me, only to let me know that you have  
received the stipend.  After hearing this information, do you still want to participate in the 
interview?  If “no”, thank the individual for their time.  If “yes”, then proceed with the 
interview – see questions below. 
1) Have you heard about the human papillomavirus (HPV) vaccine, GARDASIL®? 
 
Interviewer Script (if participant has not heard about the HPV vaccine): GARDASIL® is 
a vaccine that prevents infection with four types of HPV – two that are the major causes 
of genital warts and two that are major causes of cervical cancer.  The vaccine requires 
three doses given over a six-month period, and each dose costs $120 for a total cost of 
$360. 
 
2) What are some benefits of becoming vaccinated against HPV?  
  
3) What are some barriers that would prevent you from becoming vaccinated against 
     HPV?  
 
Probing question (if participant does not report cost):  Would the cost of the vaccine 
prevent you from becoming vaccinated? 
 
4) How would the cost prevent you from becoming vaccinated? 
 
5) Would lack of health insurance coverage prevent you from getting the vaccine? 
Probing question: Do you know whether you currently have health insurance that helps      
                             you to pay for your doctor visits or medications? 
 
Interviewer Script: Women between the ages of 19 to 26, but have no health insurance or 
who cannot afford the vaccine because they make less than $19,600 per year, can obtain 
the vaccine through Merck’s patient assistance program. The woman has to wait a period   
of time, from approximately 15 to 20 minutes, to obtain a approval from Merck to  
receive the vaccine from her health care provider.   
 
6) Would this process of waiting a certain period of time to obtain approval to receive 
     the vaccine prevent you from getting vaccinated? Why or why not? 
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Thank you for time in participating in this interview! 
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Question 1 - Knowledge of the HPV vaccine, GARDASIL® 
 
Fourteen out of the 15 participants (93%) heard about the vaccine, and one 
participant (7%) had not heard about the vaccine. 
 
 
Question 2 - Benefits of becoming vaccinated against HPV 
 
 
 
 
 
One of the 15 participants (7%) reported that a benefit of becoming vaccinated 
against HPV is for health and because it prevents diseases.  
 
Matching Quote: 
 
“Health.”  “To prevent diseases.” 
 
 
 
 
 
One of the 15 participants (7%) reported that a benefit of becoming vaccinated 
against HPV is that it can help to raise awareness about HPV among college 
students, because HPV is not common to talk about separate from other STIs. 
 
Matching Quote: 
 
“Help raise awareness about HPV, and that it is a risk, good to raise awareness.  Don’t 
think college students know about it, it is not very common to talk about it because it is 
usually packed with other types of STDs”. 
Theme: Promotes health 
and prevents disease 
Theme: Increases HPV 
awareness 
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-  
 
Seven out of the 15 participants (47%) reported that a benefit of the vaccine was that it 
protects against HPV, so they were aware that it directly prevents the STI.   
 
Matching Quotes: 
 
“It guards against different strands of HPV, and you feel safer, in general, about that.”  
 
“From what I’ve heard, anybody can get HPV, so any vaccine you can get for it, you can 
benefit from.” 
 
“Do what you can to protect yourself.  Heard only protects against six strands, you are 
protecting that much and doing your part, taking measures.” 
 
“Protection against HPV.” 
 
“There are social problems that go with it, it is taboo to talk about it, but you have to 
protect yourself and you have the responsibility to protect others.” – This participant was 
vaccinated with the first two shots in the three-shot series.  
 
“Well, for one thing, I mean, it will prevent among college students and high school 
students, it will protect against STDs that were once incurable, so it will make students 
and people safer because they are going to do it (have sex) anyway.  At least the risk of 
getting these four types of HPV are significantly lowered.” 
 
“It can help prevent ovarian cancer…” this participant also responded…”and some 
forms of HPV and genital herpes.” 
 
 
 
 
 
Eight out of the 15 participants (53%) reported that a benefit of the HPV vaccine 
was that it prevents cancer and half of these participants (27% of all participants) 
specifically referred to the vaccine preventing cervical cancer.   
 
Matching Quotes: 
 
“Less chance of getting cervical cancer” 
Theme: Protects against 
HPV  
Theme: Prevents cancer 
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“I saw the commercials about cervical cancer on T.V. and it scared me.” “It can give 
you cancer…” – this same participant responded…”and it can make you infertile”.  – 
This participant had been vaccinated with the first shot in the three-shot series.  
 
“For students that are younger to prevent them from getting it (HPV), so prevent cancers 
that HPV will bring at an earlier age.” 
 
“That it prevents cervical cancer, as far as I know that’s it (the only benefit).” 
 
“All that information that I know, it can protect you against a couple of different types of 
HPV that can cause cervical cancer, and that is why I was vaccinated.” This participant 
had been vaccinated – it is not known how many shots she received.  
 
“If there is a way to protect yourself for cancer which is very hard to do, then by all 
means do it.” - This participant was vaccinated with the first two shots in the three-shot 
series.  
 
“Obviously preventing cancer and that is a good benefit, it gives good security for 
women knowing that there is something out there for them.  Primary benefit is that it can 
prevent cancer.”  
 
“It can help prevent ovarian cancer…” this participant also responded…”and some 
forms of HPV and genital herpes.” 
 
 
 
 
 
 
One participant (7%) reported that she was previously treated for an abnormal Pap test, 
and because of her experience, thinks every woman would benefit from getting 
vaccinated against HPV. 
 
Matching Quote: 
 
“I was treated for an abnormal Pap when I was 18, and I’m 22.  When I found out you 
can get vaccinated against HPV, in my opinion, I want every woman to get it.” - This 
participant was vaccinated with the first two shots in the three-shot series.  
Theme: Personal experience 
with abnormal Pap/HPV 
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Matching Quotes: 
 
Two participants (13%) reported that getting vaccinated against HPV is beneficial 
because of their personal experience in knowing someone who had HPV or who had 
developed cancer, and one of these participants got vaccinated because of a family 
member being diagnosed with ovarian cancer. 
 
“Personally, I know two girls that have developed symptoms of the virus, so that is scary, 
and I would want to get vaccinated to prevent anything from happening to me.”  
 
“My mom was just diagnosed with ovarian cancer.” – This participant had been 
vaccinated with the first shot in the three-shot series.  
 
 
 
 
 
 
Two out of 15 participants (13%) reported that a reason to become vaccinated 
against HPV is related to the fact that HPV has no symptoms.  
 
Matching Quotes: 
 
“A guy can have it and pass it on and not even know that he has it, for that a reason.  
Because it is an unsure thing, and if a girl is sexually active, she may get it and may not 
know it.” 
 
“Sexual partners may have it but they may not tell.”- This participant was vaccinated 
with the first two shots in the three-shot series.  
Theme: Personal experience 
with HPV and cancer 
Theme: HPV has no 
symptoms 
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Question 3: Barriers to becoming vaccinated against HPV 
 
-   
 
Fourteen out of 15 participants (93%) identified cost as a barrier that would 
prevent them from becoming vaccinated against HPV. 
 
Matching Quotes: 
 
“Cost, $360 is a lot of money.”   
 
“Cost.  I am not sure if it is covered.”   
 
“The only thing I can think of is I’m a poor college student so I don’t know what the cost 
is…” 
 
“Maybe a little, but in the end it would be better to spend the money instead of getting cervical 
cancer.” 
 
“Cost.” 
 
“Money.” 
 
“Price of the vaccine. Because I don’t have health insurance.  I saw the price and it is 
very expensive for me, and that is why I didn’t get the vaccine.” 
 
“The cost.” 
 
“The cost of the vaccine, mainly.  That would be it (the only barrier), nothing else. 
 
“Cost of it is pretty high, good if it was discounted.” 
 
“Cost, money.  Being able to afford the shots.  A social worker at the student health 
center at Western helped me to get the financial assistance based upon a limited college 
student income”.  Getting treatment is way more expensive than getting the 3-dose shot.” 
This participant was vaccinated with the first two shots in the three-shot series.  
 
“It is expensive, actually my mom called around to find out who offered it at the cheapest 
price and Western was the cheapest place we found.” This participant had been 
vaccinated – it is not known how many shots she received.  
Theme: Cost 
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“It is very expensive I think, but my insurance covers it.  If it did not cover it, then I 
would not be able to pay for it.” 
 
“The cost if insurance does not cover it.  If the cost is $350 or whatever you said, $360, if 
insurance does not cover it, then high school students and college students are not going 
to be able to pull it out of their pocket.” – This was the one participant who had not heard 
about the HPV vaccine, GARDASIL®. 
 
“No.  My parents thought I should get it, my parents are taking care of the cost. My 
parents were more concerned and got me informed on that.  My mom was just diagnosed 
with ovarian cancer.” This participant had been vaccinated with the first shot in the 
three-shot series.   
 
If “cost” was a response, the participants were asked the following question: 
 
Question 4: How would the cost prevent you from becoming vaccinated? 
 
Participants reported that cost would prevent them from becoming vaccinated for 
the following reasons:  the high cost of the vaccine at $360 (73%); because of being a 
college student and not having enough money to pay for the vaccine (60%); having 
other items to pay for that are of higher priority than becoming vaccinated, such as 
rent, books, tuition, student loans, and one participant also reported paying for 
birth control (13%) .    
 
Two out of the 15 participants (13%) that reported that cost would prevent them 
from becoming vaccinated also  reported there can be other ways to prevent HPV, 
instead of the vaccine, and one out of the two participants reported having safe sex.  
 
Matching Quotes: 
 
“For college students, $360 is more than a month’s rent.  Could prevent it (HPV) in 
other ways, instead of the vaccine.” 
 
“If it is not covered by your insurance, if it cost too much, too.  In general, college 
students don’t have a lot of money lying around.” 
 
“Well, as of right now, I have pretty crappy health insurance, and I’m not working and 
thousands of dollars in debt, so $50 is a lot of money (referring to a dollar amount, not 
the cost of the vaccine). 
 
“Three-hundred and sixty dollars is a lot of money for a college kid.” 
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“It cost too much being a college student.  That is why I haven’t done it.” 
“Cost too much money to get vaccinated.” 
“I am already paying for birth control out of my pocket.  I pay for everything on my own.  
I don’t ask my parents for money.  If I had the money, I would do it.” 
 
“It is too expensive.  It is 300 and some dollars.  I am a college student, and I don’t have 
the means to come up with the extra $300 for the vaccine.” 
 
“It is expensive, and since I’m a student, I can’t afford to pay for it.” 
    
“Spending that much money on something you may or may not get.  If you have 
 the same boyfriend for a while, you are not really going to get it.  However,  you don’t 
know what it is going to be like in a year, what you will be doing and you may not know 
who your boyfriend has been with.” 
 
“Without the fact that they have a social worker and you have to go to the clinic            
on campus, it (financial assistance) is not well publicized.  Financial assistance is not 
very well known.” This participant was vaccinated with the first two shots in the three-
shot series.  
 
“Big chunk of change for a college student, have to worry about student loans, books, 
and everything.” 
 
“I guess, personally, cost doesn’t matter to me and I wanted to get it no matter what, and 
honestly, I wanted to find a place where it was the cheapest.  But I can imagine where it 
can be expensive for a college student because each shot cost so much.”  This participant 
had been vaccinated – it is not known how many shots she received.  
 
“Being the age I am and in college, there are a lot of other costs that are higher in 
priority than the vaccination, like rent, books, and tuition.  There are other things that 
are more important than the vaccination.” 
 
“Well, at the current cost of $360, with that type of cost, I would just say I would just 
rather practice safe sex than get the vaccine.” 
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Question 5: Would lack of health insurance coverage prevent you from getting the 
vaccine? 
 
 
 
 
 
Eight participants (53%) reported that lack of health insurance would prevent them 
from getting vaccinated and five out of the eight participants (62%) had health 
insurance but they did not  know or did not think that their insurance would cover 
the vaccine.  The remaining three participants (37%) reported that they did not 
have health insurance.   
 
Seven participants (47%) reported that lack of health insurance would not prevent 
them from getting vaccinated, and six out of seven of these participants (86%) had 
health insurance. Only one of these participants did not have health insurance, but 
reported that they would do get vaccinated if they had the money.   
 
(Four out of the 15 participants (27%) did not have health insurance.) 
 
 
Matching Quotes: 
 
“Yes. It depends on your health insurance, because could still have health insurance but 
it may not cover it.  I have health insurance but I do not think it would cover it.”  
Response to probing question on whether they currently have health insurance that helps 
them to pay for doctor’s visits or medications - “I have health insurance that helps me to 
pay for doctor visits but not medications.” 
 
“Yes.” Response to probing question on whether they currently have health insurance that helps 
them to pay for doctor’s visits or medications – “I have insurance. I don’t know if it would cover 
the vaccine or not.” 
 
“Probably, I don’t know what the health insurance covers, it covers basic services.”   
Response to probing question on whether they currently have health insurance that helps 
them to pay for doctor’s visits or medications – “Helps pay, don’t know what the 
percentage is because I’m paying more now for doctor visits and medications than I did 
for my previous insurance.  I used to pay $10 for a doctor visit, now I pay more, $75 per 
visit.” 
Theme: Lack of health 
insurance 
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“No.”  Response to probing question on whether they currently have health insurance 
that helps them to pay for doctor’s visits or medications – “Yes, yes it does.  I am pretty 
sure it does.  Not prescriptions, most doctor visits.” – This same participant had been  
vaccinated with the first shot in the three-shot series, and she also reported that her 
parents are taking care of the cost.  
 
“I don’t know if it would fully prevent me, but it would definitely have an impact.  I am not sure if 
my health insurance would cover the vaccine.  I would probably still go ahead and get it because 
you never know the long-term effects.” Response to probing question on whether they 
currently have health insurance that helps them to pay for doctor’s visits or medications – 
“Yes, it does.  It pays for emergency visits, but I do not get doctor visits.” 
 
“Yes. I don’t have health insurance.” 
 
“Yes.  I do not have health insurance”. 
 
“No.  I would do it if I had the money.”  This participant also reported that they did not 
have health insurance. 
 
“No.” Response to probing question on whether they currently have health insurance that 
helps them to pay for doctor’s visits or medications – “Yes, it pays for doctor visits and 
medications.” – This participant reported that she already had HPV. 
 
“Yes, that, too.”  Response to probing question on whether they currently have health 
insurance that helps them to pay for doctor’s visits or medications – “No, I don’t have 
health insurance.” 
 
“No.  I have health insurance but I am not sure if it covers the vaccine.”  This participant 
did not answer the probing question on whether they currently have health insurance that 
helps them to pay for doctor’s visits or medications. 
 
“No, there is financial assistance.  I had a hard time getting it.  I do have health 
insurance but it doesn’t cover it for each shot.” Response to probing question on whether 
they currently have health insurance that helps them to pay for doctor’s visits or 
medications –  “Yes, for doctor visits and medications.” This participant was vaccinated 
with the first two shots in the three-shot series.  
 
“Personally, no, because well, I do have health insurance but mine didn’t cover it, but I 
still obviously got it.”  Response to probing question on whether they currently have 
health insurance that helps them to pay for doctor’s visits or medications – “It covers 
doctors’ visits but I don’t have coverage for prescriptions.” This participant had been 
vaccinated – it is not known how many shots she received.  
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“Don’t think it really would, so eventually, even if I did not have health insurance, 
because the cost of the vaccine is nothing compared to paying for cancer bills.” 
Response to probing question on whether they currently have health insurance that helps 
them to pay for doctor’s visits or medications – “Yes, pays for both, I’m still on my mom’s 
insurance.” 
 
“Yes.  The next question is how many partners am I gonna have sex with and how safe of 
sex will I be practicing.  Those are the two things that would dictate whether I would get 
the vaccine.” Response to probing question on whether they currently have health 
insurance that helps them to pay for doctor’s visits or medications – “My health 
insurance covers everything.  I have a $15 co-pay.  Some things are not covered.” 
 
 
    
 
 
Four of the 15 participants (27%) reported that barriers were access and 
availability, such as having a hard time finding a place where they had access to the 
vaccine, or where or when the vaccine was available. 
 
Matching Quotes: 
    
“Also, availability, if the vaccine were not available to you.” 
 
“Availability.  I don’t know when it is offered and where it is offered.” 
 
“…and I’m going home (for the summer) and I don’t know where to get it.  So, this 
summer, I’m checking into my regular doctors with my mom.” 
 
“One of the hard things that I had problems with was finding a place that I had access to 
it.  Being a college student, it is harder around here to find a place to get it done.” This 
participant had been vaccinated – it is not known how many shots she received.  
 
 
     
 
 
Two out of the 15 participants (13%) reported a barrier that would prevent them 
from becoming vaccinated would be getting multiple shots. 
 
Matching Quotes: 
 
“Inconvenience. I heard you have to get several shots”. 
Theme: Access & 
Availability 
Theme: Having to get 
multiple shots 
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“Vaccination is over a long period, it takes a long time to get three shots, so people may forget.” 
 
 
 
 
 
Three out of the 15 participants (20%) reported that lack of information about the 
vaccine would be a barrier that would prevent them from becoming vaccinated 
against HPV. 
 
Matching Quotes: 
 
“Lack of information in general.  I tried to look it up online and could not find anything that was 
useful.”  
 
“Lack of knowledge and resources”. 
 
“I didn’t hear anything about it, they were not promoting it on T.V.  I think I heard one 
commercial.” 
 
 
 
 
 
Five out of the 15 participants (33%) reported that potential side effects of the 
vaccine would be a barrier that would prevent them from becoming vaccinated 
against HPV. 
 
 
Matching Quotes: 
 
“If there are side effects to it, otherwise, no barriers.”  
 This participant was asked the probing question of would the cost prevent her from 
getting the vaccine, and she responded, “No.  My parents thought I should get it, my 
parents are taking care of the cost.”  “My parents were more concerned and got me 
informed about that.” - This participant had been vaccinated with the first shot in the 
three-shot series and her mother was diagnosed with ovarian cancer.  
 
“No barriers for me, unless there are serious side effects, but probably not.” 
 
“Possible side effects.” 
 
“Because it so new, I don’t know what the side effects I would get in the long-term.”  
This participant was vaccinated with the first two shots in the three-shot series. 
Theme: Lack of available 
information about the vaccine 
Theme: Side 
effects 
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“Well, there are always potential side effects because it is a vaccine it could hurt 
someone.  I don’t know what the side effects are, I am not familiar with the studies that 
were done on the vaccine.  I don’t know if the potential side effects outweigh the good of 
the vaccine.” 
 
 
 
 
 
One out of the 15 participants (7%) reported a barrier that would prevent her from 
becoming vaccinated against HPV was that she already had HPV. 
 
Matching Quote: 
 
“I already have HPV.”  This participant reported that cost also was a barrier. 
 
 
 
 
One out of the 15 participants (7%) reported that fear of getting the vaccine would 
be a barrier. 
 
Matching Quote: 
 
“Scary to do, like getting an AIDS test, because it is something that you may get, it is  
something real.” 
 
  
 
 
 
 
 
One out of the 15 participants (7%) reported that the social stigma of getting the 
vaccine could be barrier that would prevent someone from getting the vaccine – not 
for her, as she has already been vaccinated with two out of the three shots.  
Matching Quote: 
 
“Also, taboo, they don’t want to talk about it, there is a social stigma.  Because when people ask 
you why you are going to the health clinic, you do not want to really say “Oh, because I am 
getting an HPV vaccine.” 
Theme: Personal experience 
with HPV 
Theme: Fear 
Theme: Social stigma of 
getting a vaccine to prevent 
HPV  
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One out of the 15 participants (7%) reported that skepticism about whether the 
vaccine really does what it is supposed to may be a barrier that would prevent her 
from becoming vaccinated against HPV. 
 
Matching Quote: 
 
“The vaccine is to prevent cancer, so people may think that cannot be and people may be 
skeptical to what the long term effects are and if it really is to do what they say.” 
 
 
 
 
 
One out of the 15 participants (7%) reported that having to get the vaccine again 
after several years of getting the vaccine, because the initial vaccine was no longer 
effective, would be a barrier that would prevent her from becoming vaccinated 
against HPV. 
 
Matching Quote: 
 
“Also, how long is the vaccine effective for?  If I have to shell out money to get it and 
then need it again in four years, and it will cost $180, then I would not get it.  What is 
going to be the return on the investment?  Information about how it is not known whether 
women will need a booster should be shared with them before they are vaccinated.” 
 
 
 
 
 
 
 
Twelve out of the 15 participants (80%) reported that waiting a certain period of 
time to receive the vaccine for free would not be a barrier.  The participants 
reported that time would not be a factor for the following reasons:  waiting 15 to 20 
minutes is not that much time; waiting is worth it if you want the vaccine; it is worth 
waiting to get the vaccine for free; it is important to get vaccinated; waiting to get 
the vaccine and getting the vaccine is better than getting cervical cancer; you 
already have to wait during doctors’ appointments; you have to wait to get the 
vaccine over a six month period. 
Theme: Skepticism about 
how well the vaccine works 
Theme: Additional booster shots 
Theme: Waiting a certain period of 
time for approval to receive the 
vaccine for free 
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Matching Quotes: 
 
“I don’t think waiting 15 to 20 minutes is that much time.  If you are working or really 
busy, it may not be worth it.  I would do it, waiting 15 to 20 minutes would not prevent 
me from getting vaccinated.” 
 
“Perhaps.  I suppose if I was dead set on getting it, nothing would stop me from getting 
it.  But, otherwise, it would be an inconvenience to wait.” 
 
“No, I would wait.” 
 
“No, not at all.  I would want the vaccination, so waiting 15 to 20 minutes is not anything 
at all.”  This participant had been vaccinated with the first shot in the three-shot series 
and her mother was diagnosed with ovarian cancer.  
 
“No. I don’t think 15 minutes or a couple of days is a problem getting it.  Because in the 
end, I’d rather wait a couple of days to get the vaccine and get the vaccine, than getting 
cervical cancer.” 
 
“Yes, just having to wait, you would get tired, even though it is free.  If it was immediate, 
that would be different.” 
 
“No.  It is important and the wait time would not be a factor.” 
 
“No.  It could help me.  Waiting 15 to 20 minutes wouldn’t kill me.  Fifteen to 20 minutes 
is nothing.” 
 
“No.  Because if waiting 15 to 20 minutes or waiting a day is what you have to do to get  
protection, then it is worth it.” 
 
“Not at all.  I’d rather have the vaccine.  I don’t care if I have to wait, if they can pay for 
it.” 
 
“No.  Because waiting 15 to 20 minutes for a vaccine that you know will be free of 
charge is worth it, you can read a magazine during that time, and you have to wait for 
your appointment anyway.  But it would not be worth it if you had to wait for a longer 
period of time, like three to five days, or had to fill out the form, go home and then go 
back to the health center.” 
 
“It is a long process in getting the vaccine, day after day to get paperwork faxed and 
approved, that is why I have not yet gotten the 3rd one (shot) yet, because I’ve been out of 
town.  Right now, it is preventing me from getting the 3rd shot, because I am having to 
wait a long period of time.  I am months behind on my last shot.  A month ago, I had to 
leave and I could just get it because I had approval.  Because it has been over a month  
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since approval, they had to re-approve it.  It takes a lot of persistence and I would really 
like to get it done at this point.”  This participant was vaccinated with the first two shots 
in the three-shot series.  
 
“No.  Because I think that, obviously, the outcome of me waiting would be a great 
advantage to myself and being able to get the vaccine would be obviously worth the 
wait.”  This participant had been vaccinated – it is not known how many shots she 
received.  
 
“I don’t think so, no.  I think that’s actually a good plan, it is a hunk of time but not bad 
at all.  You wait that long in a doctor’s office.  I think it’s worth it.” 
 
“No.  I can say I understand business and red tape.  If I want the vaccine, and knowing 
that I can get it for free, waiting and filling out paperwork is not going to be a big deal, if 
it is going to take six months to get it anyway.” 
 
 
 
 
 
One out of 15 participants (7%) reported that having to tell your parents about having an 
abnormal Pap test could be a barrier; and this was based on the participant’s personal 
experience.  However, this was not a barrier for this participant as she had been 
vaccinated with two out of the three shots.   
  
Matching Quote: 
 
“Also, you have to tell your parents when you get an abnormal Pap test, why you have 
this.” 
 
Additional comments from the interview, not related to the questions: 
 
“I would have called you regardless of the incentive.  I think everyone should get this.  
I’ve been really trying to advocate.” 
 
One out of the 15 participants (7%) reported that a consequence – more so than a barrier-  
of the vaccine would be that younger girls would think they could go out and start having 
sex and be safe.  
 
Matching Quote: 
 
“The only thing would be for younger girls because they would think they could go out 
and start having sex and be safe.” – This same participant responded, ““No barriers for 
me, unless there are serious side effects, but probably not.” 
Telling your parents 
 292
Appendix F: Panel of Experts 
 
The following panel of experts participated in a review to refine the survey instrument 
which measures HPV and HPV vaccine knowledge, acceptance of the HPV vaccine, and 
attitudes, beliefs and intentions regarding practicing safer sex behaviors.  This group of 
specialists included members with substantive experience in the areas noted that were 
identified as necessary to the revision process.   
  
Gregory Zimet, Ph.D.    Author of numerous articles on HPV  
prevention and STI/HPV vaccine 
acceptance, among adolescents, parents and 
pediatricians. 
 
Richard Roetzheim, M.D. Expertise in family medicine.  Involved in 
research on HPV knowledge and awareness 
among college students. 
 
Jeffrey Kromrey, Ph.D.   Expertise in educational research and  
      measurement 
 
Karen Perrin, Ph.D. Expertise in research design and 
methodology and behavioral change 
theories.  Involved in research on womens’  
diagnosis and acceptance of the HPV 
vaccine. 
 
Ellen Daley, Ph.D. Expertise in research design and 
methodology.  Involved in research on 
womens’ perceptions about HPV, reactions 
to HPV diagnosis and acceptance of the 
HPV vaccine.  Principal investigator of a 
longitudinal study assessing the emotional 
and cognitive responses to HPV diagnosis 
among men 
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Robert McDermott, Ph.D. Author of numerous articles on health 
behavior and health education, including 
those on risk behaviors associated with 
STIs. Expertise in research design and 
methodology.  Involved in research on 
womens’ perceptions about HPV, reactions 
to HPV diagnosis and acceptance of the 
HPV vaccine. 
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Appendix G: Factor Analysis of Survey Constructs  
Construct: Knowledge 
Factor Matrix  
  
Factor 
1 
HPVis more common 
than HIV .846 
You can always tell 
when someone else has 
HPV  
.510 
Only women get HPV 
.418 
Extraction Method: Principal Axis Factoring. 
 
Construct: Knowledge about the HPV vaccine 
  
Factor Matrix 
  
Factor 
1 
Women will not need to 
get Pap smears any more 
if they get this 
.033 
Men will not be able to 
get this vaccine -.400 
The vaccine is safe .543 
The vaccine prevents 
women from getting 
high risk HPV 
.633 
The  vaccine will cost a 
lot of money .220 
The vaccine will prevent 
women from getting 
genital warts 
.255 
Only people with 
insurance will be able to 
get this vaccine 
.006 
The vaccine will protect 
against cervical cancer .497 
The vaccine consists of 
three shots over a six 
month period 
.491 
I have not heard about 
the HPV vaccine -.510 
Extraction Method: Principal Axis Factoring.  
 295
 
Appendix G (Continued) Factor Analysis of Survey Constructs  
 
Construct: HPV vaccine acceptance – Universal acceptance 
 
Factor Matrix 
  
Factor 
1 
How important do you 
think vaccinations are in 
general 
.727 
Have you received at 
least one dose of the 
HPV vaccine 
.503 
The vaccine is currently 
available for young girls 
and women 
.603 
Extraction Method: Principal Axis Factoring.  
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Construct: HPV vaccine acceptance – Issues that would influence and barriers to 
becoming vaccinated 
  
Rotated Factor Matrix 
  
Factor 
1 2 
If my friends think I 
should get it .480 .183 
If my health insurance 
covers it .475 .287 
If I had an abnormal Pap 
smear 
.773   
If my family thinks I 
should get it .543   
If my sex partner thinks 
I should get it .506   
If my health care 
provider thinks I should 
get it 
.647   
If someone in my family 
has cancer .652   
Whether I practice safe 
sex 
.449   
Number of sex partners 
Ive had .225   
The cost of the vaccine 
would prevent me from 
becoming vaccinated. 
.225 .373 
Getting three shots over 
a six month period 
would prevent me from 
becoming vaccinated. 
  .639 
Fear of vaccines would 
prevent me from 
becoming vaccinated. 
  .733 
Possible side effects of 
the vaccine would 
prevent me from 
becoming vaccinated. 
-.361 .556 
Lack of health insurance 
would prevent me from 
becoming vaccinated. 
.199 .268 
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Rotated Factor Matrix (Continued) 
Having to get 
additional boosters 
after getting three shots 
would prevent me from 
becoming vaccinated. 
-.284 .569 
Having to wait at my 
doctors office for 
approval to get the 
vaccine would prevent 
me from becoming 
vaccinated. 
.135 .556 
Not knowing where to 
get the vaccine would 
prevent me from 
becoming vaccinated. 
.205 .503 
Extraction Method: Principal Axis Factoring.  
Rotation Method: Varimax with Kaiser Normalization. 
 
Construct:  Attitudes towards practicing safer sex behaviors  
 
Factor Matrix 
  
Factor 
1 
Telling a partner that I 
will not be sexually 
active with them until 
they have been tested for 
sexually transmitted 
infections would be very 
easy for me. 
.995 
Avoiding the use of 
drugs or alcohol before 
engaging in sexual 
activity would be very 
easy for me. 
.428 
Refusing to have sex 
with a partner if they 
will not use a condom 
would be very easy for 
me. 
.380 
Extraction Method: Principal Axis Factoring. 
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Construct:  Normative beliefs about practicing safer sex behaviors 
 
Factor Matrix 
  
  
Factor 
1 
Most college 
students would tell 
a partner to get 
tested for sexually 
transmitted 
infections before 
becoming sexually 
active with them. 
.691 
Most college 
students would 
avoid using drugs 
or alcohol before 
engaging in sexual 
activity. 
.516 
Most college 
students would ask 
their health care 
provider about how 
to reduce their risk 
for sexually 
transmitted 
infections. 
 
.483 
Extraction Method: Principal Axis Factoring. 
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Construct: Intentions to practice safer sex behaviors 
 
Factor Matrix 
  
Factor 
1 
I intend to tell a partner 
to get tested for 
sexually transmitted 
infections before I 
become sexually active 
with them. 
.935 
I intend to refuse to 
have sex with a partner 
if they will not use a 
condom. 
.395 
I intend to avoid drugs 
or alcohol before 
engaging in sexual 
activity. 
.366 
Extraction Method: Principal Axis Factoring. 
 
Construct: Susceptibility to HPV 
 
 Factor Matrix 
  
Factor 
1 
What is the likelihood 
that you could get 
HPV sometime in your 
life? 
.846 
How likely is it that 
you currently have 
HPV? 
.808 
What is the likelihood 
that you could get 
HPV within the next 
year? 
.749 
Doyouthinkyouarelikel
ytocontractHPV .746 
Doyouthinkyourfriend
sorpeersarelikelytocont
ractHPV 
.344 
Extraction Method: Principal Axis Factoring. 
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Construct: Severity of HPV 
 
Factor Matrix 
  
Factor 
1 
Do you think there 
are immediate, 
negative health 
effects of getting 
HPV? 
.201 
How serious a health 
problem would HPV 
be for you? 
.591 
If you get HPV, it is 
not a big problem 
because it is very 
easy to treat. 
.352 
If you get HPV, how 
likely is it to be 
painful? 
.249 
If you get HPV, how 
likely is it that you 
will get genital warts? 
.485 
If you get HPV, how 
likely is it that you 
will get cancer? 
.459 
Extraction Method: Principal Axis Factoring. 
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Scale:  Knowledge 
Reliability Statistics 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items 
N of 
Items 
.531 .620 3 
 
Item Statistics 
  
Mean 
Std. 
Deviation N 
HPV is more common 
than HIV. .91 .293 54 
Only women get HPV. .74 .442 54 
You can always tell when 
someone else has HPV. .98 .136 54 
 
 
Scale: Knowledge about the HPV Vaccine  
 
Reliability Statistics 
Cronbach's 
Alpha 
N of 
Items 
.602 4 
 
Item Statistics 
  
Mean 
Std. 
Deviation N 
The vaccine is safe. .65 .482 54 
The vaccine prevents 
women from getting 
high risk HPV. 
.81 .392 54 
The vaccine will 
protect against 
cervical cancer. 
.70 .461 54 
The vaccine consists 
of three shots over a 
six month period. 
.78 .420 54 
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Scale: HPV Vaccine Acceptance – General Vaccine Acceptance 
  
Reliability Statistics 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items 
N of 
Items 
.501 .618 3 
 
Item Statistics 
  
Mean 
Std. 
Deviation N 
How important do you 
think vaccinations are, in 
general? 
2.65 .533 40 
Have you received at 
least one dose of the 
HPVvaccine? 
1.08 .267 40 
The vaccine is currently 
available for young girls 
and women between the 
ages of 9 through 26.  
How likely is it that you 
will get vaccinated 
against HPV? 
3.50 1.281 40 
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Scale: HPV Vaccine Acceptance – Issues That Would Influence One to Become 
Vaccinated Against HPV 
 
Reliability Statistics 
Cronbach's 
Alpha 
N of 
Items 
.781 8 
 
Item Statistics 
  
Mean 
Std. 
Deviation N 
If my friends think I 
should get it 1.79 .656 39 
If my health insurance 
covers it 2.72 .560 39 
If I had an abnormal Pap 
smear 
2.85 .489 39 
If my family thinks I 
should get it 2.41 .715 39 
If my sex partner thinks 
I should get it 2.41 .677 39 
If my health care 
provider thinks I should 
get it 
2.82 .506 39 
If someone in my family 
has cancer 2.74 .442 39 
Whether I practice safe 
sex 
2.69 .521 39 
 
 
Scale: HPV Vaccine Acceptance – Issues That Would Prevent One from Becoming 
Vaccinated Against HPV 
 
Reliability Statistics 
Cronbach's 
Alpha 
N of 
Items 
.825 7 
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Item Statistics 
  
Mean 
Std. 
Deviation N 
The cost of the 
vaccine would 
prevent me from 
becoming 
vaccinated. 
2.21 .801 39 
Getting three shots 
over a six month 
period would 
prevent me from 
becoming 
vaccinated. 
1.49 .756 39 
Fear of vaccines 
would prevent me 
from becoming 
vaccinated. 
1.44 .754 39 
Possible side effects 
of the vaccine 
would prevent me 
from becoming 
vaccinated. 
1.97 .628 39 
Having to get 
additional boosters 
after getting three 
shots would prevent 
me from becoming 
vaccinated. 
1.67 .701 39 
Having to wait at 
my doctors office 
for approval to get 
the vaccine would 
prevent me from 
becoming 
vaccinated. 
1.41 .595 39 
Not knowing where 
to get the vaccine 
would prevent me 
from becoming 
vaccinated. 
1.54 .555 39 
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Subscale:  Attitudes 
 
Reliability Statistics 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items 
N of 
Items 
.674 .701 3 
 
 
Item Statistics 
  Mean 
Std. 
Deviation N 
Refusing to have sex 
with a partner if they 
will not use a condom 
would be very easy for 
me. 
4.22 .861 54 
Telling a partner that I 
will not be sexually 
active with them until 
they have been tested for 
sexually transmitted 
infections would be very 
easy for me. 
3.91 .917 54 
Avoiding the use of 
drugs or alcohol before 
engaging in sexual 
activity would be very 
easy for me. 
3.98 1.157 54 
 
 
Scale: Normative Beliefs 
 
Reliability Statistics 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items 
N of 
Items 
.763 .765 3 
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Item Statistics 
  Mean 
Std. 
Deviation N 
Most college 
students would 
avoid using drugs 
or alcohol before 
engaging in sexual 
activity. 
2.41 .942 54 
Most college 
students would ask 
their health care 
provider about 
how to reduce 
their risk for 
sexually 
transmitted 
infections. 
2.98 .858 54 
Most college 
students would tell 
a partner to get 
tested for sexually 
transmitted 
infections before 
becoming sexually 
active with them. 
2.78 1.022 54 
 
 
Scale: Control Beliefs 
 
Reliability Statistics 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items 
N of 
Items 
.860 .866 5 
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Item Statistics 
  Mean 
Std. 
Deviation N 
How much control 
do you have in 
being abstinent 
from sexual 
activity until you 
are married? 
4.31 .961 52 
How much control 
do you have in 
refusing to have 
sex with a partner 
that will not use a 
condom? 
4.62 .661 52 
How much control 
do you have in 
avoiding the use of 
drugs or alcohol 
before engaging in 
sexual activity? 
4.50 .804 52 
How much control 
do you have in 
telling a partner to 
get tested for 
sexually 
transmitted 
infections before 
becoming sexually 
active with them? 
4.44 .669 52 
How much control 
do you have in 
asking a health 
care provider 
about how to 
reduce your risk 
for sexually 
transmitted 
infections? 
4.71 .572 52 
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Scale:  Intentions 
 
Reliability Statistics 
Cronbach's 
Alpha 
N of 
Items 
.659 3 
 
Item Statistics 
  Mean 
Std. 
Deviation N 
I intend to tell a partner 
to get tested for 
sexually transmitted 
infections before 
becoming sexually 
active with them. 
3.96 .889 54 
I intend to refuse to 
have sex with a partner 
if they will not use a 
condom. 
4.13 .953 54 
I intend to avoid drugs 
or alcohol before 
engaging in sexual 
activity. 
4.02 1.073 54 
 
 
Scale:  Severity of HPV 
 
Reliability Statistics 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items 
N of 
Items 
.512 .527 3 
 
 309
Appendix H (Continued) HPV Survey Instrument – Internal Consistency Reliability 
 
Item Statistics 
  Mean 
Std. 
Deviation N 
How serious a health 
problem would HPV be 
for you? 
3.76 .612 54 
If you get HPV how 
likely is it that you will 
get genital warts? 
3.28 .960 54 
If you get HPV how 
likely is it 
that you will get 
cancer? 
3.52 .885 54 
 
Scale:  Susceptibility to HPV 
 
Reliability Statistics 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items 
N of 
Items 
.822 .850 5 
 
Item Statistics 
  Mean SD N 
Do you think you 
are likely to 
contract HPV? 
1.274 .3612 53 
How likely is it 
that you currently 
have HPV? 
1.585 1.0640 53 
Do you think your 
friends or peers 
are likely to 
contract HPV? 
1.698 .3445 53 
What is the 
likelihood that you 
could get HPV 
within the next 
year? 
1.698 1.1533 53 
What is the 
likelihood that you 
could get HPV 
sometime in your  
life? 
2.396 1.2761 53 
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Correlations – “Knowledge about HPV”  
 
Mean 
Knowledge 
Score 1 
Mean 
Knowledge 
Score 2 
Mean Knowledge 
Score 1 
Pearson Correlation 1 .809(**) 
  Sig. (2-tailed) 
  .000 
  N 54 54 
Mean Knowledge 
Score 2 
Pearson Correlation 
.809(**) 1 
  Sig. (2-tailed) .000   
  N 54 54 
**Correlation is significant at the 0.01 level (2-tailed). 
 
Correlations – “Knowledge about the HPV Vaccine”  
  
Mean HPV 
Vaccine 
Knowledge 
Score1 
Mean HPV  
Vaccine 
Knowledge 
Score 2 
Mean HPV Vaccine 
Knowledge Score 1 
Pearson Correlation 1 .444(**) 
  Sig. (2-tailed) 
  .001 
  N 54 54 
Mean HPV Vaccine 
Knowledge Score 2 
Pearson Correlation 
.444(**) 1 
  Sig. (2-tailed) .001   
  N 54 54 
**Correlation is significant at the 0.01 level (2-tailed). 
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Correlations – HPV Vaccine Acceptance – “General Acceptance” 
  
Mean Score 
General 
Vaccine 
Acceptance 1 
Mean Score 
General 
Vaccine 
Acceptance 2 
Mean Score 
General Vaccine 
Acceptance 1 
Pearson Correlation 
1 .649(**) 
  Sig. (2-tailed) 
  .000 
  N 54 54 
Mean Score 
General Vaccine 
Acceptance 2 
Pearson Correlation 
.649(**) 1 
  Sig. (2-tailed) .000   
  N 54 54 
**Correlation is significant at the 0.01 level (2-tailed). 
 
Correlations – HPV Vaccine Acceptance – “Influences to Being Vaccinated” 
 
Mean Score 
HPV Vaccine 
Acceptance 
Influence 1 
Mean Score 
HPV Vaccine 
Acceptance 
Influence 2 
Mean Score HPV 
Vaccine Acceptance 
Influence 1 
Pearson Correlation 
1 .582(**) 
  Sig. (2-tailed) 
  .000 
  N 40 38 
Mean Score HPV 
Vaccine Acceptance 
Influence 2 
Pearson Correlation 
.582(**) 1 
  Sig. (2-tailed) .000   
  N 38 42 
**Correlation is significant at the 0.01 level (2-tailed). 
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Correlations – HPV Vaccine Acceptance – “Issues That Would Prevent Being Vaccinated” 
  
Mean Score 
HPV Vaccine 
Acceptance 
Prevent 1 
Mean Score 
HPV Vaccine 
Acceptance 
Prevent 2 
Mean Score HPV 
Vaccine Acceptance 
Prevent 1 
Pearson Correlation 
1 .678(**) 
  Sig. (2-tailed) 
  .000 
  N 40 38 
Mean Score HPV 
Vaccine Acceptance 
Prevent 2 
Pearson Correlation 
.678(**) 1 
  Sig. (2-tailed) .000   
  N 38 42 
**Correlation is significant at the 0.01 level (2-tailed). 
 
Correlations – Attitudes towards practicing safer sex behaviors 
  
MeanAttitude
Score 1 
MeanAttitude 
Score 2 
Mean Attitude 
Score 1 
Pearson Correlation 1 .769(**) 
  Sig. (2-tailed) 
  .000 
  N 54 54 
Mean Attitude 
Score 2 
Pearson Correlation 
.769(**) 1 
  Sig. (2-tailed) .000   
  N 54 54 
**Correlation is significant at the 0.01 level (2-tailed). 
 
Correlations – Normative beliefs about practicing safer sex behaviors 
  
Mean 
Normative 
Beliefs Score 
1 
Mean 
Normative 
Beliefs Score 
2 
Mean Normative 
Beliefs Score 1 
Pearson Correlation 1 .476(**) 
  Sig. (2-tailed) 
  .000 
  N 54 54 
Mean Normative 
Beliefs Score 2 
Pearson Correlation 
.476(**) 1 
  Sig. (2-tailed) .000   
  N 54 54 
**Correlation is significant at the 0.01 level (2-tailed). 
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Correlations – Control beliefs about practicing safer sex behaviors 
  
Mean Score 
Control 
Beliefs 1 
Mean Score 
Control 
Beliefs 2 
Mean Score 
Control Beliefs 
1 
Pearson Correlation 
1 .722(**) 
  Sig. (2-tailed) 
  .000 
  N 54 54 
Mean Score 
Control Beliefs 
2 
Pearson Correlation 
.722(**) 1 
  Sig. (2-tailed) .000   
  N 54 54 
**Correlation is significant at the 0.01 level (2-tailed) 
 
Correlations – Intentions to practice safer sex behaviors 
  
Mean 
Intentions 
Score1 
Mean 
Intentions 
Score2 
Mean Intentions 
Score 1 
Pearson 
Correlation 1 .780(**) 
  Sig. (2-tailed) 
  .000 
  N 54 54 
Mean Intentions 
Score 2 
Pearson 
Correlation .780(**) 1 
  Sig. (2-tailed) .000   
  N 54 54 
**Correlation is significant at the 0.01 level (2-tailed). 
 
Correlations – HPV Susceptibility 
  
Mean Score 
HPV 
Susceptibility 
1 
Mean Score 
HPV 
Susceptibility
2 
Mean Score HPV 
Susceptibility 1 
Pearson Correlation 1 .884(**) 
  Sig. (2-tailed) 
  .000 
  N 54 54 
Mean Score HPV 
Susceptibility 2 
Pearson Correlation 
.884(**) 1 
  Sig. (2-tailed) .000   
  N 54 54 
**Correlation is significant at the 0.01 level (2-tailed). 
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Correlations – HPV Severity 
  
Mean Score 
HPV  
Severity 1 
Mean Score 
HPV 
Severity 2 
Mean Score HPV 
Severity 1 
Pearson 
Correlation 1 .202 
  Sig. (2-tailed) 
  .142 
  N 54 54 
Mean Score HPV 
Severity 2 
Pearson 
Correlation .202 1 
  Sig. (2-tailed) .142   
  N 54 54 
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Correlations – HPV Severity  
  
Mean HPV 
Severity 
Score 1 
Mean HPV 
Severity 
Score 2 
Mean HPV 
Severity 
Score 1 
Pearson Correlation 
1 .609(**) 
  Sig. (2-tailed) 
  .001 
  N 27 27 
Mean HPV 
Severity 
Score 2 
Pearson Correlation 
.609(**) 1 
  Sig. (2-tailed) .001   
  N 27 27 
**Correlation is significant at the 0.01 level (2-tailed). 
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Table 1. ANOVA - Missing Data for Ethnicity 
  
Sum of 
Squares df Mean Square F Sig. 
Between 
Groups 1.743 8 .218 2.951 .003 
Within Groups   198.649 2690 .074   
Total   200.392 2698    
 
 
Table 2.  Tukey HSD for Mean Differences in Missing Data for Ethnicity 
Dependent Variable: Missing Data  
How do you describe 
yourself? 
Check all that apply. 
(J) How do you 
describe yourself? 
Check all that apply. 
Mean 
Difference 
(I-J) Std. Error Sig. 
African-American Hispanic or Latino .073 .026 .102 
Asian .040 .035 .969 
American Indian or 
Alaska Native 
-.099 .137 .999 
Native Hawaiian or 
other Pacific Islander 
.151 .104 .879 
Arab-American -.016 .081 1.000 
White .079* .019 .001 
Multi-racial .074 .025 .087 
Other .151 .056 .154 
*The mean difference is significant at the .05 level. 
 
 
Table 3. ANOVA – Missing Data for Age 
How old are 
you? 
Sum of 
Squares df Mean Square F Sig. 
Between 
Groups 
.128 6 .021 .280 .946 
Within Groups 206.163 2699 .076   
Total 206.292 2705    
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Table 4. ANOVA – Missing Data for Sexual Orientation 
  
Sum of 
Squares df Mean Square F Sig. 
Between 
Groups 
.652 3 .217 2.930 .032 
Within Groups 199.740 2695 .074   
Total 200.392 2698    
 
Table 5. Tukey HSD for Mean Differences in Missing Data for Sexual Orientation 
Dependent Variable: Missing Data  
What is your sexual 
orientation? 
(J) What is your 
sexual orientation? 
Mean 
Difference 
(I-J) Std. Error Sig. 
I have sex with  men. I have sex with 
women. 
-.094 .038 .061 
I have sex with men 
and women. 
.008 .032 .995 
I don't have sex. -.025 .015 .326 
I have sex with 
women. 
I have sex with  men. .094 .038 .061 
  I have sex with men 
and women. 
.102 .049 .158 
I don't have sex. .070 .040 .298 
I have sex with men 
and women. 
I have sex with  men. -.008 .032 .995 
  I have sex with 
women. 
-.102 .049 .158 
I don't have sex. -.033 .034 .778 
I don't have sex. I have sex with  men. .025 .015 .326 
  I have sex with 
women. 
-.070 .040 .298 
I have sex with men 
and women. 
.033 .034 .778 
*The mean difference is significant at the .05 level. 
  
Table 6. ANOVA  - Missing Data for Marital Status  
What is your 
marital status? 
Sum of 
Squares df Mean Square F Sig. 
Between 
Groups 
.173 4 .043 .581 .676 
Within Groups 200.219 2694 .074   
Total 200.392 2698    
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Table 7.  ANOVA – Missing Data for Number of Sexual Partners  
Within the past 
12 months, with 
how many  
partners, if any, 
have you had 
oral, anal or 
vaginal sex?  
Sum of 
Squares df Mean Square F Sig. 
Between 
Groups .676 16 .042 .640 .853 
Within Groups 174.946 2653 .066     
Total 175.621 2669       
 
 
Table 8. Independent Samples T-Test – Missing Data for Those Participants That Are   
or Are Not Currently Sexually Active 
  
Levene's Test 
for Equality 
of Variances t-test for Equality of Means 
Have you 
had oral, 
anal or 
vaginal 
sex with a 
partner in 
the past 
60 days? F Sig. t df 
Sig. 
2-
tailed 
Mean 
Diff. 
Std.  
Error 
Diff. 95% C.I. 
Missing 
Data               Lower Upper 
Equal 
variances 
assumed 
  
 
 
.058 
  
 
 .810 
 
 
 
-.120 
 
 
 
 
2690 
 
 
 
.905 
 
 
 
-.001 
 
 
 
.011 
 
 
 
-.024 
 
 
 
.021 
Equal 
variances 
not 
assumed 
    
 
 
-.120 
 
 
1505.568 
 
 
.904 
 
 
-.001 
 
 
.011 
 
 
-.024 
 
 
.021 
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Table 9. Independent Samples T-Test – Missing Data for Those Participants With or   
Without Children 
  
Levene's Test 
for Equality 
of Variances t-test for Equality of Means 
Do you 
have 
children? F Sig. t df 
Sig. 
2-
tailed 
Mean 
Diff. 
Std.  
Error 
Diff. 95% C.I. 
Missing 
Data               Lower Upper 
Equal 
variances 
assumed 
  
 
 
1.813 
  
 
 .178 
 
 
 
-.691 
 
 
 
 
2696 
 
 
 
.490 
 
 
 
-.023 
 
 
 
.033 
 
 
 
-.089 
 
 
 
.042 
Equal 
variances 
not 
assumed 
    
 
 
-.616 
 
 
69.744 
 
 
.540 
 
 
-.023 
 
 
.037 
 
 
-.098 
 
 
.052 
 
  
  
Table 10. ANOVA - Missing Data for Year in College  
What is your 
current year in 
college? 
Sum of 
Squares df Mean Square F Sig. 
Between 
Groups 
.235 3 .078 1.046 .371 
Within Groups 201.846 2697 .075   
Total 202.081 2700    
 
  
Table 11. ANOVA – Missing Data for University Enrollment  
What university 
are you 
attending? 
Sum of 
Squares df Mean Square F Sig. 
Between 
Groups 
.164 2 .082 1.085 .338 
Within Groups 203.603 2700 .075   
Total 203.767 2702    
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Table 12. Independent Samples T-Test – Missing Data for Health Insurance Coverage of   
HPV Vaccine 
  
Levene's Test 
for Equality 
of Variances t-test for Equality of Means 
Do you 
currently 
have 
health 
insurance 
that 
covers 
the cost 
of the 
HPV 
vaccine? F Sig. t df 
Sig. 
2-
tailed 
Mean 
Diff. 
Std.  
Error 
Diff. 95% C.I. 
Missing 
Data               Lower Upper 
Equal 
variances 
assumed 
  
 
 
9.522 
  
 
 .002 
 
 
 
-1.529 
 
 
 
 
1771 
 
 
 
.126 
 
 
 
-.021 
 
 
 
.014 
 
 
 
-.048 
 
 
 
.006 
Equal 
variances 
not 
assumed 
    
 
 
-1.577 
 
 
1497.918 
 
 
.115 
 
 
-.021 
 
 
.013 
 
 
-.047 
 
 
.005 
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Appendix L: Statistics Tables for Demographic Variables 
 
 Subjects were asked questions regarding their age, ethnicity, sexual orientation, 
number of sexual partners, current sexual activity, marital status, whether they had 
children, current year in college, what university they were attending, and whether they 
had health insurance that covered the cost of the HPV vaccine.  These tables are to 
demonstrate that there were normal distributions of the population for the majority of the 
demographic variables, except for the number of sexual partners.  Skewness and kurtosis 
values between + 2 are considered to be in an acceptable range.   
 
 
Table 1.  Age  
N Valid 2706 
Missing 0 
Mean 20.72 
Std. Error of Mean .030 
Median 21.00 
Mode 21 
Std. Deviation 1.580 
Variance 2.497 
Skewness .249 
Std. Error of Skewness .047 
Kurtosis -.656 
Std. Error of Kurtosis .094 
Range 6 
Minimum 18 
Maximum 24 
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Table 2.  Ethnicity 
N Valid 2699 
Missing 7 
Meana 6.07 
Std. Error of Mean .042 
Median 7.00 
Mode 7 
Std. Deviation 2.189 
Variance 4.791 
Skewness -1.501 
Std. Error of Skewness .047 
Kurtosis .586 
Std. Error of Kurtosis .094 
Range 8 
Minimum 1 
Maximum 9 
Note.  a   Mean frequency rating where 1 = African-American, 2 = Hispanic  
or Latino, 3 = Asian, 4 = American Indian or Alaska Native,  
5 = Native Hawaiian or other Pacific Islander, 6 = Arab-American, 
7 = White, 8 = Multi-racial, and 9 = Other  
  
 
Table 3.  University 
N Valid 2703 
Missing 3 
Meana 2.23 
Std. Error of Mean .009 
Median 2.00 
Mode 2 
Std. Deviation .456 
Variance .208 
Skewness .790 
Std. Error of Skewness .047 
Kurtosis -.174 
Std. Error of Kurtosis .094 
Range 2 
Minimum 1 
Maximum 3 
Note.  a   Mean frequency rating where 1 = Central Michigan University, 
2 = University of South Florida and 3 = Western Michigan University 
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Table 4.  Year in college  
N Valid 2701 
Missing 5 
Mean a 3.18 
Std. Error of Mean .018 
Median 3.00 
Mode 4 
Std. Deviation .910 
Variance .828 
Skewness -.832 
Std. Error of Skewness .047 
Kurtosis -.299 
Std. Error of Kurtosis .094 
Range 3 
Minimum 1 
Maximum 4 
Note.  a   Mean frequency rating where 1 = Freshman, 2 = Sophomore,  
3 = Junior, and 4 = Senior 
 
 
Table 5.  Sexual orientation 
N Valid 2699 
Missing 7 
Mean a 1.53 
Std. Error of Mean .021 
Median 1.00 
Mode 1 
Std. Deviation 1.102 
Variance 1.214 
Skewness 1.690 
Std. Error of Skewness .047 
Kurtosis .972 
Std. Error of Kurtosis .094 
Range 3 
Minimum 1 
Maximum 4 
Note.  a Mean frequency rating where 1 = I have sex with men, 
2 = I have sex with women, 3 = I have sex with men  
and women, and 4 = I don’t have sex  
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Table 6. Marital Status 
N Valid 2699 
Missing 7 
Mean a 4.63 
Std. Error of Mean .016 
Median 4.00 
Mode 4 
Std. Deviation .844 
Variance .713 
Skewness .357 
Std. Error of Skewness .047 
Kurtosis -.807 
Std. Error of Kurtosis .094 
Range 4 
Minimum 2 
Maximum 6 
Note.  a Mean frequency rating where 1 = Widowed, 2 = Separated/Divorced 
3 = Married, 4 = Single and in a monogamous relationship,                                                                                                                             
5 = Single and sexually active, and 6 = Single and abstinent  
 
 
Table 7.  Number of sexual partners in the past 12 months 
N Valid 2670 
Missing 36 
Mean  1.61 
Std. Error of Mean .034 
Median 1.00 
Mode 1 
Std. Deviation 1.748 
Variance 3.056 
Skewness 3.057 
Std. Error of Skewness .047 
Kurtosis 15.608 
Std. Error of Kurtosis .095 
Range 20 
Minimum 0 
Maximum 20 
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Table 8.  Current sexual activity 
N Valid 2692 
Missing 14 
Mean a 1.70 
Std. Error of Mean .009 
Median 2.00 
Mode 2 
Std. Deviation .457 
Variance .208 
Skewness -.894 
Std. Error of Skewness .047 
Kurtosis -1.202 
Std. Error of Kurtosis .094 
Range 1 
Minimum 1 
Maximum 2 
Note. a Mean frequency rating where 1 = No and 2 = Yes  
 
Table 9.  Children  
N Valid 2698 
Missing 8 
Mean a 1.03 
Std. Error of Mean .003 
Median 1.00 
Mode 1 
Std. Deviation .157 
Variance .025 
Skewness 6.062 
Std. Error of Skewness .047 
Kurtosis 34.769 
Std. Error of Kurtosis .094 
Range 1 
Minimum 1 
Maximum 2 
Note. a Mean frequency rating where 1 = No and 2 = Yes  
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Table 10.  Health insurance 
N Valid 2698 
Missing 8 
Mean a 1.586 
Std. Error of Mean .0076 
Median 1.500 
Mode 2.0 
Std. Deviation .3961 
Variance .157 
Skewness -.316 
Std. Error of Skewness .047 
Kurtosis -1.342 
Std. Error of Kurtosis .094 
Range 1.0 
Minimum 1.0 
Maximum 2.0 
Note.  a Mean frequency rating where 1 = No and 2 = Yes 
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Appendix M: HPV Vaccine Survey - Item Frequencies, Means, and Standard Deviations 
 
Section One.  Knowledge about HPV 
 
1.  HPV is more common than HIV. 
 
    True False Total 
N Missing Mean SD % % % 
2702 4 .89 .310 89.2 10.8 100.0 
 
2.  Only women get HPV. 
 
    True False Total 
N Missing Mean SD % % % 
2702 4 .77 .422 23.2 76.8 100.0 
 
3.  You can always tell when someone else has HPV. 
 
    True False Total 
N Missing Mean SD % % % 
2703 3 .99 .072 .5 99.5 100.0 
 
4.  Has a health care provider ever told you that you have HPV? 
 
    Yes No Not sure Total 
N Missing Mean SD % % % % 
2702 4 1.171 .3701 16.1 82.0 1.9 100.0 
 
 
Section Two.   Attitudes and intentions regarding practicing safer sex behaviors 
 
1.  Refusing to have sex with a partner if they will not use a condom would be very easy  
     for me.  
 
    
Stro
ngly 
agree
 
A
gree
 
S
o
m
ew
hat
 
agree
 
D
isag
ree
 
Stro
ngly 
disag
ree
 
 
Total 
N Missing Mean SD % % % % % % 
2703 3 4.20 1.001 51.8 26.0 14.9 5.8 1.6 100.0 
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2.  I intend to tell a partner to get tested for sexually transmitted infections before I  
     become sexually active with them.   
 
    
Stro
ngly 
agree
 
A
gree
 
S
o
m
ew
hat
 
agree
 
D
isag
ree
 
Stro
ngly 
disag
ree
 
 
Total 
N Missing Mean SD % % % % % % 
2701 5 3.66 1.068 27.2 28.7 28.2 14.6 1.3 100.0 
 
 
3.  Telling a partner that I will not be sexually active with them until they have been    
     tested for sexually transmitted infections would be very easy for me. 
 
    
Stro
ngly 
agree
 
A
gree
 
S
o
m
ew
hat
 
agree
 
D
isag
ree
 
Stro
ngly 
disag
ree
 
 
Total 
N Missing Mean SD % % % % % % 
2700 6 3.54 1.136 25.7 26.3 26.6 19.0 2.5 100.0 
 
 
4.  I intend to refuse to have sex with a partner if they will not use a condom. 
 
    
Stro
ngly 
agree
 
A
gree
 
S
o
m
ew
hat
 
agree
 
D
isag
ree
 
Stro
ngly 
disag
ree
 
 
Total 
N Missing Mean SD % % % % % % 
2698 8 4.05 1.110 48.0 23.4 16.1 10.6 1.9 100.0 
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5.  Avoiding the use of drugs or alcohol before engaging in sexual activity would be very  
     easy for me. 
 
    
Stro
ngly 
agree
 
A
gree
 
S
o
m
ew
hat
 
agree
 
D
isag
ree
 
Stro
ngly 
disag
ree
 
 
Total 
N Missing Mean SD % % % % % % 
2698 8 4.13 1.071 51.1 22.3 16.1 8.9 1.5 100.0 
 
 
6.  I intend to avoid drugs or alcohol before engaging in sexual activity. 
 
    
Stro
ngly 
agree
 
A
gree
 
S
o
m
ew
hat
 
agree
 
D
isag
ree
 
Stro
ngly 
disag
ree
 
 
Total 
N Missing Mean SD % % % % % % 
2699 7 3.90 1.131 41.5 23.5 21.3 11.5 2.2 100.0 
 
 
Section Three.  Knowledge about the HPV Vaccine 
 
1.  The vaccine is safe. 
 
     
Checked 
 
Not 
checked 
 
Total 
N Missing Mean SD % % % 
2706 0 .68 .466 68.1 31.9 100.0 
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2.  The vaccine prevents women from getting high risk HPV.  
 
     
Checked 
 
Not 
checked 
 
Total 
N Missing Mean SD % % % 
2706 0 .81 .393 81.0 19.0 100.0 
 
 
3.  The vaccine will protect against cervical cancer. 
 
     
Checked 
 
Not 
checked 
 
Total 
N Missing Mean SD % % % 
2706 0 .78 .411 78.4 21.6 100.0 
 
 
4.  The vaccine consists of three shots over a six month period. 
 
     
Checked 
 
Not 
checked 
 
Total 
N Missing Mean SD % % % 
2706 0 .77 .421 77.1 22.9 100.0 
 
 
5.  I have not heard about the HPV vaccine.  
 
     
Checked 
 
Not 
checked 
 
Total 
N Missing Mean SD % % % 
2706 0 .03 .158 2.5 97.5 100.0 
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Section Four.  Normative Beliefs Regarding Practicing Safer Sex Behaviors 
 
1.  Most college students would avoid using drugs or alcohol before engaging in sexual 
     activity. 
 
    
Stro
ngly 
agree
 
A
gree
 
S
o
m
ew
hat
 
agree
 
D
isag
ree
 
Stro
ngly 
disag
ree
 
 
Total 
N Missing Mean SD % % % % % % 
2704 2 2.16 .829 1.3 4.3 23.2 51.7 19.6 100.0 
 
 
2.  Most college students would ask their health care provider about how to reduce their  
     risk for sexually transmitted infections. 
 
    
Stro
ngly 
agree
 
A
gree
 
S
o
m
ew
hat
 
agree
 
D
isag
ree
 
Stro
ngly 
disag
ree
 
 
Total 
N Missing Mean SD % % % % % % 
2697 9 2.62 .933 2.8 13.7 35.3 38.7 9.5 100.0 
 
 
3.  Most college students would tell a partner to get tested for sexually transmitted  
     infections before becoming sexually active with them. 
 
    
Stro
ngly 
agree
 
A
gree
 
S
o
m
ew
hat
 
agree
 
D
isag
ree
 
Stro
ngly 
disag
ree
 
 
Total 
N Missing Mean SD % % % % % % 
2704 2 2.14 .782 0.4 4.8 21.7 54.5 18.6 100.0 
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Section Five.  Acceptance of the HPV vaccine 
 
1.  How important do you think vaccinations are, in general? 
 
    
V
ery 
 
im
p
o
rtant
 
S
o
m
ew
hat
 
im
portant
 
N
ot
 at
 all
 
im
portant
 
 
Total 
N Missing Mean SD % % % % 
2700 6 2.67 .506 68.9 29.4 1.7 100.0 
 
 
2.  Have you received at least one dose of the HPV vaccine? 
 
     
Yes 
 
No 
 
Total 
N Missing Mean SD % % % 
2699 7 1.37 .484 37.3 62.7 100.0 
 
 
3.  The vaccine is currently available for young girls and women between the ages of 9 
through  
     26.  How likely is it that you will get vaccinated against HPV? 
 
     
V
ery likely
 
Likely
 
S
o
m
ew
hat
 
lik
ely
 
A
 little
 likely
 
V
ery 
u
nlikely
 
N Skippeda Missing Mean SD % % % % % 
1695 1006 5 2.72 1.313 11.8% 17.4% 24.7% 22.8% 23.2% 
Note. aThese participants skipped the question because they received the HPV vaccine. 
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4.  How important are the following issues in influencing your decision to become  
     vaccinated against HPV? 
 
If my friends think I should get it 
     
V
ery 
im
p
o
rtant
 
S
o
m
ew
hat
 
im
p
o
rtant
 
N
ot
 
im
p
o
rtant
 at
 
all
 
 
Total 
N Skippeda Missing Mean SD % % % % 
1698 1006 2 1.60 .666 10.1 39.5 50.4 100.0 
Note. aThese participants skipped the question because they received the HPV vaccine. 
 
If my health insurance covers it 
     
V
ery 
im
p
o
rtant
 
S
o
m
ew
hat
 
im
p
o
rtant
 
N
ot
 
im
p
o
rtant
 at
 
all
 
Total 
N Skippeda Missing Mean SD % % % % 
1697 1006 3 2.57 .673 67.2 22.4 10.4 100.0 
Note. aThese participants skipped the question because they received the HPV vaccine. 
 
If I had an abnormal pap smear 
     
V
ery 
im
p
o
rtant
 
S
o
m
ew
hat
 
im
p
o
rtant
 
N
ot
 
im
p
o
rtant
 at
 
all
 
Total 
N Skippeda Missing Mean SD % % % % 
1692 1006 8 2.74 .519 77.2 19.0 3.7 100.0 
Note. aThese participants skipped the question because they received the HPV vaccine. 
 
If my family thinks I should get it  
     
V
ery 
im
p
o
rtant
 
S
o
m
ew
hat
 
im
p
o
rtant
 
N
ot
 
im
p
o
rtant
 at
 
all
 
Total 
N Skippeda Missing Mean SD % % % % 
1693 1006 7 2.36 .671 46.7 42.3 11.0 100.0 
Note. aThese participants skipped the question because they received the HPV vaccine. 
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If my sex partner thinks I should get it 
     
V
ery 
im
p
o
rtant
 
S
o
m
ew
hat
 
im
p
o
rtant
 
N
ot
 
im
p
o
rtant
 at
 
all
 
Total 
N Skippeda Missing Mean SD % % % % 
1692 1006 8 2.30 .685 42.6 44.4 13.0 100.0 
Note. aThese participants skipped the question because they received the HPV vaccine. 
 
If my health care provider thinks I should get it 
     
V
ery 
im
p
o
rtant
 
S
o
m
ew
hat
 
im
p
o
rtant
 
N
ot
 
im
p
o
rtant
 at
 
all
 
Total 
N Skippeda Missing Mean SD % % % % 
1696 1006 4 2.57 .614 63.6 29.8 6.6 100.0 
Note. aThese participants skipped the question because they received the HPV vaccine. 
 
If someone in my family has cancer 
     
V
ery 
im
p
o
rtant
 
S
o
m
ew
hat
 
im
p
o
rtant
 
N
ot
 
im
p
o
rtant
 at
 
all
 
Total 
N Skippeda Missing Mean SD % % % % 
1697 1006 3 2.57 .632 64.4 27.9 7.7 100.0 
Note. aThese participants skipped the question because they received the HPV vaccine. 
 
Whether I practice safe sex 
     
V
ery 
im
p
o
rtant
 
S
o
m
ew
hat
 
im
p
o
rtant
 
N
ot
 
im
p
o
rtant
 at
 
all
 
Total 
N Skippeda Missing Mean SD % % % % 
1694 1006 6 2.54 .671 63.6 26.4 10.0 100.0 
Note. aThese participants skipped the question because they received the HPV vaccine. 
 335
Appendix M (Continued) HPV Vaccine Survey – Item Frequencies and Means 
 
5. How important are the following issues in preventing you from becoming vaccinated       
    against HPV? 
 
The cost of the vaccine 
     
V
ery 
im
p
o
rtant
 
S
o
m
ew
hat
 
im
p
o
rtant
 
N
ot
 
im
p
o
rtant
 at
 
all
 
Total 
N Skippeda Missing Mean SD % % % % 
1696 1006 4 2.30 .753 48.0 34.2 17.8 100.0 
Note. aThese participants skipped the question because they received the HPV vaccine. 
 
Getting three shots over a six month period 
     
V
ery 
im
p
o
rtant
 
S
o
m
ew
hat
 
im
p
o
rtant
 
N
ot
 
im
p
o
rtant
 at
 
all
 
Total 
N Skippeda Missing Mean SD % % % % 
1697 1006 3 1.41 .644 8.6 24.2 67.2 100.0 
Note. aThese participants skipped the question because they received the HPV vaccine. 
 
Fear of vaccines 
     
V
ery 
im
p
o
rtant
 
S
o
m
ew
hat
 
im
p
o
rtant
 
N
ot
 
im
p
o
rtant
 at
 
all
 
Total 
N Skippeda Missing Mean SD % % % % 
1697 1006 3 1.37 .655 9.8 17.6 72.6 100.0 
Note. aThese participants skipped the question because they received the HPV vaccine. 
 
Possible side effects of the vaccine 
     
V
ery 
im
p
o
rtant
 
S
o
m
ew
hat
 
im
p
o
rtant
 
N
ot
 
im
p
o
rtant
 at
 
all
 
Total 
N Skippeda Missing Mean SD % % % % 
1696 1006 4 2.07 .726 30.2 46.8 23.1 100.0 
Note. aThese participants skipped the question because they received the HPV vaccine. 
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Having to get additional boosters after getting three shots 
     
V
ery 
im
p
o
rtant
 
S
o
m
ew
hat
 
im
p
o
rtant
 
N
ot
 
im
p
o
rtant
 at
 
all
 
Total 
N Skippeda Missing Mean SD % % % % 
1690 1006 10 1.71 .714 15.3 40.9 43.8 100.0 
Note. aThese participants skipped the question because they received the HPV vaccine. 
 
Having to wait at my doctor’s office for approval to get the vaccine 
     
V
ery 
im
p
o
rtant
 
S
o
m
ew
hat
 
im
p
o
rtant
 
N
ot
 
im
p
o
rtant
 at
 
all
 
Total 
N Skippeda Missing Mean SD % % % % 
1690 1006 10 1.46 .639 8.0 29.7 62.3 100.0 
Note. aThese participants skipped the question because they received the HPV vaccine. 
 
Not knowing where to get the vaccine 
     
V
ery 
im
p
o
rtant
 
S
o
m
ew
hat
 
im
p
o
rtant
 
N
ot
 
im
p
o
rtant
 at
 
all
 
Total 
N Skippeda Missing Mean SD % % % % 
1694 1006 6 1.66 .755 17.3 31.7 51.0 100.0 
Note. aThese participants skipped the question because they received the HPV vaccine. 
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Section Six.   Control beliefs about practicing safer sex behaviors 
 
1.  How much control do you have in being abstinent from sexual activity until you are 
married? 
 
    
C
o
m
plete
 
co
ntrol
 
A
 lot
 of
 
co
ntrol
 
S
o
m
e
 
co
ntrol
 
Little
 
co
ntrol
 
N
o
 co
ntrol
 
 
Total 
N Missing Mean SD % % % % % % 
2701 5 3.74 1.379 42.1 22.0 15.8 8.4 11.7 100.0 
 
2. How much control do you have in refusing to have sex with a partner who will not use 
a condom? 
 
    
C
o
m
plete
 
co
ntrol
 
A
 lot
 of
 
co
ntrol
 
S
o
m
e
 
co
ntrol
 
Little
 
co
ntrol
 
N
o
 co
ntrol
 
 
Total 
N Missing Mean SD % % % % % % 
2694 12 4.49 .767 62.5 26.4 8.9 1.7 .5 100.0 
 
3. How much control do you have in avoiding the use of drugs or alcohol before 
engaging in sexual activity? 
 
    
C
o
m
plete
 
co
ntrol
 
A
 lot
 of
 
co
ntrol
 
S
o
m
e
 
co
ntrol
 
Little
 
co
ntrol
 
N
o
 co
ntrol
 
 
Total 
N Missing Mean SD % % % % % % 
2699 7 4.49 .804 65.5 21.4 10.4 2.4 .4 100.0 
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4. How much control do you have in telling a partner to get tested for sexually 
transmitted infections before becoming sexually active with them? 
 
    
C
o
m
plete
 
co
ntrol
 
A
 lot
 of
 
co
ntrol
 
S
o
m
e
 
co
ntrol
 
Little
 
co
ntrol
 
N
o
 co
ntrol
 
 
Total 
N Missing Mean SD % % % % % % 
2696 10 4.10 .980 45.2 27.0 21.4 5.5 .9 100.0 
 
5.  How much control do you have in asking a health care provider about how to reduce 
your risk of sexually transmitted infections? 
 
    
C
o
m
plete
 
co
ntrol
 
A
 lot
 of
 
co
ntrol
 
S
o
m
e
 
co
ntrol
 
Little
 
co
ntrol
 
N
o
 co
ntrol
 
 
Total 
N Missing Mean SD % % % % % % 
2696 10 4.55 .748 67.8 21.6 8.7 1.6 .4 100.0 
 
 
Section Seven.  Perceived susceptibilty to HPV 
 
1.  Do you think you are likely to contract HPV? 
 
     
Yes 
 
No 
 
Not sure 
 
Total 
N Missing Mean SD % % % % 
2701 5 1.32 .388 18.6 54.8 26.6 100.0 
 
 
2.  How likely is it that you currently have HPV? 
 
    
V
ery likely
 
Likely
 
S
o
m
ew
hat
 
likley
 
A
 little
 
lik
ely
 
V
ery 
u
nlikely
 
 
Total 
N Missing Mean SD % % % % % % 
2702 4 1.69 1.23 8.3 2.8 6.9 13.8 68.3 100.0 
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3.  Do you think your friends or peers are likely to contract HPV? 
 
     
Yes 
 
No 
 
Not sure 
 
Total 
N Missing Mean SD % % % % 
2692 14 1.70 .330 50.2 40.1 9.7 100.0 
 
 
4.  What is the likelihood that you could get HPV within the next year? 
 
    
V
ery likely
 
Likely
 
S
o
m
ew
hat
 
likley
 
A
 little
 
lik
ely
 
V
ery 
u
nlikely
 
 
Total 
N Missing Mean SD % % % % % % 
2694 12 1.63 1.094 5.1 3.1 8.2 16.8 66.8 100.0 
 
 
5.  What is the likelihood that you could get HPV some time in your life? 
 
    
V
ery likely
 
Likely
 
S
o
m
ew
hat
 
likley
 
A
 little
 
lik
ely
 
V
ery 
u
nlikely
 
 
Total 
N Missing Mean SD % % % % % % 
2697 9 2.49 1.348 13.3 9.2 19.5 28.8 29.1 100.0 
 
 
Section Eight.  Perceived severity of HPV 
 
1.  How serious a health problem would HPV be for you? 
 
    
The
 m
o
st
 
serio
u
s
 
S
erio
u
s
 
N
ot
 su
re
 
A
 little
 
serio
u
s
 
N
ot
 at
 all
 
serio
u
s
 
 
Total 
N Missing Mean SD % % % % % % 
2701 5 3.66 .805 10.6 53.7 27.5 7.0 1.1 100.0 
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2.  If you get HPV, it is not a big problem because it is very easy to treat. 
 
    
Stro
ngly 
agree
 
S
o
m
ew
hat
 
agree
 
N
ot
 su
re
 
S
o
m
ew
hat
 
disag
ree
 
Stro
ngly 
disag
ree
 
 
Total 
N Missing Mean SD % % % % % % 
2701 5 2.37 .998 23.6 29.5 33.9 12.3 .7 100.0 
 
 
3.  If you get HPV, how likely is it that you will get genital warts? 
 
    
V
ery likely
 
S
o
m
ew
hat
 
lik
ely
 
N
ot
 su
re
 
S
o
m
ew
hat
 
u
nlikely
 
V
ery 
u
nlikely
 
 
Total 
N Missing Mean SD % % % % % % 
2698 8 3.31 .904 9.5 27.4 52.5 5.7 5.0 100.0 
 
 
4.  If you get HPV, how likely is it that you will get cancer? 
 
    
V
ery likely
 
S
o
m
ew
hat
 
lik
ely
 
N
ot
 su
re
 
S
o
m
ew
hat
 
u
nlikely
 
V
ery 
u
nlikely
 
 
Total 
N Missing Mean SD % % % % % % 
2699 7 3.59 .803 9.7 48.9 33.6 6.5 1.3 100.0 
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Sexual Activity by Marital Status 
 
Table 1.  Perceived Control in Being Abstinent from Sexual Activity by Marital Status 
 
C
o
m
plete
 
co
ntrol
 
A
 lot
 of
 
co
ntrol
 
S
o
m
e
 
co
ntrol
 
Little
 
co
ntrol
 
N
o
 co
ntrol
 
  
Totals 
Marital status (N) % (N) % (N) % (N) % (N) % (N) % 
Separated/ 
Divorced 
 
(4) 100.0 (0) .0 (0) .0 (0) .0 (0) .0 (4) 100 
Married 
 
(41) 41.0 (22) 22.0 (22) 22.0 (6) 6.0 (9) 9.0 (100) 100 
Single and in a 
monogamous 
relationship 
 
(517) 39.2 (266) 20.2 (217) 16.4 
 
(126) 9.5 (194) 14.7 (1320) 100 
Single and  
sexually active 
 
(231) 31.3 (161)  21.8 (150) 20.4 (88) 11.9 (107) 14.5 (737) 100 
Single and  
abstinent 
 
(343) 64.4 (143) 26.8 (36) 6.8 (6) 1.1 (5) .9 (533) 100 
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Tables 1-3.  Multiple Linear Regression Results for Predictors of Intentions to Practice Safer  
                    Sex Behaviors 
 
1. Model Summary 
Model R R Square 
Adjusted 
R Square 
Std. Error of 
the Estimate 
1 .730(a) .533 .532 .55279 
a  Predictors: (Constant), Mean Control Beliefs, Mean Normative Beliefs, Mean Attitude 
 
 
2.  ANOVA(b) 
Model   
Sum of 
Squares df Mean Square F Sig. 
1 Regression 942.040 3 314.013 1027.602 .000(a) 
  Residual 825.674 2702 .306     
  Total 1767.715 2705       
a. Predictors: (Constant), Mean Control Beliefs, Mean Normative Beliefs,  
                      Mean Attitude 
b. Dependent Variable: Mean Intentions 
 
 
3.  Coefficientsa 
Model 
  
Unstandardized 
Coefficients 
Standardized 
Coefficients  
95% Confidence 
Interval for B 
  
 
B 
 
Std. 
Error 
 
 
Beta 
 
 
t 
 
 
Sig. 
 
Lower 
Bound 
 
Upper 
Bound 
1 
(Constant) 
 
.547 
 
.076  
 
7.194 
 
.000 
 
.398 
 
.697 
Mean 
Attitude 
 
    .680 
 
.016 
 
.666 
 
43.258 
 
.000 
 
.649 
 
.711 
Mean 
Normative 
Beliefs 
 
 
    .096 
 
 
.017 
 
 
.076 
 
 
5.631 
 
 
.000 
 
 
.062 
 
 
.129 
Mean 
Control 
Beliefs 
 
 
.097 
 
 
.018 
 
 
.082 
 
 
5.424 
 
 
.000 
 
 
.062 
 
 
.132 
a. Dependent Variable: Mean Intentions 
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Table 4. Correlation Between Knowledge about HPV and Attitudes Towards Practicing  
  Safer Sex Behaviors 
  
  Mean Knowledge Mean Attitude 
Mean Knowledge Pearson 
Correlation 1 -.097(**) 
  Sig. (2-tailed) 
  .000 
  N 2706 2706 
Mean Attitude Pearson 
Correlation -.097(**) 1 
  Sig. (2-tailed) .000   
  N 2706 2706 
**Correlation is significant at the 0.01 level (2-tailed). 
 
Table 5. Correlation Between Knowledge about HPV and Normative Beliefs Towards  
   Practicing Safer Sex Behaviors  
 
 Mean Knowledge 
Mean Normative 
Beliefs 
Mean Knowledge Pearson 
Correlation 1 -.033 
  Sig. (2-tailed) 
  .084 
  N 2706 2706 
Mean Normative Beliefs Pearson 
Correlation -.033 1 
  Sig. (2-tailed) .084   
  N 2706 2706 
 
Table 6. Correlation Between Knowledge about HPV and Control Beliefs Towards  
   Practicing Safer Sex Behaviors 
 
 
Mean 
Knowledge 
Mean Control 
Beliefs 
Mean Knowledge Pearson 
Correlation 1 -.034 
  Sig. (2-tailed) 
  .078 
  N 2706 2706 
Mean Control Beliefs Pearson 
Correlation -.034 1 
  Sig. (2-tailed) .078   
  N 2706 2706 
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Table 7. Correlation Between Knowledge about HPV and Intentions To Practice Safer Sex    
  Behaviors 
 
   Mean Knowledge 
Mean 
Intentions 
Mean Knowledge Pearson 
Correlation 1 -.099(**) 
  Sig. (2-tailed) 
  .000 
  N 2706 2706 
Mean Intentions Pearson 
Correlation -.099(**) 1 
  Sig. (2-tailed) .000   
  N 2706 2706 
**Correlation is significant at the 0.01 level (2-tailed). 
 
Table 8.  Correlation Between Knowledge of HPV Vaccine and General Vaccine Acceptance 
 
  
Mean 
Knowledge of 
Vaccine 
Mean General 
Vaccine 
Acceptance 
Mean Knowledge of 
Vaccine 
Pearson 
Correlation 1 .215(**) 
  Sig. (2-
tailed)   .000 
  N 2706 2705 
Mean General Vaccine 
Acceptance 
Pearson 
Correlation .215(**) 1 
  Sig. (2-
tailed) .000   
  N 2705 2705 
**Correlation is significant at the 0.01 level (2-tailed). 
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Table 9.  Correlation Between Knowledge of the HPV Vaccine and Influential Factors to  
   Becoming Vaccinated Against HPV 
  
  
Mean Knowledge 
of Vaccine 
Mean Vaccine  
Acceptance - 
Influential 
Factors 
Mean Knowledge of 
Vaccine 
Pearson 
Correlation 1 .034 
  Sig. (2-
tailed)   .166 
  N 2706 1701 
Mean VaccineAcceptance 
Influential Factors 
Pearson 
Correlation .034 1 
  Sig. (2-
tailed) .166   
  N 1701 1701 
 
 
Table 10.  Correlation Between Knowledge of the HPV Vaccine and Barriers to Becoming 
    Vaccinated Against HPV 
 
  
Mean 
Knowledge
of Vaccine 
Mean  Vaccine 
Acceptance - 
Barriers 
Mean Knowledge of 
Vaccine 
Pearson Correlation 1 -.010 
  Sig. (2-tailed) 
  .680 
  N 2706 1702 
Mean Vaccine 
Acceptance Factors That 
Would Prevent 
Pearson Correlation 
-.010 1 
  Sig. (2-tailed) 
.680   
  N 1702 1702 
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Tables 11-14.  Multiple Linear Regression Results for the Relationship Between Knowledge of  
                        the HPV Vaccine and the Importance of Influential Factors to Becoming  
           Vaccinated Against HPV 
 
11.  Model Summary 
Model R R Square 
Adjusted 
R Square 
Std. Error of 
the Estimate 
1 .113(a) .013 .012 .21631 
2 .130(b) .017 .016 .21593 
a.  Predictors: (Constant), If someone in my family has cancer 
b.  Predictors: (Constant), If someone in my family has cancer, If my friends think I should get it 
 
12.  ANOVA(c) 
Model   
Sum of 
Squares df 
Mean 
Square F Sig. 
1 Regression 1.027 1 1.027 21.940 .000(a) 
  Residual 78.697 1682 .047     
  Total 79.724 1683       
2 Regression 1.346 2 .673 14.433 .000(b) 
  Residual 78.378 1681 .047     
  Total 79.724 1683       
a.  Predictors: (Constant), If someone in my family has cancer 
b.  Predictors: (Constant), If someone in my family has cancer, If my friends think I should get it 
c.  Dependent Variable: Mean Knowledge of Vaccine 
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13.  Coefficientsa 
Model 
  
Unstandardized 
Coefficients 
Standardized 
Coefficients  
95% Confidence 
Interval for B 
  
 
B 
 
Std. 
Error 
 
 
Beta 
 
 
t 
 
 
Sig. 
 
Lower 
Bound 
 
Upper 
Bound 
1 
(Constant) 
 
         .509 
         
.022  
  
23.046 
    
 .000 
 
     .465 
 
     .552 
If someone 
in my 
family has 
cancer 
 
 
.039 
 
.008 
 
.113 
  
4.684 
 
.000 
 
 
        
.023 
 
 
 
.055 
2  
(Constant) 
 
 
 
        .528 
 
 
.023 
 
 
  
22.720 
 
 
.000 
 
 
         
.482 
 
 
.574 
If someone 
in my 
family has 
cancer  
 
 
 
 
 
.045 
 
.009 
 
.130 
 
5.206 
 
.000 
 
 
 
.028 
 
.062 
If my 
friends 
think I 
should get 
it 
 
 
-.021 .008 -.065 -2.617 .009 
 
 
-.037 -.005 
Dependent Variable: Mean Knowledge of Vaccine 
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14.  Excluded Variables(c) 
Model   
Beta In 
 
t 
  
Sig. 
  
Partial 
Correlation 
  
Collinearity 
Statistics 
Tolerance 
1 If my friends thinkI 
should get it -.065(a) -2.617 .009 -.064 .934 
  If my health insurance 
covers it .020(a) .774 .439 .019 .882 
  If I had an abnormal 
Pap smear -.009(a) -.346 .729 -.008 .789 
  If my family thinks I 
should get it -.050(a) -1.944 .052 -.047 .876 
  If my sex partner 
thinks I should get it -.050(a) -1.935 .053 -.047 .882 
  If my health care 
provider thinks I 
should get it 
-.031(a) -1.155 .248 -.028 .840 
  Whether I practice 
safe sex .011(a) .446 .655 .011 .888 
2 If my health insurance 
covers it .038(b) 1.451 .147 .035 .830 
  If I had an abnormal 
Pap smear .000(b) .002 .998 .000 .775 
  If my family thinks I 
should get it -.029(b) -1.061 .289 -.026 .758 
  If my sex partner 
thinks I should get it -.030(b) -1.071 .284 -.026 .769 
  If my health care 
provider thinks I 
should get it 
-.016(b) -.605 .545 -.015 .801 
  Whether I practice 
safe sex .022(b) .844 .399 .021 .868 
a  Predictors in the Model: (Constant), If someone in my family has cancer 
b  Predictors in the Model: (Constant), If someone in my family has cancer, If my friends think I  
          should get it 
c  Dependent Variable: Mean Knowledge of Vaccine 
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Table 15-18.  Multiple Linear Regression Results for the Relationship Between Knowledge of the  
    HPV Vaccine and the Importance of Barriers to Becoming Vaccinated     
                 Against HPV 
 
15.  Model Summary 
Model R R Square 
Adjusted 
R Square 
Std. Error of 
the Estimate 
1 .118(a) .014 .013 .21620 
2 .132(b) .017 .016 .21588 
a.  Predictors: (Constant), Possible side effects of the vaccine would prevent me from becoming    
                                          vaccinated 
b.  Predictors: (Constant), Possible side effects of the vaccine would prevent me from becoming  
                                          vaccinated, Not knowing where to get the vaccine would prevent me  
                                          from becoming vaccinated 
 
16.  ANOVA(c) 
Model                          Sum of Squares df 
Mean 
Square F Sig. 
1 Regression 1.101 1 1.101 23.550 .000(a) 
  Residual 78.481 1679 .047     
  Total 79.582 1680       
2 Regression 1.379 2 .689 14.793 .000(b) 
  Residual 78.203 1678 .047     
  Total 79.582 1680       
a  Predictors: (Constant), Possible side effects of the vaccine would prevent me from becoming 
                                         vaccinated 
b  Predictors: (Constant), Possible side effects of the vaccine would prevent me from becoming    
                                         vaccinated, Not knowing where to get the vaccine would prevent me  
     from becoming vaccinated 
c  Dependent Variable:    Mean Knowledge of Vaccine 
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17.  Coefficientsa 
Model 
  
Unstandardized 
Coefficients 
Standardized 
Coefficients  
95% Confidence 
Interval for B 
  
 
B 
 
Std. 
Error 
 
 
Beta 
 
 
t 
 
 
Sig. 
 
Lower 
Bound 
 
Upper 
Bound 
1 
(Constant) 
 
.682 
 
.016  
 
42.794 
 
.000 
 
.651 
 
.713 
Possible 
side effects 
of the 
vaccine  
 
 
 
-.035 
 
 
 
.007 
 
 
 
-.118 
 
 
 
-4.853 
 
 
 
.000 
 
 
 
-.049 
 
 
 
-.021 
2 
(Constant) 
 
 
 
.708 
 
 
.019 
 
 
 
37.145 
 
 
.000 
 
 
  .670 
 
 
.745 
Possible 
side effects 
of the 
vaccine  
 
 
 
 
 
-.034 
 
 
 
 
.007 
 
 
 
 
-.113 
 
 
 
 
-4.656 
 
 
 
 
.000 
 
 
 
 
-.048 
 
 
 
 
-.020 
Not 
knowing 
where to 
get the 
vaccine 
 
 
 
 
-.017 
 
 
 
 
.007 
 
 
 
 
-.059 
 
 
 
 
-2.442 
 
 
 
 
.000 
 
 
 
 
-.031 
 
 
 
 
-.003 
Dependent Variable: Mean Knowledge of Vaccine 
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18.  Excluded Variables(c) 
Model   Beta In 
t 
  
Sig. 
  
Partial 
Correlation 
  
Collinearity 
Statistics 
Tolerance 
1 The cost of the vaccine  
.019(a) .803 .422 .020 1.000 
  Getting three shots over a 
six month period  -.054(a) -2.205 .028 -.054 .963 
  Fear of vaccines  
-.032(a) -1.239 .215 -.030 .878 
  Having to get additional 
boosters after getting 
three shots 
-.049(a) -1.882 .060 -.046 .848 
  Having to wait at my 
doctors office for 
approval to get the 
vaccine 
-.036(a) -1.458 .145 -.036 .970 
  Not knowing where to get 
the vaccine  -.059(a) -2.442 .015 -.060 .994 
2 The cost of the vaccine  
.038(b) 1.522 .128 .037 .927 
  Getting three shots over a 
six month period  -.046(b) -1.843 .065 -.045 .938 
  Fear of vaccines 
-.031(b) -1.198 .231 -.029 .878 
  Having to get additional 
boosters after getting 
three shots 
-.040(b) -1.481 .139 -.036 .822 
  Not knowing where to get 
the vaccine -.016(b) -.598 .550 -.015 .837 
a.  Predictors in the Model: (Constant), Possible side effects of the vaccine  
b.  Predictors in the Model: (Constant), Possible side effects of the vaccine, Not knowing where  
                                             to get the vaccine  
c.  Dependent Variable: Mean Knowledge of Vaccine 
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Table 19.  Correlation Between General Vaccine Acceptance and Perceived Susceptibility 
     of HPV 
  
  
Mean General 
Vaccine 
Acceptance 
Mean 
Susceptibility 
Mean General 
Vaccine 
Acceptance 
Pearson Correlation 
1 .067(**) 
  Sig. (2-tailed) 
  .001 
  N 2705 2705 
Mean 
Susceptibility 
Pearson Correlation 
.067(**) 1 
  Sig. (2-tailed) .001   
  N 2705 2706 
**Correlation is significant at the 0.01 level (2-tailed). 
 
 
Table 20.  Correlation Between Universal Vaccine Acceptance and Perceived Susceptibility 
     of HPV 
  
  
Mean 
Susceptibility 
How important 
do you think 
vaccinations are 
in general? 
How important do you 
think vaccinations are in 
general?  
Pearson Correlation 
.008 1 
  Sig. (2-tailed) 
  .696 
  N 2700 2700 
Mean Susceptibility Pearson Correlation 1 .008 
  Sig. (2-tailed) .696   
  N 2706 2700 
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Tables 21-22.  Chi-Square for Relationship Between Whether Participants Received At Least One 
                        Dose of the Vaccine and Perceived Susceptiblity 
 
20. Cross-Tabulation 
Received At Least One Dose of 
the HPV Vaccine 
Mean Susceptibility 
Low 
.60-1.60 
Medium 
1.70-2.60 
High 
2.70-3.80 
No N % N % N % 
952 56.2% 497 29.4% 244 14.4% 
Yes 
 
672 66.8% 224 22.3% 110 10.9% 
 
22.  Chi-Square Tests 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 63.945(a) 31 .000 
Likelihood Ratio 66.885 31 .000 
Linear-by-Linear 
Association 23.860 1 .000 
N of Valid Cases 2699     
a. 13 cells (20.3%) have expected count less than 5. The minimum expected count is .37. 
 
Table 23.  Correlation Between Perceived Susceptibility of HPV and Likelihood of 
     Getting Vaccinated Against HPV 
 
  
Likelihood of 
getting 
vaccinated 
against HPV Mean Susceptibility 
Likelihood of 
getting vaccinated 
against HPV  
Pearson Correlation 
1 .145(**) 
  Sig. (2-tailed) 
  .000 
  N 1695 1695 
Mean 
Susceptibility 
Pearson Correlation 
.145(**) 1 
  Sig. (2-tailed) .000   
  N 1695 2706 
**Correlation is significant at the 0.01 level (2-tailed). 
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Table 24.  Correlation Between Perceived Susceptibility of HPV and Influential Factors to  
     Becoming Vaccinated Against HPV 
 
  
Mean 
Vaccine 
Acceptance -
Influential 
Factors 
Mean 
Susceptibility 
Mean Vaccine 
Acceptance - Influential 
Factors 
Pearson Correlation 
1 .009 
  Sig. (2-tailed) 
  .724 
  N 1701 1701 
Mean Susceptibility Pearson Correlation .009 1 
  Sig. (2-tailed) .724   
  N 1701 2706 
 
 
Table 25.  Correlation Between Perceived Susceptibility of HPV and Barriers to  
     Becoming Vaccinated Against HPV 
 
  
Mean 
Vaccine 
Acceptance 
Factors - 
Barriers 
Mean 
Susceptibility 
Mean Vaccine 
Acceptance - Barriers 
Pearson Correlation 1 .020 
  Sig. (2-tailed) 
  .400 
  N 1702 1702 
Mean Susceptibility Pearson Correlation .020 1 
  Sig. (2-tailed) .400   
  N 1702 2706 
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Tables 26-29.  Multiple Linear Regression Results for the Relationship Between Susceptibilty to 
 HPV and the Importance of Influential Factors to Becoming Vaccinated Against       
 HPV  
 
26.  Model Summary 
Model R R Square 
Adjusted 
R Square 
Std. Error of 
the Estimate 
1 .150(a) .023 .022 .72881 
2 .162(b) .026 .025 .72769 
3 .172(c) .030 .028 .72662 
a.  Predictors: (Constant), If my health insurance covers it 
b.  Predictors: (Constant), If my health insurance covers it, If my health care provider thinks I  
                                          should get it 
c.  Predictors: (Constant), If my health insurance covers it, If my health care provider thinks I  
                                          should get it, If I had an abnormal Papsmear 
  
27.  ANOVA(d) 
Model   
Sum of 
Squares df Mean Square F Sig. 
1 Regression 20.613 1 20.613 38.806 .000(a) 
  Residual 893.422 1682 .531     
  Total 914.035 1683       
2 Regression 23.900 2 11.950 22.567 .000(b) 
  Residual 890.135 1681 .530     
  Total 914.035 1683       
3 Regression 27.040 3 9.013 17.071 .000(c) 
  Residual 886.995 1680 .528     
  Total 914.035 1683       
a.  Predictors: (Constant), If my health insurance covers it 
b.  Predictors: (Constant), If my health insurance covers it, If my health care provider thinks I  
                                         should get it 
c.  Predictors: (Constant), If my health insurance covers it, If my health care provider thinks I  
                                          should get it, If I had an abnormal Pap smear 
d.  Dependent Variable: Mean Susceptibility 
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28.  Coefficientsa 
Model 
  
Unstandardized 
Coefficients 
Standardized 
Coefficients  
95% Confidence 
Interval for B 
  
 
B 
 
Std. 
Error 
 
 
Beta 
 
 
t 
 
 
Sig. 
 
Lower 
Bound 
 
Upper 
Bound 
1 (Constant)  
1.338 
 
.070  
 
19.096 
 
     .000 
 
1.201 
 
1.475 
If my health 
insurance 
covers it   
 
 
 
.164 
 
 
 
.026 
 
 
 
.150 
 
 
 
6.229 
 
 
 
.000 
 
 
 
.113 
 
 
 
.216 
2 (Constant) 
 
 
 
1.211 
 
 
.087 
 
 
 
13.973 
 
 
.000 
 
 
  1.041 
 
 
1.381 
If my health 
insurance 
covers it   
 
 
 
 
.135 
 
 
 
 
.029 
 
 
 
 
.124 
 
 
 
 
4.690 
 
 
 
 
.000 
 
 
 
 
.079 
 
 
 
 
.192 
If my health 
care provider 
thinks I 
should get it 
 
 
 
 
.079 
 
 
 
 
.032 
 
 
 
 
.066 
 
 
 
 
2.491 
 
 
 
 
.013 
 
 
 
 
.017 
 
 
 
 
.141 
3(Constant) 
 
 
1.355 
 
.105  
 
12.935 
 
     .000 
 
1.149 
 
1.560 
If my health 
insurance 
covers it   
 
.157 .030 .143 5.208 .000 
 
.098 .216 
If my health 
care provider 
thinks I 
should get it 
 
 
.103 
 
.033 
 
.086 
 
 
3.119 
 
.002 
 
.038 
 
.168 
If I had an 
abnormal Pap 
smear 
 
-.096 
 
.039 -.068 -2.439 .015 
 
-.173 -.019 
a.  Dependent Variable: Mean Susceptibility  
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29.  Excluded Variables(d) 
Model 
   
 
 
Beta In 
 t Sig. 
Partial 
Correlation 
Collinearity 
Statistics 
Tolerance                                               
1 If my friends think I 
should get it .011(a) .416 .678 .010 .906 
  If I had an abnormal 
Pap smear -.041(a) -1.559 .119 -.038 .827 
  If my family thinks I 
should get it -.025(a) -1.003 .316 -.024 .906 
  If my sex partner 
thinks I should get it .029(a) 1.114 .265 .027 .882 
  If my health care 
provider thinks I 
should get it 
.066(a) 2.491 .013 .061 .835 
  If someone in my 
family has cancer .045(a) 1.761 .078 .043 .882 
  Whether I practice 
safe sex -.025(a) -1.005 .315 -.025 .939 
2 If my friends think I 
should get it -.002(b) -.069 .945 -.002 .871 
  If I had an abnormal 
Pap smear -.068(b) -2.439 .015 -.059 .750 
  If my family thinks I 
should get it -.055(b) -2.020 .044 -.049 .792 
  If my sex partner 
thinks I should get it .006(b) .221 .825 .005 .765 
  If someone in my 
family has cancer .028(b) 1.058 .290 .026 .801 
  Whether I practice 
safe sex -.041(b) -1.613 .107 -.039 .891 
3 If my friends think I 
should get it .002(c) .091 .928 .002 .868 
  If my family thinks I 
should get it -.044(c) -1.584 .113 -.039 .763 
  If my sex partner 
thinks I should get it .020(c) .718 .473 .018 .735 
  If someone in my 
family has cancer .054(c) 1.900 .058 .046 .726 
  Whether I practice 
safe sex -.030(c) -1.167 .244 -.028 .858 
a.  Predictors in the Model: (Constant), If my health insurance covers it 
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b.  Predictors in the Model: (Constant), If my health insurance covers it, If my health care  
                                                                provider thinks I should get it 
c.  Predictors in the Model: (Constant), If my health insurance covers it, If my health care    
                                                                provider thinks I should get it, If I had an abnormal Pap     
                                                                smear 
d.  Dependent Variable: Mean Susceptibility 
 
 
Tables 30-33.  Multiple Linear Regression Results for the Relationship Between Susceptibilty to 
 HPV and the Importance of Barriers to Becoming Vaccinated Against       
 HPV  
 
30.  Model Summary 
Model R R Square 
Adjusted 
R Square 
Std. Error of 
the Estimate 
1 .087(a) .008 .007 .73439 
2 .107(b) .011 .010 .73315 
a.  Predictors: (Constant), Possible side effects of the vaccine  
b.  Predictors: (Constant), Possible side effects of the vaccine, The cost of the vaccine  
 
 
31.  ANOVA(c) 
Model  
Sum of 
Squares df Mean Square F Sig. 
1 Regression 6.867 1 6.867 12.732 .000(a) 
  Residual 905.539 1679 .539     
  Total 912.405 1680       
2 Regression 10.463 2 5.231 9.733 .000(b) 
  Residual 901.943 1678 .538     
  Total 912.405 1680       
a.  Predictors: (Constant), Possible side effects of the vaccine 
b.  Predictors: (Constant), Possible side effects of the vaccine, The cost of the vaccine  
c.  Dependent Variable: Mean Susceptibility 
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32.  Coefficientsa 
Model 
  
Unstandardized 
Coefficients 
Standardized 
Coefficients  
95% Confidence 
Interval for B 
  
 
B 
 
Std. 
Error 
 
 
Beta 
 
 
t 
 
 
Sig. 
 
Lower 
Bound 
 
Upper 
Bound 
1 (Constant)  
1.934 
 
.054  
 
35.879 
 
     .000 
 
1.836 
 
2.049 
Possible side 
effects of the 
vaccine   
 
 
 
-.088 
 
 
 
.025 
 
 
 
-.087 
 
 
 
-3.568 
 
 
 
.000 
 
 
 
-.136 
 
 
 
-.040 
2 (Constant) 
 
 
 
1.802 
 
 
.077 
 
 
 
23.505 
 
 
.000 
 
 
  1.652 
 
 
1.952 
Possible side 
effects of the 
vaccine   
 
 
 
 
-.088 
 
 
 
 
.025 
 
 
 
 
-.087 
 
 
 
 
-3.590 
 
 
 
 
.000 
 
 
 
 
-.137 
 
 
 
 
-.040 
The cost of 
the vaccine 
 
 
 
 
.061 
 
 
 
 
.024 
 
 
 
 
.063 
 
 
 
 
2.587 
 
 
 
 
.010 
 
 
 
 
.015 
 
 
 
 
.108 
a.  Dependent Variable: Mean Susceptibility  
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33.  Excluded Variables(c) 
Model 
    Beta In 
 
t Sig. 
Partial 
Correlation 
Collinearity 
Statistics 
Tolerance 
1 The cost of the vaccine  
.063(a) 2.587 .010 .063 1.000 
  Getting three shots over a 
six month period -.004(a) -.168 .866 -.004 .963 
  Fear of vaccines  
.002(a) .063 .950 .002 .878 
  Having to get additional 
boosters after getting 
three shots 
-.009(a) -.329 .742 -.008 .848 
  Having to wait at my 
doctors office for 
approval to get the 
vaccine 
.051(a) 2.077 .038 .051 .970 
  Not knowing where to get 
the vaccine  .051(a) 2.097 .036 .051 .994 
2 Getting three shots over a 
six month period  -.013(b) -.523 .601 -.013 .945 
  Fear of vaccines 
.003(b) .134 .894 .003 .877 
  Having to get additional 
boosters after getting 
three shots 
-.019(b) -.728 .467 -.018 .829 
  Having to wait at my 
doctors office for 
approval to get the 
vaccine 
.039(b) 1.538 .124 .038 .921 
  Not knowing where to get 
the vaccine .037(b) 1.453 .146 .035 .921 
a.  Predictors in the Model: (Constant), Possible side effects of the vaccine  
b.  Predictors in the Model: (Constant), Possible side effects of the vaccine, The cost of the    
                                                                vaccine  
c.  Dependent Variable: MeanSusceptibility 
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 Table 34.  Correlation Between General Vaccine Acceptance and Perceived Severity 
      of HPV 
 
  
Mean 
General 
Vaccine 
Acceptance Mean Severity 
Mean General 
Vaccine 
Acceptance 
Pearson Correlation 
1 .088(**) 
  Sig. (2-tailed) 
  .000 
  N 2705 2705 
Mean Severity Pearson Correlation .088(**) 1 
  Sig. (2-tailed) .000   
  N 2705 2706 
**Correlation is significant at the 0.01 level (2-tailed). 
 
 
Table 35.  Correlation Between Universal Vaccine Acceptance and Perceived Severity 
      of HPV 
 
  
How 
important do 
you think 
vaccinations
are in 
general? Mean Severity 
How important do you 
think vaccinations are in 
general? 
Pearson Correlation 
1 .077(**) 
  Sig. (2-tailed) 
  .000 
  N 2700 2700 
MeanSeverity Pearson Correlation .077(**) 1 
  Sig. (2-tailed) .000   
  N 2700 2706 
** Correlation is significant at the 0.01 level (2-tailed). 
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Tables 36-37.  Chi-Square for Relationship Between Whether Participants Received At Least One 
                        Dose of the Vaccine and Perceived Severity 
 
36. Cross-Tabulation 
Received At Least One Dose of 
the HPV Vaccine 
Mean Severity 
Low 
1.00-2.00 
Medium 
2.25-3.25 
High 
3.50-4.50 
No N % N % N % 
28 1.6% 1048 61.9% 617 36.4% 
Yes 
 
19 1.9% 626 62.2% 361 35.9% 
 
37.  Chi-Square Tests 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 8.964(a) 13 .776 
Likelihood Ratio 9.228 13 .756 
Linear-by-Linear 
Association .393 1 .531 
N of Valid Cases 2699     
a  7 cells (25.0%) have expected count less than 5. The minimum expected count is .37. 
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Table 38.  Correlation Between Perception of HPV Not Being a Problem Because It is  
                 Very Easy to Treat and Likelihood of Getting Vaccinated Against HPV 
 
  
If you get 
HPV it is not 
a big problem 
because it is 
very easy to 
treat 
Likelihood of 
getting vaccinated 
against HPV 
If you get HPV it is 
not a big problem 
because it is very 
easy to treat  
Pearson Correlation 
1 -.009 
  Sig. (2-tailed) 
  .717 
  N 2701 1692 
Likelihood of 
getting vaccinated 
against HPV 
Pearson Correlation 
-.009 1 
  Sig. (2-tailed) 
.717   
  N 1692 1695 
 
 
Table 39.  Correlation Between Perceived Severity of HPV and Likelihood of Getting 
                 Vaccinated Against HPV 
 
  
Likelihood of 
getting 
vaccinated 
against HPV Mean Severity 
Likelihood of 
getting vaccinated 
against HPV 
Pearson Correlation 
1 .110(**) 
  Sig. (2-tailed) 
  .000 
  N 1695 1695 
Mean Severity Pearson Correlation .110(**) 1 
  Sig. (2-tailed) .000   
  N 1695 2706 
**Correlation is significant at the 0.01 level (2-tailed). 
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Table 40.  Correlation Between Perceived Severity of HPV and Influential Factors to  
                 Becoming Vaccinated Against HPV 
 
  
Mean 
Vaccine 
Acceptance – 
Influential 
Factors 
Mean 
Severity 
Mean Vaccine 
Acceptance - Influential 
Factors 
Pearson Correlation 
1 .072(**) 
  Sig. (2-tailed) 
  .003 
  N 1701 1701 
Mean Severity Pearson Correlation .072(**) 1 
  Sig. (2-tailed) .003   
  N 1701 2706 
**Correlation is significant at the 0.01 level (2-tailed). 
 
 
Table 41.  Correlation Between Perceived Severity of HPV and Barriers to  
                 Becoming Vaccinated Against HPV 
 
  
Mean 
Vaccine 
Acceptance - 
Barriers 
Mean 
Severity 
Mean Vaccine 
Acceptance - Barriers 
Pearson Correlation 1 .025 
  Sig. (2-tailed) 
  .308 
  N 1702 1702 
Mean Severity Pearson Correlation .025 1 
  Sig. (2-tailed) .308   
  N 1702 2706 
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Tables 42-45.  Multiple Linear Regression Results for the Relationship Between Perceived  
                        Severity and the Importance of Influential Factors to Becoming Vaccinated  
                        Against HPV  
 
42.  Model Summary 
Model R R Square 
Adjusted 
R Square 
Std. Error of 
the Estimate 
1 .140(a) .020 .019 .43895 
2 .152(b) .023 .022 .43833 
a  Predictors: (Constant), If someone in my family has cancer 
b  Predictors: (Constant), If someone in my family has cancer, If my family thinks I should get it 
 
43.  ANOVA(c) 
Model   Sum of Squares df Mean Square F Sig. 
1 Regression 6.498 1 6.498 33.724 .000(a) 
  Residual 324.085 1682 .193     
  Total 330.583 1683       
2 Regression 7.614 2 3.807 19.816 .000(b) 
  Residual 322.969 1681 .192     
  Total 330.583 1683       
a.  Predictors: (Constant), If someone in my family has cancer 
b.  Predictors: (Constant), If someone in my family has cancer, If my family thinks I should get it 
c.  Dependent Variable: MeanSeverity 
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44.  Coefficientsa 
Model 
  
Unstandardized 
Coefficients 
Standardized 
Coefficients  
95% Confidence 
Interval for B 
  
 
B 
 
Std. 
Error 
 
 
Beta 
 
 
t 
 
 
Sig. 
 
Lower 
Bound 
 
Upper 
Bound 
1 (Constant)  
2.970 
 
.045  
 
66.314 
 
     .000 
 
2.882 
 
3.058 
If someone in 
my family 
has cancer   
 
 
 
.098 
 
 
 
.017 
 
 
 
.140 
 
 
 
5.807 
 
 
 
     .000 
 
 
 
.065 
 
 
 
.132 
2 (Constant) 
 
 
 
2.913 
 
 
.051 
 
 
 
57.500 
 
 
.000 
 
 
  2.814 
 
 
3.012 
If someone in 
my family 
has cancer   
 
 
 
 
.083 
 
 
 
 
.018 
 
 
 
 
.118 
 
 
 
 
4.594 
 
 
 
 
.000 
 
 
 
 
.048 
 
 
 
 
.118 
If my family 
thinks I 
should get it 
 
 
 
 
.041 
 
 
 
 
.017 
 
 
 
 
.062 
 
 
 
 
2.411 
 
 
 
 
.016 
 
 
 
 
.008 
 
 
 
 
.074 
a.  Dependent Variable: Mean Severity  
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45.  Excluded Variables(c) 
Model 
    Beta In t Sig. 
Partial 
Correlation 
Collinearity 
Statistics 
Tolerance 
1 If my friends think I 
should get it .028(a) 1.125 .261 .027 .934 
  If my health insurance 
covers it .061(a) 2.387 .017 .058 .882 
  If I had an abnormal 
Pap smear .060(a) 2.223 .026 .054 .789 
  If my family thinks I 
should get it .062(a) 2.411 .016 .059 .876 
  If my sex partner thinks 
I should get it .046(a) 1.779 .075 .043 .882 
  If my health care 
provider thinks I should 
get it 
.050(a) 1.900 .058 .046 .840 
  Whether I practice safe 
sex 
.033(a) 1.285 .199 .031 .888 
2 If my friends think I 
should get it .007(b) .262 .794 .006 .809 
  If my health insurance 
covers it .050(b) 1.922 .055 .047 .842 
  If I had an abnormal 
Pap smear .047(b) 1.676 .094 .041 .740 
  If my sex partner thinks 
I should get it .024(b) .834 .405 .020 .722 
  If my sex partner thinks 
I should get it .032(b) 1.149 .251 .028 .743 
  Whether I practice safe 
sex 
.024(b) .932 .351 .023 .867 
a  Predictors in the Model: (Constant), If someone in my family has cancer 
b  Predictors in the Model: (Constant), If someone in my family has cancer, If my family thinks I   
                                                               should get it 
c  Dependent Variable: Mean Severity  
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Tables 46-49.  Multiple Linear Regression Results for the Relationship Between Perceived  
                        Severity and the Importance of Barriers to Becoming Vaccinated Against HPV  
 
46.  Model Summary 
Model R R Square 
Adjusted 
R Square 
Std. Error of 
the Estimate 
1 .059(a) .003 .003 .44256 
a  Predictors: (Constant), The cost of the vaccine 
 
47.  ANOVA(b) 
Model  
Sum of 
Squares df Mean Square F Sig. 
1 Regression 1.145 1 1.145 5.848 .016(a) 
  Residual 328.849 1679 .196     
  Total 329.994 1680       
a.  Predictors: (Constant), The cost of the vaccine  
b.  Dependent Variable: Mean Severity 
 
48.  Coefficientsa 
Model 
  
Unstandardized 
Coefficients 
Standardized 
Coefficients  
95% Confidence 
Interval for B 
  
 
B 
 
Std. 
Error 
 
 
Beta 
 
 
t 
 
 
Sig. 
 
Lower 
Bound 
 
Upper 
Bound 
1 (Constant)  
3.143 
 
.035  
 
90.524 
 
     .000 
 
3.075 
 
3.211 
The cost of 
the vaccine 
 
 
 
.035 
 
 
 
.014 
 
 
 
.059 
 
 
 
2.418 
 
 
 
.016 
 
 
 
.007 
 
 
 
.063 
a.  Dependent Variable: Mean Severity 
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49.  Excluded Variables(b) 
Model 
    
 
 
Beta In 
 
t  Sig. 
Partial 
Correlation 
Collinearity 
Statistics 
Tolerance 
1 Getting three shots 
over a six month 
period  
-.016(a) -.633 .527 -.015 .982 
  Fear of vaccines 
-.023(a) -.931 .352 -.023 .999 
  Possible side effects 
of the vaccine -.016(a) -.638 .523 -.016 1.000 
  Having to get 
additional boosters 
after getting three 
shots 
.003(a) .108 .914 .003 .980 
  Having to wait at 
my doctors office 
for approval to get 
the vaccine 
-.009(a) -.340 .734 -.008 .951 
  Not knowing where 
to get the vaccine .043(a) 1.691 .091 .041 .927 
a.  Predictors in the Model: (Constant), The cost of the vaccine  
b.  Dependent Variable: MeanSeverity 
 
 
Table 50.  Correlation Between Attitudes About Practicing Safer Sex Behaviors and General   
                 Vaccine Acceptance 
 
  
Mean 
Attitude 
Mean 
General 
Vaccine 
Acceptance 
Mean Attitude Pearson Correlation 1 .029 
  Sig. (2-tailed) 
  .128 
  N 2706 2705 
Mean General 
Vaccine 
Acceptance 
Pearson Correlation 
.029 1 
  Sig. (2-tailed) .128   
  N 2705 2705 
 
 370
Appendix O (Continued) Summary Tables of Correlation 
and Multiple Linear Regression Results 
 
 
Table 51.  Correlation Between Attitudes About Practicing Safer Sex Behaviors and Universal 
     Vaccine Acceptance 
 
  
Mean 
Attitude 
How important 
do you think 
vaccinations 
are in general? 
Mean Attitude Pearson 
Correlation 1 .059(**) 
  Sig. (2-tailed) 
  .002 
  N 2706 2700 
How important do you 
think vaccinations are in 
general? 
Pearson 
Correlation .059(**) 1 
  Sig. (2-tailed) .002   
  N 2700 2700 
** Correlation is significant at the 0.01 level (2-tailed). 
 
 
Table 52.  Correlation Between Attitudes About Practicing Safer Sex Behaviors and Likelihood 
                 of Getting Vaccinated Against HPV 
 
  MeanAttitude 
Likelihood of 
getting vaccinated 
against HPV 
MeanAttitude Pearson Correlation 1 .024 
  Sig. (2-tailed) 
  .326 
  N 2706 1695 
Likelihood of 
getting vaccinated 
against HPV 
Pearson Correlation 
.024 1 
  Sig. (2-tailed) 
.326   
  N 1695 1695 
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Tables 53-54.  Chi-Square for Relationship Between Whether Participants Received at Least One 
                        Dose of the HPV Vaccine and Attitudes Towards Practicing Safer Sex Behaviors 
 
53. Cross-Tabulation 
Received At Least One Dose of 
the HPV Vaccine 
Mean Attitude 
Low 
1.00-2.00 
Medium 
2.33-3.67 
High 
4.00-5.00 
No N % N % N % 
39 2.3% 625 36.9% 1029 60.8% 
Yes 
 
26 2.6% 415 41.3% 565 56.1% 
 
 
54.  Chi-Square Tests 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 15.543(a) 12 .213 
Likelihood Ratio 16.704 12 .161 
Linear-by-Linear 
Association 2.249 1 .134 
N of Valid Cases 2699     
a.  5 cells (19.2%) have expected count less than 5. The minimum expected count is .37. 
 
 
Tables 55-58.  Multiple Linear Regression Results for the Relationship Between Influential  
            Factors to Becoming Vaccinated Against HPV  
             
Table 55.  Model Summary 
Model R R Square 
Adjusted 
R Square 
Std. Error of 
the Estimate 
1 .128(a) .016 .016 .78562 
2 .195(b) .038 .037 .77713 
a.  Predictors: (Constant), If my health insurance covers it 
b.  Predictors: (Constant), If my health insurance covers it, Whether I practice safe sex 
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Table 56.  ANOVA(c) 
Model  
Sum of 
Squares df 
Mean 
Square F Sig. 
1 Regression 17.188 1 17.188 27.849 .000(a) 
  Residual 1038.123 1682 .617     
  Total 1055.311 1683       
2 Regression 40.107 2 20.053 33.205 .000(b) 
  Residual 1015.204 1681 .604     
  Total 1055.311 1683       
a.  Predictors: (Constant), If my health insurance covers it 
b.  Predictors: (Constant), If my health insurance covers it, Whether I practice safe sex 
c.  Dependent Variable: Mean Attitude 
 
 
57.  Coefficientsa 
Model 
  
Unstandardized 
Coefficients 
Standardized 
Coefficients  
95% Confidence 
Interval for B 
  
 
B 
 
Std. 
Error 
 
 
Beta 
 
 
t 
 
 
Sig. 
 
Lower 
Bound 
 
Upper 
Bound 
1 (Constant)  
4.334 
 
.076  
 
57.378 
 
     .000 
 
4.186 
 
4.482 
If my health 
insurance 
covers it   
 
 
 
-.150 
 
 
 
.028 
 
 
 
-.128 
 
 
 
-5.277 
 
 
 
     .000 
 
 
 
-.206 
 
 
 
-.094 
2 (Constant) 
 
 
 
3.992 
 
 
.093 
 
 
 
42.896 
 
 
.000 
 
 
  3.809 
 
 
4.174 
If my health 
insurance 
covers it   
 
 
 
 
-.194 
 
 
 
 
.029 
 
 
 
 
-.165 
 
 
 
 
-6.692 
 
 
 
 
.000 
 
 
 
 
-.251 
 
 
 
 
-.137 
Whether I 
practice safe 
sex 
 
 
 
 
.180 
 
 
 
 
.029 
 
 
 
 
.152 
 
 
 
 
6.160 
 
 
 
 
.000 
 
 
 
 
.122 
 
 
 
 
.237 
a.  Dependent Variable: Mean Attitude 
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58.  Excluded Variables(c) 
Model 
   
 
Beta In  
 
t  Sig. 
Partial 
Correlation 
Collinearity 
Statistics 
Tolerance 
1 If my friends think I 
should get it .060(a) 2.357 .019 .057 .906 
  If I had an abnormal 
Pap smear .070(a) 2.642 .008 .064 .827 
  If my family thinks I 
should get it .043(a) 1.707 .088 .042 .906 
  If my sex partner 
thinks I should get it .023(a) .877 .381 .021 .882 
  If my health care 
provider thinks I 
should get it 
.051(a) 1.936 .053 .047 .835 
  If someone in my 
family has cancer .060(a) 2.319 .021 .056 .882 
  Whether I practice 
safe sex .152(a) 6.160 .000 .149 .939 
2 If my friends think I 
should get it .036(b) 1.432 .152 .035 .883 
  If I had an abnormal 
Pap smear .032(b) 1.176 .240 .029 .776 
  If my family thinks I 
should get it .014(b) .561 .575 .014 .873 
  If my sex partner 
thinks I should get it -.015(b) -.573 .566 -.014 .834 
  If my sex partner 
thinks I should get it .016(b) .577 .564 .014 .792 
  If someone in my 
family has cancer .018(b) .673 .501 .016 .815 
a.  Predictors in the Model: (Constant), If my health insurance covers it 
b.  Predictors in the Model: (Constant), If my health insurance covers it, Whether I practice safe  
                                                                sex 
c.  Dependent Variable: Mean Attitude 
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Tables 59-62.  Multiple Linear Regression Results for the Relationship Between Attitude and  
                        Barriers to Becoming Vaccinated Against HPV 
 
59.  Model Summary 
Model R R Square 
Adjusted 
R Square 
Std. Error of 
the Estimate 
1 .145(a) .021 .020 .78370 
2 .167(b) .028 .027 .78119 
a.  Predictors: (Constant), The cost of the vaccine  
b.  Predictors: (Constant), The cost of the vaccine, Not knowing where to get the vaccine  
 
 
60.  ANOVA(c) 
Model  
Sum of 
Squares df Mean Square F Sig. 
1 Regression 22.208 1 22.208 36.159 .000(a) 
  Residual 1031.221 1679 .614     
  Total 1053.430 1680       
2 Regression 29.414 2 14.707 24.100 .000(b) 
  Residual 1024.015 1678 .610     
  Total 1053.430 1680       
a.  Predictors: (Constant), The cost of the vaccine 
b.  Predictors: (Constant), The cost of the vaccine, Not knowing where to get the vaccine 
c.  Dependent Variable: Mean Attitude  
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61.  Coefficientsa 
Model 
  
Unstandardized 
Coefficients 
Standardized 
Coefficients  
95% Confidence 
Interval for B 
  
 
B 
 
Std. 
Error 
 
 
Beta 
 
 
t 
 
 
Sig. 
 
Lower 
Bound 
 
Upper 
Bound 
1 (Constant)  
4.300 
 
.061  
 
69.928 
 
     .000 
 
4.179 
 
4.420 
The cost of 
the vaccine   
 
 
 
-.153 
 
 
 
.025 
 
 
 
-.145 
 
 
 
-6.013 
 
 
 
     .000 
 
 
 
-.202 
 
 
 
-.103 
2 (Constant) 
 
 
 
4.393 
 
 
.067 
 
 
 
65.493 
 
 
.000 
 
 
  4.262 
 
 
4.525 
The cost of 
the vaccine   
 
 
 
 
-.128 
 
 
 
 
.026 
 
 
 
 
-.122 
 
 
 
 
-4.880 
 
 
 
 
.000 
 
 
 
 
-.180 
 
 
 
 
-.077 
Not knowing 
where to get 
the vaccine 
 
 
 
 
-.090 
 
 
 
 
.026 
 
 
 
 
-.086 
 
 
 
 
-3.436 
 
 
 
 
.001 
 
 
 
 
-.142 
 
 
 
 
-.039 
a.  Dependent Variable: Mean Attitude 
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62.   Excluded Variables(c) 
Model     Beta In t Sig. 
Partial 
Correlation 
Collinearity 
Statistics 
Tolerance 
1 Getting three 
shots over a six 
month period 
-.035(a) -1.418 .156 -.035 .982 
  Fear of vaccines  
-.013(a) -.544 .586 -.013 .999 
  Possible side 
effects of the 
vaccine 
.035(a) 1.445 .149 .035 1.000 
  Having to get 
additional 
boosters after 
getting three shots 
-.001(a) -.046 .964 -.001 .980 
  Having to wait at 
my doctors office 
for approval to 
get the vaccine 
-.069(a) -2.795 .005 -.068 .951 
  Not knowing 
where to get the 
vaccine 
-.086(a) -3.436 .001 -.084 .927 
2 Getting three 
shots over a six 
month period 
-.023(b) -.950 .342 -.023 .963 
  Fear of vaccines 
-.009(b) -.367 .714 -.009 .997 
  Possible side 
effects of the 
vaccine 
.042(b) 1.726 .084 .042 .994 
  Having to get 
additional 
boosters after 
getting three shots 
.013(b) .509 .611 .012 .955 
  Having to wait at 
my doctors office 
for approval to 
get the vaccine 
-.046(b) -1.740 .082 -.042 .842 
a.  Predictors in the Model: (Constant), The cost of the vaccine  
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b.  Predictors in the Model: (Constant), The cost of the vaccine, Not knowing where to get the  
                                                                vaccine  
c.  Dependent Variable: Mean Attitude 
 
Table 63.  Correlation Between Normative Beliefs About Practicing Safer Sex Behaviors and  
                 Universal Vaccine Acceptance 
  
  
Mean 
Normative 
Beliefs 
Mean General 
Vaccine 
Acceptance 
Mean Normative 
Beliefs 
Pearson Correlation 1 .113(**) 
  Sig. (2-tailed) 
  .000 
  N 2706 2705 
Mean General 
Vaccine Acceptance 
Pearson Correlation 
.113(**) 1 
  Sig. (2-tailed) .000   
  N 2705 2705 
**Correlation is significant at the 0.01 level (2-tailed). 
 
 
Table 63.  Correlation Between Normative Beliefs About Practicing Safer Sex Behaviors and  
                 Likelihood of Getting Vaccinated Against HPV 
  
  
Mean 
Normative 
Beliefs 
Likelihood of 
getting 
vaccinated 
against HPV 
Mean Normative 
Beliefs 
Pearson Correlation 1 .111(**) 
  Sig. (2-tailed) 
  .000 
  N 2706 1695 
Likelihood of getting 
vaccinated against 
HPV 
Pearson Correlation 
.111(**) 1 
  Sig. (2-tailed) 
.000   
  N 1695 1695 
**Correlation is significant at the 0.01 level (2-tailed). 
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Tables 64-65.  Chi-Square for Relationship Between Whether Participants Received at Least One 
                        Dose of the HPV Vaccine and Normative Beliefs Towards Practicing Safer Sex  
                        Behaviors 
 
64.  Cross-Tabulation 
Received At Least One Dose of 
the HPV Vaccine 
Mean Normative Beliefs 
Low 
.33- 1.67 
Medium 
2.00-3.67 
High 
4.00-5.00 
No N % N % N % 
358 21.1% 1302 76.9% 33 2.0% 
Yes 
 
203 20.2% 782 77.7% 21 2.1% 
 
65.  Chi-Square Tests 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 20.169(a) 13 .091 
Likelihood Ratio 20.175 13 .091 
Linear-by-Linear 
Association 5.502 1 .019 
N of Valid Cases 2699     
a.  7 cells (25.0%) have expected count less than 5. The minimum expected count is .37. 
 
Tables 66-69.  Multiple Linear Regression Results for the Relationship Between Attitude and  
                        Barriers to Becoming Vaccinated Against HPV 
 
66.  Model Summary 
Model R R Square 
Adjusted 
R Square 
Std. Error of 
the Estimate 
1 .126(a) .016 .015 .63688 
2 .150(b) .023 .021 .63490 
3 .159(c) .025 .024 .63422 
a.  Predictors: (Constant), Whether I practice safe sex 
b.  Predictors: (Constant), Whether I practice safe sex, If my friends think I should get it 
c.  Predictors: (Constant), Whether I practice safe sex, If my friends think I should get it,  
                                          If my family thinks I should get it 
 379
Appendix O (Continued) Summary Tables of Correlation 
and Multiple Linear Regression Results 
 
67.  ANOVA(d) 
Model  
Sum of 
Squares df 
Mean 
Square F Sig. 
1 Regression 10.998 1 10.998 27.114 .000(a) 
  Residual 682.252 1682 .406     
  Total 693.250 1683       
2 Regression 15.648 2 7.824 19.410 .000(b) 
  Residual 677.602 1681 .403     
  Total 693.250 1683       
3 Regression 17.506 3 5.835 14.507 .000(c) 
  Residual 675.744 1680 .402     
  Total 693.250 1683       
a  Predictors: (Constant), WhetherI practice safe sex 
b  Predictors: (Constant), Whether I practice safe sex, If my friends think I should get it 
c  Predictors: (Constant), Whether I practice safe sex, If my friends think Ishould get it, If my  
                                          family thinks I should get it 
d  Dependent Variable: Mean Normative Beliefs 
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68.  Coefficientsa 
Model 
  
Unstandardized 
Coefficients 
Standardized 
Coefficients  
95% Confidence 
Interval for B 
  
 
B 
 
Std. 
Error 
 
 
Beta 
 
 
t 
 
 
Sig. 
 
Lower 
Bound 
 
Upper 
Bound 
1 (Constant)  
1.994 
 
.061  
 
32.850 
 
     .000 
 
1.875 
 
2.113 
Whether I 
practice safe 
sex   
 
 
 
.121 
 
 
 
.023 
 
 
 
.126 
 
 
 
5.207 
 
 
 
.000 
 
 
 
.075 
 
 
 
.166 
2 (Constant) 
 
 
 
1.910 
 
 
.065 
 
 
 
29.199 
 
 
.000 
 
 
  1.782 
 
 
2.038 
Whether I 
practice safe 
sex   
 
 
 
 
.103 
 
 
 
 
.024 
 
 
 
 
.107 
 
 
 
 
4.346 
 
 
 
 
.000 
 
 
 
 
.056 
 
 
 
 
.149 
If my friends 
think I should 
get it 
 
 
 
 
.081 
 
 
 
 
.024 
 
 
 
 
.084 
 
 
 
 
3.396 
 
 
 
 
.001 
 
 
 
 
.034 
 
 
 
 
.128 
3(Constant) 
 
 
1.837 
 
.074  
 
24.938 
 
     .000 
 
1.693 
 
1.981 
Whether I 
practice safe 
sex   
 
.094 .024 .098 3.894 .000 
 
.046 .141 
If my friends 
think I should 
get it 
 
 
.059 
 
 
.026 
 
 
.062 
 
 
2.300 
 
 
     .022 
 
 
.009 
 
 
.110 
If my family 
thinks I 
should get it 
 
.056  .026 .058 2.149 .032 
 
.005 .106 
a.  Dependent Variable: Mean Normative Beliefs 
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69.  Excluded Variables(d) 
Model  
Beta In t Sig. 
Partial 
Correlation 
Collinearity 
Statistics 
    Tolerance 
1 If my friends think I 
should get it .084(a) 3.396 .001 .083 .951 
  If my health insurance 
covers it .015(a) .613 .540 .015 .939 
  If I had an abnormal 
Pap smear .014(a) .549 .583 .013 .897 
  If my family thinks I 
should get it .082(a) 3.296 .001 .080 .937 
  If my sex partner thinks 
I should get it .041(a) 1.600 .110 .039 .911 
  If my health care 
provider thinks I should 
get it 
.060(a) 2.388 .017 .058 .910 
  If someone in my 
family has cancer .029(a) 1.119 .263 .027 .888 
2 If my health insurance 
covers it 
-
.008(b) -.304 .761 -.007 .872 
  If I had an abnormal 
Pap smear 
-
.001(b) -.043 .966 -.001 .869 
  If my family thinks I 
should get it .058(b) 2.149 .032 .052 .796 
  If my sex partner thinks 
I should get it .010(b) .366 .715 .009 .785 
  If my health care 
provider thinks I should 
get it 
.042(b) 1.610 .107 .039 .855 
  If someone in my 
family has cancer .012(b) .458 .647 .011 .853 
3 If my health insurance 
covers it -.018(c) -.696 .486 -.017 .844 
  If I had an abnormal 
Pap smear -.017(c) -.651 .515 -.016 .805 
  If my sex partner thinks 
I should get it -.013(c) -.444 .657 -.011 .681 
  If my health care 
provider thinks I should 
get it 
.027(c) .961 .336 .023 .764 
  If someone in my 
family has cancer -.002(c) -.059 .953 -.001 .804 
a.  Predictors in the Model: (Constant), Whether I practice safe sex 
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b.  Predictors in the Model: (Constant), Whether I practice safe sex, If my friends  
                                                               think I should get it 
 
c.  Predictors in the Model: (Constant), Whether I practice safe sex, If my friends think I should              
                                                               get it, If my family thinks I should get it 
d.  Dependent Variable: Mean Normative Beliefs 
 
 
Table 70.  Correlation Between Control Beliefs About Practicing Safer Sex Behaviors  
                 and General Vaccine Acceptance 
  
  
Mean Control 
Beliefs 
Mean General 
Vaccine 
Acceptance 
Mean Control 
Beliefs 
Pearson Correlation 1 .005 
  Sig. (2-tailed) 
  .778 
  N 2706 2705 
Mean General 
Vaccine 
Acceptance 
Pearson Correlation 
.005 1 
  Sig. (2-tailed) .778   
  N 2705 2705 
 
  
Table 71.  Correlation Between Control Beliefs About Practicing Safer Sex Behaviors  
                 and Universal Vaccine Acceptance 
 
  
Mean Control 
Beliefs 
How 
important do 
you think 
vaccinations 
are in 
general? 
Mean  Control Beliefs Pearson Correlation 1 .054(**) 
  Sig. (2-tailed) 
  .005 
  N 2706 2700 
How important do you 
think vaccinations are in 
general? 
Pearson Correlation 
.054(**) 1 
  Sig. (2-tailed) .005   
  N 2700 2700 
**Correlation is significant at the 0.01 level (2-tailed). 
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Table 72.  Correlation Between Control Beliefs About Practicing Safer Sex Behaviors  
                 and Likelihood of Getting Vaccinated Against HPV  
 
  
Mean Control 
Beliefs 
Likelihood of 
getting vaccinated 
against HPV 
Mean Control 
Beliefs 
Pearson Correlation 1 -.029 
  Sig. (2-tailed) 
  .226 
  N 2706 1695 
Likelihood of 
getting vaccinated 
against HPV 
Pearson Correlation 
-.029 1 
  Sig. (2-tailed) 
.226   
  N 1695 1695 
 
 
Tables 73-74.  Chi-Square for Relationship Between Whether Participants Received at Least One 
                        Dose of the HPV Vaccine and Control Beliefs Towards Practicing Safer Sex  
                        Behaviors 
 
73.  Cross-Tabulation 
Received At Least One Dose of 
the HPV Vaccine 
Mean Control Beliefs 
Low 
1.00-2.60 
Medium 
2.80-3.80 
High 
4.00-5.00 
No N % N % N % 
43 2.5% 436 25.8% 1214 71.7% 
Yes 
 
16 1.6% 275 27.3% 715 71.1% 
 
74.  Chi-Square Tests 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 21.011(a) 19 .336 
Likelihood Ratio 23.305 19 .224 
Linear-by-Linear 
Association .059 1 .808 
N of Valid Cases 2699     
a  11 cells (27.5%) have expected count less than 5. The minimum expected count is .37. 
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Tables 75-78.  Multiple Linear Regression Results for the Relationship Between Control Beliefs  
 About Practicing Safer Sex Behaviors and Influential Factors to Becoming    
 Vaccinated Against HPV 
 
75.  Model Summary 
Model R R Square 
Adjusted 
R Square 
Std. Error of 
the Estimate 
1 .125(a) .016 .015 .67779 
2 .163(b) .027 .025 .67421 
a  Predictors: (Constant), If my health insurance covers it 
b  Predictors: (Constant), If my health insurance covers it, Whether I practice safe sex 
 
76.  ANOVA(c) 
Model  
Sum of 
Squares df Mean Square F Sig. 
1 Regression 12.214 1 12.214 26.587 .000(a) 
  Residual 772.717 1682 .459     
  Total 784.931 1683       
2 Regression 20.815 2 10.408 22.896 .000(b) 
  Residual 764.116 1681 .455     
  Total 784.931 1683       
a  Predictors: (Constant), If my health insurance covers it 
b  Predictors: (Constant), If my health insurance covers it, Whether I practice safe sex 
c  Dependent Variable: Mean Control Beliefs 
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77.  Coefficientsa 
Model 
  
Unstandardized 
Coefficients 
Standardized 
Coefficients  
95% Confidence 
Interval for B 
  
 
B 
 
Std. 
Error 
 
 
Beta 
 
 
t 
 
 
Sig. 
 
Lower 
Bound 
 
Upper 
Bound 
1 (Constant)  
4.585 
 
.065  
 
70.366 
 
     .000 
 
4.457 
 
4.713 
If my health 
insurance 
covers it   
 
 
 
-.127 
 
 
 
.025 
 
 
 
-.125 
 
 
 
-5.156 
 
 
 
     .000 
 
 
 
-.175 
 
 
 
-.078 
2 (Constant) 
 
 
 
4.376 
 
 
.081 
 
 
 
54.200 
 
 
.000 
 
 
4.218 
 
 
4.534 
If my health 
insurance 
covers it   
 
 
 
 
-.154 
 
 
 
 
.025 
 
 
 
 
-.151 
 
 
 
 
-6.098 
 
 
 
 
.000 
 
 
 
 
-.203 
 
 
 
 
-.104 
Whether I 
practice safe 
sex 
 
 
 
 
.110 
 
 
 
 
.025 
 
 
 
 
.108 
 
 
 
 
4.350 
 
 
 
 
.001 
 
 
 
 
.060 
 
 
 
 
.160 
a.  Dependent Variable: Mean Control Beliefs 
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78.  Excluded Variables(c) 
Model 
    Beta In t Sig. 
Partial 
Correlation 
Collinearity 
Statistics 
Tolerance 
1 If my friends think I 
should get it -.001(a) -.055 .956 -.001 .906 
  If I had an abnormal 
Pap smear .021(a) .776 .438 .019 .827 
  If my family thinks I 
should get it .016(a) .627 .531 .015 .906 
  If my sex partner 
thinks I should get it -.012(a) -.452 .651 -.011 .882 
  If my health care 
provider thinks I 
should get it 
.037(a) 1.390 .165 .034 .835 
  If someone in my 
family has cancer .030(a) 1.163 .245 .028 .882 
  Whether I practice 
safe sex .108(a) 4.350 .000 .106 .939 
2 If my friends think I 
should get it -.019(b) -.747 .455 -.018 .883 
  If I had an abnormal 
Pap smear -.008(b) -.306 .759 -.007 .776 
  If my family thinks I 
should get it -.005(b) -.202 .840 -.005 .873 
  If my sex partner 
thinks I should get it -.040(b) -1.517 .130 -.037 .834 
  If my health care 
provider thinks I 
should get it 
.011(b) .423 .672 .010 .792 
  If someone in my 
family has cancer -.001(b) -.028 .978 -.001 .815 
a.  Predictors in the Model: (Constant), If my health insurance covers it 
b.  Predictors in the Model: (Constant), If my health insurance covers it, Whether I practice safe     
                                                               sex 
c.  Dependent Variable: Mean Control Beliefs 
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Tables 79-82.  Multiple Linear Regression Results for the Relationship Between Control Beliefs  
 About Practicing Safer Sex Behaviors and Barriers to Becoming    
 Vaccinated Against HPV 
 
79.  Model Summary 
Model R R Square 
Adjusted 
R Square 
Std. Error of 
the Estimate 
1 .141(a) .020 .019 .67633 
2 .158(b) .025 .024 .67476 
3 .166(c) .028 .026 .67402 
a.  Predictors: (Constant), The cost of the vaccine 
b.  Predictors: (Constant), The cost of the vaccine, Having to wait at my doctors office for  
                                         approval to get the vaccine 
c.  Predictors: (Constant), The cost of the vaccine, Having to wait at my doctors office for  
                                         approval to get the vaccine, Possible side effects of the vaccine  
  
80.  ANOVA(d) 
Model  
Sum of 
Squares df 
Mean 
Square F Sig. 
1 Regression 15.520 1 15.520 33.930 .000(a) 
  Residual 768.011 1679 .457     
  Total 783.532 1680       
2 Regression 19.548 2 9.774 21.467 .000(b) 
  Residual 763.984 1678 .455     
  Total 783.532 1680       
3 Regression 21.656 3 7.219 15.890 .000(c) 
  Residual 761.875 1677 .454     
  Total 783.532 1680       
a.  Predictors: (Constant), The cost of the vaccine 
b.  Predictors: (Constant), The cost of the vaccine, Having to wait at my doctors office for  
                                         approval to get the vaccine 
c.  Predictors: (Constant), The cost of the vaccine, Having to wait at my doctors office for  
                                         approval to get the vaccine, Possible side effects of the vaccine  
d.  Dependent Variable:  Mean Control Beliefs 
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81.  Coefficientsa 
Model 
  
Unstandardized 
Coefficients 
Standardized 
Coefficients  
95% Confidence 
Interval for B 
  
 
B 
 
Std. 
Error 
 
 
Beta 
 
 
t 
 
 
Sig. 
 
Lower 
Bound 
 
Upper 
Bound 
1 (Constant)  
4.554 
 
.053  
 
85.825 
 
     .000 
 
4.450 
 
4.658 
The cost of 
the vaccine 
 
 
 
-.128 
 
 
 
.022 
 
 
 
-.141 
 
 
 
6.229 
 
 
 
.000 
 
 
 
-.171 
 
 
 
-.085 
2 (Constant) 
 
 
 
4.634 
 
 
.059 
 
 
 
77.957 
 
 
.000 
 
 
4.518 
 
 
4.751 
The cost of 
the vaccine   
 
 
 
 
-.113 
 
 
 
 
.022 
 
 
 
 
-.124 
 
 
 
 
-5.033 
 
 
 
 
.000 
 
 
 
 
-.157 
 
 
 
 
-.069 
Having to 
wait at my 
doctor’s 
office to get 
the vaccine  
 
 
 
 
-.079 
 
 
 
 
.026 
 
 
 
 
-.074 
 
 
 
 
-2.974 
 
 
 
 
.003 
 
 
 
 
-.130 
 
 
 
 
-.027 
3(Constant) 
 
 
4.543 
 
.073  
 
62.210 
 
     .000 
 
4.400 
 
4.686 
The cost of 
the vaccine   
 
-.111 
 
.022 
 
-.123 
 
-4.963 
 
.000 
 
-.155 
 
-.067 
Having to 
wait at my 
doctor’s 
office to get 
the vaccine 
 
 
 
-.089 
 
 
.027 
 
 
-.083 
 
 
 
-3.310 
 
 
.001 
 
 
-.141 
 
 
-.036 
Possible side 
effects of the 
vaccine 
 
.050  .023 .053 2.154 .031 
 
.004 .095 
a.  Dependent Variable: Mean Control Beliefs 
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82.  Excluded Variables(d) 
Model   Beta In 
 
t  Sig. 
Partial 
Correlation 
Collinearity 
Statistics 
Tolerance 
1 Getting three shots 
over a six month 
period  
-.030(a) -1.242 .215 -.030 .982 
  Fear of vaccines  
-.016(a) -.651 .515 -.016 .999 
  Possible side effects 
of the vaccine  .038(a) 1.592 .112 .039 1.000 
  Having to get 
additional boosters 
after getting three 
shots 
-.008(a) -.344 .731 -.008 .980 
  Having to wait at 
my doctors office 
for approval to get 
the vaccine 
-.074(a) -2.974 .003 -.072 .951 
  Not knowing where 
to get the vaccine  -.059(a) -2.347 .019 -.057 .927 
2 Getting three shots 
over a six month 
period 
-.003(b) -.120 .904 -.003 .840 
  Fear of vaccines 
-.003(b) -.118 .906 -.003 .967 
  Possible side effects 
of the vaccine .053(b) 2.154 .031 .053 .969 
  Having to get 
additional boosters 
after getting three 
shots 
.022(b) .835 .404 .020 .842 
  Not knowing where 
to get the vaccine -.038(b) -1.430 .153 -.035 .821 
3 Getting three shots 
over a six month 
period 
-.011(c) -.426 .670 -.010 .823 
  Fear of vaccines 
-.023(c) -.873 .383 -.021 .863 
  Having to get 
additional boosters 
after getting three 
shots 
.002(c) .069 .945 .002 .734 
  Not knowing where 
to get the vaccine -.039(c) -1.477 .140 -.036 .821 
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a  Predictors in the Model: (Constant), The cost of the vaccine  
b  Predictors in the Model: (Constant), The cost of the vaccine, Having to wait at my doctors  
                                                               office for approval to get the vaccine 
c  Predictors in the Model: (Constant), The cost of the vaccine, Having to wait at my doctors  
                                                               office for approval to get the vaccine, Possible side effects      
                                                               of the vaccine 
d. Dependent Variable: Mean Control Beliefs 
 
 
Table 83.  Correlation Between Intentions to Practice Safer Sex Behaviors and General 
                 Vaccine Acceptance 
 
  
Mean 
Intentions 
Mean General 
Vaccine 
Acceptance 
Mean Intentions Pearson Correlation 1 .087(**) 
  Sig. (2-tailed) 
  .000 
  N 2706 2705 
Mean General 
Vaccine 
Acceptance 
Pearson Correlation 
.087(**) 1 
  Sig. (2-tailed) .000   
  N 2705 2705 
**Correlation is significant at the 0.01 level (2-tailed). 
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Table 84.  Correlation Between Intentions to Practice Safer Sex Behaviors and Importance of 
                 Vaccinations in General. 
 
 
Mean 
Intentions 
How 
important do 
you think 
vaccinations 
are in 
general? 
Mean Intentions Pearson Correlation 1 .081(**) 
  Sig. (2-tailed) 
  .000 
  N 2706 2700 
How important do you 
think vaccinations are in 
general? 
Pearson Correlation 
.081(**) 1 
  Sig. (2-tailed) .000   
  N 2700 2700 
**  Correlation is significant at the 0.01 level (2-tailed). 
 
 
 
Table 85.  Correlation Between Intentions to Practice Safer Sex Behaviors and Likelihood of  
                 Getting Vaccinated Against HPV 
  
  
Mean 
Intentions 
Likelihood of 
getting vaccinated 
against HPV 
Mean Intentions Pearson Correlation 1 .098(**) 
  Sig. (2-tailed) 
  .000 
  N 2706 1695 
Likelihood of 
getting vaccinated 
against HPV 
Pearson Correlation 
.098(**) 1 
  Sig. (2-tailed) 
.000   
  N 1695 1695 
** Correlation is significant at the 0.01 level (2-tailed). 
 392
Appendix O (Continued) Summary Tables of Correlation 
and Multiple Linear Regression Results 
 
Tables 86-89.  Multiple Linear Regression Results for the Relationship Between Intentions  
 to Practice Safer Sex Behaviors and Barriers to Becoming    
 Vaccinated Against HPV 
 
86.  Model Summary 
Model R R Square 
Adjusted 
R Square 
Std. Error of 
the Estimate 
1 .179(a) .032 .031 .79563 
2 .230(b) .053 .052 .78710 
3 .239(c) .057 .055 .78570 
4 .244(d) .060 .058 .78479 
a  Predictors: (Constant), Whether I practice safe sex 
b  Predictors: (Constant), Whether I practice safe sex, If my health insurance covers it 
c  Predictors: (Constant), Whether I practice safe sex, If my health insurance covers it, If someone  
                                          in my family has cancer 
d  Predictors: (Constant), Whether I practice safe sex, If my health insurance covers it, If  
                                          someone in my family has cancer, If my friends think Ishould get it 
 
87.  ANOVA(e) 
Model  
Sum of 
Squares df 
Mean 
Square F Sig. 
1 Regression 35.080 1 35.080 55.416 .000(a) 
  Residual 1064.759 1682 .633     
  Total 1099.839 1683       
2 Regression 58.420 2 29.210 47.149 .000(b) 
  Residual 1041.419 1681 .620     
  Total 1099.839 1683       
3 Regression 62.744 3 20.915 33.880 .000(c) 
  Residual 1037.095 1680 .617     
  Total 1099.839 1683       
4 Regression 65.742 4 16.436 26.685 .000(d) 
  Residual 1034.096 1679 .616     
  Total 1099.839 1683       
a  Predictors: (Constant), Whether I practice safe sex 
b  Predictors: (Constant), Whether I practice safe sex, If my health insurance covers it 
c  Predictors: (Constant), Whether I practice safe sex, If my health insurance covers it, If someone  
   in my family has cancer 
d  Predictors: (Constant), Whether I practice safe sex, If my health insurance covers it, If  
                                          someone in my family has cancer, If my friends think I should get it 
e  Dependent Variable: Mean Intentions 
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and Multiple Linear Regression Results 
88.  Coefficientsa 
Model 
  
Unstandardized 
Coefficients 
Standardized 
Coefficients  
95% Confidence 
Interval for B 
  
 
B 
 
Std. 
Error 
 
 
Beta 
 
 
t 
 
 
Sig. 
 
Lower 
Bound 
 
Upper 
Bound 
1 (Constant)  
3.318 
 
.076  
 
43.751 
 
     .000 
 
3.170 
 
3.467 
Whether I 
practice safe 
sex   
 
 
 
.215 
 
 
 
.029 
 
 
 
.179 
 
 
 
7.444 
 
 
 
     .000 
 
 
 
.159 
 
 
 
.272 
2 (Constant) 
 
 
 
3.668 
 
 
.094 
 
 
 
38.921 
 
 
.000 
 
 
3.484 
 
 
3.853  
Whether I 
practice safe 
sex   
 
 
.260 
 
 
.030 
 
 
.216 
 
 
8.808 
 
 
     .000 
 
 
.202 
 
 
.318 
If my health 
insurance 
covers it 
 
 
 
-.181 
 
 
 
.029 
 
 
 
-.150 
 
 
 
-6.138 
 
 
 
 
 
 
 
-.238 
 
 
 
-.123 
3 (Constant) 
 
 
3.556 
 
.103  
 
34.466 
 
.000 
 
3.354 
 
3.759 
Whether I 
practice safe 
sex   
 
 
     .238 
 
 
     .031 
 
 
.197 
 
 
7.756 
 
 
     .000 
 
 
.178 
 
 
.298 
If my health 
insurance 
covers it 
 
 
 
-.204 
 
 
 
.031 
 
 
 
-.170 
 
 
 
-6.649 
 
 
 
.000 
 
 
 
-.264 
 
 
 
-.144 
If someone in 
my family 
has cancer 
 
 
.089 
 
 
.034 
 
 
.069 
 
 
2.647 
 
 
.008 
 
 
.023 
 
 
.155 
4 (Constant)  
3.533 
 
.104  
 
34.101 
 
.000 
 
3.330 
 
3.736 
Whether I 
practice safe 
sex   
 
 
.230 
 
 
.031 
 
 
.191 
 
 
7.455 
 
 
.000 
 
 
.169 
 
 
.290 
If my health 
insurance 
covers it 
 
 
-.219 
 
 
.031 
 
 
-.183 
 
 
-6.982 
 
 
.000 
 
 
-.281 
 
 
-.158 
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and Multiple Linear Regression Results 
 
88.  Coefficientsa  (Continued) 
Model 
  
Unstandardized 
Coefficients 
Standardized 
Coefficients  
95% Confidence 
Interval for B 
  
 
B 
 
Std. 
Error 
 
 
Beta 
 
 
t 
 
 
Sig. 
 
Lower 
Bound 
 
Upper 
Bound 
If someone in 
my family 
has cancer 
 
 
.079 
 
 
.034 
 
 
.062 
 
 
2.335 
 
 
.020 
 
 
.013 
 
 
.145 
If my friends 
think I should 
get it 
 
 
.068 
 
 
.031 
 
 
.056 
 
 
2.206 
 
 
.027 
 
 
.008 
 
 
.129 
a.  Dependent Variable: Intentions 
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and Multiple Linear Regression Results 
89.  Excluded Variables(e) 
Model  Beta In t Sig. 
Partial 
Correlatio
n 
Collinearity 
Statistics 
          Tolerance 
1 If my friends think I 
should get it .019(a) .787 .431 .019 .951 
  If my health insurance 
covers it -.150(a) -6.138 .000 -.148 .939 
  If I had an abnormal 
Pap smear -.035(a) -1.382 .167 -.034 .897 
  If my family thinks I 
should get it .017(a) .699 .484 .017 .937 
  If my sex partner 
thinks I should get it -.026(a) -1.020 .308 -.025 .911 
  If my health care 
provider thinks I 
should get it 
-.001(a) -.046 .963 -.001 .910 
  If someone in my 
family has cancer .020(a) .768 .443 .019 .888 
2 If my friends think I 
should get it .064(b) 2.533 .011 .062 .883 
  If I had an abnormal 
Pap smear .025(b) .921 .357 .022 .776 
  If my family thinks I 
should get it .061(b) 2.397 .017 .058 .873 
  If my sex partner 
thinks I should get it .021(b) .791 .429 .019 .834 
  If my health care 
provider thinks I 
should get it 
.062(b) 2.313 .021 .056 .792 
  If someone in my 
family has cancer .069(b) 2.647 .008 .064 .815 
3 If my friends think I 
should get it .056(c) 2.206 .027 .054 .868 
  If I had an abnormal 
Pap smear .002(c) .067 .947 .002 .694 
  If I had an abnormal 
Pap smear .048(c) 1.824 .068 .044 .824 
  If my sex partner 
thinks I should get it .007(c) .258 .796 .006 .799 
  If my health care 
provider thinks I 
should get it 
.047(c) 1.692 .091 .041 .740 
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and Multiple Linear Regression Results 
 
89.  Excluded Variables(e) (Continued) 
Model  Beta In t Sig. 
Partial 
Correlatio
n 
Collinearity 
Statistics 
4          Tolerance 
 If I had an abnormal 
Pap smear -.001(d) -.033 .973 -.001 .693 
 If my family thinks I 
should get it .032(d) 1.176 .240 .029 .738 
  If my sex partner 
thinks I should get it -.012(d) -.427 .670 -.010 .726 
 If my health care 
provider thinks I 
should get it 
.039(d) 1.404 .160 .034 .726 
a  Predictors in the Model: (Constant), Whether I practice safe sex 
b.  Predictors in the Model: (Constant), Whether I practice safe sex, If my health insurance covers  
                                                               it 
c.  Predictors in the Model: (Constant), Whether I practice safe sex, If my health insurance covers  
                                                               it, If someone in my family has cancer 
d.  Predictors in the Model: (Constant), Whether I practice safe sex, If my health insurance covers  
                                                               it, If someone in my family has cancer, If my friends think  
                                                               I should get it 
e.  Dependent Variable: Mean Intentions 
 
 
Tables 90-93.  Multiple Linear Regression Results for the Relationship Between Intentions  
 to Practice Safer Sex Behaviors and Barriers to Becoming    
 Vaccinated Against HPV 
 
90.  Model Summary 
 
a.  Predictors: (Constant), The cost of the vaccine 
b.  Predictors: (Constant), The cost of the vaccine, Not knowing where to get the vaccine  
Model R R Square 
Adjusted 
R Square 
Std. Error of 
the Estimate 
1 .116(a) .014 .013 .80315 
2 .128(b) .016 .015 .80225 
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91.  ANOVA(c) 
Model   Sum of Squares df Mean Square F Sig. 
1 Regression 14.837 1 14.837 23.001 .000(a) 
  Residual 1083.041 1679 .645     
  Total 1097.878 1680       
2 Regression 17.912 2 8.956 13.916 .000(b) 
  Residual 1079.966 1678 .644     
  Total 1097.878 1680       
a.  Predictors: (Constant), The cost of the vaccine 
b.  Predictors: (Constant), The cost of the vaccine, Not knowing where to get the vaccine  
c.  Dependent Variable: Mean Intentions 
 
92.  Coefficientsa 
Model 
  
Unstandardized 
Coefficients 
Standardized 
Coefficients  
95% Confidence 
Interval for B 
  
 
B 
 
Std. 
Error 
 
 
Beta 
 
 
t 
 
 
Sig. 
 
Lower 
Bound 
 
Upper 
Bound 
1 (Constant)  
4.151 
 
.063  
 
65.882 
 
     .000 
 
4.028 
 
4.275 
The cost of 
the vaccine   
 
 
 
-.125 
 
 
 
.026 
 
 
 
-.116 
 
 
 
-4.796 
 
 
 
     .000 
 
 
 
-.176 
 
 
 
-.074 
2 (Constant) 
 
 
 
4.213 
 
 
.069 
 
 
 
61.151 
 
 
.000 
 
 
4.077 
 
 
4.348 
If my health 
insurance 
covers it   
 
 
 
 
-.109 
 
 
 
 
.027 
 
 
 
 
-.101 
 
 
 
 
-4.032 
 
 
 
 
.000 
 
 
 
 
-.162 
 
 
 
 
-.056 
Whether I 
practice safe 
sex 
 
 
 
 
-.059 
 
 
 
 
.027 
 
 
 
 
-.055 
 
 
 
 
-2.186 
 
 
 
 
.029 
 
 
 
 
-.112 
 
 
 
 
-.006 
a.  Dependent Variable: Mean Intentions 
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93.  Excluded Variables(c) 
 
Model   Beta In 
 
t  Sig. 
Partial 
Correlation 
Collinearity 
Statistics 
Tolerance 
1 Getting three 
shots over a six 
month period  
.015(a) .607 .544 .015 .982 
  Fear of vaccines 
.000(a) -.020 .984 .000 .999 
  Possible side 
effects of the 
vaccine 
.033(a) 1.375 .169 .034 1.000 
  Having to get 
additional 
boosters after 
getting three shots  
.028(a) 1.163 .245 .028 .980 
  Having to wait at 
my doctors office 
for approval to 
get the vaccine 
-.043(a) -1.738 .082 -.042 .951 
  Not knowing 
where to get the 
vaccine  
-.055(a) -2.186 .029 -.053 .927 
2 Getting three 
shots over a six 
month period 
.023(b) .924 .356 .023 .963 
  Fear of vaccines 
.002(b) .094 .925 .002 .997 
  Possible side 
effects of the 
vaccine 
.038(b) 1.554 .120 .038 .994 
  Having to get 
additional 
boosters after 
getting three shots 
.038(b) 1.533 .125 .037 .955 
  Having to wait at 
my doctors office 
for approval to 
get the vaccine 
-.028(b) -1.063 .288 -.026 .842 
a  Predictors in the Model: (Constant), The cost of the vaccine 
b  Predictors in the Model: (Constant), The cost of the vaccine, Not knowing where to get the  
                                                               vaccine  
c  Dependent Variable: Mean Intentions
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